A,O
new,O
vitamin,O
D,O
analogue,O
",",O
22,O
-,O
oxacalcitriol,B
(,O
OCT,B
),O
",",O
has,O
been,O
shown,O
to,O
have,O
promising,O
characteristics,O
.,O
This,O
study,O
was,O
undertaken,O
to,O
determine,O
the,O
effects,O
of,O
OCT,B
on,O
serum,O
PTH,O
levels,O
and,O
bone,O
turnover,O
in,O
states,O
of,O
normal,O
or,O
impaired,O
renal,O
function,O
.,O
METHODS,O
:,O
Sixty,O
dogs,O
were,O
either,O
nephrectomized,O
(,O
Nx,B
",",O
N,O
=,O
38,O
),O
or,O
sham,B
-,O
operated,O
(,O
Sham,B
",",O
N,O
=,O
22,O
),O
.,O
The,
animals,
received,
supplemental,
phosphate,
to,
enhance,
PTH,
secretion,
.,
Fourteen,
weeks,
after,
the,
start,
of,
phosphate,
supplementation,
",",
half,
of,
the,
Nx,
and,
Sham,
dogs,
received,
doses,
of,
OCT,
(,
three,
times,
per,
week,
),
;,
the,
other,
half,
were,
given,
vehicle,
for,
60,
weeks,
.,
Thereafter,
",",
the,
treatment,
modalities,
for,
a,
subset,
of,
animals,
were,
crossed,
over,
for,
an,
additional,
eight,
months,
.,
Biochemical,O
and,O
hormonal,O
indices,O
of,O
calcium,B
and,O
bone,B
metabolism,I
were,O
measured,O
throughout,O
the,O
study,O
",",O
and,O
bone,B
biopsies,I
were,O
done,O
at,O
baseline,O
",",O
60,O
weeks,O
after,O
OCT,B
or,O
vehicle,O
treatment,O
",",O
and,O
at,O
the,O
end,O
of,O
the,O
crossover,O
period,O
.,O
RESULTS,O
:,O
In,O
Nx,O
dogs,O
",",O
OCT,B
significantly,O
decreased,O
serum,O
PTH,B
levels,O
soon,O
after,O
the,O
induction,O
of,O
renal,O
insufficiency,O
.,O
In,O
long,O
-,O
standing,O
secondary,O
hyperparathyroidism,O
",",O
OCT,B
(,O
0,O
.,O
03,O
microg,O
/,O
kg,O
),O
stabilized,O
serum,O
PTH,O
levels,O
during,O
the,O
first,O
months,O
.,O
Serum,O
PTH,O
levels,O
rose,O
thereafter,O
",",O
but,O
the,O
rise,O
was,O
less,O
pronounced,O
compared,O
with,O
baseline,O
than,O
the,O
rise,O
seen,O
in,O
Nx,B
control,O
.,O
These,O
effects,O
were,O
accompanied,O
by,O
episodes,O
of,O
hypercalcemia,B
and,O
hyperphosphatemia,B
.,O
In,O
animals,O
with,O
normal,O
renal,O
function,O
",",O
OCT,B
induced,O
a,O
transient,O
decrease,O
in,O
serum,O
PTH,B
levels,O
a...re,O
of,O
bone,O
turnover,O
.,O
In,O
addition,O
",",O
OCT,B
improved,O
mineralization,O
lag,O
time,O
",",O
(,O
that,O
is,O
",",O
the,O
rate,O
at,O
which,O
osteoid,O
mineralizes,O
),O
in,O
both,O
Nx,B
and,O
Sham,B
dogs,O
.,O
CONCLUSIONS,O
:,O
These,O
results,O
indicate,O
that,O
even,O
though,O
OCT,B
does,O
not,O
completely,O
prevent,O
the,O
occurrence,O
of,O
hypercalcemia,O
in,O
experimental,O
dogs,O
with,O
renal,O
insufficiency,O
",",O
it,O
may,O
be,O
of,O
use,O
in,O
the,O
management,O
of,O
secondary,O
hyperparathyroidism,O
because,O
it,O
does,O
not,O
induce,O
low,O
bone,O
turnover,O
and,O
",",O
therefore,O
",",O
does,O
not,O
increase,O
the,O
risk,O
of,O
adynamic,O
bone,O
disease,O
.,O
Hypotension,O
",",O
bradycardia,O
",",O
and,O
asystole,O
after,O
high,O
-,O
dose,O
intravenous,O
methylprednisolone,B
in,O
a,O
monitored,O
patient,O
.,O
We,O
report,O
a,O
case,O
of,O
hypotension,O
",",O
bradycardia,O
",",O
and,O
asystole,O
after,O
intravenous,O
administration,O
of,O
high,O
-,O
dose,O
methylprednisolone,B
in,O
a,O
73,O
-,O
year,O
-,O
old,O
patient,O
who,O
underwent,O
electrocardiographic,B
(,O
ECG,I
),O
monitoring,O
throughout,O
the,O
episode,O
.,O
There,O
was,O
a,O
history,O
of,O
ischemic,B
cardiac,I
disease,I
9,O
years,O
earlier,O
.,O
The,O
patient,O
was,O
admitted,O
with,O
a,O
pulmonary,O
-,O
renal,B
syndrome,I
with,O
hemoptysis,O
",",O
rapidly,O
progressive,O
renal,B
failure,I
",",O
and,O
hypoxemia,O
that,O
required,O
mechanical,O
ventilation,O
in,O
the,O
intensive,O
care,O
unit,O
.,O
After,O
receiving,O
advanced,O
cardiopulmonary,O
resuscitation,O
",",O
the,O
patient,O
recovered,O
cardiac,I
rhythm,I
.,O
The,
ECG,
showed,
a,
junctional,
rhythm,
without,
ventricular,
arrhythmia,
.,
This,
study,
reviews,
the,
current,
proposed,
mechanisms,
of,
sudden,
death,
after,
a,
high,
dose,
of,
intravenous,
methylprednisolone,
(,
IVMP,
),
.,
These,
mechanisms,
are,
not,
well,
understood,
because,
",",
in,
most,
cases,
",",
the,
patients,
were,
not,
monitored,
at,
the,
moment,
of,
the,
event,
.,
Rapid,O
infusion,O
and,O
underlying,O
cardiac,O
disease,O
were,O
important,O
risk,O
factors,O
in,O
the,O
case,O
reported,O
here,O
",",O
and,O
the,O
authors,O
discount,O
ventricular,O
arrhythmia,O
as,O
the,O
main,O
mechanism,O
.,O
Worsening,O
of,O
levodopa,B
-,I
induced,I
dyskinesias,I
by,O
motor,O
and,O
mental,O
tasks,O
.,O
Ten,O
patients,O
who,O
had,O
Parkinson,O
',O
s,O
disease,O
with,O
disabling,O
dyskinesia,O
were,O
included,O
in,O
this,O
study,O
to,O
evaluate,O
the,O
role,O
of,O
mental,O
(,O
mental,O
calculation,O
),O
and,O
motor,O
(,O
flexion,O
/,O
extension,O
of,O
right,O
fingers,O
",",O
flexion,O
/,O
extension,O
of,O
left,O
fingers,O
",",O
flexion,O
/,O
extension,O
of,O
the,O
neck,O
",",O
speaking,O
aloud,O
),O
tasks,O
on,O
the,O
worsening,O
of,O
peak,O
-,O
dose,O
dyskinesia,O
following,O
administration,O
of,O
an,O
effective,O
single,O
dose,O
of,O
apomorphine,B
.,O
Compared,O
with,O
the,O
score,O
at,O
rest,O
(,O
1,B
.,I
3,I
+,I
/,I
-,I
0,I
.,I
3,I
),O
",",O
a,O
significant,O
aggravation,O
of,O
the,O
dyskinesia,O
score,O
was,O
observed,O
during,O
speaking,O
aloud,O
(,O
5,B
.,I
2,I
+,I
/,I
-,I
1,I
.,I
1,I
",",O
p,O
<,O
0,O
.,O
05,O
),O
",",O
movements,O
of,O
right,O
(,O
4,B
.,I
5,I
+,I
/,I
-,I
1,I
.,I
0,I
",",O
p,O
<,O
0,O
.,O
05,O
),O
and,O
left,O
(,O
3,B
.,I
7,I
+,I
/,I
-,I
0,I
.,I
8,I
",",O
p,O
<,O
0,O
.,O
05,O
),O
fingers,O
",",O
movements,O
of,O
the,O
neck,O
(,O
5,B
.,I
.,I
1,O
+,O
/,O
-,O
1,O
.,O
0,O
",",O
p,O
<,O
0,O
.,O
05,O
),O
",",O
and,O
mental,O
calculation,O
(,O
3,Ellipsis
-,I
D,I
-,I
glucosaminidase,I
(,I
NAG,I
),I
activity,O
might,O
reflect,O
increased,O
lysosomal,O
activity,O
in,O
renal,O
tubular,O
cells,O
.,O
METHODS,O
:,O
Puromycin,B
aminonucleoside,I
(,O
PAN,B
),O
was,O
administered,O
to,O
Sprague,O
Dawley,O
rats,O
to,O
induce,O
prote...verify,O
.The,O
morphological,O
appearance,O
of,O
the,O
kidneys,O
was,O
examined,O
on,O
days,B
zero,I
",",O
four,B
",",O
eight,B
RESULTS,O
:,O
Following,O
intravenous,O
PAN,B
urine,O
volume,O
and,O
urine,O
NAG,B
activity,O
increased,O
significantly,O
by,O
day,O
two,O
",",O
but,O
returned,O
to,O
normal,O
by,O
day,O
four,O
.,O
After,O
day,O
four,O
all,O
treated,O
animals,O
exhibited,O
a,O
marked,O
rise,O
in,O
urine,O
albumin,O
",",O
total,O
protein,O
excretion,O
and,O
NAG,B
activity,O
.,O
Electrophoresis,O
showed,O
a,O
generalised,O
increase,O
in,O
middle,O
and,O
high,O
molecular,O
weight,O
urine,O
proteins,O
from,O
day,O
four,O
onwards,O
.,O
Protein,B
droplets,O
first,O
appeared,O
prominent,O
in,O
tubular,O
cells,O
on,O
day,O
four,O
.,O
Peak,B
urine,O
NAG,B
activity,O
and,O
a,O
change,O
in,O
NAG,B
isoenzyme,O
pattern,O
coincided,O
with,O
both,O
the,O
peak,O
proteinuria,O
and,O
the,O
reduction,O
in,O
intracellular,O
protein,O
and,O
NAG,B
droplets,O
(,O
day,O
six,O
onwards,O
),O
.,O
CONCLUSIONS,O
:,O
This,O
animal,O
model,O
demonstrates,O
that,O
an,O
increase,O
in,O
lysosomal,O
turnover,O
and,O
hence,O
urine,O
NAG,B
activity,O
",",O
occurs,O
when,O
increased,O
protein,O
is,O
presented,O
to,O
the,O
tubular,O
cells,O
.,O
Urine,O
NAG,O
activity,O
is,O
thus,O
a,O
measure,O
of,O
altered,O
function,O
in,O
the,O
renal,O
tubules,O
and,O
not,O
simply,O
an,O
indicator,O
of,O
damage,O
.,O
Cauda,O
equina,O
syndrome,O
after,O
spinal,O
anaesthesia,O
with,O
hyperbaric,O
5,B
%,I
lignocaine,I
:,O
a,O
review,O
of,O
six,O
cases,O
of,O
cauda,O
equina,O
syndrome,O
reported,O
to,O
the,O
Swedish,O
Pharmaceutical,O
Insurance,O
1993,O
-,O
1997,O
.,O
Six,O
cases,O
of,O
cauda,B
equina,I
syndrome,I
with,O
varying,O
severity,O
were,O
reported,O
to,O
the,O
Swedish,O
Pharmaceutical,O
Insurance,O
during,O
the,O
period,O
1993,O
-,O
1997,O
.,O
All,O
were,O
associated,O
with,O
spinal,B
anaesthesia,I
using,O
hyperbaric,B
5,I
%,I
lignocaine,I
.,O
Five,O
cases,O
had,O
single,O
-,O
shot,O
spinal,B
anaesthesia,I
and,O
one,O
had,O
a,O
repeat,O
spinal,B
anaesthetic,I
due,O
to,O
inadequate,O
block,O
.,O
The,
dose,
of,
hyperbaric,
5,
%,
lignocaine,
administered,
ranged,
from,
60,
to,
120,
mg,
.,
Three,
of,
the,
cases,
were,
most,
likely,
caused,
by,
direct,
neurotoxicity,
of,
hyperbaric,
5,
%,
lignocaine,
.,
In,
the,
other,
3,
cases,
",",
direct,
neurotoxicity,
was,
also,
probable,
",",
but,
unfortunately,
radiological,
investigations,
were,
not,
done,
to,
definitely,
exclude,
a,
compressive,
aetiology,
.,
All,O
cases,O
sustained,O
permanent,O
neurological,O
deficits,O
.,O
We,O
recommend,O
that,O
hyperbaric,O
lignocaine,B
should,O
be,O
administered,O
in,O
concentrations,O
not,O
greater,O
than,O
2,O
%,O
and,O
at,O
a,O
total,O
dose,O
preferably,O
not,O
exceeding,O
60,O
mg,O
.,O
Systemic,O
toxicity,O
following,O
administration,O
of,O
sirolimus,B
(,O
formerly,O
rapamycin,O
),O
for,O
psoriasis,O
:,O
association,O
of,O
capillary,O
leak,O
syndrome,O
with,O
apoptosis,O
of,O
lesional,O
lymphocytes,O
.,O
BACKGROUND,O
:,O
Sirolimus,B
(,O
formerly,O
rapamycin,O
),O
is,O
an,O
immunosuppressive,O
agent,O
that,O
interferes,O
with,O
T,B
-,I
cell,I
activation,O
.,O
After,O
2,O
individuals,O
with,O
psoriasis,O
developed,O
a,O
capillary,O
leak,O
syndrome,O
following,O
treatment,O
with,O
oral,O
sirolimus,B
lesional,O
skin,O
cells,O
and,O
activated,O
peripheral,O
blood,O
cells,O
were,O
analyzed,O
for,O
induction,O
of,O
apoptosis,O
.,O
OBSERVATIONS,O
:,O
A,O
keratome,O
skin,O
specimen,O
from,O
1,O
patient,O
with,O
sirolimus,B
-,I
induced,I
capillary,I
leak,I
syndr...ionale,O
in,O
the,O
presence,O
of,O
sirolimus,B
.,O
CONCLUSIONS,O
:,O
Severe,O
adverse,O
effects,O
of,O
sirolimus,B
include,O
fever,B
",",O
anemia,B
",",O
and,O
capillary,B
leak,I
Effect,O
of,O
lithium,B
maintenance,I
therapy,I
on,O
thyroid,B
and,I
parathyroid,I
function,O
.,O
OBJECTIVES,O
:,O
To,O
assess,O
changes,O
induced,O
by,O
lithium,B
maintenance,I
therapy,I
on,O
the,O
incidence,O
of,O
thyroid,B
",",O
parathyroid,B
and,I
ion,I
alterations,O
.,O
These,O
were,O
evaluated,O
with,O
respect,O
to,O
the,O
duration,O
of,O
lithium,B
therapy,I
",",O
age,O
",",O
sex,O
",",O
and,O
family,O
history,O
(,O
whether,O
or,O
not,O
the,O
patient,O
had,O
a,O
first,O
-,O
degree,O
relative,O
with,O
thyroid,O
disease,O
),O
.,O
DESIGN,O
:,O
Prospective,O
study,O
.,O
SETTING,O
:,O
Affective,O
Disorders,O
Clinic,O
at,O
St,O
.,O
Mary,O
',O
s,O
Hospital,O
",",O
Montreal,O
.,O
PATIENTS,O
:,O
One,O
hundred,O
and,O
one,O
patients,O
(,O
28,O
men,O
and,O
73,O
women,O
),O
with,O
bipolar,B
disorder,I
receiving,O
lithium,B
maintenance,I
therapy,I
ranging,O
from,O
1,O
year,B
',I
s,I
to,O
32,O
years,B
',I
duration,I
.,O
The,O
control,O
group,O
consisted,O
of,O
82,O
patients,O
with,O
no,O
psychiatric,O
or,O
endocrinological,O
diagnoses,O
from,O
the,O
hospital,O
',O
s,O
out,O
-,O
patient,O
clinics,O
.,O
OUTCOME,O
MEASURES,O
:,O
Laboratory,O
analyses,O
of,O
calcium,B
",",O
magnesium,B
and,O
thyroid,B
-,O
stimulating,O
hormone,O
7,O
years,O
after,O
onset,O
of,O
lithium,B
therapy,O
),O
compared,O
with,O
patients,O
without,O
a,O
family,O
history,O
(,O
8,O
.,O
6,O
years,O
after,O
onset,O
of,O
lithium,O
therapy,O
),O
.,O
Women,O
over,O
60,O
years,O
of,O
age,O
were,O
more,O
often,O
affected,O
by,O
hypothyroidism,O
than,O
women,O
under,O
60,O
years,O
of,O
age,O
(,O
34,O
.,O
6,O
%,O
versus,O
31,O
.,O
9,O
%,O
),O
.,O
Magnesium,O
levels,O
in,O
patients,O
on,O
lithium,O
treatment,O
were,O
unchanged,O
from,O
baseline,O
levels,O
.,O
After,O
lithium,B
treatment,I
",",O
calcium,B
levels,I
were,O
higher,O
than,O
either,O
baseline,O
levels,O
or,O
control,O
levels,O
Severe,O
immune,O
hemolytic,O
anemia,O
associated,O
with,O
prophylactic,O
use,O
of,O
cefotetan,B
in,O
obstetric,O
and,O
gynecologic,O
procedures,O
.,O
Second,O
-,O
and,O
third,O
-,O
generation,O
cephalosporins,O
",",O
especially,O
cefotetan,B
",",O
are,O
increasingly,O
associated,O
with,O
severe,O
",",O
sometimes,O
fatal,O
immune,O
hemolytic,O
anemia,O
.,O
We,O
noticed,O
that,O
10,O
of,O
our,O
35,O
cases,O
of,O
cefotetan,B
-,O
induced,O
hemolytic,O
anemias,O
were,O
in,O
patients,O
who,O
had,O
received,O
cefotetan,B
prophylactically,O
for,O
obstetric,O
and,O
gynecologic,O
procedures,O
.,O
Eight,O
of,O
these,O
cases,O
of,O
severe,O
immune,B
hemolytic,I
anemia,I
are,O
described,O
.,O
Effects,O
of,O
nonsteroidal,B
anti,I
-,I
inflammatory,I
drugs,O
on,O
hemostasis,O
in,O
patients,O
with,O
aneurysmal,O
subarachnoid,O
hemorrhage,O
.,O
Platelet,O
function,O
is,O
impaired,O
by,O
nonsteroidal,B
anti,I
-,I
inflammatory,I
drugs,O
(,O
NSAIDs,B
),O
with,O
prominent,O
anti,I
-,I
inflammatory,I
properties,O
.,O
Their,O
safety,O
in,O
patients,O
undergoing,O
intracranial,O
surgery,O
is,O
under,O
debate,O
.,O
Patients,O
with,O
aneurysmal,B
subarachnoid,I
hemorrhage,I
(,O
SAH,B
),O
were,O
randomized,O
to,O
receive,O
either,O
ketoprofen,B
",",O
100,O
mg,O
",",O
three,O
times,O
a,O
day,O
(,O
ketoprofen,O
group,O
",",O
n,O
=,O
9,O
),O
or,O
a,O
weak,O
NSAID,B
",",O
acetaminophen,B
",",O
1,O
g,O
",",O
three,O
times,O
a,O
day,O
(,O
acetaminophen,O
group,O
",",O
n,O
=,O
9,O
),O
starting,O
immediately,O
after,O
the,O
diagnosis,O
of,O
aneurysmal,O
SAH,O
.,O
Treatment,O
was,O
continued,O
for,O
3,O
days,O
postoperatively,O
.,O
Test,O
blood,O
samples,O
were,O
taken,O
before,O
treatment,O
"...,",O
and,O
fifth,O
postoperative,O
mornings,O
.,O
Maximal,O
platelet,O
aggregation,O
induced,O
by,O
6,O
microM,B
of,I
adenosine,I
05,
),
in,
the,
ketoprofen,
group,
than,
in,
the,
acetaminophen,
group,
just,
before,
surgery,
and,
on,
the,
third,
postoperative,
day,
.,
In,
contrast,
",",
maximal,
platelet,
aggregation,
increased,
in,
the,
acetaminophen,
group,
on,
the,
third,
postoperative,
day,
as,
compared,
with,
the,
pretreatment,
platelet,
aggregation,
results,
(,
P,
<,
.,
05,
),
.,
One,O
patient,O
in,O
the,O
ketoprofen,B
group,O
developed,O
a,O
postoperative,O
intracranial,O
hematoma,O
.,O
Coagulation,O
(,O
prothrombi...III,B
],I
",",O
),O
was,O
comparable,O
between,O
the,O
two,O
groups,O
.,O
Ketoprofen,B
but,O
not,O
acetaminophen,O
impaired,O
If,O
ketoprofen,B
is,O
used,O
before,O
surgery,O
on,O
cerebral,B
artery,I
aneurysms,I
",",O
it,O
may,O
pose,O
an,O
additional,O
risk,O
factor,O
for,O
hemorrhage,O
.,O
Nitric,B
oxide,I
synthase,I
expression,O
in,O
the,O
course,O
of,O
lead,B
-,I
induced,I
hypertension,I
.,O
We,O
recently,O
showed,O
elevated,O
reactive,O
oxygen,O
species,O
(,O
ROS,B
),O
",",O
reduced,O
urinary,O
excretion,O
of,O
NO,B
metabolites,I
(,O
NOx,B
),O
",",O
and,O
increased,O
NO,B
sequestration,I
as,O
nitrotyrosine,O
in,O
various,O
tissues,O
in,O
rats,O
with,O
lead,B
-,I
induced,I
hypertension,I
.,O
This,O
study,O
was,O
designed,O
to,O
discern,O
whether,O
the,O
reduction,O
in,O
urinary,O
NOx,B
in,O
lead,B
-,I
induced,I
Tail,O
blood,O
pressure,O
",",O
urinary,O
NOx,B
excretion,O
",",O
plasma,O
malondialdehyde,B
(,O
MDA,I
),O
",",O
and,O
endothelial,O
and,O
inducible,O
NOS,B
(,O
eNOS,I
and,I
iNOS,I
),O
isotypes,O
in,O
the,O
aorta,O
and,O
kidney,O
were,O
measured,O
.,O
The,O
lead,O
-treated,O
group,O
exhibited,O
a,O
rise,O
in,O
blood,O
pressure,O
and,O
plasma,O
MDA,B
concentration,O
",",O
a,O
fall,O
in,O
urinary,O
NOx,B
excretion,O
",",O
and,O
a,O
paradoxical,O
rise,O
in,O
vascular,O
and,O
renal,O
tissue,O
eNOS,B
and,I
iNOS,I
expression,O
.,O
Vitamin,B
E,I
supplementation,O
ameliorated,O
hypertension,O
",",O
lowered,O
plasma,B
MDA,I
concentration,O
",",O
and,O
raised,O
urinary,O
The,O
study,O
also,O
revealed,O
significant,O
inhibition,O
of,O
NOS,B
enzymatic,O
activity,O
by,O
lead,B
in,O
cell,O
-,O
free,O
preparations,O
.,O
In,O
conclusion,O
",",O
lead,B
-,O
induced,O
hypertension,O
in,O
this,O
model,O
was,O
associated,O
with,O
a,O
compensatory,O
upregulation,O
of,O
renal,O
and,O
vascular,O
eNOS,B
and,O
iNOS,B
expression,O
.,O
This,O
is,O
",",O
in,O
part,O
",",O
due,O
to,O
ROS,B
-,O
mediated,O
NO,B
inactivation,O
",",O
lead,B
-,O
associated,O
inhibition,O
of,O
NOS,B
activity,O
",",O
and,O
perhaps,O
stimulatory,O
actions,O
of,O
increased,O
shear,O
stress,O
associated,O
with,O
hypertension,O
.,O
Glyceryl,B
trinitrate,I
induces,O
attacks,O
of,O
migraine,O
without,O
aura,O
in,O
sufferers,O
of,O
migraine,O
with,O
aura,O
.,O
Migraine,B
with,I
aura,I
and,O
migraine,O
without,O
aura,O
have,O
the,O
same,O
pain,O
phase,O
",",O
thus,O
indicating,O
that,O
migraine,O
with,O
aura,O
and,O
migraine,O
without,O
aura,O
share,O
a,O
common,O
pathway,O
of,O
nociception,O
.,O
In,O
recent,O
years,O
",",O
increasing,O
evidence,O
has,O
suggested,O
that,O
the,O
messenger,O
molecule,O
nitric,B
oxide,I
(,O
NO,B
),O
is,O
involved,O
in,O
pain,O
mechanisms,O
of,O
migraine,O
without,O
aura,O
.,O
In,O
order,O
to,O
clarify,O
whether,O
the,O
same,O
is,O
true,O
for,O
migraine,B
with,I
aura,I
",",O
in,O
the,O
present,O
study,O
we,O
examined,O
the,O
headache,O
response,O
to,O
intravenous,O
infusion,O
of,O
glyceryl,B
trinitrate,I
(,O
GTN,B
),O
(,O
0,O
.,O
5,O
microg,O
/,O
kg,O
/,O
min,O
for,O
20,O
min,O
),O
in,O
12,O
sufferers,O
of,O
migraine,B
with,I
aura,I
.,O
The,O
specific,O
aim,O
was,O
to,O
elucidate,O
whether,O
an,O
aura,O
and,O
/,O
or,O
an,O
attack,O
of,O
migraine,B
without,I
aura,I
could,O
be,O
induced,O
.,O
Fourteen,O
healthy,O
subjects,O
served,O
as,O
controls,O
.,O
Aura,O
symptoms,O
were,O
not,O
elicited,O
in,O
any,O
subject,O
At,O
this,O
time,O
the,O
induced,O
headache,O
in,O
6,O
of,O
12,O
migraineurs,O
fulfilled,O
the,O
diagnostic,O
criteria,O
for,O
migraine,B
without,O
aura,O
of,O
the,O
International,O
Headache,O
Society,O
.,O
The,O
results,O
therefore,O
suggest,O
that,O
NO,B
is,O
involved,O
in,O
the,O
pain,O
mechanisms,O
of,O
migraine,O
with,O
aura,O
.,O
Since,O
cortical,O
spreading,O
depression,O
has,O
been,O
shown,O
to,O
liberate,O
NO,B
in,O
animals,O
",",O
this,O
finding,O
may,O
help,O
our,O
understanding,O
of,O
the,O
coupling,O
between,O
cortical,O
spreading,O
depression,O
and,O
headache,O
in,O
migraine,O
with,O
aura,O
.,O
Rapid,O
reversal,O
of,O
life,O
-,O
threatening,O
diltiazem,B
-,O
induced,O
tetany,O
with,O
calcium,B
chloride,I
.,O
We,O
describe,O
a,O
patient,O
who,O
developed,O
tetany,O
with,O
sudden,O
respiratory,O
arrest,O
after,O
the,O
infusion,O
of,O
intravenous,O
diltiazem,B
.,O
The,O
administration,O
of,O
calcium,B
chloride,I
rapidly,O
resolved,O
the,O
patient,O
',O
s,O
tetany,O
with,O
prompt,O
recovery,O
of,O
respiratory,O
function,O
",",O
averting,O
the,O
need,O
for,O
more,O
aggressive,O
airway,O
management,O
and,O
ventilatory,O
support,O
.,O
The,O
emergency,O
physician,O
should,O
be,O
aware,O
that,O
life,O
-,O
threatening,O
tetany,O
may,O
accompany,O
the,O
administration,O
Little,O
information,O
is,O
available,O
to,O
predict,O
which,O
patients,O
are,O
at,O
highest,O
risk,O
for,O
this,O
complication,O
.,O
OBJECTIVE,O
:,O
To,O
quantify,O
specific,O
clinical,O
predictors,O
of,O
reduction,O
in,O
renal,B
function,I
in,O
patients,O
with,O
CHF,O
who,O
are,O
prescribed,O
angiotensin,B
-,I
converting,I
enzyme,I
inhibitor,I
therapy,I
.,O
METHOD,O
:,O
We,O
analyzed,O
data,O
from,O
the,O
Studies,O
of,O
Left,O
Ventricular,O
Dysfunction,O
(,O
SOLVD,O
),O
",",O
a,O
randomized,O
",",O
double,O
-,O
blind,O
",",O
placebo,O
-,O
controlled,O
trial,O
of,O
enalapril,O
for,O
the,O
treatment,O
of,O
CHF,O
.,O
There,O
were,O
3379,O
patients,O
randomly,O
assigned,O
to,O
enalapril,B
with,O
a,O
median,O
follow,O
-,O
up,O
of,O
974,O
day...-,O
blocker,O
therapy,O
.,O
RESULTS,O
:,O
Patients,O
randomly,O
assigned,O
to,O
enalapril,B
had,O
a,O
33,O
%,O
greater,O
likelihood,O
of,O
decreased,O
rena...y,O
and,O
higher,O
ejection,O
fraction,O
were,O
renoprotective,O
.,O
Older,O
age,O
was,O
associated,O
with,O
a,O
greater,O
risk,O
of,O
developing,O
decreased,O
renal,B
function,I
in,O
both,O
groups,O
",",O
but,O
significantly,O
more,O
so,O
in,O
the,O
enalapril,B
group,I
(,O
enalapril,B
:,O
risk,O
ratio,I
[,O
RR,O
25,O
),O
.,O
Diuretic,B
therapy,O
was,O
likewise,O
associated,O
with,O
a,O
greater,O
risk,O
of,O
decreased,O
renal,O
function,O
in,O
the,O
enalapril,B
group,O
(,O
RR,O
1,O
.,O
89,O
",",O
95,O
%,O
CI,O
1,O
.,O
70,O
-,O
2,O
.,O
08,O
),O
than,O
in,O
the,O
placebo,O
group,O
(,O
RR,O
1,O
.,O
35,O
",",O
95,O
%,O
CI,O
1,O
.,O
09,O
-,O
1,O
.,O
66,O
),O
.,O
Conversely,O
",",O
enalapril,B
had,O
a,O
relative,O
renoprotective,O
effect,O
(,O
RR,O
1,O
.,O
33,O
",",O
95,O
%,O
CI,O
1,O
13,O
-,O
1,O
.,O
53,O
),O
compared,O
with,O
placebo,O
(,O
RR,O
1,O
.,O
96,O
",",O
95,O
%,O
CI,O
1,O
.,O
57,O
-,O
2,O
.,O
44,O
),O
in,O
patients,O
with,O
diabetes,O
.,O
A,O
lower,O
risk,O
of,O
renal,O
impairment,O
was,O
seen,O
in,O
both,O
groups,O
with,O
beta,O
-,O
blocker,O
therapy,O
(,O
RR,O
0,O
.,O
70,O
",",O
95,O
%,O
CI,O
0,O
.,O
57,O
-,O
0,O
.,O
85,O
),O
and,O
higher,O
baseline,O
ejection,O
fraction,O
(,O
RR,O
0,O
.,O
93,O
per,O
5,O
%,O
increment,O
",",O
95,O
%,O
CI,O
0,O
.,O
91,
-,
0,
.,
96,
),
.,
CONCLUSIONS,
:,
Enalapril,
use,
caused,
a,
33,
%,
increase,
in,
the,
risk,
of,
decreased,
renal,
function,
in,
patients,
with,
CHF,
.,
Diuretic,
use,
and,
advanced,
age,
increased,
this,
risk,
.,
Diabetes,
was,
associated,
with,
an,
increased,
risk,
of,
renal,
impairment,
in,
all,
patients,
with,
CHF,
",",
but,
this,
risk,
was,
reduced,
in,
the,
enalapril,
group,
compared,
with,
the,
placebo,
group,
.,
beta,B
-,I
Blocker,I
therapy,O
and,O
higher,O
ejection,O
fraction,O
were,O
renoprotective,O
in,O
all,O
patients,O
regardless,O
of,O
Acetazolamide,B
-,I
induced,I
Gerstmann,I
syndrome,I
.,O
Acute,O
confusion,O
induced,O
by,O
acetazolamide,B
is,O
a,O
well,O
known,O
adverse,O
drug,O
reaction,O
in,O
patients,O
with,O
renal,O
impairment,O
.,O
We,O
report,O
a,O
case,O
of,O
acetazolamide,B
-,I
induced,I
Gerstmann,I
syndrome,I
in,O
a,O
patient,O
with,O
normal,O
renal,O
function,O
",",O
to,O
highlight,O
predisposing,O
factors,O
that,O
are,O
frequently,O
overlooked,O
.,O
Vasopressin,B-Chemical
in,O
the,O
treatment,O
of,O
milrinone,B-Chemical
-,O
induced,O
hypotension,O
in,O
severe,O
heart,O
failure,O
.,O
The,O
use,O
of,O
phosphodiesterase,O
inhibitors,O
such,O
as,O
milrinone,B-Chemical
in,O
the,O
treatment,O
of,O
severe,O
heart,O
failure,O
is,O
frequently,O
restricted,O
because,O
they,O
cause,O
vasodilation,O
and,O
hypotension,O
.,O
In,O
patients,O
with,O
decompensated,O
heart,O
failure,O
with,O
hypotension,O
after,O
treatment,O
with,O
milrinone,B-Chemical
",",O
low,O
doses,O
of,O
vasopressin,B-Chemical
restored,O
blood,O
pressure,O
without,O
inhibiting,O
the,O
inotropic,O
effect,O
of,O
milrinone,B-Chemical
.,O
Treatment,O
of,O
tacrolimus,B
-,I
related,I
adverse,I
effects,I
by,O
conversion,O
to,O
cyclosporine,B
in,O
liver,O
transplant,O
recipients,O
.,O
When,O
tacrolimus,B
side,I
effects,I
persist,O
despite,O
dose,O
reduction,O
",",O
conversion,O
to,O
cyclosporine,B
-,I
based,I
immunosuppression,I
(,O
CyA,B
),O
is,O
necessary,O
.,O
We,O
characterized,O
tacrolimus,B
side,I
effects,I
that,O
warranted,O
discontinuation,O
of,O
the,O
drug,O
",",O
and,O
outcomes,O
after,O
conversion,O
.,O
Of,O
388,O
liver,O
recipients,O
who,O
received,O
tacrolimus,B
as,O
primary,O
immunosuppression,O
",",O
70,O
required,O
conversion,O
to,O
CyA,B
.,O
We,O
recorded,O
indication,O
for,O
conversion,O
",",O
whether,O
conversion,O
was,O
early,O
or,O
late,O
after,O
transplantation,O
",",O
tacrolimus,O
dose,O
and,O
trough,O
blood,O
level,O
at,O
conversion,O
",",O
and,O
incidence,O
of,O
rejection,O
after,O
conversion,O
.,O
Conversion,
was,
early,
in,
29,
patients,
(,
41,
.,
4,
%,
),
and,
late,
in,
41,
(,
58,
.,
6,
%,
),
.,
Indications,
for,
early,
conversion,
were,
neurotoxicity,
(,
20,
),
",",
(,
insulin,
-,
dependent,
),
diabetes,
mellitus,
(,
IDDM,
),
(,
5,
),
",",
nephrotoxicity,
(,
3,
),
",",
gastrointestinal,
(,
GI,
),
toxicity,
(,
6,
),
",",
and,
cardiomyopathy,
(,
1,
),
",",
and,
for,
late,
conversion,
were,
neurotoxicity,
(,
15,
),
",",
IDDM,
(,
12,
),
",",
nephrotoxicity,
(,
3,
),
",",
GI,
toxicity,
(,
5,
),
",",
hepatotoxicity,
(,
6,
),
",",
post,
-,
transplant,
lmphoproliferate,
disease,
(,
PTLD,
),
(,
2,
),
",",
cardiomyopathy,
(,
1,
),
",",
hemolytic,
anemia,
(,
1,
),
",",
and,
pruritus,
(,
1,
),
.,
All,
early,
-,
conversion,
patients,
showed,
improvement,
/,
resolution,
of,
symptoms,
.,
Among,
late,
-,
conversion,
patients,
",",
37,
(,
90,
.,
2,
%,
),
had,
improvement,
/,
resolution,
;,
in,
4,
(,
9,
.,
8,
%,
),
",",
adverse,
effects,
persisted,
.,
The,
overall,
rejection,
rate,
was,
30,
%,
.,
Sixty,
-,
two,
patients,
(,
88,
.,
6,
%,
),
are,
alive,
with,
functioning,
grafts,
686,
+,
/,
-,
362,
days,
(,
range,
",",
154,
-,
1433,
days,
),
after,
conversion,
.,
When,O
tacrolimus,B
side,I
effects,I
are,O
unresponsive,O
to,O
dose,O
reduction,O
",",O
conversion,O
to,O
CyA,B
can,O
be,O
accomplishe...wo,I
hundred,I
and,I
ten,I
cases,I
of,O
juvenile,B
rheumatoid,I
arthritis,I
closely,O
for,O
eleven,O
years,O
.,O
Thirty,
-,
six,
of,
the,
210,
patients,
(,
17,
.,
2,
%,
),
developed,
iridocyclitis,
.,
Iridocyclitis,
was,
seen,
most,
frequently,
in,
young,
female,
patients,
(,
0,
to,
4,
years,
),
with,
the,
monoarticular,
or,
pauciatricular,
form,
of,
the,
arthritis,
.,
However,
",",
30,
%,
of,
the,
patients,
developed,
uveitis,
after,
16,
years,
of,
age,
.,
Although,
61,
%,
of,
patients,
had,
a,
noncontributory,
ocular,
history,
on,
entry,
",",
42,
%,
had,
active,
uveitis,
on,
entry,
.,
Our,O
approach,O
was,O
effective,O
in,O
detecting,O
uveitis,B
in,O
new,O
cases,O
and,O
exacerbations,O
of,O
uveitis,B
in,O
establi...uality,O
",",O
or,O
photophobia,O
",",O
in,O
order,O
of,O
decreasing,O
frequency,O
.,O
Even,
after,
early,
detection,
and,
prompt,
treatment,
",",
41,
%,
of,
cases,
of,
uveitis,
did,
not,
respond,
to,
more,
than,
six,
months,
of,
intensive,
topical,
treatment,
with,
corticosteroids,
and,
mydriatics,
.,
Despite,
this,
",",
there,
was,
a,
dramatic,
decrease,
in,
the,
50,
%,
incidence,
of,
blinding,
complications,
of,
uveitis,
cited,
in,
earlier,
studies,
.,
Cataract,
and,
band,
keratopathy,
occurred,
in,
only,
22,
and,
13,
%,
of,
our,
group,
",",
respectively,
.,
We,
used,
chloroquine,
or,
hydroxychloroquine,
in,
173,
of,
210,
cases,
and,
found,
only,
one,
case,
of,
chorioretinopathy,
attributable,
to,
these,
drugs,
.,
Systemically,
administered,
corticosteroids,
were,
used,
in,
75,
of,
210,
cases,
;,
a,
significant,
number,
of,
posterior,
subcapsular,
cataracts,
was,
found,
.,
Typical,
keratoconjunctivitis,
sicca,
developed,
in,
three,
of,
the,
uveitis,
cases,
.,
This,
association,
with,
uveitis,
and,
JRA,
was,
not,
noted,
previously,
.,
Surgical,
treatment,
of,
cataracts,
",",
band,
keratopathy,
",",
and,
glaucoma,
achieved,
uniformly,
discouraging,
results,
.,
Cyclophosphamide,
-,
induced,
cystitis,
in,
freely,
-,
moving,
conscious,
rats,
:,
behavioral,
approach,
to,
a,
new,
model,
of,
visceral,
pain,
.,
PURPOSE,O
:,O
To,O
develop,O
a,O
model,O
of,O
visceral,B
pain,I
in,O
rats,O
using,O
a,O
behavioral,O
approach,O
.,O
Cyclophosphamide,B
(,O
CP,B
),O
",",O
an,O
antitumoral,O
agent,O
known,O
to,O
produce,O
toxic,O
effects,O
on,O
the,O
bladder,O
wall,O
through,O
its,O
main,O
toxic,O
metabolite,O
acrolein,O
",",O
was,O
used,O
to,O
induce,O
cystitis,O
.,O
MATERIALS,O
AND,O
METHODS,O
:,O
CP,B
was,O
administered,O
at,O
doses,O
of,O
50,O
",",O
100,O
and,O
200,O
mg,O
.,O
/,
kg,
.,
i,
.,
p,
.,
to,
male,
rats,
",",
and,
their,
behavior,
observed,
and,
scored,
.,
The,
effects,
of,
morphine,
(,
0,
.,
5,
to,
4,
mg,
.,
/,
kg,
.,
i,
.,
v,
.,
),
on,
CP,
-,
induced,
behavioral,
modifications,
were,
tested,
administered,
alone,
and,
after,
naloxone,
(,
1,
mg,
.,
/,
kg,
.,
s,
.,
c,
.,
),
.,
In,
addition,
",",
90,
minutes,
after,
CP,
injection,
",",
that,
is,
",",
at,
the,
time,
of,
administration,
of,
morphine,
",",
the,
bladder,
was,
removed,
in,
some,
rats,
for,
histological,
examination,
.,
Finally,
",",
to,
show,
that,
the,
bladder,
is,
essential,
for,
the,
CP,
-,
induced,
behavioral,
modifications,
",",
female,
rats,
also,
received,
CP,
at,
doses,
of,
200,
mg,
.,
/,
kg,
.,
i,
.,
p,
.,
and,
of,
20,
mg,
.,
by,
the,
intravesical,
route,
",",
and,
acrolein,
at,
doses,
of,
0,
.,
5,
mg,
.,
by,
the,
intravesical,
route,
and,
of,
5,
mg,
.,
/,
kg,
.,
i,
.,
v,
.,
RESULTS,
:,
CP,
dose,
-,
relatedly,
induced,
marked,
behavioral,
modifications,
in,
male,
rats,
:,
breathing,
rate,
decrease,
",",
closing,
of,
the,
eyes,
and,
occurrence,
of,
specific,
postures,
.,
Morphine,B
dose,I
-,I
dependently,I
reversed,I
these,I
behavioral,I
disorders,I
.,O
A,O
dose,B
of,I
0,I
.,I
5,I
mg,I
.,I
/,I
kg,I
.,I
produced,I
a,I
reduction,I
of,I
almost,I
50,I
%,I
of,I
the,I
behavioral,I
score,I
induced,I
by,I
CP,B
200,I
mg,I
.,I
/,I
kg,I
.,I
This,O
effect,O
was,O
completely,O
prevented,O
by,O
pretreatment,O
with,O
naloxone,O
.,O
At,O
the,O
time,O
of,O
administration,O
of,O
morphine,B
",",O
histological,O
modifications,O
of,O
the,O
bladder,O
wall,O
",",O
such,O
as,O
chorionic,O
and,O
muscle,O
layer,O
edema,O
",",O
were,O
observed,O
.,O
In,O
female,O
rats,O
",",O
CP,B
200,I
mg,I
.,I
/,I
kg,I
.,I
i,I
.,I
p,I
.,I
produced,O
the,O
same,O
marked,Ellipsis
0,I
.,I
5,I
mg,I
.,I
intravesically,O
induced,O
behavioral,O
modifications,O
identical,O
to,O
those,O
under,O
CP,B
200,I
mg,I
/,O
kg,O
.,O
i,O
.,O
p,O
.,O
",",O
with,O
the,O
same,O
maximal,O
levels,O
.,O
Conversely,O
",",O
acrolein,B
5,I
m...[,O
indicate,O
that,O
this,O
experimental,O
model,O
of,O
CP,O
-,O
induced,O
cystitis,O
may,O
be,O
an,O
interesting,O
new,O
...,O
therapeutic,O
approach,O
to,O
them,O
.,O
Prednisolone,
-,
induced,
muscle,
dysfunction,
is,
caused,
more,
by,
atrophy,
than,
by,
altered,
acetylcholine,
receptor,
expression,
.,
Large,
doses,
of,
glucocorticoids,
can,
alter,
muscle,
physiology,
and,
susceptibility,
to,
neuromuscular,
blocking,
drugs,
by,
mechanisms,
not,
clearly,
understood,
.,
We,
investigated,
the,
effects,
of,
moderate,
and,
large,
doses,
of,
prednisolone,
on,
muscle,
function,
and,
pharmacology,
",",
and,
their,
relationship,
to,
changes,
in,
muscle,
size,
and,
acetylcholine,
receptor,
(,
AChR,
),
expression,
.,
With,
institutional,
approval,
",",
35,
Sprague,
-,
Dawley,
rats,
were,
randomly,
allocated,
to,
receive,
daily,
subcutaneous,
doses,
of,
10,
mg,
/,
kg,
prednisolone,
(,
P10,
group,
),
",",
100,
mg,
/,
kg,
prednisolone,
(,
P100,
group,
),
",",
or,
an,
equal,
volume,
of,
saline,
(,
S,
group,
),
for,
7,
days,
.,
A,
fourth,
group,
of,
rats,
was,
pair,
fed,
(,
food,
restricted,
),
with,
the,
P100,
rats,
for,
7,
days,
(,
FR,
group,
),
.,
On,
Day,
8,
",",
the,
nerve,
-,
evoked,
peak,
twitch,
tensions,
",",
tetanic,
tensions,
",",
and,
fatigability,
",",
and,
the,
dose,
-,
response,
curves,
of,
d,
-,
tubocurarine,
in,
the,
tibialis,
cranialis,
muscle,
were,
measured,
in,
vivo,
and,
related,
to,
muscle,
mass,
or,
expression,
of,
AChRs,
.,
Rate,
of,
body,
weight,
gain,
was,
depressed,
in,
the,
P100,
",",
FR,
",",
and,
P10,
groups,
compared,
with,
the,
S,
group,
.,
Tibialis,B
muscle,I
mass,I
was,O
smaller,O
in,O
the,O
P100,B
group,I
than,O
in,O
the,O
P10,B
or,O
S,B
groups,I
.,O
...,O
fn1258,B
desired,I
therapeutic,I
effect,I
;...+,I
and,O
3,O
( 1 ),O
assuming,O
that,O
a,O
...,O
the,O
p,O
-23,O
-26,O
Pa/s,O
behaves,O
approximately,O
linearly,O
...,O
6,O
+,O
/,O
-,O
5,O
.,O
4,O
),O
than,O
in,O
the,O
S,O
(,O
61,O
.,O
9,O
+,O
/,O
-,O
5,O
.,O
0,O
),O
or,O
the,O
P100,B
(,O
71,O
.,O
3,O
+,O
/,O
-,O
9,O
.,O
6,O
),O
groups,O
.,O
AChR,B
expression,O
was,O
less,O
in,O
the,O
P10,B
group,O
than,O
in,O
the,O
S,O
group,O
.,O
The,O
evoked,O
tensions,O
correlated,O
with,O
muscle,O
mass,O
(,O
r,O
(,O
2,O
),O
=,O
0,O
.,O
32,O
",",O
P,O
<,O
0,O
.,O
001,O
),O
",",O
however,O
",",O
not,O
with,O
expression,O
of,O
AChR,B
.,O
The,O
50,O
%,O
effective,O
dose,O
of,O
d,I
-,I
tubocurarine,I
did,O
not,O
correlate,O
with,O
muscle,O
mass,O
or,O
AChR,B
expression,O
.,O
Our,O
results,O
suggest,O
that,O
the,O
neuromuscular,O
dysfunction,O
after,O
prednisolone,B
is,O
dose,O
-,O
dependent,O
",",O
and,O
de...ch,O
changes,O
in,O
AChR,O
expression,O
.,O
IMPLICATIONS,O
:,O
The,O
mechanisms,O
by,O
which,O
chronic,O
glucocorticoid,O
therapy,O
We,O
suggest,O
that,O
the,O
observed,O
effects,O
are,O
dose,O
-,O
dependent,O
and,O
derive,O
primarily,O
from,O
muscle,O
atrophy,O
and,O
derive,O
less,O
from,O
changes,O
in,O
acetylcholine,B
receptor,I
expression,I
.,O
Apomorphine,B
:,O
an,O
underutilized,O
therapy,O
for,O
Parkinson,O
',O
s,O
disease,O
.,O
Apomorphine,B
was,O
the,O
first,O
dopaminergic,O
drug,O
ever,O
used,O
to,O
treat,O
symptoms,O
of,O
Parkinson,O
',O
s,O
disease,O
.,O
While,
powerful,
antiparkinsonian,
effects,
had,
been,
observed,
as,
early,
as,
1951,
",",
the,
potential,
of,
treating,
fluctuating,
Parkinson,
',
s,
disease,
by,
subcutaneous,
administration,
of,
apomorphine,
has,
only,
recently,
become,
the,
subject,
of,
systematic,
study,
.,
A,
number,
of,
small,
scale,
clinical,
trials,
have,
unequivocally,
shown,
that,
intermittent,
subcutaneous,
apomorphine,
injections,
produce,
antiparkinsonian,
benefit,
close,
if,
not,
identical,
to,
that,
seen,
with,
levodopa,
and,
that,
apomorphine,
rescue,
injections,
can,
reliably,
revert,
off,
-,
periods,
even,
in,
patients,
with,
complex,
on,
-,
off,
motor,
swings,
.,
Continuous,O
subcutaneous,O
apomorphine,B
infusions,O
can,O
reduce,O
daily,O
off,O
-,O
time,O
by,O
more,O
than,O
50,O
%,O
in,O
this,O
group,O
of,O
patients,O
",",O
which,O
appears,O
to,O
be,O
a,O
stronger,O
effect,O
than,O
that,O
generally,O
seen,O
with,O
add,O
-,O
on,O
therapy,O
with,O
oral,O
dopamine,O
agonists,O
or,O
COMT,O
inhibitors,O
.,O
Extended,O
follow,O
-,O
up,O
studies,O
of,O
up,O
to,O
8,O
years,O
have,O
demonstrated,O
long,O
-,O
term,O
persistence,O
of,O
apomorphine,O
efficacy,O
.,O
In,O
addition,O
",",O
there,O
is,O
convincing,O
clinical,O
evidence,O
that,O
monotherapy,O
with,O
continuous,O
subcutaneous,B
apomorphine,I
infusions,I
is,O
associated,O
with,O
marked,O
reductions,O
of,O
preexisting,O
levodopa,O
-,O
induced,O
dyskinesias,O
.,O
The,O
main,O
side,O
effects,O
of,O
subcutaneous,B
apomorphine,I
treatment,I
are,O
related,O
to,O
cutaneous,O
tolerability,O
problems,O
",",O
whereas,O
sedation,O
and,O
psychiatric,O
complications,O
play,O
a,O
lesser,O
role,O
.,O
Given,O
the,O
marked,O
degree,O
of,O
efficacy,O
of,O
subcutaneous,B
apomorphine,I
treatment,O
in,O
fluctuating,O
Parkinson,O
',O
s,O
This,
study,
assessed,
the,
effect,
of,
normal,
aging,
on,
(,
1,
),
the,
tropicamide,
-,
induced,
increase,
in,
pupil,
diameter,
",",
and,
(,
2,
),
the,
reversal,
of,
this,
effect,
with,
pilocarpine,
.,
Scopolamine,
was,
used,
as,
a,
positive,
control,
to,
detect,
age,
-,
dependent,
changes,
in,
central,
cholinergic,
functioning,
in,
the,
elderly,
.,
DESIGN,
:,
Randomized,
double,
-,
blind,
controlled,
trial,
.,
PARTICIPANTS,O
:,O
Ten,O
healthy,O
elderly,O
(,O
mean,O
age,O
70,O
),O
and,O
9,O
young,O
(,O
mean,O
age,O
33,O
),O
volunteers,O
.,O
INTERVENTIONS,O
:,O
Pupil,B
diameter,I
was,O
monitored,O
using,O
a,O
computerized,O
infrared,O
pupillometer,O
over,O
4,O
hours,O
.,O
The,O
study,O
involved,O
4,O
sessions,O
.,O
In,O
1,O
session,O
",",O
tropicamide,B
(,O
20,O
microL,O
",",O
0,O
.,O
01,O
%,O
),O
was,O
administered,O
to,O
one,O
eye,O
and,O
placebo,O
to,O
the,O
other,O
.,O
In,O
another,O
session,O
",",O
tropicamide,B
(,O
20,B
microL,I
",",O
0,B
.,I
01,I
%,I
),O
was,O
administered,O
to,O
5,O
mg,O
",",O
intravenously,O
),O
or,O
placebo,O
was,O
administered,O
",",O
and,O
the,O
effects,O
on,O
word,O
recall,O
RESULTS,
:,
There,
was,
no,
significant,
difference,
between,
elderly,
and,
young,
volunteers,
in,
pupillary,
response,
to,
tropicamide,
at,
any,
time,
point,
(,
p,
>,
0,
.,
05,
),
.,
The,
elderly,
group,
had,
a,
significantly,
greater,
pilocarpine,
-,
induced,
net,
decrease,
in,
pupil,
size,
85,
",",
125,
",",
165,
and,
215,
minutes,
after,
administration,
",",
compared,
with,
the,
young,
group,
(,
p,
<,
0,
.,
05,O
),O
.,O
Compared,O
with,O
the,O
young,O
group,O
",",O
the,O
elderly,O
group,O
had,O
greater,O
scopolamine,B
-,I
induced,I
impairment,I
in,O
word,O
recall,O
60,O
",",O
90,O
and,O
120,O
minutes,O
after,O
administration,O
(,O
p,O
<,O
0,O
.,O
05,O
),O
.,O
CONCLUSION,O
:,O
There,O
is,O
an,O
age,O
-,O
related,O
pupillary,O
response,O
to,O
pilocarpine,B
that,O
is,O
not,O
found,O
with,O
tropicamide,O
.,O
Thus,O
",",O
pilocarpine,O
may,O
be,O
useful,O
to,O
assess,O
variations,O
in,O
central,O
cholinergic,O
function,O
in,O
elderly,O
patients,O
.,O
Pain,O
responses,O
in,O
methadone,B
-,I
maintained,I
opioid,B
abusers,I
.,O
Providing,O
pain,O
management,O
for,O
known,O
opioid,B
a...ntrol,I
subjects,I
(,O
n,O
=,O
60,O
),O
.,O
By,O
using,O
a,O
placebo,O
-,O
controlled,O
",",O
two,B
-,I
way,I
factorial,I
design,I
",",O
tolerance,O
to,O
cold,O
-,O
Analgesic,O
effects,O
were,O
significant,O
neither,O
for,O
medication,O
nor,O
group,O
.,O
These,O
data,O
indicate,O
that,O
MM,B
opi...ny,O
.,O
High,O
-,O
dose,O
methylprednisolone,B
may,O
do,O
more,O
harm,O
for,O
spinal,O
cord,O
injury,O
.,O
Because,O
of,O
the,O
National,B
Acute,I
Spinal,I
Cord,I
Injury,I
Studies,I
(,O
NASCIS,B
),O
",",O
high,O
-,O
dose,O
methylprednisolone,O
became,O
the,O
standard,O
of,O
care,O
for,O
the,O
acute,B
spinal,I
cord,I
injury,I
.,O
In,O
the,O
NASCIS,B
",",O
there,O
was,O
no,O
mention,O
regarding,O
the,O
possibility,O
of,O
acute,O
corticosteroid,O
myopathy,O
that,O
high,O
-,O
dose,O
methylprednisolone,O
may,O
cause,O
.,O
The,
dosage,
of,
methylprednisolone,
recommended,
by,
the,
NASCIS,
3,
is,
the,
highest,
dose,
of,
steroids,
ever,
being,
used,
during,
a,
2,
-,
day,
period,
for,
any,
clinical,
condition,
.,
We,
hypothesize,
that,
it,
may,
cause,
some,
damage,
to,
the,
muscle,
of,
spinal,
cord,
injury,
patients,
.,
Further,
",",
steroid,
myopathy,
recovers,
naturally,
and,
the,
neurological,
improvement,
shown,
in,
the,
NASCIS,
may,
be,
just,
a,
recording,
of,
this,
natural,
motor,
recovery,
from,
the,
steroid,
myopathy,
",",
instead,
of,
any,
protection,
that,
methylprednisolone,
offers,
to,
the,
spinal,
cord,
injury,
.,
To,O
our,O
knowledge,O
",",O
this,O
is,O
the,O
first,O
discussion,O
considering,O
the,O
possibility,O
that,O
the,O
methylprednisolone,B
recommended,O
by,O
NASCIS,O
may,O
cause,O
acute,O
corticosteroid,O
myopathy,O
.,O
Conversion,O
to,O
rapamycin,O
immunosuppression,O
in,O
renal,O
transplant,O
recipients,O
:,O
report,O
of,O
an,O
initial,O
experience,O
.,O
BACKGROUND,O
:,O
The,O
aim,O
of,O
this,O
study,O
is,O
to,O
evaluate,O
the,O
effects,O
of,O
RAPA,B
conversion,O
in,O
patients,O
undergoing,O
cyclosporine,O
(,O
CsA,O
),O
or,O
tacrolimus,O
(,O
Tac,O
),O
toxicity,O
.,O
METHODS,
:,
Twenty,
renal,
transplant,
recipients,
were,
switched,
to,
fixed,
dose,
rapamycin,
(,
RAPA,
),
(,
5,
mg,
/,
day,
),
0,
to,
204,
months,
posttransplant,
.,
Drug,
monitoring,
was,
not,
initially,
used,
to,
adjust,
doses,
.,
The,
indications,
for,
switch,
were,
chronic,
CsA,
or,
Tac,
nephrotoxicity,
(,
12,
),
",",
acute,
CsA,
or,
Tac,
toxicity,
(,
3,
),
",",
severe,
facial,
dysmorphism,
(,
2,
),
",",
posttransplant,
lymphoproliferative,
disorder,
(,
PTLD,
),
in,
remission,
(,
2,
),
",",
and,
hepatotoxicity,
in,
1,
.,
Follow,
-,
up,
is,
7,
to,
24,
months,
.,
RESULTS,
:,
In,
the,
12,
patients,
switched,
because,
of,
chronic,
nephrotoxicity,
there,
was,
a,
significant,
decrease,
in,
serum,
creatinine,
[,
233,
+,
/,
-,
34,
to,
210,
+,
/,
-,
56,
micromol,
/,
liter,
(,
P,
<,
0,
.,
05,
),
at,
6,
months,
],
.,
Facial,
dysmorphism,
improved,
in,
two,
patients,
.,
No,
relapse,
of,
PTLD,
was,
observed,
.,
Five,O
patients,O
developed,O
pneumonia,B
(,O
two,O
Pneumocystis,B
carinii,I
pneumonia,I
",",O
one,O
infectious,O
mononucleosis,B
with,I
p...ial,O
aphtous,B
ulcers,I
in,O
one,O
.,O
RAPA,B
levels,O
were,O
high,O
(,O
>,O
15,O
ng,O
/,O
ml,O
),O
in,O
7,O
of,O
13,O
(,O
54,O
%,O
),O
pati...ce,O
and,O
adequate,O
antiviral,O
and,O
Pneumocystis,B
carinii,I
pneumonia,I
prophylaxis,I
should,O
be,O
given,O
.,O
Electro,
-,
oculography,
",",
electroretinography,
",",
visual,
evoked,
potentials,
",",
and,
multifocal,
electroretinography,
in,
patients,
with,
vigabatrin,
-,
attributed,
visual,
field,
constriction,
.,
PURPOSE,
:,
Symptomatic,
visual,
field,
constriction,
thought,
to,
be,
associated,
with,
vigabatrin,
has,
been,
reported,
.,
The,
current,
study,
investigated,
the,
visual,
fields,
and,
visual,
electrophysiology,
of,
eight,
patients,
with,
known,
vigabatrin,
-,
attributed,
visual,
field,
loss,
",",
three,
of,
whom,
were,
reported,
previously,
.,
Six,
of,
the,
patients,
were,
no,
longer,
receiving,
vigabatrin,
.,
METHODS,
:,
The,
central,
and,
peripheral,
fields,
were,
examined,
with,
the,
Humphrey,
Visual,
Field,
Analyzer,
.,
Full,
visual,
electrophysiology,
",",
including,
flash,
electroretinography,
(,
ERG,
),
",",
pattern,
electroretinography,
",",
multifocal,
ERG,
using,
the,
VERIS,
system,
",",
electro,
-,
oculography,
",",
and,
flash,
and,
pattern,
visual,
evoked,
potentials,
",",
was,
undertaken,
.,
RESULTS,O
:,O
Seven,O
patients,O
showed,O
marked,O
visual,O
field,O
constriction,O
with,O
some,O
sparing,O
of,O
the,O
temporal,O
However,O
",",O
five,O
patients,O
showed,O
delayed,O
30,O
-,O
Hz,O
flicker,O
b,B
waves,I
",",O
and,O
seven,O
patients,O
The,O
field,O
defects,O
and,O
some,O
electrophysiological,O
abnormalities,O
persist,O
when,O
vigabatrin,B
therapy,O
is,O
withdrawn,O
.,O
Until,O
now,O
",",O
the,O
test,O
has,O
been,O
focused,O
only,O
on,O
the,O
organic,B
lesion,I
in,O
the,O
coronary,B
artery,I
",",O
and,O
positive,O
DSE,B
has,O
indicated,O
the,O
presence,O
of,O
significant,O
fixed,O
coronary,B
artery,I
stenosis,I
.,O
The,O
aim,O
of,O
the,O
present,O
study,O
is,O
to,O
examine,O
whether,O
myocardial,O
ischemia,O
due,O
to,O
coronary,B
spasm,I
is,O
induced,O
by,O
dobutamine,O
.,O
We,O
performed,O
DSE,B
on,O
51,O
patients,O
with,O
coronary,O
spastic,O
angina,O
but,O
without,O
significant,O
fixed,O
coronary,O
artery,O
stenosis,O
.,O
All,O
patients,O
had,O
anginal,O
attacks,O
at,O
rest,O
with,O
ST,O
elevation,O
on,O
the,O
electrocardiogram,O
(,O
variant,O
angina,O
),O
.,O
Coronary,O
spasm,O
was,O
induced,O
by,O
intracoronary,O
injection,O
of,O
acetylcholine,B
",",O
and,O
no,O
fixed,O
coronary,O
artery,O
stenosis,O
was,O
documented,O
on,O
angiograms,O
in,O
all,O
patients,O
.,O
DSE,O
was,O
performed,O
with,O
intravenous,O
dobutamine,B
infusion,O
with,O
an,O
incremental,O
doses,O
of,O
5,O
",",O
10,O
",",O
20...+,I
chest,I
pain,I
and,O
electrocardiographic,O
changes,O
were,O
preceded,O
by,O
asynergy,O
.,O
These,O
findings,O
indicate,O
that,O
dobutamine,B
can,O
provoke,O
coronary,O
spasm,O
in,O
some,O
patients,O
with,O
coronary,O
spastic,O
angina,O
.,O
When,O
DSE,O
is,O
performed,O
to,O
evaluate,O
coronary,B
artery,I
disease,I
",",O
not,O
only,O
fixed,O
coronary,B
stenosis,I
",",O
but,O
also,O
coronary,B
spasm,I
should,O
be,O
considered,O
as,O
a,O
genesis,O
of,O
asynergy,O
.,O
Effect,O
of,O
intravenous,O
metoprolol,B
or,O
intravenous,O
metoprolol,B
plus,O
glucagon,O
on,O
dobutamine,B
-,I
induced,O
myocardial,O
ischemia,O
.,O
STUDY,O
OBJECTIVE,O
:,O
To,O
determine,O
the,O
effect,O
of,O
metoprolol,B
on,O
dobutamine,O
stress,O
testing,O
with,O
technetium,B
-,Ellipsis
and,O
ST,B
-,I
segment,I
monitoring,I
",",O
and,O
to,O
assess,O
the,O
impact,O
of,O
intravenous,O
glucagon,O
on,O
metoprolol,O
SETTING,O
:,O
Community,O
hospital,O
.,O
PATIENTS,O
:,O
Twenty,O
-,O
two,O
patients,O
with,O
known,O
reversible,O
perfusion,O
Metoprolol,
was,
dosed,
to,
achieve,
a,
resting,
predobutamine,
heart,
rate,
below,
65,
beats,
/,
minute,
or,
a,
total,
intravenous,
dose,
of,
20,
mg,
.,
MEASUREMENTS,
AND,
MAIN,
RESULTS,
:,
Metoprolol,
reduced,
maximum,
heart,
rate,
31,
%,
",",
summed,
stress,
scores,
29,
%,
",",
and,
summed,
difference,
scores,
43,
%,
versus,
control,
.,
Metoprolol,
plus,
glucagon,
also,
reduced,
the,
maximum,
heart,
rate,
29,
%,
versus,
control,
.,
Summed,O
stress,O
and,O
summed,O
difference,O
scores,O
were,O
not,O
significantly,O
reduced,O
",",O
although,O
they,O
were,O
18,O
Glucagon,B
1,O
mg,O
",",O
although,O
somewhat,O
effective,O
",",O
does,O
not,O
correct,O
this,O
effect,O
to,O
the,O
extent,O
We,O
found,O
significant,O
positive,O
correlations,O
between,O
the,O
preoperative,O
levodopa,B
responsiveness,O
of,O
motor,O
signs,O
and,O
th...D,B
.,O
We,
also,
found,
a,
highly,
significant,
correlation,
(,
P,
:,
<,
0,
.,
0001,
",",
r,
=,
0,
.,
8,
),
between,
the,
volume,
of,
the,
ventral,
lesion,
in,
the,
GPi,
and,
the,
improvement,
in,
LID,
in,
the,
contralateral,
limbs,
",",
whereas,
there,
was,
no,
correlation,
between,
the,
ventral,
volume,
and,
the,
improvement,
in,
parkinsonian,
',
off,
',
signs,
.,
The,
volumes,
of,
the,
total,
lesion,
cylinder,
and,
the,
dorsal,
lesion,
did,
not,
correlate,
with,
the,
outcome,
of,
either,
dyskinesias,
or,
parkinsonian,
',
off,
',
signs,
.,
The,O
differential,O
predictive,O
value,O
of,O
levodopa,B
responsiveness,O
for,O
the,O
outcome,O
of,O
parkinsonian,O
',O
off,O
',O
signs,O
and,O
LID,B
and,O
the,O
different,O
correlations,O
of,O
ventral,O
lesion,O
volume,O
with,O
dyskinesias,O
and,O
parkinsonian,O
',O
off,O
',O
signs,O
indicate,O
that,O
different,O
anatomical,O
or,O
pathophysiological,O
substrates,O
may,O
be,O
responsible,O
for,O
the,O
generation,O
of,O
parkinsonian,O
',O
off,O
',O
signs,O
and,O
dyskinesias,O
Whereas,O
cells,O
in,O
a,O
wider,O
area,O
of,O
the,O
GPi,B
may,O
be,O
implicated,O
in,O
parkinsonism,O
",",O
the,O
ventral,O
GPi,B
seems,O
to,O
be,O
crucial,O
for,O
the,O
manifestation,O
of,O
LID,B
.,O
We,O
suggest,O
that,O
our,O
observations,O
are,O
additional,O
proof,O
of,O
the,O
functional,O
somatotopy,O
of,O
the,O
systems,O
within,O
the,O
GPi,B
that,O
mediate,O
parkinsonism,O
and,O
dyskinesias,O
",",O
especially,O
along,O
the,O
dorsoventral,O
trajectory,O
used,O
in,O
pallidotomy,O
.,O
The,O
outcome,O
of,O
pallidotomy,O
in,O
which,O
the,O
lesion,O
involves,O
the,O
ventral,B
and,O
dorsal,B
GPi,I
could,O
be,O
the,O
net,O
effect,O
of,O
alteration,O
in,O
the,O
activity,O
of,O
pathways,O
which,O
mediate,O
different,O
symptoms,O
",",O
and,O
hence,O
could,O
be,O
variable,O
.,O
Screening,O
for,O
stimulant,O
use,O
in,O
adult,O
emergency,O
department,O
seizure,O
patients,O
.,O
OBJECTIVE,O
:,O
The,O
objective,O
of,O
this,O
study,O
was,O
to,O
determine,O
the,O
prevalence,O
of,O
positive,O
plasma,O
drug,O
screening,O
for,O
cocaine,B
or,O
amphetamine,B
in,O
adult,O
emergency,O
department,O
seizure,O
patients,O
.,O
METHODS,
:,
This,
prospective,
study,
evaluated,
consecutive,
eligible,
seizure,
patients,
who,
had,
a,
plasma,
sample,
collected,
as,
part,
of,
their,
clinical,
evaluation,
.,
Plasma,
was,
tested,
for,
amphetamine,
and,
the,
cocaine,
metabolite,
benzoylecgonine,
using,
enzyme,
-,
mediated,
immunoassay,
methodology,
.,
Plasma,
samples,
with,
benzoylecgonine,
greater,
than,
150,
ng,
/,
mL,
or,
an,
amphetamine,
greater,
than,
500,
ng,
/,
mL,
were,
defined,
as,
positive,
.,
Patient,O
demographics,O
",",O
history,O
of,O
underlying,O
drug,B
or,O
alcohol,B
-,O
related,O
seizure,B
disorder,O
",",O
estimated,O
time,O
from,O
seizure,O
to,O
sample,O
collection,O
",",O
history,O
or,O
suspicion,O
of,O
cocaine,B
or,O
amphetamine,B
abuse,O
",",O
results,O
of,O
clinical,O
urine,O
testing,O
for,O
drugs,O
of,O
abuse,O
",",O
and,O
assay,O
results,O
were,O
recorded,O
without,O
patient,O
identifiers,O
.,O
RESULTS,O
:,O
Fourteen,O
of,O
248,O
(,O
5,B
.,B
6,I
%,I
",",O
95,B
%,I
CI,I
2,I
.,I
7,I
%,I
-,I
8,I
.,I
5,I
%,I
),O
plasma,O
samples,O
were,O
positive,O
by,O
immunoassay,O
testing,O
for,O
benzoylecgonine,B
and,O
no,O
samples,O
(,O
0,B
%,I
",",O
95,B
%,I
CI,I
0,I
-,I
1,I
.,I
2,I
%,I
),O
were,O
positive,O
for,O
amphetamine,B
.,O
Positive,O
test,O
results,O
were,O
more,O
common,O
in,O
patient,O
visits,O
where,O
there,O
was,O
a,O
history,O
or,O
suspicion,O
of,O
cocaine,B
or,O
amphetamine,B
abuse,O
(,O
p,O
<,O
0,O
.,O
0005,O
),O
.,O
CONCLUSIONS,O
:,O
During,O
this,O
study,O
period,O
",",O
routine,O
plasma,O
screening,O
for,O
cocaine,B
and,O
amph...dence,O
of,O
drug,O
abuse,O
in,O
this,O
population,O
.,O
Contribution,O
of,O
sodium,B
valproate,I
to,O
the,O
syndrome,O
of,O
inappropriate,O
secretion,O
of,O
antidiuretic,O
hormone,O
.,O
We,...
treatment,O
of,O
idiopathic,O
generalized,O
tonic,O
-,O
clonic,O
convulsions,O
since,O
he,O
was,O
56,O
years,O
old,O
.,O
After,O
substituting,O
VPA,B
with,O
zonisamide,B
",",O
the,O
serum,O
sodium,O
level,O
returned,O
to,O
normal,O
.,O
We,O
consider,O
this,O
episode,O
of,O
SIADH,O
to,O
be,O
the,O
result,O
of,O
a,O
combination,O
of,O
factors,O
including,O
a,O
weakness,O
of,O
the,O
central,O
nervous,O
system,O
and,O
the,O
long,O
-,O
term,O
administration,O
of,O
VPA,B
.,O
Association,O
of,O
nitric,O
oxide,O
production,O
and,O
apoptosis,O
in,O
a,O
model,O
of,O
experimental,O
nephropathy,O
.,O
BACKGROUND,O
:,O
In,O
recent,O
studies,O
increased,O
amounts,O
of,O
nitric,B
oxide,I
(,O
NO,B
),O
and,O
apoptosis,O
have,O
METHODS,O
:,O
The,O
alteration,O
in,O
the,O
NO,B
pathway,I
was,O
assessed,O
by,O
measuring,O
nitrite,B
levels,I
in,O
serum,O
On,O
day,O
21,O
",",O
rats,O
were,O
sacrificed,O
after,O
obtaining,O
material,O
for,O
biochemical,O
analysis,O
.,O
RESULTS,O
:,O
Histopathological,O
examination,O
of,O
the,O
kidneys,O
of,O
rats,O
treated,O
with,O
ADR,B
revealed,O
focal,O
areas,O
of,O
mesangial,O
proliferation,O
and,O
mild,O
tubulointerstitial,O
inflammation,O
.,O
They,O
also,O
had,O
significantly,O
higher,O
levels,O
of,O
proteinuria,O
compared,O
with,O
control,O
and,O
treatment,O
groups,O
(,O
P,O
<,O
0,O
.,O
05,
),
.,
Urine,
nitrite,
levels,
were,
significantly,
increased,
in,
the,
ADR,
-,
nephropathy,
group,
(,
P,
<,
0,
.,
05,
),
.,
In,
the,
IPRK,
phenylephrine,
and,
acetylcholine,
related,
responses,
were,
significantly,
impaired,
in,
the,
ADR,
-,
nephropathy,
group,
.,
Apoptosis,
was,
not,
detected,
in,
controls,
.,
However,
",",
in,
the,
ADR,
-,
nephropathy,
group,
",",
numerous,
apoptotic,
cells,
were,
identified,
in,
the,
tubulointerstitial,
areas,
.,
Double,O
staining,O
revealed,O
numerous,O
interstitial,O
apoptotic,O
cells,O
to,O
stain,O
for,O
ED1,B
",",O
a,O
marker,O
for,O
mono...ed,O
nephrosis,O
.,O
CONCLUSION,O
:,O
We,O
suggest,O
that,O
interactions,O
between,O
NO,O
and,O
apoptosis,O
are,O
important,O
.,O
Dual,O
effects,O
of,O
melatonin,B
on,O
barbiturate,B
-,I
induced,I
narcosis,I
in,O
rats,O
.,O
Melatonin,B
affects,O
the,O
circadian,O
sleep,O
/,O
wake,O
cycle,O
",",O
but,O
it,O
is,O
not,O
clear,O
whether,O
it,O
may,O
influence,O
drug,O
-,I
induced,I
narcosis,I
.,O
Sodium,B
thiopenthal,I
was,O
administered,O
intraperitoneally,O
into,O
male,O
rats,O
pre,O
-,O
treated,O
with,O
melatonin,B
(,O
0,O
.,O
05,O
",",O
0,O
.,O
5,
",",
5,
and,
50,
mg,
/,
kg,
),
.,
Melatonin,
pre,
-,
treatment,
affected,
in,
a,
dual,
manner,
barbiturate,
narcosis,
",",
however,
",",
no,
dose,
-,
effect,
correlation,
was,
found,
.,
In,
particular,
",",
low,
doses,
reduced,
the,
latency,
to,
and,
prolonged,
the,
duration,
of,
barbiturate,
narcosis,
.,
In,
contrast,
",",
the,
highest,
dose,
of,
melatonin,
(,
50,
mg,
/,
kg,
),
caused,
a,
paradoxical,
increase,
in,
the,
latency,
and,
produced,
a,
sustained,
reduction,
of,
the,
duration,
of,
narcosis,
",",
and,
a,
reduction,
in,
mortality,
rate,
.,
Melatonin,B
0,O
.,O
5,O
and,O
5,O
mg,O
/,O
kg,O
influenced,O
the,O
duration,O
but,O
not,O
the,O
latency,O
of,O
ketamine,O
-,O
or,O
diazepam,O
-,O
induced,O
narcosis,O
.,O
Thus,O
",",O
the,O
dual,O
action,O
of,O
melatonin,B
on,O
pharmacological,O
narcosis,O
seems,O
to,O
be,O
specific,O
for,O
the,O
barbiturate,O
mechanism,O
of,O
action,O
.,O
Reduced,O
cardiotoxicity,O
and,O
preserved,O
antitumor,O
efficacy,O
of,O
liposome,O
-,O
encapsulated,O
doxorubicin,B
and,O
cyclophosphamide,B
compared,O
with,O
conventional,O
doxorubicin,O
and,O
cyclophosphamide,O
in,O
a,O
randomized,O
",",O
multicenter,O
trial,O
of,O
metastatic,O
breast,O
cancer,O
.,O
PURPOSE,O
:,O
To,O
determine,O
whether,O
Myocet,B
(,O
liposome,B
-,I
encapsulated,I
doxorubicin,I
;,O
The,O
Liposome,B
Company,B
",",O
Elan,B
Corporation,B
",",O
Princeton,B
",",O
NJ,B
),O
in,O
combination,O
with,O
cyclophosphamide,B
significantly,O
reduces,O
doxorubicin,O
cardiotoxicity,O
while,O
providing,O
comparable,O
antitumor,O
efficacy,O
in,O
first,O
-,O
line,O
treatment,O
of,O
metastatic,O
breast,O
cancer,O
(,O
MBC,O
),O
.,O
PATIENTS,O
AND,O
METHODS,O
:,O
Two,O
hundred,O
ninety,O
-,O
seven,O
patients,O
with,O
MBC,O
and,O
no,O
prior,O
chemotherapy,O
for,O
metastatic,O
disease,O
were,O
randomized,O
to,O
receive,O
either,O
60,O
mg,O
/,O
m,O
(,O
2,O
),O
of,O
Myocet,B
(,O
M,I
),O
or,O
conventional,O
doxorubicin,B
(,O
A,I
),O
",",O
in,O
combination,O
with,O
600,O
mg,O
/,O
m,O
(,O
2,O
),O
of,O
cyclophosphamide,B
(,O
C,I
),O
",",O
every,O
3,O
weeks,O
until,O
disease,O
progression,O
or,O
unacceptable,O
toxicity,O
.,O
Cardiotoxicity,
was,
defined,
by,
reductions,
in,
left,
-,
ventricular,
ejection,
fraction,
",",
assessed,
by,
serial,
multigated,
radionuclide,
angiography,
scans,
",",
or,
congestive,
heart,
failure,
(,
CHF,
),
.,
Antitumor,
efficacy,
was,
assessed,
by,
objective,
tumor,
response,
rates,
(,
World,
Health,
Organization,
criteria,
),
",",
time,
to,
progression,
",",
and,
survival,
.,
RESULTS,
:,
Six,
percent,
of,
MC,
patients,
versus,
21,
%,
(,
including,
five,
cases,
of,
CHF,
),
of,
AC,
patients,
developed,
cardiotoxicity,
(,
P,
=,
.,
0002,
),
.,
Median,
cumulative,
doxorubicin,
dose,
at,
onset,
was,
more,
than,
2,
",",
220,
mg,
/,
m,
(,
2,
),
for,
MC,
versus,
480,
mg,
/,
m,
(,
2,
),
for,
AC,
(,
P,
=,
.,
0001,
",",
hazard,
ratio,
",",
5,
.,
04,
),
.,
MC,
patients,
also,
experienced,
less,
grade,
4,
neutropenia,
.,
Antitumor,O
efficacy,O
of,O
MC,B
versus,O
AC,B
was,O
comparable,O
:,O
objective,O
response,O
rates,O
",",O
43,O
%,O
versus,O
The,
role,
of,
nitrergic,
system,
in,
lidocaine,
-,
induced,
convulsion,
in,
the,
mouse,
.,
The,
effects,
of,
N,
-,
nitro,
-,
L,
-,
arginine,
-,
methyl,
ester,
(,
L,
-,
NAME,
),
a,
nitric,
oxide,
(,
NO,
),
synthase,
inhibitor,
and,
L,
-,
arginine,
",",
a,
NO,
precursor,
",",
were,
investigated,
on,
lidocaine,
-,
induced,
convulsions,
.,
In,
the,
first,
experiment,
",",
four,
groups,
of,
mice,
received,
physiological,
saline,
(,
0,
.,
9,
%,
),
",",
L,
-,
arginine,
(,
300,
mg,
/,
kg,
",",
i,
.,
p,
.,
),
",",
L,
-,
NAME,
(,
100,
mg,
/,
kg,
",",
i,
.,
p,
.,
),
and,
diazepam,
(,
2,
mg,
/,
kg,
),
",",
respectively,
.,
Thirty,
minutes,
after,
these,
injections,
",",
all,
mice,
received,
lidocaine,
(,
50,
mg,
/,
kg,
",",
i,
.,
p,
.,
),
.,
In,
the,
second,
experiment,
",",
four,
groups,
of,
mice,
received,
similar,
treatment,
in,
the,
first,
experiment,
",",
and,
30,
min,
after,
these,
injections,
",",
all,
mice,
received,
a,
higher,
dose,
of,
lidocaine,
(,
80,
mg,
/,
kg,
),
.,
L,
-,
NAME,
(,
100,
mg,
/,
kg,
",",
i,
.,
p,
.,
),
and,
diazepam,
(,
2,
mg,
/,
kg,
),
significantly,
decreased,
the,
incidence,
of,
lidocaine,
(,
50,
mg,
/,
kg,
),
-,
induced,
convulsions,
.,
In,
contrast,
",",
the,
L,
-,
arginine,
treatment,
increased,
the,
incidence,
of,
lidocaine,
(,
80,
mg,
/,
kg,
",",
i,
.,
p,
.,
),
-,
induced,
convulsions,
significantly,
.,
These,
results,
may,
suggest,
that,
NO,
is,
a,
proconvulsant,
mediator,
in,
lidocaine,
-,
induced,
convulsions,
.,
Erythropoietin,
restores,
the,
anemia,
-,
induced,
reduction,
in,
cyclophosphamide,
cytotoxicity,
in,
rat,
tumors,
.,
The,
aim,
of,
this,
study,
was,
to,
examine,
the,
impact,
of,
anemia,
prevention,
by,
recombinant,
human,
erythropoietin,
(,
rHuEPO,
),
treatment,
on,
the,
cytotoxicity,
of,
cyclophosphamide,
in,
solid,
experimental,
tumors,
.,
Anemia,
was,
induced,
using,
a,
single,
dose,
of,
carboplatin,
(,
50,
mg,
/,
kg,
i,
.,
v,O
.,O
),O
resulting,O
in,O
a,O
long,O
-,O
lasting,O
reduction,O
(,O
30,O
%,O
),O
of,O
the,O
hemoglobin,O
c,O
.,O
onto,O
the,O
hind,O
food,O
dorsum,O
.,O
Neither,O
carboplatin,B
nor,O
rHuEPO,B
treatment,O
influenced,O
tumor,O
growth,O
rate,O
per,O
se,O
.,O
When,O
tumors,O
were,O
treated,O
with,O
a,O
single,O
dose,O
of,O
cyclophosphamide,B
(,O
60,O
mg,O
/,O
kg,O
i,O
.,O
p,O
.,O
),O
5,O
days,O
after,O
implantation,O
",",O
a,O
growth,O
delay,O
with,O
a,O
subsequent,O
regrowth,O
of,O
the,O
tumors,O
was,O
observed,O
.,O
In,O
the,O
anemia,O
group,O
",",O
the,O
growth,O
delay,O
was,O
significantly,O
shorter,O
compared,O
with,O
nonanemic,O
controls,O
(,O
13,O
.,O
3,O
days,O
versus,O
8,O
.,O
6,O
days,O
),O
.,O
In,O
the,O
group,O
where,O
anemia,O
was,O
prevented,O
by,O
rHuEP...lpha,B
),O
increases,O
the,O
sensitivity,O
",",O
probably,O
as,O
a,O
result,O
of,O
an,O
improved,O
oxygen,O
supply,O
to,O
tumor,O
tissue,O
.,O
Fatal,O
haemorrhagic,O
myocarditis,O
secondary,O
to,O
cyclophosphamide,B
therapy,O
.,O
Haemorrhagic,O
myocarditis,O
is,O
a,O
rare,O
but,O
important,O
complication,O
of,O
cyclophosphamide,B
therapy,O
.,O
Echocardiographic,O
identification,O
of,O
the,O
disorder,O
can,O
be,O
made,O
.,O
We,O
believe,O
that,O
the,O
ultrasound,O
features,O
of,O
this,O
disorder,O
have,O
not,O
been,O
previously,O
reported,O
.,O
Effects,O
of,O
verapamil,B
on,O
atrial,O
fibrillation,O
and,O
its,O
electrophysiological,O
determinants,O
in,O
dogs,O
.,O
BACKGROUND,O
:,O
Atrial,O
tachycardia,O
-,O
induced,O
remodeling,O
promotes,O
the,O
occurrence,O
and,O
maintenance,O
of,O
atrial,O
fibrillation,O
(,O
AF,B
),O
and,O
decreases,O
L,B
-,I
type,I
Ca,B
(,I
2,I
+,I
),I
current,O
.,O
There,O
is,O
also,O
a,O
clinical,O
suggestion,O
that,O
acute,O
L,B
-,I
type,I
Ca,B
(,I
2,I
),I
channel,O
blockade,O
can,O
promote,O
AF,O
",",O
consistent,O
with,O
an,O
AF,O
promoting,O
effect,O
of,O
Ca,B
(,I
2,I
+,I
),I
channel,O
inhibition,O
.,O
METHODS,O
:,O
To,O
evaluate,O
the,O
potential,O
mechanisms,O
of,O
AF,O
promotion,O
by,O
Ca,B
(,O
2,O
+,O
),O
channel,O
blockers,O
",",O
we,O
administered,O
verapamil,O
to,O
morphine,O
-,O
chloralose,O
anesthetized,O
dogs,O
.,O
Diltiazem,O
was,O
used,O
as,O
a,O
comparison,O
drug,O
and,O
autonomic,O
blockade,O
with,O
atropine,O
and,O
nadolol,O
was,O
applied,O
in,O
some,O
experiments,O
.,O
Epicardial,O
mapping,O
with,O
240,O
epicardial,O
electrodes,O
was,O
used,O
to,O
evaluate,O
activation,O
during,O
AF,O
.,O
RESULTS,O
:,O
Verapamil,B
caused,O
AF,B
promotion,O
in,O
six,O
dogs,O
",",O
increasing,O
mean,O
duration,O
of,O
AF,B
induced,O
by,O
burst,O
pacing,O
",",O
from,O
8,O
+,O
/,O
-,O
4,O
s,O
(,O
mean,O
+,O
/,O
-,O
S,O
.,O
E,O
.,O
),O
to,O
95,O
+,O
/,O
-,O
39,O
s,O
(,O
P,O
<,O
0,O
.,O
01,O
vs,O
.,O
control,O
),O
at,O
a,O
loading,O
dose,O
of,O
0,O
.,O
1,O
mg,O
/,O
kg,O
and,O
228,O
+,O
/,O
-,O
101,O
s,O
(,O
P,O
<,O
0,O
.,O
0005,O
vs,O
.,O
control,O
),O
at,O
a,O
dose,O
of,O
0,O
.,O
2,O
mg,O
/,O
kg,O
.,O
Underlying,
electrophysiological,
mechanisms,
were,
studied,
in,
detail,
in,
five,
additional,
dogs,
under,
control,
conditions,
and,
in,
the,
presence,
of,
the,
higher,
dose,
of,
verapamil,
.,
In,
these,
experiments,
",",
verapamil,
shortened,
mean,
effective,
refractory,
period,
(,
ERP,
),
from,
122,
+,
/,
-,
5,
to,
114,
+,
/,
-,
4,
ms,
(,
P,
<,
0,
.,
02,
),
at,
a,
cycle,
length,
of,
300,
ms,
",",
decreased,
ERP,
heterogeneity,
(,
from,
15,
+,
/,
-,
1,
to,
10,
+,
/,
-,
1,
%,
",",
P,
<,
0,
.,
05,
),
",",
heterogeneously,
accelerated,
atrial,
conduction,
and,
decreased,
the,
cycle,
length,
of,
AF,
(,
94,
+,
/,
-,
4,
to,
84,
+,
/,
-,
3,
ms,
",",
P,
<,
0,
.,
005,
),
.,
Diltiazem,
did,
not,
affect,
ERP,
",",
AF,
cycle,
length,
or,
AF,
duration,
",",
but,
produced,
conduction,
acceleration,
similar,
to,
that,
caused,
by,
verapamil,
(,
n,
=,
5,
),
.,
In,
the,
presence,
of,
autonomic,
blockade,
",",
verapamil,
failed,
to,
promote,
AF,
and,
increased,
",",
rather,
than,
decreasing,
",",
refractoriness,
.,
Neither,O
verapamil,B-Chemical
nor,O
diltiazem,B-Chemical
affected,O
atrial,O
conduction,O
in,O
the,O
presence,O
of,O
autonomic,O
blockade,O
.,O
Epicardial,O
mapping,O
suggested,O
that,O
verapamil,B-Chemical
promoted,O
AF,O
by,O
increasing,O
the,O
number,O
of,O
simultaneous,O
wavefronts,O
reflected,O
by,O
separate,O
zones,O
of,O
reactivation,O
in,O
each,O
cycle,O
.,O
CONCLUSIONS,O
:,O
Verapamil,B-Chemical
promotes,O
AF,O
in,O
normal,O
dogs,O
by,O
promoting,O
multiple,O
circuit,O
reentry,O
",",O
an,O
effect,O
dependent,O
on,O
intact,O
autonomic,O
tone,O
and,O
not,O
shared,O
by,O
diltiazem,B-Chemical
.,O
Calcitonin,
gene,
-,
related,
peptide,
levels,
during,
nitric,
oxide,
-,
induced,
headache,
in,
patients,
with,
chronic,
tension,
-,
type,
headache,
.,
It,
has,
been,
proposed,
that,
nitric,
oxide,
(,
NO,
),
induced,
headache,
in,
primary,
headaches,
may,
be,
associated,
with,
release,
of,
calcitonin,
gene,
-,
related,
peptide,
(,
CGRP,
),
.,
In,
the,
present,
study,
we,
aimed,
to,
investigate,
plasma,
levels,
of,
CGRP,
during,
headache,
induced,
by,
the,
NO,
donor,
glyceryl,
trinitrate,
(,
GTN,
),
in,
16,
patients,
with,
chronic,
tension,
-,
type,
headache,
and,
16,
healthy,
controls,
.,
The,O
subjects,O
were,O
randomly,O
allocated,O
to,O
receive,O
0,O
.,O
5,O
microg,B
/,I
kg,I
/,I
min,I
GTN,B
or,O
plac...e,O
and,O
the,O
headache,O
was,O
significantly,O
more,O
pronounced,O
in,O
patients,O
than,O
in,O
controls,O
.,O
There,O
was,O
no,O
difference,O
between,O
the,O
area,O
under,O
the,O
CGRP,B
curve,O
(,O
AUCCGRP,O
),O
on,O
GTN,B
vs,O...O
<,O
0,O
.,O
.,O
.,O
.,O
.,O
.,O
.,O
.,O
.,O
.,O
.,O
.,O
.,O
.,O
.,O
.,O
.,O
.,O
.,O
05,O
),O
.,O
The,O
present,O
study,O
indicates,O
that,O
NO,B
-,I
induced,O
immediate,O
headache,O
is,O
not,O
associated,O
with,O
release,O
of,O
CGRP,B
.,O
Fluconazole,B
-,I
induced,O
torsade,O
de,O
pointes,O
.,O
OBJECTIVE,O
:,O
To,O
present,O
a,O
case,O
of,O
fluconazole,B
-,I
associated,O
torsade,O
de,O
pointes,O
(,O
TDP,B
),O
and,O
discuss,O
fluconazole,O
',O
s,O
role,O
in,O
causing,O
TDP,O
.,O
CASE,O
SUMMARY,O
:,O
A,O
68,O
-,O
year,O
-,O
old,O
white,O
woman,O
with,O
Candida,O
glabrata,O
isolated,O
from,O
a,O
presacral,O
abscess,O
developed,O
TDP,O
eight,O
days,O
after,O
commencing,O
oral,O
fluconazole,B
The,O
patient,O
had,O
no,O
other,O
risk,O
factors,O
for,O
TDP,O
",",O
including,O
coronary,O
artery,O
disease,O
",",O
cardiomyopathy,O
",",O
congestive,O
heart,O
failure,O
",",O
and,O
electrolyte,O
abnormalities,O
There,O
was,O
a,O
temporal,O
association,O
between,O
the,O
initiation,O
of,O
fluconazole,B
and,O
TDP,O
.,O
The,O
TDP,O
resolved,O
when,O
fluconazole,B
was,O
discontinued,O
;,O
however,O
",",O
the,O
patient,O
continued,O
to,O
have,O
premature,Ellipsis
fluconazole,O
and,O
the,O
development,O
of,O
TDP,O
.,O
The,O
possible,O
mechanism,O
is,O
depression,O
of,O
rapidly,O
activating,O
delayed,O
rectifier,O
potassium,B
currents,O
.,O
In,O
our,O
patient,O
",",O
there,O
was,O
no,O
other,O
etiology,O
identified,O
that,O
could,O
explain,O
QT,O
prolongation,O
or,O
TDP,O
The,O
complete,O
disappearance,O
of,O
NSVT,O
and,O
premature,O
ventricular,O
contractions,O
followed,O
by,O
normalization,O
of,O
QT,O
interval,O
after,O
the,O
drug,O
was,O
stopped,O
strongly,O
suggests,O
fluconazole,B
as,O
the,O
etiology,O
.,O
CONCLUSIONS,O
:,O
Clinicians,O
should,O
be,O
aware,O
that,O
fluconazole,B
",",O
even,O
at,O
low,O
doses,O
",",O
may,O
cause,O
prolongation,O
of,O
the,O
QT,O
interval,O
",",O
leading,O
to,O
TDP,O
.,O
Serial,O
electrocardiographic,O
monitoring,O
may,O
be,O
considered,O
when,O
fluconazole,B
is,O
administered,O
in,O
patients,O
who,O
are,O
at,O
risk,O
for,O
ventricular,O
arrhythmias,O
.,O
Cutaneous,O
leucocytoclastic,O
vasculitis,O
associated,O
with,O
oxacillin,B
.,O
A,O
67,O
-,O
year,O
-,O
old,O
man,O
who,O
was,O
treated,O
with,O
oxacillin,B
for,O
one,O
week,O
because,O
of,O
...ski,O
##es,O
showed,O
findings,O
diagnostic,O
of,O
leuco,I
##cy,I
##t,I
##oc,I
##lastic,I
vas,I
##cu,I
##l,I
##itis,I
.,O
Oxacillin,B
was,O
discontinued,O
and,O
patient,O
was,O
treated,O
with,O
corticosteroids,B
.,O
The,O
rash,O
disappeared,O
after,O
three,O
weeks,O
and,O
renal,O
function,O
returned,O
to,O
normal,O
.,O
Leucocytoclastic,O
vasculitis,O
presents,O
as,O
palpable,O
purpura,O
of,O
the,O
lower,O
extremities,O
often,O
accompanied,O
by,O
abdominal,O
pain,O
",",O
arthralgia,O
",",O
and,O
renal,O
involvement,O
.,O
Etiologic,O
factors,O
or,O
associated,O
disorders,O
include,O
infections,B
",",O
medications,B
",",O
collagen,B
vascular,I
disease,I
and,I
neoplasia,I
.,O
However,O
",",O
in,O
half,O
of,O
the,O
cases,O
no,O
etiologic,O
factor,O
is,O
identified,O
.,O
Usually,O
it,O
is,O
a,O
self,O
-,O
limited,O
disorder,O
",",O
but,O
corticosteroid,O
therapy,O
may,O
be,O
needed,O
in,O
life,O
-,O
threatening,O
cases,O
since,O
early,O
treatment,O
with,O
corticosteroids,O
in,O
severe,O
cases,O
can,O
prevent,O
complications,O
.,O
Oxacillin,B
should,O
be,O
included,O
among,O
the,O
drugs,O
that,O
can,O
cause,O
leucocytoclastic,O
vasculitis,O
.,O
The,O
renal,O
pathology,O
in,O
a,O
case,O
of,O
lithium,B
-,I
induced,I
diabetes,I
insipidus,I
.,O
A,O
case,O
of,O
lithium,B
-,I
induced,I
diabetes,I
insipidus,I
is,O
reported,O
.,O
At,O
necropsy,O
microscopy,O
shoed,O
unique,O
and,O
extensive,O
damage,O
to,O
cells,O
lining,O
the,O
distal,O
nephron,O
.,O
It,O
is,O
suggested,O
that,O
these,O
changes,O
represent,O
a,O
specific,O
toxic,O
effect,O
of,O
lithium,B
",",O
reported,O
here,O
for,O
the,O
first,O
time,O
in,O
man,O
.,O
Cholestatic,O
jaundice,O
associated,O
with,O
the,O
use,O
of,O
metformin,B
.,O
We,O
report,O
a,O
patient,O
who,O
developed,O
cholestatic,O
jaundice,O
shortly,O
after,O
initiation,O
of,O
treatment,O
with,O
metformin,B
hydrochloride,I
.,O
Ultrasound,O
of,O
the,O
liver,B-Chemical
and,O
abdominal,O
CT,B-Chemical
were,O
normal,O
.,O
An,O
ERCP,O
showed,O
normal,O
biliary,O
anatomy,O
.,O
A,O
percutaneous,O
liver,B-Chemical
biopsy,O
was,O
obtained,O
showing,O
marked,O
cholestasis,B-Chemical
",",O
with,O
portal,O
edema,O
",",O
ductular,O
proliferation,O
",",O
and,O
acute,O
inflammation,O
.,O
Metformin,B-Chemical
hydrochloride,I-Chemical
was,O
discontinued,O
",",O
and,O
the,O
patient,O
',O
s,O
jaundice,O
resolved,O
slowly,O
over,O
a,O
period,O
of,O
several,O
months,O
.,O
Given,O
the,O
onset,O
of,O
his,O
jaundice,O
2,O
wk,O
after,O
the,O
initiation,O
of,O
metformin,B
",",O
we,O
believe,O
that,O
this,O
case,O
represents,O
an,O
example,O
of,O
metformin,O
-,O
associated,O
hepatotoxicity,O
",",O
the,O
first,O
such,O
case,O
reported,O
.,O
Systemic,O
toxicity,O
and,O
resuscitation,O
in,O
bupivacaine,B
-,O
",",O
levobupivacaine,B
-,O
",",O
or,O
ropivacaine,B
-,O
infused,O
rats,O
.,O
We,O
compared,O
the,O
systemic,O
toxicity,O
of,O
bupivacaine,B
",",O
levobupivacaine,B
",",O
and,O
ropivacaine,B
in,O
anesthetized,O
rats,O
.,O
We,O
also,O
compared,O
the,O
ability,O
to,O
resuscitate,O
rats,O
after,O
lethal,O
doses,O
of,O
these,O
local,O
anesthetics,O
.,O
Bupivacaine,B
",",O
levobupivacaine,B
",",O
or,O
ropivacaine,B
was,O
infused,O
at,O
a,O
rate,O
of,O
2,O
mg,O
.,O
kg,O
(,O
-1,O
),O
.,O
min,O
(,O
-1,O
),O
while,O
electrocardiogram,O
",",O
electroencephalogram,O
",",O
and,O
arterial,O
pressure,O
were,O
continuously,O
monitored,O
.,O
When,
asystole,
was,
recorded,
",",
drug,
infusion,
was,
stopped,
and,
a,
resuscitation,
sequence,
was,
begun,
.,
Epinephrine,
0,
.,
01,
mg,
/,
kg,
was,
administered,
at,
1,
-,
min,
intervals,
while,
external,
cardiac,
compressions,
were,
applied,
.,
Resuscitation,
was,
considered,
successful,
when,
a,
systolic,
arterial,
pressure,
>,
or,
=,
100,
mm,
Hg,
was,
achieved,
within,
5,
min,
.,
The,O
cumulative,O
doses,O
of,O
levobupivacaine,B
and,O
ropivacaine,B
that,O
produced,O
seizures,O
were,O
similar,O
and,O
were,O
The,
number,
of,
successful,
resuscitations,
did,
not,
differ,
among,
groups,
.,
However,
",",
a,
smaller,
dose,
of,
epinephrine,
was,
required,
in,
the,
Ropivacaine,
group,
than,
in,
the,
other,
groups,
.,
We,
conclude,
that,
the,
systemic,
toxicity,
of,
levobupivacaine,
is,
intermediate,
between,
that,
of,
ropivacaine,
and,
bupivacaine,
when,
administered,
at,
the,
same,
rate,
and,
that,
ropivacaine,
-,
induced,
cardiac,
arrest,
appears,
to,
be,
more,
susceptible,
to,
treatment,
than,
that,
induced,
by,
bupivacaine,
or,
levobupivacaine,
.,
Amphotericin,B
-,O
induced,O
seizures,O
in,O
a,O
patient,O
with,O
AIDS,O
.,O
OBJECTIVE,O
:,O
To,O
report,O
a,O
case,O
of,Ellipsis
and,O
the,O
drug,O
concentrations,O
decreased,O
with,O
time,O
.,O
The,O
patients,O
concurrent,O
medications,O
included,O
didanosine,B
",",O
hydroxyzine,B
",",O
promethazine,B
",",O
hydrocortisone,B
",",O
and,O
The,O
patient,O
had,O
a,O
history,O
of,O
alcohol,B
abuse,O
;,O
alcohol,B
intake,O
as,O
well,O
as,O
withdrawal,O
can,O
also,O
cause,O
seizures,O
.,O
Didanosine,B
also,O
has,O
a,O
potential,O
for,O
inducing,O
seizures,O
.,O
However,O
",",O
these,O
other,O
potential,O
causes,O
of,O
seizure,O
were,O
ruled,O
out,O
.,O
The,O
time,O
course,O
of,O
events,O
suggested,O
that,O
amphotericin,B
B,I
was,O
the,O
cause,O
of,O
the,O
seizures,O
in,O
this,O
AIDS,O
patient,O
.,O
CONCLUSIONS,O
:,O
Amphotericin,B
B,I
seems,O
to,O
be,O
the,O
probable,O
cause,O
of,O
the,O
seizures,O
.,O
To,O
date,O
",",O
only,O
three,O
cases,O
of,O
seizures,O
associated,O
with,O
amphotericin,B
have,O
been,O
reported,O
in,O
the,O
literature,O
",",O
but,O
healthcare,O
providers,O
should,O
be,O
aware,O
of,O
the,O
potential,O
for,O
this,O
rare,O
adverse,O
effect,O
.,O
Sirolimus,B
and,O
mycophenolate,O
mofetil,O
for,O
calcineurin,O
-,O
free,O
immunosuppression,O
in,O
renal,O
transplant,O
recipients,O
.,O
Calcineurin,B
inhibitors,O
",",O
such,O
as,O
cyclosporine,B
and,O
tacrolimus,B
",",O
have,O
been,O
available,O
for,O
almost,O
20,O
years,O
.,O
Although,O
these,O
drugs,O
are,O
highly,O
effective,O
and,O
represent,O
the,O
mainstay,O
of,O
transplant,O
immunosuppression,O
",",O
they,O
are,O
associated,O
with,O
acute,O
and,O
chronic,O
nephrotoxicity,O
.,O
Acute,O
nephrotoxicity,O
",",O
which,O
occurs,O
in,O
the,O
early,O
period,O
after,O
transplantation,O
",",O
leads,O
to,O
a,O
higher,O
rate,O
of,O
dialysis,O
",",O
and,O
chronic,O
nephrotoxicity,O
may,O
eventually,O
result,O
in,O
graft,O
loss,O
.,O
Acute,O
and,O
chronic,O
nephrotoxicity,O
is,O
becoming,O
more,O
common,O
as,O
the,O
use,O
of,O
marginal,O
kidneys,O
for,O
transplantation,O
increases,O
.,O
Two,O
recently,O
available,O
immunosuppressive,O
agents,O
",",O
mycophenolate,B
mofetil,I
and,O
sirolimus,B
(,O
rapamycin,I
),O
",",O
have,O
no,O
nephrotoxicity,O
.,O
The,O
use,O
of,O
these,O
drugs,O
in,O
combination,O
with,O
other,O
agents,O
has,O
led,O
to,O
the,O
development,O
of,O
new,O
paradigms,O
of,O
immunosuppressive,O
therapy,O
.,O
This,O
paper,O
reviews,O
the,O
results,O
of,O
clinical,O
trials,O
that,O
have,O
investigated,O
these,O
new,O
approaches,O
to,O
immunosuppression,O
in,O
renal,O
transplant,O
recipients,O
.,O
Tolerability,O
of,O
nimesulide,B
and,O
paracetamol,B
in,O
patients,O
with,O
NSAID,B
-,O
induced,O
urticaria,O
/,O
angioedema,O
.,O
Previous,O
studies,O
evaluated,O
the,O
tolerance,O
of,O
nimesulide,B
and,O
paracetamol,B
in,O
subjects,O
with,O
cutaneous,O
",",O
respiratory,O
and,O
anaphylactoid,O
reactions,O
induced,O
by,O
nonsteroidal,O
anti,O
-,O
inflammatory,O
drugs,O
(,O
NSAIDs,O
),O
.,O
In,O
this,O
study,O
we,O
investigated,O
tolerability,O
and,O
reliability,O
of,O
nimesulide,B
and,O
paracetamol,B
in,O
a,O
very,O
larg...edication,O
paracetamol,B
and,O
nimesulide,B
.,O
The,O
word,O
paracetamol,O
should,O
not,O
be,O
part,O
of,O
the,O
token,O
.,O
A,O
single,O
-,O
placebo,O
-,O
controlled,O
oral,O
challenge,O
procedure,O
with,O
nimesulide,B
or,O
paracetamol,B
was,O
applied,O
to,O
829,O
patients,O
with,O
a,O
history,O
of,O
NSAID,O
-,O
induced,O
urticaria,O
/,O
angioedema,O
.,O
A,O
total,O
of,O
75,O
/,O
829,O
(,O
9,O
.,O
4,O
%,O
),O
patients,O
experienced,O
reactions,O
to,O
nimesulide,B
or,O
paracetamol,B
.,O
Of,O
the,O
715,O
patients,O
tested,O
with,O
nimesulide,B
62,O
(,O
8,O
.,O
6,
%,
),
showed,
a,
positive,
test,
",",
while,
of,
114,
subjects,
submitted,
to,
the,
challenge,
with,
paracetamol,
",",
13,
(,
9,
.,
6,
%,
),
did,
not,
tolerate,
this,
drug,
.,
Furthermore,
",",
18,
.,
28,
%,
of,
patients,
with,
a,
history,
of,
chronic,
urticaria,
and,
11,
.,
8,
%,
of,
subjects,
with,
an,
history,
of,
NSAID,
-,
induced,
urticaria,
/,
angioedema,
or,
angioedema,
alone,
(,
with,
or,
without,
chronic,
urticaria,
),
resulted,
to,
be,
intolerant,
to,
alternative,
drugs,
.,
Taken,
together,
",",
our,
results,
confirm,
the,
good,
tolerability,
of,
nimesulide,
and,
paracetamol,
in,
patients,
who,
experienced,
urticaria,
/,
angioedema,
caused,
by,
NSAIDs,
.,
However,
",",
the,
risk,
of,
reaction,
to,
these,
alternative,
study,
drugs,
is,
statistically,
increased,
by,
a,
history,
of,
chronic,
urticaria,
and,
",",
above,
all,
",",
by,
a,
history,
of,
NSAID,
-,
induced,
angioedema,
.,
Comparison,O
of,O
aqueous,B
and,O
gellan,B
ophthalmic,I
timolol,I
with,O
placebo,O
on,O
the,O
24,O
-,O
hour,O
heart,O
rate,O
response,O
in,O
patients,O
on,O
treatment,O
for,O
glaucoma,O
.,O
PURPOSE,O
:,O
Topical,O
beta,O
-,O
blocker,O
treatment,O
is,O
routine,O
therapy,O
in,O
the,O
management,O
of,O
patients,O
with,O
glaucoma,O
.,O
Therapy,O
results,O
in,O
systemic,O
absorption,O
",",O
however,O
",",O
the,O
degree,O
of,O
reduction,O
of,O
resting,O
and,O
peak,O
heart,O
rate,O
has,O
not,O
been,O
quantified,O
.,O
DESIGN,O
:,O
This,O
trial,O
evaluated,O
the,O
effect,O
of,O
placebo,O
",",O
0,O
.,O
5,O
%,O
aqueous,O
timolol,B
(,O
METHODS,O
:,O
Forty,O
-,O
three,O
Caucasian,O
patients,O
with,O
primary,O
open,O
-,O
angle,O
glaucoma,O
or,O
ocular,O
hypertension,O
with,O
a,O
mean,O
(,O
+,O
/,O
On,O
the,O
13th,O
day,O
of,O
each,O
period,O
",",O
heart,O
rate,O
was,O
recorded,O
continuously,O
during,O
a,O
typical,O
5,O
%,O
change,O
in,O
mean,O
heart,O
rate,O
",",O
-,O
5,O
.,O
7,O
beats,O
/,O
min,O
),O
.,O
Timolol,B
gellan,I
showed,O
a,O
numerically,O
but,O
not,O
significantly,O
smaller,O
reduction,O
in,O
24,O
-,O
hour,O
heart,O
rate,O
",",O
compared,O
with,O
timolol,B
solution,O
.,O
During,O
the,O
night,O
",",O
the,O
mean,O
12,O
-,O
hour,O
heart,O
rate,O
on,O
placebo,O
and,O
timolol,B
gellan,I
were,O
both,O
significantly,O
less,O
than,O
on,O
timolol,B
solution,O
;,O
the,O
difference,O
between,O
solution,O
and,O
gellan,I
treatments,O
was,O
statistically,O
significant,O
(,O
P,O
=,O
.,O
01,O
),O
.,O
CONCLUSIONS,O
:,O
Both,O
timolol,B
solution,O
and,O
timolol,B
gellan,O
decrease,O
the,O
mean,O
24,O
-,O
hou...out,O
ophthalmic,B
beta,I
-,I
blocker,I
therapy,I
in,O
a,O
typical,O
patient,O
population,O
on,O
therapy,O
for,O
glaucoma,O
.,O
Although,O
exercise,O
performance,O
was,O
not,O
assessed,O
in,O
this,O
trial,O
",",O
reductions,O
of,O
this,O
magnitude,O
should,O
not,O
have,O
substantial,O
clinical,O
consequences,O
.,O
Management,O
strategies,O
for,O
ribavirin,B
-,I
induced,I
hemolytic,I
anemia,I
in,I
the,I
treatment,I
of,I
hepatitis,I
C,I
:,O
clinical,O
and,O
economic,O
implications,O
.,O
OBJECTIVES,O
:,O
Recently,O
published,O
studies,O
have,O
demonstrated,O
increased,O
efficacy,O
and,O
cost,O
-,O
effectiveness,O
of,O
combination,O
therapy,O
with,O
interferon,O
and,O
alpha,O
-,O
2b,O
/,O
ribavirin,O
compared,O
with,O
interferon,O
-,O
alpha,O
monotherapy,O
in,O
the,O
treatment,O
of,O
chronic,O
hepatitis,O
C,O
(,O
CHC,O
),O
.,O
Combination,O
therapy,O
is,O
associated,O
with,O
a,O
clinically,O
important,O
adverse,O
effect,O
:,O
ribavirin,B
-,I
induced,I
hemolytic,I
anemia,I
(,O
RIHA,B
),O
.,O
The,O
objective,O
of,O
this,O
study,O
was,O
to,O
evaluate,O
the,O
direct,O
health,O
-,O
care,O
costs,O
and,O
management,O
of,O
RIHA,B
during,O
treatment,O
of,O
CHC,O
in,O
a,O
clinical,O
trial,O
setting,O
.,O
METHODS,O
:,O
A,O
systematic,O
literature,O
review,O
was,O
conducted,O
to,O
synthesize,O
information,O
on,O
the,O
incidence,O
and,O
management,O
of,O
RIHA,B
.,O
Decision,O
-,O
analytic,O
techniques,O
were,O
used,O
to,O
estimate,O
the,O
cost,O
of,O
treating,O
RIHA,B
.,O
Uncertainty,O
was,O
evaluated,O
using,O
sensitivity,O
analyses,O
.,O
RESULTS,O
:,O
RIHA,B
",",O
defined,O
as,O
a,O
reduction,O
in,O
hemoglobin,O
to,O
less,O
than,O
100,O
g,O
/,O
L,O
",",O
occurs,O
in,O
approximately,O
7,O
%,O
to,O
9,O
%,O
of,O
patients,O
treated,O
with,O
combination,O
therapy,O
.,O
The,O
standard,O
of,O
care,O
for,O
management,O
of,O
RIHA,B
is,O
reduction,O
or,O
discontinuation,O
of,O
the,O
ribavirin,O
dosage,O
.,O
We,O
estimated,O
the,O
direct,O
cost,O
of,O
treating,O
clinically,O
significant,O
RIHA,B
to,O
be,O
170,O
per,O
patient,O
receiving,O
combination,O
therapy,O
per,O
48,O
-,O
week,O
treatment,O
course,O
(,O
range,O
68,O
-,O
692,O
),O
.,O
The,O
results,O
of,O
the,O
one,O
-,O
way,O
sensitivity,O
analyses,O
ranged,O
from,O
57,O
to,O
317,O
.,O
In,O
comparison,O
",",O
the,O
cost,O
of,O
48,O
weeks,O
of,O
combination,O
therapy,O
is,O
16,O
",",O
459,O
.,O
CONCLUSIONS,O
:,O
The,O
direct,O
cost,O
of,O
treating,O
clinically,O
significant,O
RIHA,B
is,O
1,O
%,O
(,O
170,O
/,O
16,O
",",O
459,O
),O
of,O
drug,O
treatment,O
costs,O
.,O
Questions,O
remain,O
about,O
the,O
optimal,O
dose,O
of,O
ribavirin,B
and,O
the,O
incidence,O
of,O
RIHA,B
in,O
a,O
real,O
-,O
world,O
population,O
.,O
Despite,O
these,O
uncertainties,O
",",O
this,O
initial,O
evaluation,O
of,O
the,O
direct,O
cost,O
of,O
treating,O
RIHA,B
provides,O
an,O
estimate,O
of,O
the,O
cost,O
and,O
management,O
implications,O
of,O
this,O
clinically,O
important,O
adverse,O
effect,O
.,O
Preliminary,O
efficacy,O
assessment,O
of,O
intrathecal,O
injection,O
of,O
an,O
American,B
formulation,O
of,O
adenosine,B
in,O
humans,O
.,O
BACKGROUND,O
:,O
Preclinical,O
studies,O
of,O
intrathecal,O
adenosine,B
suggest,O
it,O
may,O
be,O
effective,O
in,O
the,O
treatment,O
of,O
acute,O
and,O
chronic,O
pain,O
in,O
humans,O
",",O
and,O
preliminary,O
studies,O
in,O
volunteers,O
and,O
patients,O
with,O
a,O
Swedish,B
formulation,O
of,O
adenosine,B
suggest,O
it,O
may,O
be,O
effective,O
in,O
hypersensitivity,O
states,O
but,O
not,O
with,O
acute,O
noxious,O
stimulation,O
.,O
The,O
purpose,O
of,O
this,O
study,O
was,O
to,O
screen,O
for,O
efficacy,O
of,O
a,O
different,O
formulation,O
of,O
adenosine,B
marketed,O
in,O
the,O
US,O
",",O
using,O
both,O
acute,O
noxious,O
stimulation,O
and,O
capsaicin,B
-,O
evoked,O
mechanical,O
hypersensitivity,O
.,O
METHODS,O
:,O
Following,O
Food,O
and,O
Drug,O
Administration,O
and,O
institutional,O
review,O
board,O
approval,O
and,O
written,O
informed,O
consent,O
",",O
65,O
volunteers,O
were,O
studied,O
in,O
two,O
trials,O
:,O
an,O
open,O
-,O
label,O
",",O
dose,O
-,O
escalating,O
trial,O
with,O
intrathecal,O
adenosine,O
doses,O
of,O
0,O
.,O
25,O
-,O
2,O
.,O
0,O
mg,B
and,O
a,O
double,O
-,O
blind,O
",",O
placebo,O
-,O
controlled,O
trial,O
of,O
adenosine,...
hyperalgesia,O
and,O
allodynia,O
after,O
intradermal,O
capsaicin,B
injection,O
were,O
determined,O
.,O
RESULTS,O
:,O
Adenosine,B
produced,O
no,O
effect,O
on,O
pain,O
report,O
to,O
acute,O
noxious,O
thermal,O
or,O
chemical,O
stimula...ICENSE :,O
These,O
results,O
show,O
selective,O
inhibition,O
by,O
intrathecal,O
adenosine,O
of,O
hypersensitivity,O
",",O
presumed,O
to,O
reflect,O
central,O
sensitization,O
in,O
humans,O
after,O
peripheral,O
capsaicin,O
injection,O
.,O
The,O
long,O
-,O
lasting,O
effect,O
is,O
consistent,O
with,O
that,O
observed,O
in,O
preliminary,O
reports,O
of,O
patients,O
with,O
chronic,O
neuropathic,O
pain,O
and,O
is,O
not,O
due,O
to,O
prolonged,O
residence,O
of,O
adenosine,B
in,I
cerebrospinal,I
fluid,I
.,O
Delayed,O
-,O
onset,O
heparin,B
-,I
induced,I
thrombocytopenia,I
.,O
BACKGROUND,O
:,O
Heparin,B
-,I
induced,I
thrombocytopenia,I
presents,O
5,O
to,O
12,O
days,O
after,O
heparin,O
exposure,O
",",O
with,O
or,O
without,O
arterial,O
or,O
venous,O
thromboemboli,O
.,O
Delayed,O
recognition,O
and,O
treatment,O
of,O
heparin,B
-,I
induced,I
thrombocytopenia,I
contribute,O
to,O
poor,O
patient,O
outcomes,O
.,O
OBJECTIVE,O
:,O
To,O
describe,O
and,O
increase,O
awareness,O
of,O
a,O
clinical,O
scenario,O
in,O
which,O
the,O
onset,O
or,O
manifestations,O
of,O
heparin,B
-,I
induced,I
thrombocytopenia,I
are,O
delayed,O
.,O
DESIGN,O
:,O
Retrospective,O
case,O
series,O
.,O
SETTING,O
:,O
Three,O
large,O
urban,O
hospitals,O
(,O
with,O
active,O
cardiovascular,O
surgery,O
programs,O
),O
.,O
PATIENTS,O
:,O
14,O
patients,O
seen,O
over,O
a,O
3,O
-,O
year,O
period,O
in,O
whom,O
heparin,B
-,I
induced,I
thrombocytopenia,I
became,O
apparent,O
on,O
delayed,O
presentation,O
with,O
thromboembolic,O
complications,O
.,O
MEASUREMENTS,O
:,O
Platelet,O
counts,O
",",O
onset,O
of,O
objectively,O
determined,O
thromboembolism,O
",",O
results,O
of,O
heparin,B
-,I
induced,I
platelet,I
factor,I
4,I
antibody,I
tests,I
",",O
and,O
outcomes,O
.,O
RESULTS,O
:,O
Patients,O
went,O
home,O
after,O
hospitalizations,O
that,O
had,O
included,O
heparin,B
exposure,O
-,O
-,O
in,O
most,O
cases,O
",",O
with,O
no,O
thrombocytopenia,O
recognized,O
-,O
-,O
only,O
to,O
return,O
to,O
the,O
hospital,O
(,O
median,O
",",O
day,O
14,O
),O
with,O
thromboembolic,O
complications,O
.,O
Thromboemboli,O
were,O
venous,O
(,O
12,O
patients,O
",",O
7,O
with,O
pulmonary,O
emboli,O
),O
or,O
arterial,O
(,O
4,O
patients,O
),O
or,O
both,O
.,O
Platelet,
counts,
were,
mildly,
decreased,
in,
all,
but,
2,
patients,
on,
second,
presentation,
.,
On,
readmission,
",",
11,
patients,
received,
therapeutic,
heparin,
",",
which,
worsened,
the,
patients,
',
clinical,
condition,
and,
",",
in,
all,
11,
cases,
",",
decreased,
the,
platelet,
count,
(,
mean,
at,
readmission,
",",
143,
x,
10,
(,
9,
),
cells,
/,
L,
;,
mean,
nadir,
after,
heparin,
re,
-,
exposure,
",",
39,
x,
10,
(,
9,
),
cells,
/,
L,
),
.,
Results,O
of,O
serologic,O
tests,O
for,O
heparin,B
-,I
induced,I
antibodies,I
were,O
positive,O
in,O
all,O
patients,O
.,O
Subsequent,O
treatments,O
included,O
alternative,O
anticoagulants,O
(,O
11,O
patients,O
),O
",",O
thrombolytic,O
drugs,O
(,O
3,O
patients,O
),O
",",O
inferior,O
vena,O
cava,O
filters,O
(,O
3,O
patients,O
),O
and,O
",",O
eventually,O
",",O
warfarin,B
(,I
11,I
patients,I
),I
.,O
Three,O
patients,O
died,O
.,O
CONCLUSIONS,O
:,O
Delayed,O
-,O
onset,O
heparin,B
-,I
induced,I
thrombocytopenia,I
is,O
increasingly,O
being,O
recognized,O
.,O
To,O
avoid,O
disastrous,O
outcomes,O
",",O
physicians,O
must,O
consider,O
heparin,B
-,I
induced,I
thrombocytopenia,I
whenever,O
a,O
recently,O
hospitalized,O
patient,O
returns,O
with,O
thromboembolism,O
;,O
therapy,O
with,O
alternative,O
anticoagulants,O
",",O
not,O
heparin,B
",",I
should,O
be,O
initiated,O
.,O
Treatment,O
of,O
risperidone,B
-,O
induced,O
hyperprolactinemia,O
with,O
a,O
dopamine,O
agonist,O
in,O
children,O
.,O
BACKGROUND,O
:,O
Risperidone,B
",",O
a,O
potent,O
antagonist,O
of,O
both,O
serotonergic,B
(,O
5HT2A,B
),O
and,O
dopaminergic,B
D2,B
receptors,O
is,O
associated,O
with,O
hyperprolactinemia,O
in,O
adults,O
and,O
children,O
.,O
Chronically,O
elevated,O
prolactin,O
levels,O
in,O
children,O
with,O
prolactinomas,O
may,O
be,O
associated,O
with,O
arrested,O
growth,O
and,O
development,O
resulting,O
in,O
either,O
delayed,O
puberty,O
or,O
short,O
stature,O
.,O
These,O
possibilities,O
stress,O
the,O
importance,O
of,O
developing,O
a,O
safe,O
and,O
effective,O
approach,O
to,O
drug,B
-,I
induced,I
hyperprolactinemia,I
in,O
youth,O
.,O
We,O
report,O
the,O
successful,O
treatment,O
of,O
risperidone,B
-,I
induced,I
hyperprolactinemia,I
with,O
cabergoline,B
in,O
youth,O
.,O
METHODS,O
:,O
We,O
undertook,O
a,O
retrospective,O
case,O
review,O
of,O
four,O
children,O
with,O
risperidone,B
-,I
induced,I
hyperprolactinemia,I
treated,O
with,O
cabergoline,B
.,O
RESULTS,
:,
Four,
males,
(,
age,
6,
-,
11,
years,
),
with,
Diagnostic,
and,
Statistical,
Manual,
of,
Mental,
Disorders,
(,
fourth,
edition,
),
bipolar,
disorder,
or,
psychoses,
",",
with,
risperidone,
-,
induced,
elevations,
in,
serum,
prolactin,
levels,
(,
57,
.,
5,
-,
129,
ng,
/,
mL,
",",
normal,
5,
-,
15,
ng,
/,
mL,
),
",",
were,
treated,
with,
cabergoline,
(,
mean,
dose,
2,
.,
13,O
+,O
/,O
-,B
0,I
.,O
09,O
mg,B
/,I
week,I
),O
.,O
When,O
serum,O
prolactin,O
levels,O
normalized,O
in,O
all,O
four,O
subjects,O
(,O
mean,O
11,O
.,O
2,O
+,O
/,O
-,O
10,O
.,O
9,O
ng,B
/,I
mL,I
),O
",",O
the,O
cabergoline,O
dose,O
was,O
reduced,O
to,O
1,B
mg,I
/,I
week,I
in,O
three,O
of,O
four,O
subjects,O
.,O
The,O
mean,O
duration,O
of,O
therapy,O
with,O
cabergoline,O
was,O
523,B
.,I
5,I
+,I
/,I
-,I
129,I
.,I
7,I
days,I
",",O
and,O
the,O
mean,O
duration,O
of,O
therapy,O
with,O
risperidone,O
was,O
788,B
.,I
5,I
+,I
/,I
-,I
5,O
+,O
/,O
-,O
162,O
.,O
5,O
days,O
.,O
Cabergoline,B
was,O
well,O
tolerated,O
without,O
adverse,O
effects,O
.,O
CONCLUSIONS,O
:,O
Cabergoline,B
may,O
be,O
useful,O
for,O
the,O
treatment,O
of,O
risperidone,O
-,O
induced,O
hyperprolactinemia,O
in,O
youth,O
;,O
however,O
",",O
further,O
research,O
is,O
needed,O
.,O
Acute,O
cholestatic,O
hepatitis,O
after,O
exposure,O
to,O
isoflurane,B
.,O
OBJECTIVE,O
:,O
To,O
report,O
a,O
case,O
of,O
acute,O
cholestatic,O
hepatitis,O
following,O
exposure,O
to,O
the,O
inhalational,O
anesthetic,O
isoflurane,B
.,O
CASE,O
SUMMARY,O
:,O
A,O
70,O
-,O
year,O
-,O
old,O
healthy,O
woman,O
from,O
Iraq,O
developed,O
acute,O
cholestatic,B
hepat...etic,O
causes,O
of,O
hepatitis,O
.,O
No,O
other,O
medications,O
were,O
involved,O
except,O
for,O
dipyrone,B
for,O
analgesia,O
.,O
The,O
alanine,B
aminotransferase,I
was,O
elevated,O
to,O
a,O
peak,O
concentration,O
of,O
1533,O
U,O
/,O
L,O
and,O
the,O
CONCLUSIONS,O
:,O
Isoflurane,B-chemical
",",O
a,O
common,O
anesthetic,O
agent,O
",",O
can,O
cause,O
severe,O
cholestatic,O
hepatitis,O
.,O
Torsade,O
de,O
pointes,O
induced,O
by,O
metoclopramide,B-chemical
in,O
an,O
elderly,O
woman,O
with,O
preexisting,O
complete,O
left,O
bundle,O
branch,O
block,O
.,O
There,O
is,O
a,O
growing,O
list,O
of,O
drugs,O
implicated,O
in,O
acquired,O
long,O
QT,O
syndrome,O
and,O
torsade,O
de,O
pointes,O
.,O
However,
",",
the,
torsadogenic,
potential,
of,
metoclopramide,
",",
a,
commonly,
used,
antiemetic,
and,
prokinetic,
drug,
",",
has,
not,
been,
reported,
in,
the,
literature,
",",
despite,
its,
chemical,
similarity,
to,
procainamide,
.,
We,
report,
on,
a,
92,
-,
year,
-,
old,
woman,
with,
preexisting,
complete,
left,
bundle,
branch,
block,
who,
developed,
torsade,
de,
pointes,
after,
intravenous,
and,
oral,
administration,
of,
metoclopramide,
.,
This,O
patient,O
also,O
developed,O
torsade,B
de,I
pointes,I
when,O
cisapride,B
and,O
erythromycin,B
were,O
given,O
simultaneously,O
.,O
These,O
two,O
episodes,O
were,O
suppressed,O
successfully,O
after,O
discontinuing,O
the,O
offending,O
drugs,O
and,O
administering,O
class,O
IB,O
drugs,O
.,O
This,O
is,O
the,O
first,O
documentation,O
that,O
metoclopramide,B
provokes,O
torsade,O
de,I
pointes,I
clinically,O
.,O
Metoclopramide,B
should,O
be,O
used,O
cautiously,O
in,O
patients,O
with,O
a,O
risk,O
of,O
torsade,O
de,O
pointes,O
.,O
Dopamine,...
",",O
the,O
control,O
of,O
epileptic,O
seizures,O
arising,O
in,O
the,O
limbic,O
system,O
.,O
Excitotoxicity,O
leading,O
to,O
neuronal,O
cell,O
death,O
in,O
the,O
affected,O
areas,O
is,O
a,O
major,O
consequence,O
of,O
seizures,O
at,O
the,O
cellular,O
level,O
.,O
In,O
this,O
respect,O
",",O
little,O
is,O
known,O
about,O
the,O
role,O
of,O
DA,B
receptors,I
in,O
the,O
occurrence,O
of,O
epilepsy,O
-,O
induced,O
neuronal,O
cell,O
death,O
.,O
Here,O
we,O
analyze,O
the,O
occurrence,O
of,O
seizures,O
and,O
neurotoxicity,O
in,O
D2R,B
-,I
/,I
-,I
mice,O
treated,O
with,O
the,O
cholinergic,O
agonist,O
pilocarpine,O
.,O
We,O
compared,O
these,O
results,O
with,O
those,O
previously,O
obtained,O
with,O
kainic,B
acid,I
(,O
KA,B
),O
",",O
a,O
potent,O
glutamate,O
agonist,O
.,O
Importantly,O
",",O
D2R,O
-,O
/,O
-,O
mice,O
develop,O
seizures,O
at,O
doses,O
of,O
both,O
drugs,O
that,O
are,O
not,O
epileptogenic,O
for,O
WT,O
littermates,O
and,O
show,O
greater,O
neurotoxicity,O
.,O
However,O
",",O
pilocarpine,B
-,O
induced,O
seizures,O
result,O
in,O
a,O
more,O
widespread,O
neuronal,O
death,O
in,O
both,O
WT,O
and,O
D2R,O
-,O
/,O
-,O
brains,O
in,O
comparison,O
to,O
KA,B
.,O
Thus,
",",
the,
absence,
of,
D2R,
lowers,
the,
threshold,
for,
seizures,
induced,
by,
both,
glutamate,
and,
acetylcholine,
.,
Moreover,
",",
the,
dopaminergic,
control,
of,
epilepsy,
-,
induced,
neurodegeneration,
seems,
to,
be,
mediated,
by,
distinct,
interactions,
of,
D2R,
signaling,
with,
these,
two,
neurotransmitters,
.,
Steroid,
structure,
and,
pharmacological,
properties,
determine,
the,
anti,
-,
amnesic,
effects,
of,
pregnenolone,
sulphate,
in,
the,
passive,
avoidance,
task,
in,
rats,
.,
Pregnenolone,B
sulphate,I
(,O
PREGS,B
),O
has,O
generated,O
interest,O
as,O
one,O
of,O
the,O
most,O
potent,O
memory,O
-,O
This,O
hypothesis,O
stems,O
from,O
findings,O
that,O
PREGS,B
is,O
a,O
potent,O
positive,O
modulator,O
of,O
N,B
-,I
methyl,I
-,I
d,I
-,I
aspartate,I
receptors,I
(,O
NMDARs,B
),O
and,O
a,O
negative,O
modulator,O
of,O
gamma,B
-,I
aminobutyric,I
acid,I
(,O
A,B
),I
receptors,I
(,O
GABA,I
(,O
A,I
),I
),I
.,O
Moreover,O
",",O
PREGS,B
is,O
able,O
to,O
reverse,O
the,O
amnesic,O
-,O
like,O
effects,O
of,O
NMDAR,B
and,O
GABA,B
(,I
A,I
),I
R,I
ligands,I
.,O
To,
investigate,
this,
hypothesis,
",",
the,
present,
study,
in,
rats,
examined,
the,
memory,
-,
altering,
abilities,
of,
structural,
analogs,
of,
PREGS,
",",
which,
differ,
in,
their,
modulation,
of,
NMDAR,
and,
/,
or,
GABA,
(,
A,
),
R,
function,
.,
The,
analogs,
tested,
were,
:,
11,
-,
ketopregnenolone,
sulphate,
(,
an,
agent,
that,
is,
inactive,
at,
GABA,
(,
A,
),
Rs,
and,
NMDARs,
),
",",
epipregnanolone,
(,
[,
3beta,
-,
hydroxy,
-,
5beta,
-,
pregnan,
-,
20,
-,
one,
],
sulphate,
",",
an,
inhibitor,
of,
both,
GABA,
(,
A,
),
Rs,
and,
NMDARs,
),
",",
and,
a,
newly,
synthesized,
(,
-,
),
PREGS,
enantiomer,
(,
which,
is,
identical,
to,
PREGS,
in,
effects,
on,
GABA,
(,
A,
),
Rs,
and,
NMDARs,
),
.,
The,
memory,
-,
enhancing,
effects,
of,
PREGS,
and,
its,
analogs,
were,
tested,
in,
the,
passive,
avoidance,
task,
using,
the,
model,
of,
scopolamine,
-,
induced,
amnesia,
.,
Both,
PREGS,
and,
its,
(,
-,
),
enantiomer,
blocked,
the,
effects,
of,
scopolamine,
.,
The,
results,
show,
that,
",",
unlike,
PREGS,
",",
11,
-,
ketopregnenolone,
sulphate,
and,
epipregnanolone,
sulphate,
failed,
to,
block,
the,
effect,
of,
scopolamine,
",",
suggesting,
that,
altering,
the,
modulation,
of,
NMDA,
receptors,
diminishes,
the,
memory,
-,
enhancing,
effects,
of,
PREGS,
.,
Moreover,O
",",O
enantioselectivity,O
was,O
demonstrated,O
by,O
the,O
ability,O
of,O
natural,B
PREGS,I
to,O
be,O
an,O
order,O
of,O
magnitude,O
more,O
effective,O
than,O
its,O
synthetic,O
enantiomer,O
in,O
reversing,O
scopolamine,O
-,O
induced,O
amnesia,O
.,O
These,O
results,O
identify,O
a,O
novel,O
neuropharmacological,O
site,O
for,O
the,O
modulation,O
of,O
memory,O
processes,O
by,O
neuroactive,O
steroids,O
.,O
Activation,O
of,O
poly,B-Chemical
(,B-Chemical
ADP,I-Chemical
-,I-Chemical
ribose,I-Chemical
),I-Chemical
polymerase,I-Chemical
contributes,O
to,O
development,O
of,O
doxorubicin,B-Chemical
-,I-Chemical
induced,I-Chemical
heart,O
failure,O
.,O
Activation,O
of,O
the,O
nuclear,O
enzyme,O
poly,B-Chemical
(,B-Chemical
ADP,I-Chemical
-,I-Chemical
ribose,I-Chemical
),I-Chemical
polymerase,I-Chemical
(,I-Chemical
PARP,I-Chemical
),I-Chemical
by,O
oxidant,B-Chemical
-,I-Chemical
mediated,I-Chemical
DNA,I-Chemical
damage,O
is,O
an,O
important,O
pathway,O
of,O
cell,O
dysfunction,O
and,O
tissue,O
injury,O
in,O
conditions,O
associated,O
with,O
oxidative,O
stress,O
.,O
Increased,O
oxidative,O
stress,O
is,O
a,O
major,O
factor,O
implicated,O
in,O
the,O
cardiotoxicity,O
of,O
doxorubicin,B
(,O
DOX,I
),Ellipsis
the,B
development,I
of,I
cardiac,I
dysfunction,I
induced,I
by,I
DOX,I
.,O
PARP,B
-,I
1,I
+,I
/,I
+,I
and,O
PARP,B
-,I
1,I
-,I
/,I
-,I
mice,O
received,O
a,O
single,O
injection,O
of,Ellipsis
but,O
only,O
to,O
a,O
smaller,O
extent,O
in,O
PARP,B
-,I
1,I
-,I
/,I
-,I
ones,O
.,O
Similar,O
experiments,O
were,O
conducted,O
in,O
BALB,B
/,I
c,I
mice,O
treated,O
with,O
PJ34,B
or,O
vehicle,O
.,O
Treatment,O
with,O
a,O
PJ34,B
significantly,O
improved,O
cardiac,O
dysfunction,O
and,O
increased,O
the,O
survival,O
of,O
the,O
animals,O
.,O
In,O
addition,O
PJ34,B
significantly,O
reduced,O
the,O
DOX,B
-,I
induced,O
increase,O
in,O
the,O
serum,O
lactate,O
dehydrogenase,O
and,O
creatine,O
kinase,O
activities,O
but,O
not,O
metalloproteinase,O
activation,O
in,O
the,O
heart,O
.,O
Thus,O
",",O
PARP,O
activation,O
contributes,O
to,O
the,O
cardiotoxicity,O
of,O
DOX,B
.,O
PARP,B
inhibitors,O
may,O
exert,O
protective,O
effects,O
against,O
the,O
development,O
of,O
severe,O
cardiac,O
complications,O
associated,O
with,O
the,O
DOX,B
treatment,O
.,O
Spironolactone,B
:,O
is,O
it,O
a,O
novel,O
drug,O
for,O
the,O
prevention,O
of,O
amphotericin,B
-,I
related,I
hypokalemia,I
in,I
cancer,I
patients,I
?,O
OBJECTIVE,O
:,O
Nephrotoxicity,O
is,O
the,O
major,O
adverse,O
effect,O
of,O
amphotericin,B
(,O
AmB,B
),O
",",O
often,O
limiting,O
administration,O
of,O
full,O
dosage,O
.,O
Selective,O
distal,O
tubular,O
epithelial,O
toxicity,O
seems,O
to,O
be,O
responsible,O
for,O
the,O
profound,O
potassium,B
wasting,O
th...hey,O
are,O
taken,O
with,O
AmB,B
treatment,O
.,O
METHODS,O
:,O
In,O
this,O
study,O
26,O
patients,O
with,O
various,O
hematological,O
disorders,O
were,O
randomized,O
to,O
receive,O
either,O
intravenous,O
AmB,B
alone,O
or,O
AmB,B
and,O
oral,O
spironolactone,B
100,O
mg,O
twice,O
daily,O
when,O
developing,O
a,O
proven,O
or,O
suspected,O
fungal,O
infection,O
.,O
RESULTS,O
:,O
Patients,O
receiving,O
concomitant,O
AmB,B
and,O
spironolactone,B
had,O
significantly,O
higher,O
plasma,O
potassium,O
levels,O
than,O
those,O
receiving,O
AmB,B
alone,O
(,O
P,O
=,O
0,O
.,O
0027,
),
.,
Those,
patients,
receiving,
AmB,
and,
spironolactone,
required,
significantly,
less,
potassium,
supplementation,
to,
maintain,
their,
plasma,
potassium,
within,
the,
normal,
range,
(,
P,
=,
0,
.,
022,
),
.,
Moreover,
",",
urinary,
potassium,
losses,
were,
significantly,
less,
in,
patients,
receiving,
AmB,
and,
spironolactone,
than,
those,
receiving,
AmB,
alone,
(,
P,
=,
0,
.,
040,
),
.,
CONCLUSION,
:,
This,
study,
showed,
that,
spironolactone,
can,
reduce,
potassium,
requirements,
and,
prevent,
hypokalemia,
by,
reducing,
urinary,
potassium,
loss,
in,
neutropenic,
patients,
on,
AmB,
treatment,
.,
Erectile,
dysfunction,
occurs,
following,
substantia,
nigra,
lesions,
in,
the,
rat,
.,
Erectile,
function,
was,
assessed,
6,
weeks,
following,
uni,
-,
and,
bilateral,
injections,
of,
6,
-,
hydroxydopamine,
in,
the,
substantia,
nigra,
nucleus,
of,
the,
brain,
.,
Behavioral,
apomorphine,
-,
induced,
penile,
erections,
were,
reduced,
(,
5,
/,
8,
),
and,
increased,
(,
3,
/,
8,
),
in,
uni,
-,
and,
bilateral,
lesioned,
animals,
.,
Intracavernous,
pressures,
",",
following,
electrical,
stimulation,
of,
the,
cavernous,
nerve,
",",
decreased,
in,
lesioned,
animals,
.,
Lesions,
of,
the,
substantia,
nigra,
were,
confirmed,
by,
histology,
.,
Concentration,O
of,O
dopamine,B
and,O
its,O
metabolites,O
were,O
decreased,O
in,O
the,O
striatum,O
of,O
substantia,O
nigra,O
lesioned,O
In,
the,
present,
study,
",",
effects,
of,
nicotine,
on,
catalepsy,
induced,
by,
morphine,
in,
mice,
have,
been,
investigated,
.,
Morphine,
but,
not,
nicotine,
induced,
a,
dose,
-,
dependent,
catalepsy,
.,
The,
response,
of,
morphine,
was,
potentiated,
by,
nicotine,
.,
Intraperitoneal,
administration,
of,
atropine,
",",
naloxone,
",",
mecamylamine,
",",
and,
hexamethonium,
to,
mice,
reduced,
catalepsy,
induced,
by,
a,
combination,
of,
morphine,
with,
nicotine,
.,
Intracerebroventricular,O
injection,O
of,O
atropine,B
",",O
hexamethonium,B
",",O
and,O
naloxone,B
also,O
decreased,O
catalepsy,O
induced,O
by,O
morphine,O
plus,O
nicotine,O
.,O
Intraperitoneal,O
administration,O
of,O
atropine,B
",",O
but,O
not,O
intraperitoneal,O
or,O
intracerebroventricular,O
injection,O
of,O
hexamethonium,B
",",O
decreased,O
the,O
effect,O
of,O
a,O
single,O
dose,O
of,O
morphine,O
.,O
It,O
was,O
concluded,O
that,O
morphine,B
catalepsy,O
can,O
be,O
elicited,O
by,O
opioid,B
and,O
cholinergic,B
receptors,O
",",O
and,O
the,O
potentiation,O
of,O
morphine,B
induced,O
by,O
nicotine,O
may,O
also,O
be,O
mediated,O
through,O
cholinergic,B
receptor,O
mechanisms,O
.,O
Force,O
overflow,O
and,O
levodopa,B
-,I
induced,I
dyskinesias,I
in,O
Parkinson,O
',O
s,O
disease,O
.,O
We,O
assessed,O
force,O
coordination,O
of,O
the,O
hand,O
in,O
Parkinson,O
',O
s,O
disease,O
and,O
its,O
relationship,O
to,O
motor,O
complications,O
of,O
levodopa,B
therapy,O
",",O
particularly,O
to,O
levodopa,B
-,I
induced,I
dyskinesias,I
(,O
LID,O
),O
.,O
We,O
studied,O
two,O
groups,O
of,O
Parkinson,B
',I
s,I
disease,I
patients,O
with,O
(,O
Parkinson,B
',I
s,I
disease,I
+,O
LID,B
",",O
n,O
=,O
23,O
),O
and,O
without,O
levodopa,B
-,I
induced,I
dyskinesias,I
(,O
Parkinson,B
',I
s,I
disease,I
-,I
LID,B
",",O
n,O
=,O
10,O
),O
",",O
and,O
age,O
-,O
matched,O
healthy,O
controls,O
.,O
The,O
motor,O
score,O
of,O
the,O
Unified,O
Parkinson,B
',I
s,I
Disease,I
Rating,I
Scale,I
",",O
a,O
dyskinesia,O
score,O
and,O
force,O
in,O
a,O
grip,O
-,O
lift,O
paradigm,O
were,O
assessed,O
ON,O
and,O
OFF,O
levodopa,O
.,O
A,O
pathological,O
increase,O
of,O
forces,O
was,O
seen,O
in,O
ON,B
-,I
state,I
in,O
Parkinson,O
',O
s,O
disease,O
+,O
LID,B
only,O
.,O
In,O
Parkinson,O
',O
s,O
disease,O
+,O
LID,B
",",O
the,O
force,O
involved,O
in,O
pressing,O
down,O
the,O
object,O
before,O
lifting,O
was,O
significantly,O
increased,O
by,O
levodopa,O
(,O
by,O
61,O
%,O
",",O
P,O
<,O
0,O
.,O
05,O
),O
.,O
An,O
overshooting,O
of,O
peak,O
grip,O
force,O
by,O
51,O
%,O
(,O
P,O
<,O
0,O
.,O
05,O
),O
and,O
of,O
static,O
grip,O
force,O
by,O
45,O
%,O
(,O
P,O
<,O
0,O
.,O
01,O
),O
was,O
observed,O
in,O
the,O
ON,O
-,O
compared,O
with,O
the,O
OFF,O
-,O
drug,O
condition,O
.,O
In,O
contrast,O
",",O
no,O
excessive,O
force,O
was,O
found,O
in,O
Parkinson,B
',I
s,I
disease,I
-,O
LID,B
.,O
Peak,O
grip,O
force,O
in,O
ON,O
-,O
state,O
was,O
140,O
%,O
(,O
P,O
<,O
0,O
.,O
05,O
),O
higher,O
in,O
Parkinson,B
',I
s,I
disease,I
+,O
LID,B
than,O
in,O
Parkinson,B
',I
s,I
disease,I
-,O
LID,B
",",O
while,O
static,O
grip,O
force,O
was,O
increased,O
by,O
138,O
%,O
(,O
P,O
<,O
0,O
.,O
05,O
),O
01,O
),O
between,O
groups,O
.,O
Severity,O
of,O
peak,O
-,O
dose,O
dyskinesias,O
was,O
strongly,O
correlated,O
with,O
grip,O
force,O
in,O
ON,B
-,O
state,I
(,O
r,O
=,O
0,O
.,O
79,O
with,O
peak,O
force,O
",",O
P,O
<,O
0,O
.,O
01,O
),O
.,O
No,O
correlation,O
was,O
observed,O
between,O
forces,O
and,O
the,O
motor,O
score,O
as,O
well,O
as,O
with,O
the,O
daily,O
dose,O
of,O
dopaminergic,O
medication,O
.,O
Force,O
excess,O
was,O
only,O
observed,O
in,O
patients,O
with,O
LID,B
and,O
motor,O
fluctuations,O
.,O
A,O
close,O
relationship,O
was,O
seen,O
between,O
the,O
overshooting,O
of,O
forces,O
and,O
dyskinesias,B
in,O
the,O
ON,B
-,O
drug,O
condition,O
.,O
We,O
postulate,O
that,O
both,O
LID,O
and,O
grip,O
force,O
excess,O
share,O
common,O
pathophysiological,O
mechanisms,O
related,O
to,O
motor,O
fluctuations,O
.,O
Behavioral,O
effects,O
of,O
MK,B
-,I
801,I
on,O
reserpine,O
-,O
treated,O
mice,O
.,O
The,O
effects,O
of,O
dizocilpine,B
(,O
MK,O
-,O
801,O
),O
",",O
a,O
noncompetitive,O
N,O
-,O
methyl,O
-,O
D,O
-,O
aspartate,O
(,O
NMDA,O
),O
receptor,O
antagonist,O
",",O
were,O
studied,O
on,O
dopamine,O
-,O
related,O
behaviors,O
induced,O
by,O
reserpine,O
treatments,O
.,O
This,
study,
focuses,
on,
behavioral,
syndromes,
that,
may,
used,
as,
models,
for,
Parkinson,
',
s,
disease,
",",
or,
tardive,
dyskinesia,
",",
and,
its,
response,
after,
glutamatergic,
blockage,
.,
Reserpine,
(,
1,
mg,
/,
kg,
),
",",
administered,
once,
every,
other,
day,
for,
4,
days,
",",
produced,
increases,
in,
orofacial,
dyskinesia,
",",
tongue,
protrusion,
and,
vacuous,
chewing,
in,
mice,
",",
which,
are,
signs,
indicative,
of,
tardive,
dyskinesia,
.,
Reserpine,
also,
produced,
tremor,
and,
catalepsy,
",",
which,
are,
signs,
suggestive,
of,
Parkinson,
',
s,
disease,
.,
MK,
-,
801,
(,
0,
.,
1,
mg,
/,
kg,
),
",",
administered,
30,
min,
before,
the,
observation,
test,
",",
prevented,
the,
vacuous,
chewing,
movements,
",",
tongue,
protrusions,
and,
catalepsy,
induced,
by,
reserpine,
.,
However,
",",
MK,
-,
801,
injection,
produced,
a,
significant,
increase,
of,
tremor,
in,
reserpine,
-,
treated,
mice,
.,
Reserpine,B
(,O
1,B
mg,I
/,I
kg,I
),O
",",O
administered,O
90,O
min,O
before,O
the,O
test,O
and,O
followed,O
by,O
apo...reserpine,O
.,O
MK,B
-,I
801,I
(,O
0,B
.,I
1,I
mg,I
/,I
kg,I
),O
administration,O
attenuated,O
the,O
catalepsy,O
Pretreatment,O
with,O
reserpine,B
(,O
1,O
mg,O
/,O
kg,O
),O
24,O
h,O
before,O
the,O
observation,O
test,O
produced,O
increa...ed,O
the,O
effects,O
of,O
reserpine,O
.,O
These,O
results,O
show,O
that,O
reserpine,B
produces,O
different,O
and,O
abnormal,O
movements,O
",",O
which,O
are,O
related,O
to,O
dose,O
and,O
schedule,O
employed,O
and,O
can,O
be,O
considered,O
as,O
parkinsonian,O
-like,O
and,O
tardive,O
dsykinesia,O
signs,O
.,O
The,O
glutamatergic,O
blockage,O
produced,O
by,O
NMDA,B
can,O
restore,O
these,O
signs,O
",",O
such,O
as,O
vacuous,O
chewing,O
Two,O
schizophrenic,O
patients,O
",",O
who,O
had,O
a,O
prior,O
history,O
of,O
LSD,B
abuse,O
and,O
who,O
had,O
previously,O
d...eridone,O
.,O
They,O
both,O
reported,O
short,O
episodes,O
of,O
transient,O
visual,O
disturbances,O
",",O
which,O
appeared,O
immediately,O
after,O
starting,O
treatment,O
with,O
risperidone,O
.,O
This,O
imagery,O
resembled,O
visual,O
disturbances,O
previously,O
experienced,O
as,O
flashbacks,O
related,O
to,O
prior,O
LSD,B
consumption,O
...f,O
risperidone,O
or,O
interfere,O
with,O
treatment,O
.,O
Conclusions,O
based,O
on,O
two,O
case,O
reports,O
should,O
be,O
taken,O
with,O
appropriate,O
caution,O
.,O
Topiramate,B
-,I
induced,Ellipsis
to,O
inhibition,O
of,O
carbonic,O
anhydrase,O
.,O
In,O
addition,O
",",O
a,O
distal,O
tubular,O
acidification,B
defect,O
may,O
result,O
",",O
thus,O
impairing,O
the,O
normal,O
compensatory,O
drop,O
in,O
urine,O
pH,O
.,O
These,O
factors,O
can,O
lead,O
to,O
the,O
development,O
of,O
calcium,B
phosphate,I
nephrolithiasis,I
.,O
We,O
report,O
the,O
first,O
two,O
cases,O
of,O
topiramate,B
-,I
induced,I
nephrolithiasis,I
in,O
the,O
urologic,O
literature,O
.,O
Ketamine,B
in,O
war,O
/,O
tropical,O
surgery,O
(,O
a,O
final,O
tribute,O
to,O
the,O
racemic,O
mixture,O
),O
.,O
A,O
t...Uganda,O
in,O
1999,O
for,O
64,O
operations,O
in,O
62,O
patients,O
",",O
aged,O
from,O
6,O
weeks,O
to,O
70,O
years,O
",",O
Operations,
lasting,
up,
to,
2h,
could,
be,
performed,
in,
the,
absence,
of,
sophisticated,
equipment,
such,
as,
pulse,
oximeters,
or,
ventilators,
in,
patients,
on,
spontaneous,
ventilation,
breathing,
air,
/,
oxygen,
only,
.,
After,
premedication,
with,
diazepam,
",",
glycopyrrolate,
and,
local,
anaesthesia,
",",
and,
induction,
with,
standard,
doses,
of,
ketamine,
",",
a,
maintenance,
dose,
of,
10,
-,
20,
microg,
/,
kg,
/,
min,
of,
ketamine,
proved,
safe,
and,
effective,
.,
Emphasis,O
was,O
placed,O
on,O
bedside,O
clinical,O
monitoring,O
",",O
relying,O
heavily,O
on,O
the,O
heart,O
rate,O
.,O
Diazepam,B
",",O
unless,B
contraindicated,I
or,I
risky,I
",",O
remains,O
the,O
only,O
necessary,O
complementary,O
drug,O
to,O
ketamine,O
as,O
it,O
buffers,O
its,O
cardiovascular,O
response,O
and,O
decreases,O
the,O
duration,O
and,O
intensity,O
of,O
operative,O
and,O
postoperative,O
hallucinations,O
.,O
Local,O
anaesthetic,B
blocks,O
were,O
useful,O
in,O
decreasing,O
the,O
requirement,O
for,O
postoperative,O
analgesia,O
.,O
An,O
antisialogu...s,O
where,O
",",O
e,O
.,O
.,O
.,O
.,O
.,O
g,O
.,O
amputation,O
and,O
rapid,O
extrication,O
were,O
required,O
.,O
Intravenous,O
ribavirin,B
treatment,O
for,O
severe,O
adenovirus,B
disease,I
in,O
immunocompromised,O
children,O
.,O
BACKGROUND,O
:,O
Adenovirus,B
is,O
an,O
important,O
cause,O
of,O
morbidity,O
There,O
are,O
no,O
approved,O
antiviral,B
agents,O
with,O
proven,O
efficacy,O
for,O
the,O
treatment,O
of,O
severe,O
adenovirus,B
disease,O
",",O
nor,O
are,O
there,O
any,O
prospective,O
randomized,O
",",O
controlled,O
trials,O
of,O
potentially,O
useful,O
anti,B
-,I
adenovirus,I
therapies,O
.,O
Apparent,O
clinical,O
success,O
in,O
the,O
treatment,O
of,O
severe,O
adenovirus,B
disease,O
is,O
limited,O
to,O
a,O
few,O
case,O
reports,O
and,O
small,O
series,O
.,O
Experience,
is,
greatest,
with,
intravenous,
ribavirin,
and,
cidofovir,
.,
Ribavirin,
",",
a,
guanosine,
analogue,
",",
has,
broad,
antiviral,
activity,
against,
both,
RNA,
and,
DNA,
viruses,
",",
including,
documented,
activity,
against,
adenovirus,
in,
vitro,
.,
Ribavirin,
is,
licensed,
in,
aerosol,
form,
for,
the,
treatment,
of,
respiratory,
syncytial,
virus,
infection,
",",
and,
orally,
in,
combination,
with,
interferon,
to,
treat,
hepatitis,
C,
.,
Intravenous,O
ribavirin,B
is,O
the,O
treatment,O
of,O
choice,O
for,O
infection,O
with,O
hemorrhagic,O
fever,O
viruses,O
.,O
The,O
mo...virus,O
infection,O
has,O
been,O
limited,O
by,O
adverse,O
effects,O
",",O
the,O
most,O
significant,O
of,O
which,O
is,O
nephrotoxicity,O
.,O
OBJECTIVE,
:,
We,
report,
our,
experience,
with,
intravenous,
ribavirin,
therapy,
for,
severe,
adenovirus,
disease,
in,
a,
series,
of,
immunocompromised,
children,
and,
review,
the,
literature,
.,
DESIGN,
/,
METHODS,
:,
We,
retrospectively,
reviewed,
the,
medical,
records,
of,
5,
children,
treated,
with,
intravenous,
ribavirin,
for,
documented,
severe,
adenovirus,
disease,
.,
Two,O
patients,O
developed,O
adenovirus,B
hemorrhagic,I
cystitis,I
after,O
cardiac,O
and,O
bone,O
marrow,O
transplants,O
",",O
respectively,O
The,O
remaining,O
infant,O
had,O
recently,O
undergone,O
a,O
cardiac,B
transplant,I
.,O
Intravenous,O
ribavirin,B
was,O
administered,O
on,O
a,O
compassionate,O
-,O
use,O
protocol,O
.,O
RESULTS,O
:,O
Complete,O
clinical,O
recovery,O
followed,O
later,O
by,O
viral,O
clearance,O
was,O
observed,O
in,O
2,O
children,O
:,O
the,O
cardiac,B
transplant,I
recipient,O
with,O
adenovirus,B
hemorrhagic,I
cystitis,I
and,O
the,O
immunocompetent,O
neonate,O
with,O
adenovirus,B
pneumonia,I
.,O
The,O
remaining,O
3,O
children,O
died,O
of,O
adenovirus,B
disease,I
.,O
Intravenous,O
ribavirin,B
therapy,I
was,O
well,O
tolerated,O
Although,
intravenous,
ribavirin,
was,
not,
effective,
for,
all,
children,
with,
severe,
adenovirus,
disease,
in,
this,
series,
or,
in,
the,
literature,
",",
therapy,
is,
unlikely,
to,
be,
of,
benefit,
if,
begun,
late,
in,
the,
course,
of,
the,
infection,
.,
Early,
identification,
",",
eg,
by,
polymerase,
chain,
reaction,
of,
those,
patients,
at,
risk,
of,
disseminated,
adenovirus,
disease,
may,
permit,
earlier,
antiviral,
treatment,
and,
better,
evaluation,
of,
therapeutic,
response,
.,
CONCLUSIONS,O
:,O
Two,O
of,O
5,O
children,O
with,O
severe,O
adenovirus,B
disease,I
treated,O
with,O
intravenous,O
ribavirin,B
recovered,O
.,O
The,O
availability,O
of,O
newer,O
rapid,O
diagnostic,O
techniques,O
",",O
such,O
as,O
polymerase,O
chain,O
reaction,O
Delayed,O
asystolic,O
cardiac,O
arrest,O
after,O
diltiazem,B
overdose,O
;,O
resuscitation,O
with,O
high,O
dose,O
intravenous,O
calcium,B
.,O
A,O
51,O
year,O
old,O
man,O
took,O
a,O
mixed,O
overdose,O
including,O
1,O
.,O
8,O
-,O
3,O
.,O
6,O
g,O
of,O
diltiazem,B
",",O
paracetamol,B
",",O
aspirin,B
",",O
isosorbide,B
nitrate,I
",",O
and,O
alcohol,B
.,O
He,O
initially,O
presented,O
to,O
hospital,O
after,O
six,O
hours,O
with,O
mild,O
hypotension,O
and,O
was,O
treated,O
with,O
activated,O
charcoal,O
and,O
intravenous,O
fluids,O
.,O
Eighteen,O
hours,O
after,O
the,O
overdose,O
he,O
had,O
two,O
generalised,B
tonic,I
-,I
clonic,I
seizures,I
.,O
The,O
patient,O
remained,O
unresponsive,O
with,O
junctional,O
bradycardia,O
",",O
unrecordable,O
blood,O
pressure,O
",",O
and,O
then,O
became,O
asystolic,O
.,O
He,O
was,O
resuscitated,O
with,O
high,O
dose,O
(,O
13,O
.,O
5,O
g,O
),O
intravenous,O
calcium,B
and,O
adrenaline,B
(,I
epinephrine,I
),I
.,O
He,O
required,O
inotropic,O
support,O
and,O
temporary,O
pacing,O
over,O
the,O
next,O
48,O
hours,O
.,O
This,O
case,O
suggests,O
The,O
case,O
also,O
highlights,O
the,O
problems,O
with,O
delayed,O
toxicity,O
when,O
whole,O
bowel,O
irrigation,O
is,O
not,O
Unfractionated,O
heparin,O
(,O
UH,B
),O
is,O
currently,O
the,O
substitute,O
for,O
selected,O
patients,O
.,O
Low,O
-,O
METHODS,
:,
For,
this,
paper,
",",
the,
current,
medical,
literature,
on,
LMWH,
in,
patients,
with,
mechanical,
heart,
valves,
was,
extensively,
reviewed,
.,
RESULTS,
:,
There,
were,
eight,
series,
and,
six,
case,
reports,
.,
None,
of,
the,
studies,
was,
randomized,
",",
and,
only,
one,
was,
prospective,
.,
Data,
to,
establish,
the,
thromboembolic,
risk,
were,
incomplete,
.,
After,O
excluding,O
case,B
reports,I
",",O
the,O
following,O
groups,O
were,O
constructed,O
:,O
(,O
a,O
),O
short,B
-,I
term,I
administration,I
",",O
after,O
valve,O
insertion,O
(,O
n,O
=,O
212,O
),O
;,O
(,O
b,O
),O
short,B
-,I
term,I
",",O
perioperative,O
(,O
noncardiac,O
),O
/,O
periprocedural,O
(,O
n,O
=,O
114,O
),O
;,O
(,O
c,O
),O
long,B
-,I
term,I
",",O
due,O
to,O
intolerance,O
to,O
OAC,B
(,O
n,O
=,O
16,O
),O
;,O
(,O
d,O
),O
long,B
-,I
term,I
",",O
in,O
pregnancy,O
(,O
n,O
=,O
10,O
),O
.,O
The,
incidence,
rate,
of,
thromboembolism,
was,
0,
.,
9,
%,
for,
all,
the,
studies,
and,
0,
.,
5,
",",
0,
",",
20,
",",
and,
0,
%,
in,
groups,
a,
",",
b,
",",
c,
",",
and,
d,
",",
respectively,
;,
for,
hemorrhage,
",",
the,
overall,
rate,
was,
3,
.,
4,
%,
(,
3,
.,
8,
",",
2,
.,
6,
",",
10,
",",
and,
0,
%,
for,
the,
respective,
groups,
),
.,
CONCLUSIONS,
:,
In,
patients,
with,
mechanical,
heart,
valves,
",",
short,
-,
term,
LMWH,
therapy,
compares,
favorably,
with,
UH,
.,
Data,O
on,O
mid,B
-,I
and,I
long,B
-,I
term,I
LMWH,B
administration,O
in,O
these,O
patients,O
are,O
sparse,O
.,O
Further,O
randomized,O
studies,O
are,O
needed,O
to,O
confirm,O
the,O
safety,O
and,O
precise,O
indications,O
for,O
the,O
use,O
of,O
LMWH,B
in,O
patients,O
with,O
mechanical,O
heart,O
valves,O
.,O
Cardiac,O
arrest,O
after,O
intravenous,O
metoclopramide,B
-,I
a,I
case,I
of,I
five,I
repeated,I
injections,I
of,I
metoclopramide,I
causing,O
five,O
episodes,O
of,O
cardiac,O
arrest,O
.,O
We,O
describe,O
a,O
patient,O
where,O
intravenous,O
injection,O
of,O
metoclopramide,B
was,O
immediately,O
followed,O
by,O
asystole,O
repeatedl...or,O
asystole,O
.,O
The,O
patient,O
received,O
metoclopramide,B
10,O
mg,O
i,O
.,O
v,O
five,O
times,O
during,O
48,O
h,O
.,O
After,O
interviewing,O
the,O
attending,O
nurses,O
and,O
reviewing,O
the,O
written,O
documentation,O
",",O
it,O
is,O
clear,O
that,O
every,O
administration,O
of,O
metoclopramide,B
was,O
immediately,O
(,O
within,O
s,O
),O
followed,O
by,O
asystole,O
.,O
The,O
asystole,O
lasted,O
15,O
-,O
30,O
s,O
on,O
four,O
occasions,O
",",O
on,O
one,O
occasion,O
it,O
lasted,O
2,O
min,O
.,O
The,O
patient,O
received,O
atropine,B
0,I
.,I
5,I
-,I
1,I
mg,I
and,O
chest,O
compressions,O
",",O
before,O
sinus,O
rhythm,O
again,O
took,O
over,O
.,O
We,O
interpret,O
this,O
as,O
episodes,O
of,O
cardiac,O
arrest,O
caused,O
by,O
metoclopramide,B
.,O
The,O
rapid,O
injection,O
via,O
the,O
central,O
venous,O
route,O
and,O
the,O
concomitant,O
tapering,O
of,O
dopamine,O
infusion,O
might,O
have,O
contributed,O
in,O
precipitating,O
the,O
adverse,O
drug,O
reaction,O
.,O
Immunohistochemical,O
study,O
on,O
inducible,B-Chemical
type,I-Chemical
of,I-Chemical
nitric,I-Chemical
oxide,I-Chemical
(,O
iNOS,B-Chemical
),O
",",O
basic,B-Chemical
fibroblast,I-Chemical
growth,I-Chemical
factor,I-Chemical
(,O
bFGF,B-Chemical
),O
and,O
tumor,B-Chemical
growth,I-Chemical
factor,I-Chemical
-,O
beta1,I-Chemical
(,O
TGF,B-Chemical
-,I-Chemical
beta1,I-Chemical
),O
in,O
arteritis,O
induced,O
in,O
rats,O
by,O
fenoldopam,O
and,O
theophylline,O
",",O
vasodilators,O
.,O
Arteritis,O
induced,O
in,O
rats,O
by,O
vasodilators,O
",",O
fenoldopam,O
and,O
theophylline,O
",",O
was,O
examined,O
immunohistochemically,O
for,O
expressions,O
of,O
inducible,B-Chemical
type,I-Chemical
of,I-Chemical
nitric,I-Chemical
oxide,I-Chemical
synthase,I-Chemical
(,O
iNOS,B-Chemical
),O
",",O
basic,B-Chemical
fibroblast,I-Chemical
growth,I-Chemical
factor,I-Chemical
(,O
bFGF,B-Chemical
),O
and,O
tumor,B-Chemical
growth,I-Chemical
factor,I-Chemical
-,O
beta1,I-Chemical
(,O
TGF,B-Chemical
-,I-Chemical
beta1,I-Chemical
),O
.,O
Rats,O
were,O
administered,O
fenoldopam,B-Chemical
for,O
24,O
hours,O
by,O
intravenous,O
infusion,O
with,O
or,O
without,O
following,O
repeate...aphans,O
on,O
and,O
after,O
5,O
DPI,O
.,O
These,O
results,O
suggest,O
that,O
the,O
peak,O
expression,O
of,O
iNOS,B
antigen,I
was,O
followed,O
by,O
that,O
of,O
bFGF,B
The,O
striatum,B
as,O
a,O
target,O
for,O
anti,O
-,O
rigor,O
effects,O
of,O
an,O
antagonist,O
of,O
mGluR1,B
",",O
but,O
not,O
an,O
agonist,O
of,O
group,O
II,B
metabotropic,I
glutamate,I
receptors,I
.,O
The,O
aim,O
of,O
the,O
present,O
study,O
was,O
to,O
find,O
out,O
whether,O
the,O
metabotropic,O
receptor,O
1,O
(,O
mGluR1,B
),O
and,O
group,O
II,B
mGluRs,I
",",O
localized,O
in,O
the,O
striatum,B
",",O
are,O
involved,O
in,O
antiparkinsonian,O
-,O
like,O
effects,O
in,O
rats,O
.,O
Haloperidol,B-chemical
(,O
1,O
mg,O
/,O
kg,O
ip,O
),O
induced,O
parkinsonian,O
-,O
like,O
muscle,O
rigidity,O
",",O
measured,O
as,O
an,O
increased,O
resistance,O
of,O
a,O
rat,O
',O
s,O
hind,O
foot,O
to,O
passive,O
flexion,O
and,O
extension,O
at,O
the,O
ankle,O
joint,O
.,O
(,O
RS,B-chemical
),O
-,O
1,O
-,O
aminoindan,B-chemical
-,O
1,O
",",O
5,O
-,O
dicarboxylic,O
acid,O
(,O
AIDA,B-chemical
;,O
0,O
.,O
5,O
-,O
15,O
microg,O
/,O
0,O
.,O
5,O
microl,O
),O
",",O
a,O
potent,O
and,O
selective,O
mGluR1,O
antagonist,O
",",O
or,O
(,O
2R,O
",",O
4R,O
),O
-,O
4,O
-,O
aminopyrrolidine,B-chemical
-,O
2,O
",",O
4,O
-,O
dicarboxylate,O
(,O
2R,O
",",O
4R,O
-,O
APDC,B-chemical
;,O
7,O
.,O
5,O
-,O
15,O
microg,B
/,O
0,O
.,O
5,O
microl,B
),O
",",O
a,O
selective,O
group,O
II,O
agonist,O
",",O
was,O
injected,O
bilaterally,O
into,O
the,O
striatum,O
of,O
haloperidol,O
-,O
treated,O
animals,O
.,O
AIDA,B
in,O
doses,O
of,O
7,O
.,O
5,O
-,O
15,O
microg,B
/,O
0,O
.,O
5,O
microl,B
diminished,O
the,O
haloperidol,O
-,O
induced,O
muscle,O
rigidity,O
.,O
In,O
contrast,O
",",O
2R,B
",",O
4R,B
-,I
APDC,I
injections,O
were,O
ineffective,O
.,O
The,O
present,O
results,O
may,O
suggest,O
that,O
the,O
blockade,O
of,O
striatal,B
mGluR1,I
",",O
but,O
not,O
the,O
stimulation,O
of,O
group,O
II,O
mGluRs,I
",",O
may,O
ameliorate,O
parkinsonian,O
muscle,O
rigidity,O
.,O
A,O
phase,O
II,O
study,O
of,O
thalidomide,B
in,O
advanced,O
metastatic,O
renal,O
cell,O
carcinoma,O
.,O
OBJECTIVES,O
:,O
To,O
evaluate,O
the,O
toxicity,O
and,O
activity,O
of,O
thalidomide,B
in,O
patients,O
with,O
advanced,O
metastatic,O
renal,O
cell,O
cancer,O
and,O
to,O
measure,O
changes,O
of,O
one,O
angiogenic,O
factor,O
",",O
vascular,O
endothelial,O
growth,O
factor,O
(,O
VEGF,B
),O
165,I
",",O
with,O
therapy,O
.,O
PATIENTS,
AND,
METHODS,
:,
29,
patients,
were,
enrolled,
on,
a,
study,
of,
thalidomide,
using,
an,
intra,
-,
patient,
dose,
escalation,
schedule,
.,
Patients,
began,
thalidomide,
at,
400,
mg,
/,
d,
and,
escalated,
as,
tolerated,
to,
1200,
mg,
/,
d,
by,
day,
54,
.,
Fifty,
-,
nine,
per,
cent,
of,
patients,
had,
had,
previous,
therapy,
with,
IL,
-,
2,
and,
52,
%,
were,
performance,
status,
2,
or,
3,
.,
Systemic,O
plasma,O
VEGF165,B
levels,O
were,O
measured,O
by,O
dual,O
monoclonal,O
ELISA,O
in,O
8,O
patients,O
.,O
RESULTS,O
:,O
24,O
patients,O
were,O
evaluable,O
for,O
response,O
with,O
one,O
partial,O
response,O
of,O
11,O
months,O
duration,O
of,O
a,O
patient,O
with,O
hepatic,O
and,O
pulmonary,O
metastases,O
(,O
4,O
%,O
),O
",",O
one,O
minor,O
response,O
",",O
and,O
2,O
patients,O
stable,O
for,O
over,O
6,O
months,O
.,O
Somnolence,O
and,O
constipation,O
were,O
prominent,O
toxicities,O
and,O
most,O
patients,O
could,O
not,O
tolerate,O
the,O
1200,O
mg,O
/,O
day,O
dose,O
level,O
.,O
Systemic,O
plasma,O
VEGF165,B
levels,O
did,O
not,O
change,O
with,O
therapy,O
.,O
CONCLUSION,O
:,O
These,O
results,O
are,O
consistent,O
with,O
a,O
low,O
level,O
of,O
activity,O
of,O
thalidomide,B
in,O
renal,O
cell,O
carcinoma,O
.,O
Administration,O
of,O
doses,O
over,O
800,O
mg,O
/,O
day,O
was,O
difficult,O
to,O
achieve,O
in,O
this,O
patient,O
population,O
",",O
however,O
lower,O
doses,O
were,O
practical,O
.,O
The,O
dose,O
-,O
response,O
relationship,O
",",O
if,O
any,O
",",O
of,O
thalidomide,B
for,O
renal,O
cell,O
carcinoma,O
is,O
One,O
hundred,O
and,O
thirty,O
-,O
five,O
patients,O
were,O
assigned,O
to,O
one,O
of,O
three,O
groups,O
in,O
a,O
6,O
mg,O
x,O
kg,O
(,O
-,O
1,O
),O
.,O
Morphine,B
0,O
.,O
1,O
mg,O
x,O
kg,O
(,O
-,O
1,O
),O
Following,
administration,
of,
these,
agents,
",",
the,
presence,
",",
and,
degree,
of,
fasciculation,
were,
assessed,
visually,
on,
a,
four,
point,
scale,
by,
one,
investigator,
who,
was,
blinded,
to,
the,
drug,
administered,
.,
The,
blood,
pressure,
and,
heart,
rate,
of,
each,
patient,
were,
monitored,
on,
nine,
occasions,
.,
Twenty,
-,
four,
hours,
later,
",",
any,
myalgia,
experienced,
was,
assessed,
according,
to,
a,
structured,
questionaire,
and,
graded,
by,
a,
four,
point,
scale,
by,
one,
investigator,
blinded,
to,
the,
intraoperative,
management,
.,
The,O
results,O
indicate,O
that,O
muscle,O
fasciculation,O
was,O
not,O
found,O
in,O
Group,O
PR,O
while,O
the,O
patients,O
in,O
The,O
changes,O
in,O
systolic,O
and,O
diastolic,O
blood,O
pressure,O
and,O
heart,O
rate,O
were,O
not,O
significant,O
among,O
the,Ellipsis
2,B
-,I
subunits,I
.,O
Sodium,B
channel,I
beta,B
-,I
subunits,I
modulate,O
channel,O
gating,O
",",O
assembly,O
",",O
and,O
cell,O
surface,O
expression,O
in,O
heterologous,O
cell,O
systems,O
.,O
We,O
generated,O
beta2,B
(,I
-,I
/,I
-,I
),I
mice,O
to,O
investigate,O
the,O
role,O
of,O
beta2,B
in,O
control,O
of,O
sodium,O
channel,O
density,O
",",O
localization,O
",",O
and,O
function,O
in,O
neurons,O
in,O
vivo,O
.,O
Measurements,O
of,O
[,O
(,O
3,O
),O
H,O
],O
saxitoxin,B
(,I
STX,I
),I
binding,O
showed,O
a,O
significant,O
reduction,O
in,O
the,O
level,O
of,O
plasma,O
membrane,O
sodium,O
channels,O
in,O
beta2,B
(,I
-,I
/,I
-,I
),I
neurons,O
.,O
The,
loss,
of,
beta2,
resulted,
in,
negative,
shifts,
in,
the,
voltage,
dependence,
of,
inactivation,
as,
well,
as,
significant,
decreases,
in,
sodium,
current,
density,
in,
acutely,
dissociated,
hippocampal,
neurons,
.,
The,
integral,
of,
the,
compound,
action,
potential,
in,
optic,
nerve,
was,
significantly,
reduced,
",",
and,
the,
threshold,
for,
action,
potential,
generation,
was,
increased,
",",
indicating,
a,
reduction,
in,
the,
level,
of,
functional,
plasma,
membrane,
sodium,
channels,
.,
In,
contrast,
",",
the,
conduction,
velocity,
",",
the,
number,
and,
size,
of,
axons,
in,
the,
optic,
nerve,
",",
and,
the,
specific,
localization,
of,
Na,
(,
v,
),
1,
.,
6,
channels,
in,
the,
nodes,
of,
Ranvier,
were,
unchanged,
.,
beta2,
(,
-,
/,
-,
),
mice,
displayed,
increased,
susceptibility,
to,
seizures,
",",
as,
indicated,
by,
reduced,
latency,
and,
threshold,
for,
pilocarpine,
-,
induced,
seizures,
",",
but,
seemed,
normal,
in,
other,
neurological,
tests,
.,
Our,O
observations,O
show,O
that,O
beta2,B
-,I
subunits,O
play,O
an,O
important,O
role,O
in,O
the,O
regulation,O
of,O
sodium,B
cha...cidual,B
liver,I
failure,I
possibly,O
associated,O
with,O
concurrent,O
use,O
of,O
bupropion,B
and,I
carbimazole,I
.,O
OBJECTIVE,O
:,O
To,O
report,O
a,O
case,O
of,O
fatal,O
liver,O
failure,O
possibly,O
associated,O
with,O
concurrent,O
use,O
of,O
bupropion,O
and,O
carbimazole,O
.,O
CASE,
SUMMARY,
:,
A,
41,
-,
year,
-,
old,
Chinese,
man,
with,
a,
history,
of,
hyperthyroidism,
had,
been,
treated,
with,
carbimazole,
and,
propranolol,
for,
the,
past,
5,
years,
.,
He,
received,
a,
10,
-,
day,
course,
of,
bupropion,
as,
an,
aid,
for,
smoking,
cessation,
10,
weeks,
prior,
to,
presentation,
.,
He,
developed,
acute,
liver,
failure,
with,
rapid,
deterioration,
of,
renal,
function,
.,
Liver,B
biopsy,I
showed,O
evidence,O
of,O
nonspecific,O
drug,O
-,O
induced,O
acute,O
liver,O
injury,O
.,O
His,O
condition,O
was,O
further,O
complicated,O
by,O
sepsis,O
and,O
coagulopathy,O
.,O
Death,O
resulted,O
19,O
days,O
after,O
the,O
onset,O
of,O
symptoms,O
.,O
The,B
likelihood,O
that,O
bupropion,B
induced,O
hepatotoxicity,O
in,O
our,O
patient,O
was,O
possible,O
",",O
based,O
on,O
the,O
Naranjo,O
probability,O
scale,O
.,O
DISCUSSION,
:,
Although,
there,
is,
increasing,
evidence,
of,
hepatotoxicity,
induced,
by,
bupropion,
",",
this,
is,
the,
first,
case,
of,
fatality,
that,
could,
have,
resulted,
from,
acute,
liver,
failure,
in,
a,
patient,
receiving,
bupropion,
while,
on,
concomitant,
treatment,
with,
carbimazole,
.,
CONCLUSIONS,
:,
Clinicians,
should,
be,
aware,
of,
the,
possibility,
of,
acute,
liver,
insult,
induced,
by,
bupropion,
given,
concurrently,
with,
other,
hepatotoxic,
drugs,
.,
Pyeloureteral,B
filling,I
defects,I
associated,O
with,O
systemic,O
anticoagulation,B
:,I
a,I
case,I
report,I
.,I
The,O
etiology,O
of,O
pyeloureteritis,B
cystica,I
has,O
long,O
been,O
attributed,O
to,O
chronic,O
infection,O
and,O
inflammation,O
.,O
A,B
case,I
is,O
presented,O
that,O
is,O
unique,O
in,O
that,O
the,O
acute,O
onset,O
and,O
the,O
rapid,O
resolution,O
of,O
pyeloureteral,B
filling,I
defects,I
in,I
this,I
patient,I
were,O
documented,O
by,O
radiography,O
.,O
There,O
is,O
no,O
evidence,O
of,O
antecedent,O
or,O
concurrent,O
infection,O
in,O
this,O
patient,O
.,O
The,O
disease,O
Nephrotoxic,O
effects,O
in,O
high,O
-,O
risk,O
patients,O
undergoing,O
angiography,O
.,O
BACKGROUND,O
:,O
The,O
use,O
of,O
iodinated,B-Chemical
contrast,I-Chemical
medium,I-Chemical
can,O
result,O
in,O
nephropathy,O
.,O
Whether,O
iso,B-Chemical
-,I-Chemical
osmolar,I-Chemical
contrast,I-Chemical
medium,I-Chemical
is,O
less,O
nephrotoxic,O
than,O
low,B-Chemical
-,I-Chemical
osmolar,I-Chemical
contrast,I-Chemical
medium,I-Chemical
in,O
high,O
-,O
risk,O
patients,O
is,O
uncertain,O
.,O
METHODS,O
:,O
We,O
conducted,O
a,O
randomized,O
",",O
double,O
-,O
blind,O
",",O
prospective,O
",",O
multicenter,O
study,O
comparing,O
the,O
nephrotoxic,O
effects,O
of,O
an,O
iso,B-Chemical
-,I-Chemical
osmolar,I-Chemical
",",I-Chemical
dimeric,I-Chemical
",",I-Chemical
nonionic,I-Chemical
contrast,I-Chemical
medium,I-Chemical
",",I-Chemical
iodixanol,I-Chemical
",",I-Chemical
with,O
those,O
of,O
a,O
low,B-Chemical
-,I-Chemical
osmolar,I-Chemical
",",I-Chemical
nonionic,I-Chemical
",",I-Chemical
monomeric,I-Chemical
contrast,I-Chemical
medium,I-Chemical
",",I-Chemical
iohexol,I-Chemical
.,O
The,O
study,O
involved,O
129,O
patients,O
with,O
diabetes,O
with,O
serum,O
creatinine,B
concentrations,O
of,O
1,O
.,O
5,O
to,O
...about,O
serum,O
creatinine,B
concentration,O
during,O
the,O
three,O
days,O
after,O
angiography,O
.,O
Other,O
end,O
points,O
were,O
an,O
increase,O
in,O
the,O
creatinine,B
concentration,I
of,I
0,I
.,I
5,I
mg,I
per,I
deciliter,I
or,I
more,I
",",I
an,I
increase,I
of,I
1,I
.,I
0,I
mg,I
per,I
deciliter,I
or,I
more,I
",",I
and,I
a,I
change,O
in,O
the,O
creatinine,B
concentration,I
from,I
day,I
0,I
to,I
day,I
7,I
.,I
RESULTS,O
:,O
The,O
creatinine,B
concentration,I
increased,O
significantly,O
less,O
in,O
patients,O
who,O
received,O
iodixanol,O
.,O
From,O
day,O
0,O
to,O
day,O
3,O
",",O
the,O
mean,O
peak,O
increase,O
in,O
creatinine,B
was,O
0,O
.,O
13,O
mg,O
22,O
],O
),O
.,O
Two,O
of,O
the,O
64,O
patients,O
in,O
the,O
iodixanol,B
group,I
(,O
3,O
percent,O
),O
had,O
a,O
increase,O
in,O
the,O
creatinine,O
concentration,O
of,O
0,O
.,O
5,O
mg,O
per,O
deciliter,O
or,O
more,O
",",O
as,O
compared,O
with,O
17,O
of,O
the,O
65,O
patients,O
in,O
the,O
iohexol,B
group,I
(,O
26,O
percent,O
),O
(,O
P,O
=,O
0,O
.,O
002,O
;,O
odds,O
ratio,O
for,O
such,O
an,O
increase,O
in,O
the,O
iodixanol,B
group,I
",",O
0,O
.,O
09,O
[,O
95,B
percent,I
confidence,I
interval,I
",",O
0,B
.,I
02,I
to,I
0,I
.,I
41,I
],I
),O
.,O
No,O
patient,O
receiving,O
iodixanol,B
had,O
an,O
increase,O
of,O
1,O
.,O
0,B
mg,I
per,I
deciliter,I
or,O
more,O
",",O
but,O
10,O
patients,O
in,O
the,O
iohexol,B
group,I
(,I
15,I
percent,I
),I
did,O
.,O
The,O
mean,O
change,O
in,O
the,O
creatinine,B
concentration,I
from,O
day,O
0,O
to,O
day,O
7,O
was,O
0,O
.,O
07,B
mg,I
per,I
deciliter,I
in,O
the,O
iodixanol,B
group,I
and,O
0,O
.,O
24,
mg,
per,
deciliter,
in,
the,
iohexol,
group,
(,
P,
=,
0,
.,
003,
;,
value,
in,
the,
iodixanol,
group,
minus,
the,
value,
in,
the,
iohexol,
group,
",",
-,
0,
.,
17,
mg,
per,
deciliter,
[,
95,
percent,
confidence,
interval,
",",
-,
0,
.,
34,
to,
-,
0,
.,
07,
],
),
.,
CONCLUSIONS,
:,
Nephropathy,
induced,
by,
contrast,
medium,
may,
be,
less,
likely,
to,
develop,
in,
high,
-,
risk,
patients,
when,
iodixanol,
is,
used,
rather,
than,
a,
low,
-,
osmolar,
",",
nonionic,
contrast,
medium,
.,
Protective,O
effect,O
of,O
edaravone,B
against,O
streptomycin,B
-,I
induced,I
vestibulotoxicity,I
in,O
the,O
guinea,O
pig,O
.,O
This,O
study,O
investigated,O
alleviation,O
of,O
streptomycin,B
-,I
induced,I
vestibulotoxicity,I
by,O
edaravone,B
in,O
guinea,O
pigs,O
.,O
Edaravone,B
",",O
a,O
free,O
radical,O
scavenger,O
",",O
has,O
potent,O
free,O
radical,O
quenching,O
action,O
and,O
is,O
used,O
in,O
clinical,O
practice,O
to,O
treat,O
cerebral,O
infarction,O
.,O
Streptomycin,B-chemical
was,O
administered,O
to,O
the,O
inner,O
ear,O
by,O
osmotic,O
pump,O
for,O
24,O
h,O
",",O
and,O
edaravone,B...O
injected,O
with,O
edaravone,B-chemical
.,O
We,O
observed,O
horizontal,O
vestibulo,O
-,O
ocular,O
reflex,O
as,O
a,O
marker,O
.,O
These,O
results,O
suggest,O
that,O
edaravone,B
suppresses,O
streptomycin,B
-,I
induced,I
vestibulotoxicity,I
.,O
Levodopa,B
-,I
induced,I
oroma...n,B
',I
s,I
disease,I
and,O
multiple,O
system,O
atrophy,O
.,O
Cranial,B
dystonias,I
are,O
rare,O
in,O
patients,O
with,O
progressive,O
supranuclear,O
palsy,O
(,O
PSP,O
),O
.,O
In,
this,
report,
we,
describe,
an,
unusual,
case,
of,
reversible,
levodopa,
-,
induced,
Oromandibular,
dystonia,
(,
OMD,
),
in,
a,
PSP,
patient,
to,
highlight,
the,
importance,
of,
recognizing,
this,
drug,
related,
complication,
in,
the,
management,
of,
PSP,
",",
and,
discuss,
the,
possible,
underlying,
pathophysiology,
.,
Case,
report,
:,
Dexatrim,
(,
Phenylpropanolamine,
),
as,
a,
cause,
of,
myocardial,
infarction,
.,
Phenylpropanolamine,B
(,O
PPA,B
),O
is,O
a,O
sympathetic,O
amine,O
used,O
in,O
over,O
-,O
the,O
-,O
counter,O
cold,O
"remedie...ção de PPA com lesões miocárdicas, especialmente quando há overdose.",O
"
",O
We,O
report,O
here,O
the,O
first,O
case,O
of,O
Dexatrim,B
(,O
PPA,I
),O
-,O
induced,O
myocardial,O
injury,O
in,O
a,O
young,O
woman,O
who,O
was,O
using,O
it,O
at,O
recommended,O
doses,O
for,O
weight,O
control,O
.,O
In,O
addition,O
",",O
we,O
review,O
the,O
7,O
other,O
cases,O
of,O
PPA,B
related,O
myocardial,O
injury,O
that,O
have,O
been,O
reported,O
so,O
far,O
.,O
Physicians,O
and,O
patients,O
should,O
be,O
alert,O
to,O
the,O
potential,O
cardiac,O
risk,O
associated,O
with,O
the,O
use,O
of,O
PPA,B
",",O
even,O
at,O
doses,O
generally,O
considered,O
to,O
be,O
safe,O
.,O
Differential,
diagnosis,
of,
high,
serum,
creatine,
kinase,
levels,
in,
systemic,
lupus,
erythematosus,
.,
We,
report,
the,
clinical,
and,
bioptic,
findings,
for,
a,
57,
-,
year,
-,
old,
woman,
with,
severe,
chloroquine,
-,
induced,
myopathy,
.,
Since,
1989,
",",
she,
had,
been,
suffering,
from,
systemic,
lupus,
erythematosus,
(,
SLE,
),
with,
renal,
involvement,
and,
undergone,
periods,
of,
treatment,
with,
azathioprine,
and,
cyclophosphamide,
.,
Additional,
therapy,
with,
chloroquine,
(,
CQ,
),
was,
started,
because,
of,
arthralgia,
.,
At,
the,
same,
time,
",",
slightly,
increased,
creatine,
kinase,
(,
CK,
),
levels,
were,
noted,
.,
Myositis,
was,
suspected,
",",
and,
the,
patient,
was,
treated,
with,
steroids,
.,
The,
CK,
increase,
persisted,
",",
however,
",",
and,
she,
developed,
progressive,
muscular,
weakness,
and,
muscular,
atrophy,
.,
Routine,
controls,
revealed,
markedly,
elevated,
CK,
levels,
of,
1,
",",
700,
U,
/,
l,
.,
The,
neurological,
and,
electrophysiological,
findings,
were,
not,
typical,
of,
myositis,
.,
Thus,
",",
muscle,
biopsy,
of,
the,
deltoid,
muscle,
was,
performed,
in,
order,
to,
exclude,
polymyositis,
or,
toxic,
myopathy,
.,
As,
it,
revealed,
chloroquine,
-,
induced,
myopathy,
",",
medication,
was,
stopped,
.,
Discriminating,O
between,O
primary,O
SLE,B
-,I
induced,O
affection,O
of,O
the,O
musculoskeletal,O
system,O
and,O
drug,O
-,O
induced,O
side,O
effects,O
is,O
important,O
for,O
appropriate,O
treatment,O
of,O
SLE,B
patients,O
.,O
Seizure,O
associated,O
with,O
sleep,O
deprivation,O
and,O
sustained,O
-,O
release,O
bupropion,O
.,O
This,O
case,O
report,O
describes,O
a,O
generalized,O
seizure,O
associated,O
with,O
sustained,O
-,O
release,O
bupropion,O
use,O
and,O
sleep,O
deprivation,O
.,O
The,O
subject,O
",",O
a,O
31,O
-,O
The,O
patient,O
had,O
no,O
other,O
risk,O
factors,O
for,O
seizures,O
.,O
We,O
suggest,O
that,O
sleep,O
deprivation,O
may,O
add,O
to,O
the,O
risk,O
of,O
bupropion,B
-,I
associated,I
seizures,I
.,O
Postoperative,O
myalgia,O
after,O
succinylcholine,B
:,O
no,O
evidence,O
for,O
an,O
inflammatory,O
origin,O
.,O
A,O
common,O
side,O
effect,O
associated,O
with,O
succinylcholine,B
is,O
postoperative,O
myalgia,O
.,O
The,O
pathogenesis,O
of,O
this,O
myalgia,O
is,O
still,O
unclear,O
;,O
inflammation,O
has,O
been,O
suggested,O
but,O
without,O
convinc...treated,O
with,O
saline,O
or,O
dexamethasone,B
before,O
succinylcholine,I
(,O
n,O
=,O
32,O
for,O
each,O
),O
.,O
"
",O
"
",O
Incidence,O
and,O
severity,O
of,O
myalgia,O
did,O
not,O
differ,O
significantly,O
between,O
the,O
two,O
groups,O
:,O
15,O
patients,O
in,O
the,O
dexamethasone,B
group,I
complained,O
of,O
myalgia,O
compared,O
with,O
18,O
patients,O
in,O
the,O
saline,B
group,I
",",O
and,O
severe,O
myalgia,O
was,O
reported,O
by,O
five,O
patients,O
and,O
three,O
patients,O
",",O
respectively,O
(,O
not,O
significant,O
),O
.,O
At,O
48,O
h,O
after,O
surgery,O
",",O
12,O
patients,O
in,O
both,O
groups,O
still,O
suffered,O
from,O
myalgia,O
(,O
not,O
significant,O
),O
.,O
In,O
addition,O
",",O
interleukin,B
-,O
6,I
(,I
IL,I
-,I
6,I
),I
as,O
an,O
early,O
marker,O
of,O
inflammation,O
was,O
assessed,O
in,O
a,O
subgroup,O
of,O
10,O
patients,O
pretreated,O
with,O
saline,O
.,O
We,O
found,O
an,O
increase,O
of,O
IL,B
-,I
6,I
for,O
only,O
three,O
patients,O
",",O
but,O
only,O
one,O
patient,O
reported,O
myalgia,O
;,O
no,O
relationship,O
between,O
myalgia,O
and,O
the,O
increase,O
of,O
IL,B
-,I
6,I
was,O
found,O
.,O
In,O
conclusion,O
",",O
there,O
is,O
no,O
evidence,O
for,O
an,O
inflammatory,O
origin,O
of,O
succinylcholine,B
-,I
associated,I
myalgia,I
.,O
IMPLICATIONS,O
:,O
Administration,O
of,O
dexamethasone,O
before,O
succinylcholine,B
was,O
not,O
effective,O
in,O
decreasing,O
the,O
incidence,O
or,O
the,O
severity,O
of,O
succinylcholine,B
-,I
induced,I
postoperative,I
myalgia,I
.,O
Furthermore,O
",",O
there,O
was,O
no,O
significant,O
relationship,O
between,O
postoperative,O
myalgia,O
and,O
time,O
course,O
of,O
interleukin,B
-,I
6,I
concentrations,I
",",O
a,O
marker,O
of,O
inflammation,O
.,O
Pretreatment,O
with,O
dexamethasone,B
is,O
not,O
justified,O
to,O
prevent,O
postoperative,O
myalgia,O
after,O
succinylcholine,B
.,O
Effect,O
of,O
lindane,B
on,O
hepatic,O
and,O
brain,O
cytochrome,O
P450s,O
and,O
influence,O
of,O
P450,O
modulation,O
in,O
lindane,O
induced,O
neurotoxicity,O
.,O
Oral,O
administration,O
of,O
lindane,B
(,O
2,O
.,O
5,O
",",O
5,O
",",O
10,O
and,O
15,O
mg,O
/,O
kg,O
",",O
body,O
weight,O
),O
for,O
5,O
days,O
was,O
found,O
to,O
produce,O
a,O
dose,O
-,O
dependent,O
increase,O
in,O
the,O
activity,O
of,O
P450,B
dependent,I
7,I
-,I
ethoxyresorufin,I
-,I
O,I
-,I
deethylase,I
(,O
EROD,O
),O
",",O
7,O
-,O
pentoxyresorufin,O
-,O
O,O
-,O
dealkylase,O
(,O
PROD,O
),O
and,O
N,B
-,I
nitrosodimethylamine,I
demethylase,O
(,O
NDMA,O
-,O
d,O
),O
in,O
rat,O
brain,O
and,O
liver,O
.,O
A,O
significant,O
increase,O
in,O
the,O
hepatic,B
and,O
brain,B
P450,I
monooxygenases,I
was,O
also,O
observed,O
when,O
the,O
Western,O
blotting,O
studies,O
have,O
indicated,O
that,O
the,O
increase,O
in,O
the,O
P450,B
enzymes,I
could,O
be,O
due,O
to,O
...2B1,B
/,O
2B2,I
",",O
1A1,B
/,O
1A2,I
and,O
2E1,B
isoenzymes,I
",",O
respectively,O
.,O
Induction,
studies,
have,
further,
shown,
that,
while,
pretreatment,
of,
3,
-,
methylcholanthrene,
(,
MC,
),
",",
an,
inducer,
of,
P4501A1,
/,
1A2,
",",
did,
not,
produce,
any,
significant,
effect,
in,
the,
incidence,
of,
lindane,
induced,
convulsions,
",",
pretreatment,
with,
phenobarbital,
(,
PB,
),
",",
an,
inducer,
of,
P450,
2B1,
/,
2B2,
or,
ethanol,
",",
an,
inducer,
of,
P450,
2E1,
catalysed,
reactions,
",",
significantly,
increased,
the,
incidence,
of,
lindane,
induced,
convulsions,
.,
Similarly,
",",
when,
the,
P450,
-,
mediated,
metabolism,
of,
lindane,
was,
blocked,
by,
cobalt,
chloride,
incidence,
of,
convulsions,
was,
increased,
in,
animals,
treated,
with,
lindane,
indicating,
that,
lindane,
per,
se,
or,
its,
metabolites,
formed,
by,
PB,
or,
ethanol,
inducible,
P450,
isoenzymes,
are,
involved,
in,
its,
neurobehavioral,
toxicity,
.,
Absolute,O
and,O
attributable,O
risk,O
of,O
venous,B
thromboembolism,I
in,O
women,O
on,O
combined,O
cyproterone,B
acetate,I
and,O
ethinyl...—,O
COCs,O
.,O
METHODS,
:,
From,
the,
Danish,
National,
Register,
of,
Patients,
(,
NRP,
),
",",
1996,
to,
1998,
",",
the,
records,
of,
1,
.,
1,
million,
Danish,
women,
",",
ages,
15,
to,
44,
years,
",",
were,
searched,
for,
evidence,
of,
VTE,
.,
COC,
use,
was,
ascertained,
through,
mailed,
questionnaires,
.,
Sales,
statistics,
of,
COCs,
and,
CPA,
/,
EE,
were,
provided,
through,
Danish,
Drug,
Statistics,
.,
RESULTS,O
:,O
During,O
the,O
time,O
frame,O
of,O
the,O
study,O
",",O
330,O
women,O
were,O
found,O
to,O
have,O
had,O
VTE,B-Chemical
while,O
on,O
COCs,B-Chemical
.,O
Of,O
these,O
women,O
",",O
67,O
were,O
on,O
levonorgestrel,B-Chemical
-,I-Chemical
containing,I-Chemical
COCs,I-Chemical
.,O
Eleven,O
were,O
on,O
CPA,B-Chemical
/,I-Chemical
EE,I-Chemical
.,O
The,O
corresponding,O
absolute,O
risk,O
of,O
VTE,B-Chemical
was,O
3,O
.,O
4,O
(,O
range,O
",",O
3,O
.,O
1,O
-,O
3,O
.,O
8,O
),O
per,O
10,O
000,O
women,O
years,O
among,O
the,O
women,O
on,O
COCs,B-Chemical
",",O
4,O
.,O
2,O
(,O
range,O
",",O
3.2,O
-,O
5.2),O
per,O
10,O
000,O
women,O
years,O
among,O
women,O
on,O
levonorgestrel,B
-,O
containing,O
COCs,O
",",O
and,O
3.1,O
(,O
range,O
",",O
1.3,O
-,O
4.9),O
per,O
10,O
000,O
women,O
years,O
among,O
the,O
women,O
on,O
CPA,B
/,I
EE,I
.,O
CONCLUSION,O
:,O
Our,O
results,O
suggest,O
the,O
absolute,O
risk,O
of,O
VTE,O
among,O
Danish,O
women,O
on,O
COCs,O
is,O
similar,O
to,O
that,O
among,O
women,O
taking,O
CPA,B
/,I
EE,I
.,O
Comparison,O
of,O
developmental,O
toxicology,O
of,O
aspirin,B
(,O
acetylsalicylic,I
acid,I
),O
in,O
rats,O
using,O
selected,O
dosing,O
paradigms,O
.,O
BACKGROUND,O
:,O
Analysis,O
of,O
the,O
literature,O
for,O
nonsteroidal,O
anti,O
-,O
inflammatory,O
drugs,O
(,O
NSAIDs,B
),O
suggests,O
that,O
a,O
low,O
incidence,O
of,O
developmental,O
anomalies,O
occurs,O
in,O
rats,O
given,O
NSAIDs,O
on,O
specific,O
days,O
during,O
organogenesis,O
.,O
Aspirin,B
(,O
acetylsalicylic,B
acid,I
[,O
ASA,B
],O
),O
",",O
an,O
irreversible,O
cyclooxygenase,B
1,I
and,I
2,I
inhibitor,I
",",O
induces,O
developmental,O
anomalies,O
when,O
administered,O
to,O
Wistar,O
rats,O
on,O
gestational,O
day,O
(,O
GD,O
),O
9,O
",",O
10,O
",",O
or,O
11,O
(,O
Kimmel,O
CA,O
",",O
Wilson,O
JG,O
",",O
Schumacher,O
HJ,O
.,O
Teratology,O
4,O
:,O
15,O
-,O
24,O
",",O
1971,O
),O
.,O
There,O
are,O
no,O
published,O
ASA,B
studies,O
using,O
the,O
multiple,O
dosing,O
paradigm,O
of,O
GDs,O
6,O
to,O
17,O
.,O
Objectives,O
of,O
the,O
current,O
study,O
were,O
to,O
compare,O
results,O
between,O
Sprague,B
-,I
Dawley,I
(,O
SD,B
),O
and,O
Wistar,B
strains,O
when,O
ASA,B
is,O
administered,O
on,O
GD,B
9,B
",",O
10,B
",",O
or,O
11,B
;,O
to,O
compare,O
the,O
malformation,O
patterns,O
following,O
single,O
and,O
multiple,O
dosings,O
during,O
organogenesis,O
in,O
SD,B
rats,O
;,O
and,O
to,O
test,O
the,O
hypothesis,O
that,O
maternal,O
gastrointestinal,O
toxicity,O
confounds,O
the,O
detection,O
of,O
low,O
incidence,O
malformations,O
with,O
ASA,B
when,O
a,O
multiple,O
dosing,O
paradigm,O
is,O
used,O
.,O
METHODS,
:,
ASA,
was,
administered,
as,
a,
single,
dose,
on,
GD,
9,
(,
0,
",",
250,
",",
500,
",",
or,
625,
mg,
/,
kg,
),
",",
10,
(,
0,
",",
500,
",",
625,
",",
or,
750,
mg,
/,
kg,
),
",",
or,
11,
(,
0,
",",
500,
",",
750,
",",
or,
1000,
mg,
/,
kg,
),
and,
from,
GD,
6,
to,
GD,
17,
(,
0,
",",
50,
",",
125,
",",
or,
250,
mg,
/,
kg,
a,
day,
),
in,
the,
multiple,
dose,
study,
to,
SD,
rats,
.,
Animals,
were,
killed,
on,
GD,
21,
",",
and,
fetuses,
were,
examined,
viscerally,
.,
RESULTS,O
:,O
The,O
literature,O
evaluation,O
suggested,O
that,O
NSAIDs,B
induce,O
ventricular,O
septal,O
defects,O
(,O
VSDs,B
),O
and,O
midline,O
defects,O
(,O
MDs,B
),O
in,O
rats,O
and,O
diaphragmatic,O
hernia,O
(,O
DH,B
),O
",",O
MDs,B
",",O
and,O
VSDs,B
in,O
rabbits,O
(,O
Cook,O
JC,O
et,O
al,O
.,O
",",O
2003,O
),O
;,O
hence,O
",",O
the,O
present,O
study,O
focused,O
on,O
these,O
malformations,O
",",O
even,O
though,O
ASA,O
induces,O
several,O
other,O
low,O
-,O
incidence,O
malformations,O
.,O
In,
single,
dose,
studies,
",",
DH,
",",
MD,
",",
and,
VSD,
were,
induced,
on,
GDs,
9,
and,
10,
.,
VSD,
also,
was,
noted,
following,
treatment,
on,
GD,
11,
.,
In,
contrast,
",",
DH,
and,
MD,
were,
noted,
in,
the,
multiple,
dose,
study,
design,
only,
in,
the,
high,
-,
dose,
group,
",",
and,
VSD,
was,
noted,
across,
all,
dose,
groups,
.,
CONCLUSIONS,
:,
High,
concordance,
in,
major,
developmental,
anomalies,
between,
Wistar,
and,
SD,
rats,
were,
noted,
with,
the,
exception,
of,
VSD,
in,
the,
SD,
rats,
and,
hydrocephalus,
in,
the,
Wistar,
rats,
.,
Variations,O
and,O
malformations,O
were,O
similar,O
when,O
ASA,B
was,O
administered,O
as,O
a,O
single,O
dose,O
or,O
during,O
the,O
period,O
of,O
organogenesis,O
(,O
GDs,B
6,I
to,I
17,I
),O
.,O
It,O
was,O
also,O
evident,O
that,O
",",O
by,O
titrating,O
the,O
dose,O
to,O
achieve,O
a,O
maximum,O
tolerated,O
dose,O
",",O
malformations,O
that,O
normally,O
occur,O
at,O
low,O
incidence,O
",",O
as,O
reported,O
from,O
previous,O
single,O
dose,O
studies,O
",",O
could,O
also,O
be,O
induced,O
with,O
ASA,B
given,O
at,O
multiple,O
doses,O
.,O
Reversal,O
of,O
central,O
benzodiazepine,B
effects,O
by,O
flumazenil,B
after,O
intravenous,O
conscious,O
sedation,O
with,O
diazepam,B
and,O
opioids,B
:,O
report,O
of,O
a,O
double,O
-,O
blind,O
multicenter,O
study,O
.,O
The,O
Flumazenil,B
in,O
Intravenous,O
Conscious,O
Sedation,O
with,O
Diazepam,B
Multicenter,O
Study,O
Group,O
II,O
.,O
The,O
efficacy,O
and,O
safety,O
of,O
a,O
new,O
benzodiazepine,O
antagonist,O
",",O
flumazenil,B
",",O
were,O
assessed,O
in,O
a,O
double,O
-,O
blind,O
multicenter,O
study,O
.,O
Flumazenil,B
(,O
mean,O
dose,O
",",O
0,O
.,O
76,O
mg,O
),O
or,O
placebo,B
(,O
mean,O
dose,O
",",O
8,O
.,O
9,O
ml,O
),O
was,O
administered,O
intravenously,O
to,O
130,O
and,O
67,O
patients,O
",",O
respectively,O
",",O
who,O
had,O
been,O
given,O
diazepam,O
in,O
conjunction,O
with,O
an,O
opioid,B
(,O
fentanyl,B
",",O
meperidine,B
",",O
or,O
morphine,B
),O
for,O
the,O
induction,O
and,O
maintenance,O
of,O
intravenous,O
conscious,O
sedation,O
for,O
diagnostic,O
or,O
therapeutic,O
surgical,O
procedures,O
.,O
The,O
group,O
assessable,O
for,O
efficacy,O
comprised,O
122,O
patients,O
treated,O
with,O
flumazenil,B
and,O
64,O
patients,O
given,O
pl...ed,O
patients,O
",",O
were,O
completely,O
awake,O
and,O
alert,O
",",O
as,O
indicated,O
by,O
a,O
score,O
of,O
5,O
on,O
the,O
Observer,O
',O
s,O
Assessment,O
of,O
Alertness,O
/,O
Sedation,O
Scale,O
.,O
Ninety,O
-,O
five,O
percent,O
of,O
patients,O
in,O
each,O
group,O
who,O
attained,O
a,O
score,O
of,O
5,O
at,O
the,O
5,O
-,O
minute,O
assessment,O
showed,O
no,O
loss,O
of,O
alertness,O
throughout,O
the,O
180,O
-,O
minute,O
assessment,O
period,O
.,O
Flumazenil,B
-,I
treated,I
patients,O
also,O
performed,O
significantly,O
better,O
on,O
the,O
Finger,B
-,I
to,I
-,I
Nose,I
Test,I
and,O
the,O
recall,O
of,O
pictures,O
shown,O
at,O
the,O
5,O
-,O
minute,O
assessment,O
.,O
Flumazenil,B
was,O
well,O
tolerated,O
",",O
with,O
no,O
serious,O
adverse,O
effects,O
reported,O
.,O
Thirty,O
-,O
nine,O
(,O
30,O
%,O
),O
of,O
flumazenil,B
-,O
treated,O
patients,O
",",O
compared,O
with,O
17,O
(,O
25,O
%,O
),O
of,O
placebo,B
-,O
treated,O
patients,O
had,O
one,O
or,O
more,O
drug,O
-,O
related,O
adverse,O
experiences,O
.,O
The,O
most,O
common,O
adverse,O
effects,O
were,O
nausea,O
and,O
vomiting,O
in,O
the,O
flumazenil,B
group,O
and,O
nausea,O
and,O
injection,O
-,O
site,O
pain,O
in,O
the,O
placebo,B
group,O
.,O
Flumazenil,B
was,O
found,O
to,O
promptly,O
reverse,O
sedation,O
induced,O
by,O
diazepam,B
in,O
the,O
presence,O
of,O
opioids,B
.,O
Methylphenidate,B
-,I
induced,I
obsessive,I
-,I
compulsive,I
symptoms,I
in,O
an,O
elderly,O
man,O
.,O
An,O
82,O
-,O
year,O
-,O
old,O
man,O
with,O
treatment,O
-,O
resistant,O
depression,O
and,O
early,O
Alzheimer,O
',O
s,O
disease,O
was,O
started,O
on,O
methylphenidate,B
.,O
Significant,O
obsessive,B
-,I
compulsive,I
behavior,I
ensued,O
but,O
diminished,O
over,O
several,O
weeks,O
when,O
methylphenidate,B
was,O
r...ve,I
disorder,I
.,O
It,O
appears,O
that,O
methylphenidate,O
precipitated,O
the,O
patient,O
',O
s,O
pathological,O
behavior,O
.,O
Ciprofloxacin,B
-,I
induced,O
acute,O
interstitial,O
nephritis,O
and,O
autoimmune,O
hemolytic,O
anemia,O
.,O
Ciprofloxacin,B
has,O
been,O
associate...,O
ciprofloxacin,O
-,I
induced,O
interstitial,O
nephritis,O
and,O
autoimmune,O
hemolytic,O
anemia,O
.,O
Hemolytic,O
anemia,O
improved,O
after,O
stopping,O
the,O
drug,O
and,O
initiation,O
of,O
steroid,B
therapy,B
.,O
Unfortunately,O
",",O
18,O
patients,O
",",O
referred,O
to,O
a,O
radiocontrast,B
study,O
",",O
considered,O
at,O
risk,O
because,O
of,O
preexisting,O
renal,O
insufficiency,O
",",O
were,O
enrolled,O
in,O
a,O
prospective,O
",",O
randomized,O
",",O
controlled,O
trial,O
",",O
performed,O
at,O
the,O
secondary,O
care,O
center,O
of,O
a,O
1,O
",",O
100,O
-,O
bed,O
private,O
university,O
hospital,O
.,O
In,O
addition,O
to,O
fluids,O
",",O
the,O
treatment,O
group,O
received,O
furosemide,B
(,O
mean,O
dose,O
110,O
mg,O
),O
intravenously,O
30,O
min,O
prior,O
to,O
the,O
injection,O
of,O
contrast,O
material,O
.,O
The,O
control,O
group,O
received,O
fluids,O
(,O
mean,O
3,O
liters,O
),O
.,O
Radiological,O
studies,O
were,O
mostly,O
angiographies,B
performed,O
with,O
both,O
ionic,B
and,O
non,I
-,I
ionic,I
contrast,I
material,I
",",O
at,O
an,O
average,O
dose,O
of,O
245,O
ml,O
.,O
Renal,O
function,O
significantly,O
deteriorated,O
in,O
the,O
group,O
pretreated,O
with,O
furosemide,B
(,O
p,O
<,O
0,O
.,O
005,O
by,O
ANOVA,O
),O
",",O
with,O
a,O
rise,O
in,O
serum,O
creatinine,O
from,O
145,O
+,O
/,O
-,O
13,O
to,O
182,O
+,O
/,O
-,O
16,O
mumol,O
/,O
l,O
at,O
24,O
h,O
",",O
while,O
no,O
change,O
occurred,O
in,O
the,O
control,O
group,O
(,O
from,O
141,O
+,O
/,O
-,O
6,O
to,O
142,O
+,O
/,O
-,O
7,O
mumol,O
/,O
l,O
),O
.,O
Renal,O
failure,O
was,O
associated,O
with,O
weight,O
loss,O
in,O
the,O
furosemide,B
-,I
treated,I
group,O
.,O
Furosemide,B
may,O
be,O
deleterious,O
in,O
the,O
prevention,O
of,O
radiocontrast,O
nephropathy,O
.,O
Progestational,O
agents,O
and,O
blood,O
coagulation,O
.,O
VII,O
.,O
Thromboembolic,O
and,O
other,O
complications,O
of,O
oral,O
contraceptive,O
therapy,O
in,O
relationship,O
to,O
pretreatment,O
levels,O
of,O
blood,O
coagulation,O
factors,O
:,O
summary,O
report,O
of,O
a,O
ten,O
-,O
year,O
study,O
.,O
During,O
a,O
ten,B
-,I
year,I
period,I
",",O
348,O
women,O
were,O
studied,O
for,O
a,O
total,O
of,O
5,O
",",O
877,O
patient,O
months,O
in,O
four,O
separate,O
studies,O
relating,O
oral,O
contraceptives,O
to,O
changes,O
in,O
hematologic,O
parameters,O
.,O
Significant,O
increases,O
in,O
certain,O
factors,O
of,O
the,O
blood,O
coagulation,O
and,O
fibrinolysin,O
systems,O
(,O
factors,O
I,B
",",I
II,B
",",O
VII,B
",",I
VIII,B
",",I
IX,B
",",I
and,O
X,B
and,O
plasminogen,B
),O
were,O
observed,O
in,O
the,O
treated,O
groups,O
.,O
Severe,O
complications,O
developed,O
in,O
four,O
patients,O
.,O
All,O
four,O
had,O
an,O
abnormal,O
blood,O
coagulation,O
profile,O
...,O
increased,O
further,O
during,O
therapy,O
.,O
One,O
of,O
these,O
patients,O
developed,O
a,O
myocardial,B
infarction,I
before,O
receiving,O
any,O
medication,O
",",O
shortly,O
after,O
the,O
base,O
-,O
line,O
values,O
were,O
obtained,O
.,O
One,O
patient,O
developed,O
retinopathy,B
19,I
months,I
after,O
she,O
began,O
therapy,O
",",O
and,O
another,O
developed,O
thrombophlebitis,B
after,O
27,I
months,I
of,O
therapy,O
.,O
The,O
fourth,O
patient,O
developed,O
thrombophlebitis,B
14,I
days,I
after,O
initiation,O
of,O
contraceptive,O
therapy,O
.,O
All,O
four,O
patients,O
were,O
of,O
the,O
A,B
or,O
AB,B
blood,O
group,O
.,O
Previous,O
studies,O
suggested,O
the,O
Orthostatic,O
hypotension,O
occurs,O
following,O
alpha,B
2,I
-,I
adrenoceptor,I
blockade,I
in,O
chronic,O
prazosin,B
-,I
pretreated,I
conscious,I
spontaneously,I
hypertensive,I
rats,I
.,O
1,O
.,O
Studies,O
were,O
performed,O
to,O
evaluate,O
whether,O
chronic,O
prazosin,B
treatment,I
alters,O
the,O
alpha,B
2,I
-,I
adrenoceptor,I
function,I
for,O
orthostatic,O
control,O
of,O
arterial,O
blood,O
pressure,O
in,O
conscious,O
spontaneously,O
hypertensive,O
rats,O
(,O
SHR,O
),O
.,O
2,O
.,O
Conscious,O
SHR,O
(,O
male,O
300,O
-,O
350,O
g,O
),O
were,O
subjected,O
to,O
90,O
degrees,O
head,O
-,O
up,O
tilts,O
for,O
60,O
s,O
following,O
acute,O
administration,O
of,O
prazosin,B
(,O
0,O
.,O
1,O
mg,O
kg,O
-,O
1,O
i,O
.,O
p,O
.,O
),O
or,O
rauwolscine,B
(,O
3,O
mg,O
kg,O
-,O
1,O
i,O
.,O
v,O
.,O
),O
.,O
Orthostatic,O
hypotension,O
was,O
determined,O
by,O
the,O
average,O
decrease,O
(,O
%,O
),O
in,O
mean,O
arterial,O
pressure,O
(,O
MAP,O
femoral,O
),O
over,O
the,O
60,O
-,O
s,O
tilt,O
period,O
.,O
The,O
basal,O
MAP,O
of,O
conscious,O
SHR,O
was,O
reduced,O
to,O
a,O
similar,O
extent,O
by,O
prazosin,B
(,O
-,O
23,I
%,I
(,I
),I
-,I
26,I
%,I
MAP,I
),I
and,O
rauwolscine,B
(,O
-,O
16,I
%,I
(,I
),I
-,I
33,I
%,I
MAP,I
),I
.,O
However,O
",",O
the,O
head,O
-,O
up,O
tilt,O
induced,O
orthostatic,O
hypotension,O
in,O
the,O
SHR,O
treated,O
with,O
prazosin,B
(,O
-,O
16,I
%,I
MAP,I
",",I
n,I
=,I
6,I
),I
",",O
but,O
not,O
in,O
the,O
SHR,O
treated,O
with,O
rauwolscine,B
(,O
less,O
than,O
+,O
2,O
%,O
MAP,O
",",O
n,I
=,I
6,I
),I
.,O
3,O
.,O
Conscious,O
SHR,O
were,O
treated,O
for,O
4,O
days,O
with,O
prazosin,B
at,O
2,O
mg,O
kg,O
-,O
1,O
day,O
-,O
1,O
i,O
.,O
p,O
.,O
for,O
chronic,O
alpha,O
1,O
-,O
adrenoceptor,O
blockade,O
.,O
MAP,O
in,O
conscious,O
SHR,O
after,O
chronic,O
prazosin,B
treatment,O
was,O
14,O
%,O
lower,O
than,O
in,O
the,O
untreated,O
SHR,O
(,O
n,O
=,O
8,O
),O
.,O
Head,O
-,O
up,O
tilts,O
in,O
these,O
rats,O
did,O
not,O
produce,O
orthostatic,O
hypotension,O
when,O
performed,O
either,O
prior,O
to,O
or,O
after,O
acute,O
dosing,O
of,O
prazosin,B
(,O
0,O
.,O
1,O
mg,B
kg,I
-,I
1,I
i,I
.,I
p,I
.,I
),I
.,I
Conversely,O
",",O
administration,O
of,O
rauwolscine,B
(,I
3,I
mg,I
kg,I
-,I
1,I
i,I
.,I
v,I
.,I
),I
in,O
chronic,O
prazosin,O
treated,O
SHR,O
decreased,O
the,O
basal,O
MAP,O
by,O
12,O
-,O
31,O
%,O
(,O
n,O
=,O
4,O
),O
",",O
and,O
subsequent,O
tilts,O
induced,O
further,O
drops,O
of,O
MAP,O
by,O
19,O
-,O
23,O
%,O
in,O
these,O
rats,O
.,O
4,O
.,O
The,O
pressor,O
responses,O
and,O
bradycardia,O
to,O
the,O
alpha,B
1,I
-,I
agonist,I
cirazoline,I
(,I
0,I
.,I
6,O
and,O
2,O
micrograms,O
kg,O
-,O
1,O
i,O
.,O
v,O
.,O
),O
",",O
the,O
alpha,O
2,O
-,O
agonist,O
Abbott,O...
= 4,O
),O
as,O
compared,O
to,O
the,O
untreated,O
SHR,O
(,O
n,O
=,O
4,O
),O
.,O
On,
the,
other,
hand,
",",
the,
pressor,
effects,
of,
Abbott,
-,
53693,
were,
similar,
in,
both,
groups,
of,
SHR,
",",
but,
the,
accompanying,
bradycardia,
was,
greater,
in,
SHR,
with,
chronic,
prazosin,
treatment,
than,
without,
such,
treatment,
.,
Furthermore,
",",
the,
bradycardia,
that,
accompanied,
the,
noradrenaline,
-,
induced,
pressor,
effect,
in,
SHR,
was,
similar,
with,
and,
without,
chronic,
prazosin,
treatment,
despite,
a,
47,
-,
71,
%,
reduction,
of,
the,
pressor,
effect,
in,
chronic,
alpha,
1,
-,
receptor,
blocked,
SHR,
.,
(,O
ABSTRACT,O
TRUNCATED,O
AT,O
400,O
WORDS,O
),O
Hemolytic,B
-,O
uremic,B
syndrome,I
associated,O
with,O
ingestion,O
of,O
quinine,Ellipsis
immune,O
thrombocytopenia,O
may,O
be,O
related,O
to,O
this,O
phenomenon,O
.,O
A,O
diminution,O
in,O
erythrocyte,O
G,O
-6-,O
P,O
Treatment,O
has,O
included,O
use,O
of,O
plasma,B
exchange,I
",",O
prednisone,B
",",O
aspirin,B
",",O
and,O
dipyridamole,B
.,O
The,O
patients,O
have,O
all,O
regained,O
some,O
degree,O
of,O
renal,O
function,O
.,O
However,O
",",O
it,O
is,O
unclear,O
whether,O
pharmacological,O
treatment,O
or,O
spontaneous,O
resolution,O
is,O
responsible,O
for,O
the,O
improvement,O
.,O
Quinine,B
-,I
associated,I
hemolytic,B
-,I
uremic,I
syndrome,I
probably,O
occurs,O
more,O
often,O
than,O
is,O
recognized,O
.,O
It,
is,
important,
to,
recognize,
this,
reaction,
when,
it,
occurs,
and,
to,
avoid,
further,
quinine,
exposure,
",",
since,
the,
reaction,
seems,
to,
be,
recurrent,
.,
Amnestic,
syndrome,
associated,
with,
propranolol,
toxicity,
:,
a,
case,
report,
.,
An,
elderly,
woman,
developed,
an,
Alzheimer,
-,
like,
subacute,
dementia,
as,
a,
result,
of,
propranolol,
toxicity,
.,
Analysis,
of,
the,
manifestations,
showed,
that,
severe,
impairment,
of,
memory,
accounted,
for,
virtually,
all,
of,
the,
abnormalities,
.,
There,
is,
evidence,
that,
cerebral,
reactions,
to,
drug,
toxicity,
can,
exhibit,
patterns,
that,
suggest,
highly,
selective,
involvement,
of,
functional,
subdivisions,
of,
the,
brain,
.,
Cefotetan,
-,
induced,
immune,
hemolytic,
anemia,
.,
Immune,
hemolytic,
anemia,
due,
to,
a,
drug,
-,
adsorption,
mechanism,
has,
been,
described,
primarily,
in,
patients,
receiving,
penicillins,
and,
first,
-,
generation,
cephalosporins,
.,
We,
describe,
a,
patient,
who,
developed,
anemia,
while,
receiving,
intravenous,
cefotetan,
.,
Cefotetan,
-,
dependent,
antibodies,
were,
detected,
in,
the,
patient,
',
s,
serum,
and,
in,
an,
eluate,
prepared,
from,
his,
red,
blood,
cells,
.,
The,O
eluate,O
also,O
reacted,O
weakly,O
with,O
red,O
blood,O
cells,O
in,O
the,O
absence,O
of,O
cefotetan,B
",",O
suggesting,O
the,O
concomitant,O
formation,O
of,O
warm,O
-,O
reactive,O
autoantibodies,O
.,O
These,O
observations,O
",",O
in,O
conjunction,O
with,O
clinical,O
and,O
laboratory,O
evidence,O
of,O
extravascular,O
hemolysis,O
",",O
are,O
consistent,O
with,O
drug,O
-,O
induced,O
hemolytic,O
anemia,O
",",O
possibly,O
involving,O
both,O
drug,O
-,O
adsorption,O
and,O
autoantibody,O
formation,O
mechanisms,O
.,O
This,O
case,O
emphasizes,O
the,O
need,O
for,O
increased,O
awareness,O
of,O
hemolytic,O
reactions,O
to,O
all,O
cephalosporins,B
.,O
Use,O
of,O
dexamethasone,B
with,O
mesna,B
for,O
the,O
prevention,O
of,O
ifosfamide,B
-,O
induced,O
hemorrhagic,O
cystitis,O
.,O
AIM,O
:,O
Hemorrhagic,O
cystitis,O
(,O
HC,B
),O
is,O
a,O
limiting,O
side,O
-,O
effect,O
of,O
chemotherapy,O
with,O
ifosfamide,B
(,O
IFS,B
),O
.,O
In,O
the,O
study,O
presented,O
here,O
",",O
we,O
investigated,O
the,O
use,O
of,O
dexamethasone,B
in,O
combination,O
with,O
mesna,B
for,O
the,B
prevention,I
of,I
IFS,I
-,I
induced,I
HC,I
.,O
METHODS,O
:,O
Male,B
Wistar,I
rats,I
(,O
150,B
-,I
200,I
g,I
;,O
6,B
rats,I
per,I
group,I
),O
were,O
treated,O
with,O
saline,B
or,O
mesna,B
5,I
min,I
(,O
i,B
.,I
p,I
.,I
),O
before,O
and,O
2,B
and,O
6,B
h,I
after,I
(,O
v,I
.,I
o,I
.,I
),O
administration,O
of,O
IFS,B
.,O
One,O
",",O
two,O
or,O
three,O
doses,O
of,O
mesna,B-Chemical
were,O
replaced,O
with,O
dexamethasone,B-Chemical
alone,O
or,O
with,O
dexamethasone,B-Chemical
plus,O
mesna,B-Chemical
.,O
Cystitis,O
was,O
evaluated,O
24,O
h,O
after,O
its,O
induction,O
by,O
the,O
changes,O
in,O
bladder,O
wet,O
weight,O
and,O
by,O
macroscopic,O
and,O
microscopic,O
analysis,O
.,O
RESULTS,O
:,O
The,O
replacement,O
of,O
the,O
last,O
dose,O
or,O
the,O
last,O
two,O
doses,O
of,O
mesna,B-Chemical
with,O
dexamethasone,B-Chemical
reduced,O
the,O
increase,O
in,O
bladder,O
wet,O
weight,O
induced,O
by,O
IFS,O
by,O
84,O
.,O
79,O
%,O
and,O
89.13,O
%,O
",",O
respectively,O
.,O
In,O
addition,O
",",O
it,O
almost,O
abolished,O
the,O
macroscopic,O
and,O
microscopic,O
alterations,O
induced,O
by,O
IFS,B
.,O
Moreover,O
",",O
the,O
addition,O
of,O
dexamethasone,B
to,O
the,O
last,O
two,O
doses,O
of,O
mesna,O
was,O
more,O
efficient,O
than,O
three,O
doses,O
of,O
mesna,O
alone,O
when,O
evaluated,O
microscopically,O
.,O
CONCLUSION,O
:,O
Dexamethasone,B
in,O
combination,O
with,O
mesna,O
was,O
efficient,O
in,O
blocking,O
IFS,B
-,I
induced,I
HC,I
.,O
However,O
",",O
the,O
replacement,O
of,O
last,O
two,O
doses,O
of,O
mesna,B-Chemical
with,I-Chemical
saline,I-Chemical
or,O
all,O
of,O
the,O
mesna,B-Chemical
doses,I-Chemical
with,I-Chemical
dexamethasone,I-Chemical
did,O
not,O
prevent,O
HC,O
.,O
All,O
-,O
trans,O
-,O
retinoic,O
acid,B-Chemical
-,O
induced,O
erythema,O
nodosum,O
in,O
patients,O
with,O
acute,O
promyelocytic,O
leukemia,O
.,O
Erythema,O
nodosum,O
associated,O
with,O
all,O
-,O
trans,O
-,O
retinoic,O
acid,B-Chemical
(,O
ATRA,O
),O
for,O
acute,O
promyelocytic,O
leukemia,O
(,O
APL,O
),O
is,O
very,O
rare,O
.,O
We,O
describe,O
four,O
patients,O
with,O
classic,O
APL,B
who,O
developed,O
erythema,O
nodosum,O
during,O
ATRA,O
therapy,O
.,O
Fever,O
and,O
subsequent,O
multiple,O
painful,O
erythematous,O
nodules,O
over,O
extremities,O
developed,O
on,O
D11,O
",",O
D16,O
",",O
D17,O
",",O
and,O
D19,O
",",O
respectively,O
",",O
after,O
ATRA,O
therapy,O
.,O
The,O
skin,O
biopsy,O
taken,O
from,O
each,O
patient,O
was,O
consistent,O
with,O
erythema,O
nodosum,O
.,O
All,O
patients,O
received,O
short,O
course,O
of,O
steroids,B
.,O
Fever,O
subsided,O
rapidly,O
and,O
the,O
skin,O
lesions,O
regress...ed,O
erythema,O
nodosum,O
.,O
Short,O
-,O
term,O
use,O
of,O
steroid,O
is,O
very,O
effective,O
in,O
ATRA,O
-,O
induced,O
Effect,
of,
some,
convulsants,
on,
the,
protective,
activity,
of,
loreclezole,
and,
its,
combinations,
with,
valproate,
or,
clonazepam,
in,
amygdala,
-,
kindled,
rats,
.,
Loreclezole,
(,
5,
mg,
/,
kg,
),
exerted,
a,
significant,
protective,
action,
in,
amygdala,
-,
kindled,
rats,
",",
reducing,
both,
seizure,
and,
afterdischarge,
durations,
.,
The,
combinations,
of,
loreclezole,
(,
2,
.,
5,O
mg,O
/,O
kg,O
),O
with,O
valproate,B
",",O
clonazepam,B
",",O
or,O
carbamazepine,B
(,O
applied,O
at,O
their,O
subprotective...and,O
BAY,B
k,I
-,I
8644,I
(,I
the,I
opener,I
of,I
L,I
-,I
type,I
calcium,I
channels,I
),I
reversed,O
the,O
protective,O
activity,O
of,O
loreclezole,B
alone,O
and,O
its,O
combination,O
with,O
valproate,B
.,O
On,O
the,O
other,O
hand,O
",",O
bicuculline,B
",",O
aminophylline,B
and,O
BAY,B
k,I
-,I
8644,I
inhibited,O
the,O
anticonvulsive,O
action,O
of,O
loreclezole,O
combined,O
with,O
clonazepam,O
.,O
The,O
results,O
support,O
the,O
hypothesis,O
that,O
the,O
protective,O
activity,O
of,O
loreclezole,O
and,O
its,O
combinations,O
with,O
other,O
antiepileptics,O
may,O
involve,O
potentiation,O
of,O
GABAergic,O
neurotransmission,O
and,O
blockade,O
of,O
L,O
-,O
type,O
of,O
calcium,O
channels,O
.,O
Mitochondrial,B
DNA,I
and,O
its,O
respiratory,O
chain,O
products,O
are,O
defective,O
in,O
doxorubicin,O
nephrosis,O
.,O
BACKGROUND,O
:,O
Doxorubicin,O
induces,O
a,O
self,O
-,O
perpetuating,O
nephropathy,O
characterized,O
by,O
early,O
glomerular,O
and,O
late,O
-,O
onset,O
tubular,O
lesions,O
in,O
rats,O
.,O
We,O
investigated,O
the,O
potential,O
role,O
of,O
mitochondrial,O
injury,O
in,O
the,B
onset,I
of,I
these,I
lesions,I
.,O
METHODS,O
:,O
Rats,O
were,O
treated,O
with,O
intravenous,O
doxorubicin,B
(,O
1,O
mg,O
kg,O
(,O
-,O
1,O
),O
week,O
(,O
-,O
1,O
),O
),O
for,O
7,O
weeks,O
and,O
were,O
sacrificed,O
either,O
1,O
week,O
(,O
',O
short,O
-,O
term,O
',O
),O
or,O
30,O
weeks,O
(,O
',O
long,O
-,O
term,O
',O
),O
following,O
the,O
last,O
dose,O
.,O
Additional,O
rats,O
received,O
a,O
single,O
dose,O
either,O
6,O
days,O
or,O
2,O
h,O
prior,O
to,O
euthanasia,O
.,O
All,O
rats,O
were,O
killed,O
at,O
48,O
weeks,O
of,O
age,O
.,O
Glomerular,B
and,O
tubular,B
injury,O
was,O
monitored,O
and,O
correlated,O
to,O
the,O
activity,O
or,O
expression,O
of,O
respiratory,O
chain,O
components,O
.,O
Finally,O
",",O
we,O
quantified,O
both,O
nuclear,O
and,O
mitochondrial,O
DNA,B
(,O
mtDNA,O
),O
as,O
well,O
as,O
superoxide,O
production,O
and,O
the,O
4834,O
base,O
pair,O
',O
common,B
',O
mtDNA,I
deletion,O
.,O
RESULTS,O
:,O
The,O
',O
long,O
-,O
term,O
',O
group,O
had,O
significant,O
glomerular,B
and,O
tubular,B
lesions,O
",",O
depressed,O
activities,O
of,O
mtDNA,I
-,O
encoded,O
NADH,O
dehydrogenase,O
and,O
cytochrome,O
-,O
c,O
oxidase,O
(,O
COX,O
),O
and,O
increased,O
citrate,O
synthase,O
activity,O
.,O
In,
addition,
",",
expression,
of,
the,
mtDNA,
-,
encoded,
COX,
subunit,
I,
was,
reduced,
and,
mtDNA,
levels,
were,
decreased,
.,
In,
',
short,
-,
term,
',
rats,
",",
there,
were,
fewer,
tubular,
lesions,
",",
but,
similar,
numbers,
of,
glomerular,
lesions,
activity,
.,
Among,
all,
animals,
",",
glomerular,
and,
tubular,
injury,
were,
inversely,
correlated,
with,
mtDNA,
levels,
",",
mtDNA,
-,
encoded,
respiratory,
chain,
activities,
and,
with,
the,
expression,
of,
the,
mtDNA,
-,
encoded,
respiratory,
chain,
subunit,
COX,
-,
I,
.,
Injury,O
was,O
positively,O
correlated,O
with,O
superoxide,B
production,I
and,O
the,O
activities,O
of,O
nucleus,B
-,I
encoded,I
mitochondrial,I
or,O
cytoplasmic,B
enzymes,I
.,O
Kidneys,O
from,O
the,O
',O
long,O
-,O
term,O
',O
group,O
showed,O
more,O
mtDNA,B
deletions,I
than,O
in,O
',O
short,O
-,O
term,O
',O
animals,O
and,O
these,O
were,O
not,O
observed,O
in,O
the,O
other,O
groups,O
.,O
CONCLUSIONS,O
:,O
These,O
results,O
suggest,O
an,O
important,O
role,O
for,O
quantitative,O
and,O
qualitative,O
mtDNA,B
alterations,I
through,O
the,O
reduction,O
of,O
mtDNA,B
-,I
encoded,I
respiratory,I
chain,I
function,I
and,O
induction,O
of,O
superoxide,O
in,O
doxorubicin,O
-,O
induced,O
renal,O
lesions,O
.,O
A,O
randomized,O
",",O
placebo,O
-,O
controlled,O
",",O
crossover,O
study,O
of,O
ephedrine,B
for,O
SSRI,O
-,O
induced,O
female,O
sexual,O
dysfunction,O
.,O
The,O
objective,O
of,O
this,O
study,O
was,O
to,O
determine,O
whether,O
ephedrine,O
",",O
an,O
alpha,O
-,O
and,O
beta,O
-,O
adrenergic,O
agonist,O
previously,O
shown,O
to,O
enhance,O
genital,O
blood,O
flow,O
in,O
women,O
",",O
has,O
beneficial,O
effects,O
in,O
reversing,O
antidepressant,O
-,O
induced,O
sexual,O
dysfunction,O
.,O
Nineteen,
sexually,
dysfunctional,
women,
receiving,
either,
fluoxetine,
",",
sertraline,
",",
or,
paroxetine,
participated,
in,
an,
eight,
-,
week,
",",
double,
-,
blind,
",",
placebo,
-,
controlled,
",",
cross,
-,
over,
study,
of,
the,
effects,
of,
ephedrine,
(,
50,
mg,
),
on,
self,
-,
report,
measures,
of,
sexual,
desire,
",",
arousal,
",",
orgasm,
",",
and,
sexual,
satisfaction,
.,
Although,O
there,O
were,O
significant,O
improvements,O
relative,O
to,O
baseline,O
in,O
sexual,O
desire,O
and,O
orgasm,O
intensity,O
/,O
pleasure,O
on,O
50,B
mg,I
ephedrine,I
1,I
-,I
hr,I
prior,I
to,I
sexual,I
activity,I
",",O
significant,O
improvements,O
in,O
these,O
measures,O
",",O
as,O
well,O
as,O
in,O
sexual,O
arousal,O
and,O
orgasmic,O
ability,O
also,O
were,O
noted,O
with,O
placebo,B
.,O
These,O
findings,O
highlight,O
the,O
importance,O
of,O
conducting,O
placebo,O
-,O
controlled,O
trials,O
for,O
this,O
condition,O
.,O
Does,O
hormone,O
therapy,O
for,O
the,O
treatment,O
of,O
breast,O
cancer,O
have,O
a,O
detrimental,O
effect,O
on,O
memory,O
and,O
cognition,O
?,O
A,O
pilot,O
study,O
.,O
This,O
pilot,O
study,O
examines,O
whether,O
hormone,O
therapy,O
for,O
breast,O
cancer,O
affects,O
cognition,O
.,O
Patients,O
participating,O
in,O
a,O
randomised,O
trial,O
of,O
anastrozole,B
",",O
tamoxifen,B
alone,I
or,I
combined,I
(,I
ATAC,I
),I
(,O
n,O
=,O
94,O
),O
and,O
a,O
group,O
of,O
women,O
without,O
breast,O
cancer,O
(,O
n,O
=,O
35,O
),O
completed,O
a,O
battery,O
of,O
neuropsychological,O
measures,O
.,O
Compared,O
with,O
the,O
control,O
group,O
",",O
the,O
patients,O
were,O
impaired,O
on,O
a,O
processing,O
speed,O
task,O
(,O
p,O
=,O
0,O
.,O
032,O
),O
and,O
on,O
a,O
measure,O
of,O
immediate,O
verbal,O
memory,O
(,O
p,O
=,O
0,O
.,O
026,O
),O
after,O
controlling,O
for,O
the,O
use,O
of,O
hormone,O
replacement,O
therapy,O
in,O
both,O
groups,O
.,O
Patient,O
group,O
performance,O
was,O
not,O
significantly,O
related,O
to,O
length,O
of,O
treatment,O
or,O
measures,O
of,O
psychological,O
morbidity,O
.,O
The,O
results,O
showed,O
specific,O
impairments,O
in,O
processing,O
speed,O
and,O
verbal,O
memory,O
in,O
women,O
receiving,O
hormonal,B
therapy,I
for,O
the,O
treatment,O
of,O
breast,O
cancer,O
.,O
Verbal,O
memory,O
may,O
be,O
especially,O
sensitive,O
to,O
changes,O
in,O
oestrogen,B
levels,O
",",O
a,O
finding,O
commonly,O
reported,O
in,O
studies,O
of,O
hormone,O
replacement,O
therapy,O
in,O
healthy,O
women,O
.,O
In,O
view,O
of,O
the,O
increased,O
use,O
of,O
hormone,B
therapies,O
in,O
an,O
adjuvant,B
and,I
preventative,I
setting,O
their,O
impact,O
on,O
cognitive,O
functioning,O
should,O
be,O
investigated,O
more,O
thoroughly,O
.,O
Expression,O
of,O
p300,B
protects,O
cardiac,O
myocytes,O
from,O
apoptosis,O
in,O
vivo,O
.,O
Doxorubicin,B
is,O
an,O
anti,B
-,I
tumor,I
agent,O
that,O
represses,O
cardiac,O
-,I
specific,I
gene,I
expression,I
and,O
induces,O
myocardial,O
cell,O
apoptosis,O
.,O
Doxorubicin,B
depletes,O
cardiac,O
p300,B
",",O
a,O
transcriptional,O
coactivator,O
that,O
is,O
required,O
for,O
the,O
maintenance,O
of,O
the,O
differentiated,O
phenotype,O
of,O
cardiac,O
myocytes,O
.,O
However,O
",",O
the,O
role,O
of,O
p300,B
in,O
protection,O
against,O
doxorubicin,O
-,O
induced,O
apoptosis,O
is,O
unknown,O
.,O
Transgenic,O
mice,O
overexpressing,O
p300,B
in,O
the,O
heart,O
and,O
wild,O
-,O
type,O
mice,O
were,O
subjected,O
to,O
doxorubicin,O
treatment,O
.,O
Compared,O
with,O
wild,B
-,I
type,I
mice,I
",",O
transgenic,B
mice,I
exhibited,O
higher,O
survival,O
rate,O
as,O
well,O
as,O
more,O
preserved,O
left,O
ventricular,O
function,O
and,O
cardiac,O
expression,O
of,O
alpha,B
-,I
sarcomeric,I
actin,I
.,O
Doxorubicin,B
induced,O
myocardial,O
cell,O
apoptosis,O
in,O
wild,B
-,I
type,I
mice,I
but,O
not,O
in,O
transgenic,B
mice,I
.,O
Expression,O
of,O
p300,B
increased,O
the,O
cardiac,O
level,O
of,O
bcl,B
-,I
2,I
and,O
mdm,B
-,I
2,I
",",O
but,O
not,O
that,O
of,O
p53,B
or,O
other,O
members,O
of,O
the,O
bcl,B
-,I
2,I
family,I
.,O
These,O
findings,O
demonstrate,O
that,O
overexpression,O
of,O
p300,B
protects,O
cardiac,O
myocytes,O
from,O
doxorubicin,B
-,I
induced,I
apo...,O
and,O
generally,O
well,O
-,O
tolerated,O
antithyroid,O
agent,O
.,O
A,O
43,O
-,O
year,O
-,O
old,O
woman,O
had,O
severe,O
jaundice,O
and,O
itching,O
1,O
month,O
after,O
receiving,O
Methimazole,B
-,O
induced,O
cholestasis,O
was,O
diagnosed,O
",",O
and,O
propranolol,O
therapy,O
was,O
resumed,O
.,O
Over,O
the,O
fol...drug,O
can,O
cause,O
severe,O
and,O
reversible,O
cholestatic,B
jaundice,I
.,O
Physicians,O
and,O
patients,O
should,O
be,O
aware,O
of,O
this,O
adverse,O
effect,O
so,O
that,O
",",O
upon,O
occurrence,O
",",O
they,O
can,O
discontinue,O
methimazole,B
therapy,I
and,O
avoid,O
unnecessary,O
invasive,O
procedures,O
.,O
Atrial,B
fibrillation,I
following,O
chemotherapy,B
for,O
stage,O
IIIE,O
diffuse,O
large,O
B,O
-,O
cell,O
gastric,O
lymphoma,O
in,O
a,O
patient,O
with,O
myotonic,O
dystrophy,O
(,O
Steinert,O
',O
s,O
disease,O
),O
.,O
The,O
authors,O
describe,O
the,O
unusual,O
association,O
between,O
diffuse,O
B,B
-,I
cell,I
gastric,I
lymphoma,I
and,O
myotonic,B
dy...thromycin,I
-,I
based,I
chemotherapy,I
in,O
the,O
same,O
patient,O
.,O
Atrial,O
fibrillation,O
or,O
other,O
cardiac,O
arrhythmias,O
are,O
unusual,O
complications,O
in,O
patients,O
treated,O
with,O
chemotherapy,O
.,O
The,O
cardiac,O
toxicity,O
intrinsically,O
associated,O
with,O
the,O
aggressive,O
chemotherapy,O
employed,O
could,O
function,O
as,O
a,O
tr...riment - induced,I
liver,I
injury,I
.,O
OBJECTIVE,O
:,O
To,O
assess,O
lymphocyte,O
reactivity,O
to,O
dilevalol,O
and,O
to,O
serum,O
PATIENT,O
:,O
A,O
58,O
-,O
year,O
-,O
old,O
woman,O
with,O
a,O
clinical,O
diagnosis,O
of,O
dilevalol,B
-,I
induced,I
l... of a,O
volunteer,O
before,O
and,O
after,O
dilevalol,B
intake,O
.,O
A,O
similar,O
protocol,O
was,O
performed,O
with,O
lymphocytes,O
from,O
a,O
healthy,O
subject,O
.,O
RESULTS,O
:,O
No,O
lymphocyte,O
proliferation,O
was,O
observed,O
either,O
in,O
the,O
patient,O
or,O
in,O
the,O
healthy,O
volunteer,O
in,O
the,O
presence,O
of,O
dilevalol,B
solutions,O
.,O
A,O
significant,O
proliferative,O
response,O
to,O
serum,O
collected,O
after,O
dilevalol,B
intake,O
was,O
observed,O
in,O
the,O
case,O
of,O
the,O
patient,O
compared,O
with,O
the,O
proliferative,O
response,O
to,O
the,O
serum,O
collected,O
before,O
the,O
drug,O
intake,O
.,O
No,O
reactivity,O
was,O
found,O
when,O
lymphocytes,O
from,O
the,O
healthy,O
subject,O
were,O
tested,O
under,O
similar,O
conditions,O
.,O
CONCLUSIONS,O
:,O
The,O
methodology,O
used,O
allowed,O
the,O
detection,O
of,O
lymphocyte,O
sensitization,O
to,O
sera,O
containing,O
ex,B
-,I
vivo,I
-,I
prepared,I
dilevalol,I
antigens,I
",",O
suggesting,O
the,O
involvement,O
of,O
an,O
immunologic,O
mechanism,O
in,O
dilevalol,O
-,O
induced,O
liver,O
injury,O
.,O
Increased,O
expression,O
and,O
apical,O
targeting,O
of,O
renal,B
ENaC,I
subunits,I
in,O
puromycin,B
aminonucleoside,I
-,I
induced,I
nephrotic,B
syndrome,I
in,O
rats,O
.,O
Nephrotic,O
syndrome,O
is,O
often,O
accompanied,O
by,O
sodium,O
retention,O
and,O
generalized,O
edema,O
.,O
However,O
",",O
the,O
molecular,O
basis,O
for,O
the,O
decreased,O
renal,B
sodium,I
excretion,I
remains,O
undefined,O
.,O
We,O
hypothesized,O
that,O
epithelial,O
Na,B
channel,O
(,O
ENaC,B
),O
subunit,O
dysregulation,O
may,O
be,O
responsible,O
for,O
the,O
increased,O
sodium,O
retention,O
.,O
An,O
experimental,O
group,O
of,O
rats,O
was,O
treated,O
with,O
puromycin,B
aminonucleoside,I
(,I
PAN,I
;,I
180,I
mg,I
/,I
kg,I
iv,I
),I
",",O
whereas,O
the,O
control,O
group,O
received,O
only,O
vehicle,O
.,O
After,O
7,O
days,O
",",O
PAN,B
treatment,O
induced,O
significant,O
proteinuria,O
",",O
hypoalbuminemia,O
",",O
decreased,O
urinary,O
sodium,O
excretion,O
",",O
and,O
extensive,O
ascites,O
.,O
The,O
protein,O
abundance,O
of,O
alpha,B
-,I
ENaC,I
and,O
beta,B
-,I
ENaC,I
was,O
increased,O
in,O
the,O
inner,O
stripe,O
of,O
the,O
outer,O
medulla,O
(,O
ISOM,B
),O
and,O
in,O
the,O
inner,O
medulla,O
(,O
IM,B
),O
but,O
was,O
not,O
altered,O
in,O
the,O
cortex,O
.,O
gamma,B
-,I
ENaC,I
abundance,O
was,O
increased,O
in,O
the,O
cortex,O
",",O
ISOM,B
",",O
and,O
IM,B
.,O
Immunoperoxidase,O
brightfield,O
-,O
and,O
laser,O
-,O
scanning,O
confocal,O
fluorescence,O
microscopy,O
demonstrated,O
increased,O
targeting,O
of,O
alpha,B
-,I
ENaC,I
",",O
beta,B
-,I
ENaC,I
",",O
and,O
gamma,B
-,I
ENaC,I
subunits,O
to,O
the,O
apical,O
plasma,O
membrane,O
in,O
the,O
distal,O
convoluted,O
tubule,O
(,O
DCT2,B
),O
",",O
connecting,O
tubule,O
",",O
and,O
cortical,O
and,O
medullary,O
collecting,O
duct,O
segments,O
.,O
Immunoelectron,O
microscopy,O
further,O
revealed,O
an,O
increased,O
labeling,O
of,O
alpha,B
-,I
ENaC,I
in,O
the,O
apical,O
plasma,O
membrane,O
of,O
cortical,O
collecting,O
duct,O
principal,O
cells,O
of,O
PAN,O
-,O
treated,O
rats,O
",",O
indicating,O
enhanced,O
apical,O
targeting,O
of,O
alpha,B
-,I
ENaC,I
subunits,O
.,O
In,O
contrast,O
",",O
the,O
protein,O
abundances,O
of,O
Na,B
(,I
+,I
),I
/,I
H,I
(,I
+,I
),I
exchanger,I
type,I
3,I
(,I
NHE3,I
),I
",",O
Na,B
(,I
+,I
),I
-,I
K,I
(,I
+,I
),I
-,I
2Cl,I
(,I
-,I
),I
cotransporter,I
(,I
BSC,I
-,I
1,I
),I
",",O
and,O
thiazide,O
-,O
sensitive,O
Na,B
(,I
+,I
),I
-,I
Cl,I
(,I
-,I
),I
cotransporter,I
(,I
TSC,I
),I
were,O
decreased,O
.,O
Moreover,O
",",O
the,O
abundance,O
of,O
the,O
alpha,B
(,I
1,I
),I
-,I
subunit,I
of,O
the,O
Na,B
-,I
K,I
-,I
ATPase,I
was,O
decreased,O
in,O
the,O
cortex,O
and,O
ISOM,B
",",O
but,O
it,O
remained,O
unchanged,O
in,O
the,O
IM,B
.,O
In,O
conclusion,O
",",O
the,O
increased,O
or,O
sustained,O
expression,O
of,O
ENaC,B
subunits,O
combined,O
with,O
increased,O
apical,O
targeting,O
in,O
the,O
DCT2,O
",",O
connecting,O
tubule,O
",",O
and,O
collecting,O
duct,O
are,O
likely,O
to,O
play,O
a,O
role,O
in,O
the,O
sodium,O
retention,O
associated,O
with,O
PAN,B
-,I
induced,I
nephrotic,I
syndrome,I
.,O
The,O
decreased,O
abundance,O
of,O
NHE3,B
",",O
BSC,B
-,I
1,I
",",O
TSC,B
",",O
and,O
Na,B
-,I
K,I
-,I
ATPase,I
may,O
play,O
a,O
compensatory,O
role,O
to,O
promote,O
sodium,O
excretion,O
.,O
Pallidal,O
stimulation,O
:,O
an,O
alternative,O
to,O
pallidotomy,O
?,O
A,O
resurgence,O
of,O
interest,O
in,O
the,O
surgical,O
treatment,O
of,O
Parkinson,O
',O
s,O
disease,O
(,O
PD,O
),O
came,O
with,O
the,O
rediscovery,O
of,O
posteroventral,O
pallidotomy,O
by,O
Laitinen,O
in,O
1985,O
.,O
Laitinen,B
',O
s,O
procedure,O
improved,O
most,O
symptoms,O
in,O
drug,O
-,O
resistant,O
PD,O
",",O
which,O
engendered,O
wide,O
in...lied,O
to,O
stimulate,O
the,O
nucleus,O
ventralis,O
intermedius,O
",",O
producing,O
high,O
long,O
-,O
term,O
success,O
rates,O
and,O
Pallidal,O
stimulation,O
has,O
not,O
met,O
with,O
the,O
same,O
success,O
.,O
According,O
to,O
the,O
literature,O
pallidotomy,O
impr...y,O
",",O
and,O
on,O
-,O
off,O
fluctuations,O
.,O
Pallidal,O
stimulation,O
improves,O
bradykinesia,O
and,O
rigidity,O
to,O
a,O
Stimulation,
often,
produces,
an,
improvement,
in,
the,
hyper,
-,
or,
dyskinetic,
upper,
limbs,
",",
but,
increases,
the,
O,
Effects,
of,
the,
cyclooxygenase,
-,
2,
specific,
inhibitor,
valdecoxib,
versus,
nonsteroidal,
antiinflammatory,
agents,
and,
placebo,
on,
cardiovascular,
thrombotic,
events,
in,
patients,
with,
arthritis,
.,
There,
have,
been,
concerns,
that,
the,
risk,
of,
cardiovascular,
thrombotic,
events,
may,
be,
higher,
with,
cyclooxygenase,
(,
COX,
),
-,
2,
-,
specific,
inhibitors,
than,
nonselective,
nonsteroidal,
antiinflammatory,
drugs,
(,
NSAIDs,
),
.,
We,O
evaluated,O
cardiovascular,O
event,O
data,O
for,O
valdecoxib,B
",",O
a,O
new,O
COX,O
-,O
2,O
-,O
specific,O
inhibitor,O
in,O
approximately,O
8000,O
patients,O
with,O
osteoarthritis,O
and,O
rheumatoid,O
arthritis,O
treated,O
with,O
this,O
agent,O
in,O
randomized,O
clinical,O
trials,O
.,O
The,O
incidence,O
of,O
cardiovascular,O
thrombotic,O
events,O
(,O
cardiac,B
",",O
cerebrovascular,B
and,O
peripheral,O
vascular,O
",",O
or,O
arterial,O
thrombotic,O
),O
was,O
determined,O
by,O
analyzing,O
pooled,O
valdecoxib,B
(,O
10,B
-,I
80,I
mg,I
daily,I
),I
",",O
nonselective,O
NSAID,O
(,O
diclofenac,B
75,B
mg,I
bid,I
",",O
ibuprofen,B
800,B
mg,I
tid,I
",",O
or,O
naproxen,B
500,B
mg,I
bid,I
),I
and,O
placebo,O
data,O
from,O
10,O
randomized,O
osteoarthritis,O
and,O
rheumatoid,O
arthritis,O
trials,O
that,O
were,O
6,O
-,O
52,O
weeks,O
in,O
duration,O
.,O
The,O
incidence,O
rates,O
of,O
events,O
were,O
determined,O
in,O
all,O
patients,O
(,O
n,O
=,O
7934,O
),O
and,O
in,O
users,O
of,O
low,O
-,O
dose,O
(,O
<,O
or,O
=,O
325,O
mg,O
daily,O
),O
aspirin,B
(,I
n,I
=,I
1051,I
),I
and,O
nonusers,O
of,O
aspirin,B
(,I
n,I
=,I
6883,I
),I
.,O
Crude,O
and,O
exposure,O
-,O
adjusted,O
incidences,O
of,O
thrombotic,O
events,O
were,O
similar,O
for,O
valdecoxib,B
",",O
NSAIDs,B
",",O
and,O
placebo,B
.,O
The,O
risk,O
of,O
serious,O
thrombotic,O
events,O
was,O
also,O
similar,O
for,O
each,O
valdecoxib,O
dose,O
.,O
Thrombotic,
risk,
was,
consistently,
higher,
for,
users,
of,
aspirin,
users,
than,
nonusers,
of,
aspirin,
(,
placebo,
",",
1,
.,
4,
%,
vs,
.,
0,
%,
;,
valdecoxib,
",",
1,
.,
7,
%,
vs,
.,
0,
.,
2,
%,
;,
NSAIDs,
",",
1,
.,
9,
%,
vs,
.,
0,
.,
5,
%,
),
.,
The,
rates,
of,
events,
in,
users,
of,
aspirin,
were,
similar,
for,
all,
3,
treatment,
groups,
and,
across,
valdecoxib,
doses,
.,
Short,
-,
and,
intermediate,
-,
term,
treatment,
with,
therapeutic,
(,
10,
or,
20,
mg,
daily,
),
and,
supratherapeutic,
(,
40,
or,
80,
mg,
daily,
),
valdecoxib,
doses,
was,
not,
associated,
with,
an,
increased,
incidence,
of,
thrombotic,
events,
relative,
to,
nonselective,
NSAIDs,
or,
placebo,
in,
osteoarthritis,
and,
rheumatoid,
arthritis,
patients,
in,
controlled,
clinical,
trials,
.,
Hypersensitivity,
myocarditis,
complicating,
hypertrophic,
cardiomyopathy,
heart,
.,
The,
present,
report,
describes,
a,
case,
of,
eosinophilic,
myocarditis,
complicating,
hypertrophic,
cardiomyopathy,
.,
The,
47,
-,
year,
-,
old,
female,
patient,
",",
known,
to,
have,
hypertrophic,
cardiomyopathy,
",",
was,
admitted,
with,
biventricular,
failure,
and,
managed,
aggressively,
with,
dobutamine,
infusion,
and,
other,
drugs,
while,
being,
assessed,
for,
heart,
transplantation,
.,
On,O
transthoracic,O
echocardiogram,O
",",O
she,O
had,O
moderate,O
left,O
ventricular,O
dysfunction,O
with,O
regional,O
variability,O
and,O
mod...rare,O
and,O
eosinophilic,B
myocarditis,I
is,O
rarer,O
.,O
It,O
is,O
likely,O
that,O
the,O
hypersensitivity,B
(,O
eosinophilic,I
),O
myocarditis,B
was,O
related,O
to,O
dobutamine,O
infusion,O
therapy,O
.,O
Eosinophilic,B
myocarditis,I
has,O
been,O
reported,O
with,O
an,O
incidence,O
of,O
2,O
.,O
4,O
%,O
to,O
7,O
.,O
2,O
%,O
in,O
explanted,O
hearts,O
and,O
may,O
be,O
related,O
to,O
multidrug,O
therapy,O
.,O
Time,O
trends,O
in,O
warfarin,O
-,O
associated,O
hemorrhage,O
.,O
The,O
annual,O
incidence,O
of,O
warfarin,B
-,I
related,I
bleeding,I
at,O
Brigham,B
and,I
Women,I
',I
s,I
Hospital,I
increased,O
from,O
0,O
.,O
97,O
/,O
1,O
",",O
000,O
patient,O
admissions,O
in,O
the,O
first,O
time,O
period,O
(,O
January,B
1995,I
to,I
October,I
1998,I
),I
to,O
1,O
.,O
19,O
/,O
1,O
",",O
000,O
patient,O
admissions,O
in,O
the,O
second,O
time,O
period,O
(,O
November,B
1998,I
to,I
August,I
2002,I
),I
of,O
this,O
study,O
.,O
The,O
proportion,O
of,O
patients,O
with,O
major,B
and,I
intracranial,I
bleeding,I
increased,O
from,O
20,O
.,O
2,O
%,O
and,O
1,O
.,O
9,O
%,O
",",O
respectively,O
",",O
in,O
the,O
first,O
time,O
period,O
",",O
to,O
33,O
.,O
3,O
%,O
and,O
7,O
.,O
8,O
%,O
",",O
respectively,O
",",O
in,O
the,O
second,O
.,O
Yohimbine,B
treatment,O
of,O
sexual,O
side,O
effects,O
induced,O
by,O
serotonin,O
reuptake,O
blockers,O
.,O
BACKGROUND,O
:,O
Preclinical,O
and,O
clinical,O
studies,O
suggest,O
that,O
yohimbine,O
facilitates,O
sexual,O
behavior,O
and,O
may,O
be,O
helpful,O
in,O
the,O
treatment,O
of,O
male,O
impotence,O
.,O
A,O
single,O
case,O
report,O
suggests,O
that,O
yohimbine,B
may,O
be,O
used,O
to,O
treat,O
the,O
sexual,O
side,O
effects,O
of,O
clomipramine,B
.,O
This,O
study,O
evaluated,O
yohimbine,B
as,O
a,O
treatment,O
for,O
the,O
sexual,O
side,O
effects,O
caused,O
by,O
serotonin,O
reuptake,O
blockers,O
.,O
METHOD,O
:,O
Six,O
patients,O
with,O
either,O
obsessive,O
compulsive,O
disorder,O
",",O
trichotillomania,O
",",O
anxiety,O
",",O
or,O
affective,O
disorders,O
who,O
suffered,O
sexual,O
side,O
effects,O
after,O
treatment,O
with,O
serotonin,O
reuptake,O
blockers,O
were,O
given,O
yohimbine,B
on,O
a,O
p,O
.,O
r,O
.,O
n,O
.,O
basis,O
in,O
an,O
open,O
clinical,O
trial,O
.,O
Various,O
doses,O
of,O
yohimbine,B
were,O
used,O
to,O
determine,O
the,O
ideal,O
dose,O
for,O
each,O
patient,O
.,O
RESULTS,O
:,O
Five,O
of,O
the,O
six,O
patients,O
experienced,O
improved,O
sexual,O
functioning,O
after,O
taking,O
yohimbine,B
.,O
One,O
patient,O
who,O
failed,O
to,O
comply,O
with,O
yohimbine,B
treatment,O
had,O
no,O
therapeutic,O
effects,O
.,O
Side,
effects,
of,
yohimbine,
included,
excessive,
sweating,
",",
increased,
anxiety,
",",
and,
a,
wound,
-,
up,
feeling,
in,
some,
patients,
.,
CONCLUSION,
:,
The,
results,
of,
this,
study,
indicate,
that,
yohimbine,
may,
be,
an,
effective,
treatment,
for,
the,
sexual,
side,
effects,
caused,
by,
serotonin,
reuptake,
blockers,
.,
Future,
controlled,
studies,
are,
needed,
to,
further,
investigate,
the,
effectiveness,
and,
safety,
of,
yohimbine,
for,
this,
indication,
.,
Hemorrhagic,
cystitis,
complicating,
bone,
marrow,
transplantation,
.,
Hemorrhagic,
cystitis,
is,
a,
potentially,
serious,
complication,
of,
high,
-,
dose,
cyclophosphamide,
therapy,
administered,
before,
bone,
marrow,
transplantation,
.,
As,
standard,
practice,
at,
our,
institution,
",",
patients,
who,
are,
scheduled,
to,
receive,
a,
bone,
marrow,
transplant,
are,
treated,
prophylactically,
with,
forced,
hydration,
and,
bladder,
irrigation,
.,
In,O
an,O
attempt,O
to,O
obviate,O
the,O
inconvenience,O
of,O
bladder,O
irrigation,O
",",O
we,O
conducted,O
a,O
feasibility,O
trial,O
of,O
uroprophylaxis,O
with,O
mesna,B
",",O
which,O
neutralizes,O
the,O
hepatic,O
metabolite,O
of,O
cyclophosphamide,B
that,O
causes,O
hemorrhagic,O
cystitis,O
.,O
Of,O
97,O
patients,O
who,O
received,O
standard,O
prophylaxis,O
",",O
4,O
had,O
symptomatic,O
hemorrhagic,O
cystitis,O
.,O
In,O
contrast,O
",",O
two,O
of,O
four,O
consecutive,O
patients,O
who,O
received,O
mesna,B-Chemical
uroprophylaxis,I-Chemical
before,O
allogeneic,O
bone,B-Chemical
marrow,I-Chemical
transplantation,I-Chemical
had,O
severe,O
hemorrhagic,O
cystitis,O
for,O
at,O
least,O
2,O
weeks,O
.,O
Because,O
of,O
this,O
suboptimal,O
result,O
",",O
we,O
resumed,O
the,O
use,O
of,O
bladder,O
irrigation,O
and,O
forced,O
hydration,O
to,O
minimize,O
the,O
risk,O
of,O
hemorrhagic,O
cystitis,O
.,O
Consensus,O
statement,O
concerning,O
cardiotoxicity,O
occurring,O
during,O
haematopoietic,B
stem,I
cell,I
transplantation,I
in,O
the,O
treatment,O
Worldwide,O
",",O
over,O
650,O
patients,O
have,O
been,O
transplanted,O
in,O
the,O
context,O
of,O
phase,O
I,O
and,O
II,O
clinical,O
trials,O
.,O
The,O
results,O
are,O
encouraging,O
enough,O
to,O
begin,O
randomised,O
phase,O
III,O
trials,O
.,O
However,O
",",O
as,O
predicted,O
",",O
significant,O
transplant,O
-,O
related,O
morbidity,O
and,O
mortality,O
have,O
been,O
observed,O
.,O
This,O
is,O
primarily,O
due,O
to,O
complications,O
related,O
to,O
either,O
the,O
stage,O
of,O
the,O
disease,O
at,O
transplant,O
or,O
due,O
to,O
infections,O
.,O
The,O
number,O
of,O
deaths,O
related,O
to,O
cardiac,B
toxicity,I
is,O
low,O
.,O
However,O
",",O
caution,O
is,O
required,O
when,O
cyclophosphamide,B
or,O
anthracyclines,B
such,O
as,O
mitoxantrone,B
are,O
used,O
in,O
patients,O
with,O
a,O
possible,O
underlying,O
heart,O
damage,O
",",O
for,O
example,O
",",O
systemic,O
sclerosis,O
patients,O
.,O
In,O
November,O
2002,O
",",O
a,O
meeting,O
was,O
held,O
in,O
Florence,B
",",O
bringing,O
together,O
a,O
number,O
of,O
experts,O
in,O
various,O
fields,O
",",O
including,O
rheumatology,O
",",O
cardiology,B
",",O
neurology,O
",",O
pharmacology,O
and,O
transplantation,O
medicine,O
.,O
The,O
object,O
of,O
the,O
meeting,O
was,O
to,O
analyse,O
existing,O
data,O
",",O
both,O
published,O
or,O
available,O
",",O
in,O
the,O
European,O
Group,O
for,O
Blood,B
and,I
Marrow,I
Transplantation,I
autoimmune,O
disease,O
database,O
",",O
and,O
to,O
propose,O
a,O
safe,O
approach,O
to,O
such,O
patients,O
.,O
A,O
full,O
cardiological,O
assessment,O
before,O
and,O
during,O
the,O
transplant,O
emerged,O
as,O
the,O
major,O
recommendation,O
.,O
Does,O
supplemental,O
vitamin,B
C,I
increase,O
cardiovascular,O
disease,O
risk,O
in,O
women,O
with,O
diabetes,O
?,O
BACKGROUND,O
:,O
Vitamin,B
C,I
acts,O
as,O
a,O
potent,O
antioxidant,O
;,O
however,O
",",O
it,O
can,O
also,O
be,O
a,O
prooxidant,O
and,O
glycate,O
protein,O
under,O
certain,O
circumstances,O
in,O
vitro,O
.,O
These,O
observations,O
led,O
us,O
to,O
hypothesize,O
that,O
a,O
high,O
intake,O
of,O
vitamin,B
C,I
in,O
diabetic,O
persons,O
might,O
promote,O
atherosclerosis,O
.,O
OBJECTIVE,O
:,O
The,O
objective,O
was,O
to,O
examine,O
the,O
relation,O
between,O
vitamin,B
C,I
intake,O
and,O
mortality,O
from,O
cardiovascular,O
disease,O
.,O
DESIGN,O
:,O
We,O
studied,O
the,O
relation,O
between,O
vitamin,B
C,I
intake,O
and,O
mortality,O
from,O
total,O
cardiovascular,O
disease,O
(,O
n,O
=,O
281,O
),O
",",O
coronary,O
artery,O
disease,O
(,O
n,O
=,O
175,O
),O
",",O
and,O
stroke,O
(,O
n,O
=,O
57,O
),O
in,O
1923,O
postmenopausal,O
women,O
who,O
reported,O
being,O
diabetic,O
at,O
baseline,O
.,O
Diet,O
was,O
assessed,O
with,O
a,O
food,O
-,O
frequency,O
questionnaire,O
at,O
baseline,O
",",O
and,O
subjects,O
initially,O
free,O
of,O
coronary,O
artery,O
disease,O
were,O
prospectively,O
followed,O
for,O
15,O
y,O
.,O
RESULTS,O
:,O
After,O
adjustment,O
for,O
cardiovascular,O
disease,O
risk,O
factors,O
",",O
type,O
of,O
diabetes,O
medication,O
used,O
",",O
duration,O
of,O
diabetes,O
",",O
and,O
intakes,O
of,O
folate,B
",",I
vitamin,B
E,I
",",I
and,I
beta,B
-,I
carotene,I
",",I
the,O
adjusted,O
relative,O
risks,O
of,O
total,O
cardiovascular,O
disease,O
mortality,O
were,O
1,O
.,O
0,
",",
0,
.,
97,
",",
1,
.,
11,
",",
1,
.,
47,
",",
and,
1,
.,
84,
(,
P,
for,
trend,
<,
0,
.,
01,
),
across,
quintiles,
of,
total,
vitamin,
C,
intake,
from,
food,
and,
supplements,
.,
Adjusted,
relative,
risks,
of,
coronary,
artery,
disease,
were,
1,
.,
0,
",",
0,
.,
81,
",",
0,
.,
99,
",",
1,
.,
26,
",",
and,
1,
.,
91,
(,
P,
for,
trend,
=,
0,
.,
01,
),
and,
of,
stroke,
were,
1,
.,
0,
",",
0,
.,
52,
",",
1,
.,
23,
",",
2,
.,
22,
",",
and,
2,
.,
57,O
(,O
P,B
for,I
trend,I
<,I
0,I
.,I
01,I
),I
.,I
When,O
dietary,O
and,O
supplemental,O
vitamin,B
C,I
were,O...O
postmenopausal,O
women,O
with,O
diabetes,O
.,O
Optical,O
coherence,O
tomography,O
can,O
measure,O
axonal,O
loss,O
in,O
patients,O
with,O
ethambutol,B
-,I
induced,I
optic,I
neuropathy,I
.,O
PURPOSE,O
:,O
To,O
map,O
and,O
identify,O
the,O
pattern,O
",",O
in,O
vivo,O
",",O
of,O
axonal,O
degeneration,O
in,O
ethambutol,B
-,I
induced,I
optic,I
neuropathy,I
using,O
optical,O
coherence,O
tomography,O
(,O
OCT,O
),O
.,O
Ethambutol,B
is,O
an,O
antimycobacterial,O
agent,O
often,O
used,O
to,O
treat,O
tuberculosis,O
.,O
A,O
serious,O
complication,O
of,O
ethambutol,B
is,O
an,O
optic,O
neuropathy,O
that,O
impairs,O
visual,O
acuity,O
",",O
contrast,O
sensitivity,O
",",O
and,O
color,O
vision,O
.,O
However,O
",",O
early,O
on,O
",",O
when,O
the,O
toxic,O
optic,O
neuropathy,O
is,O
mild,O
and,O
partly,O
reversible,O
",",O
the,O
funduscopic,O
findings,O
are,O
often,O
subtle,O
and,O
easy,O
to,O
miss,O
.,O
METHODS,O
:,O
Three,O
subjects,O
with,O
a,O
history,O
of,O
ethambutol,B
(,O
EMB,O
),O
-,O
induced,O
optic,O
neuropathy,O
of,O
short,O
-,O
",",O
intermediate,O
-,O
and,O
long,O
-,O
term,O
visual,O
deficits,O
were,O
administered,O
a,O
full,O
neuro,O
-,O
ophthalmologic,O
examination,O
including,O
visual,O
acuity,O
",",O
color,O
vision,O
",",O
contrast,O
sensitivity,O
",",O
and,O
fundus,O
examination,O
.,O
In,O
addition,O
",",O
OCT,B
(,O
OCT,B
3000,I
",",O
Humphrey,O
-,O
Zeiss,O
",",O
Dublin,O
",",O
CA,O
),O
was,O
In,O
all,O
subjects,O
with,O
history,O
of,O
EMB,B
-,I
induced,I
optic,B
neuropathy,I
",",O
there,O
was,O
a,O
mean,O
loss,O
of,O
72,O
%,O
nerve,O
fiber,O
layer,O
thickness,O
in,O
the,O
temporal,O
quadrant,O
(,O
patient,O
A,O
",",O
with,O
eventual,O
recovery,O
of,O
visual,O
acuity,O
and,O
fields,O
",",O
58,O
%,O
loss,O
;,O
patient,O
B,O
",",O
with,O
intermediate,O
visual,O
deficits,O
",",O
68,O
%,O
loss,O
;,O
patient,O
C,O
",",O
with,O
chronic,O
visual,O
deficits,O
",",O
90,O
%,O
loss,O
),O
",",O
with,O
an,O
average,O
mean,O
optic,B
nerve,I
thickness,I
of,O
26,O
+,O
/,O
-,O
16,O
microm,O
.,O
There,
was,
a,
combined,
mean,
loss,
of,
46,
%,
of,
fibers,
from,
the,
superior,
",",
inferior,
",",
and,
nasal,
quadrants,
in,
the,
(,
six,
),
eyes,
of,
all,
three,
subjects,
(,
mean,
average,
thickness,
of,
55,
+,
/,
-,
29,
microm,
),
.,
In,
both,
sets,
(,
four,
),
of,
eyes,
of,
the,
subjects,
with,
persistent,
visual,
deficits,
(,
patients,
B,
and,
C,
),
",",
there,
was,
an,
average,
loss,
of,
79,
%,
of,
nerve,
fiber,
thickness,
in,
the,
temporal,
quadrant,
.,
CONCLUSIONS,O
:,O
The,O
OCT,O
results,O
in,O
these,O
patients,O
with,O
EMB,B
-,O
induced,O
optic,O
neuropathy,O
show,O
considerable,O
loss,O
especially,O
of,O
the,O
temporal,O
fibers,O
.,O
This,O
is,O
consistent,O
with,O
prior,O
histopathological,O
studies,O
that,O
show,O
predominant,O
loss,O
of,O
parvo,B
-,I
cellular,I
axons,I
(,O
or,O
small,O
-,O
caliber,O
axons,O
),O
within,O
the,O
papillo,O
-,O
macular,O
bundle,O
in,O
toxic,O
or,O
hereditary,O
optic,O
neuropathies,O
.,O
OCT,O
can,O
be,O
a,O
valuable,O
tool,O
in,O
the,O
quantitative,O
analysis,O
of,O
optic,O
neuropathies,O
.,O
Additionally,O
",",O
in,O
terms,O
of,O
management,O
of,O
EMB,B
-,I
induced,I
optic,I
neuropathy,I
",",O
it,O
is,O
important,O
to,O
properly,O
manage,O
ethambutol,O
dosing,O
in,O
patients,O
with,O
renal,O
impairment,O
and,O
to,O
achieve,O
proper,O
transition,O
to,O
a,O
maintenance,O
dose,O
once,O
an,O
appropriate,O
loading,O
dose,O
has,O
been,O
reached,O
.,O
Hypoxia,O
in,O
renal,O
disease,O
with,O
proteinuria,B
and,O
/,O
or,O
glomerular,B
hypertension,O
.,O
Despite,O
the,O
increasing,O
nee...us,B
and,O
generated,O
a,O
novel,O
hypoxia,B
-,I
sensing,I
transgenic,O
rat,O
.,O
We,O
then,O
applied,O
this,O
animal,O
model,O
to,O
the,O
detection,O
of,O
tubulointerstitial,B
hypoxia,I
in,O
the,O
diseased,O
k...,I
the,O
observation,O
period,O
",",O
reaching,O
2,O
.,O
2,O
-,O
fold,O
at,O
2,O
weeks,O
in,O
the,O
puromycin,B
aminonucleoside,I
model,O
and,O
2,O
.,O
6,O
-,O
fold,O
at,O
4,O
weeks,O
in,O
the,O
remnant,O
kidney,O
model,O
",",O
whereas,O
that,O
of,O
vascular,O
endothelial,O
growth,O
factor,O
showed,O
a,O
mild,O
decrease,O
",",O
reflecting,O
distinct,O
behaviors,O
of,O
the,O
two,O
genes,O
.,O
The,O
degree,O
of,O
hypoxia,O
showed,O
a,O
positive,O
correlation,O
with,O
microscopic,O
tubulointerstitial,O
injury,O
in,O
both,O
models,O
.,O
Finally,O
",",O
we,O
identified,O
the,O
localization,O
of,O
proliferating,B
cell,I
nuclear,I
antigen,I
-,I
positive,I
",",O
ED,B
-,I
1,I
-,I
positive,I
",",O
and,O
terminal,O
dUTP,B
nick,I
-,I
end,I
labeled,I
",",O
positive,B
cells,I
in,O
the,O
hypoxic,O
cortical,O
area,O
in,O
the,O
remnant,O
kidney,O
model,O
.,O
We,O
propose,O
here,O
a,O
possible,O
pathological,O
tie,O
between,O
chronic,B
tubulointerstitial,I
hypoxia,I
and,O
progressive,O
glomerular,O
diseases,O
.,O
Adequate,O
timing,O
of,O
ribavirin,B
reduction,O
in,O
patients,O
with,O
hemolysis,O
during,O
combination,O
therapy,O
of,O
interferon,O
and,O
ribavirin,B
for,O
chronic,O
hepatitis,O
C,O
.,O
BACKGROUND,O
:,O
Hemolytic,O
anemia,O
is,O
one,O
of,O
the,O
major,O
adverse,O
events,O
of,O
the,O
combination,O
therapy,O
of,O
interferon,O
and,O
ribavirin,B
.,O
Because,O
of,O
ribavirin,O
-,O
related,O
hemolytic,O
anemia,O
",",O
dose,O
reduction,O
is,O
a,O
common,O
event,O
in,O
this,O
therapy,O
.,O
In,O
this,O
clinical,O
retrospective,O
cohort,O
study,O
we,O
have,O
examined,O
the,O
suitable,O
timing,O
of,O
ribavirin,B
reduction,O
in,O
patients,O
with,O
hemolysis,B
during,O
combination,O
therapy,O
.,O
METHODS,O
:,O
Thirty,O
-,O
seven,O
of,O
160,O
patients,O
who,O
had,O
HCV,B
-,O
genotype,O
1b,O
",",O
had,O
high,O
virus,O
load,O
",",O
and,O
received,O
24,O
-,O
week,O
combination,O
therapy,O
developed,O
anemia,B
with,O
hemoglobin,O
level,O
<,O
10,O
g,O
/,O
dl,O
or,O
anemia,O
-,O
related,O
signs,O
during,O
therapy,O
.,O
After,O
that,O
",",O
these,O
37,O
patients,O
were,O
reduced,O
one,O
tablet,O
of,O
ribavirin,B
(,O
200,B
mg,I
),O
per,O
...c,B
therapy,O
because,O
their,O
<,O
8,O
.,O
5,
g,
/,
dl,
hemoglobin,
values,
decreased,
to,
or,
anemia,
-,
related,
severe,
side,
effects,
occurred,
(,
group,
B,
),
.,
We,
assessed,
the,
final,
efficacy,
and,
safety,
after,
reduction,
of,
ribavirin,
in,
groups,
A,
and,
B,
.,
RESULTS,
:,
A,
sustained,
virological,
response,
(,
SVR,
),
was,
29,
.,
6,
%,
(,
8,
/,
27,
),
in,
group,
A,
and,
10,
%,
(,
1,
/,
10,
),
in,
group,
B,
",",
respectively,
.,
A,O
34,O
.,O
4,O
%,O
(,O
12,O
/,O
27,O
),O
of,O
SVR,B
+,O
biological,B
response,I
in,O
group,O
A,O
was,O
higher,O
than,O
10,O
%,O
(,O
1,O
/,O
10,O
),O
in,O
group,O
B,O
(,O
P,O
=,O
0,O
.,O
051,O
),O
",",O
with,O
slight,O
significance,B
.,O
With,O
respect,O
to,O
hemoglobin,O
level,O
at,O
the,O
time,O
of,O
ribavirin,O
reduction,O
",",O
a,O
rate,O
of,O
continuation,O
of,O
therapy,O
in,O
patients,O
with,O
>,O
or,O
=,O
10,O
g,O
/,O
dl,O
hemoglobin,O
was,O
higher,O
than,O
that,O
in,O
patients,O
with,O
<,O
10,O
g,O
/,O
dl,O
(,O
P,O
=,O
0,O
.,O
036,O
),O
.,O
CONCLUSIONS,O
:,O
Reduction,O
of,O
ribavirin,B
at,O
hemoglobin,O
level,O
>,O
or,O
=,O
10,O
g,O
/,O
The,O
study,O
was,O
performed,O
on,O
sexually,O
mature,O
male,O
rats,O
.,O
Serum,O
concentrations,O
of,O
prolactin,B
(,I
PRL,I
),I
and,O
testosterone,B
(,I
T,I
),I
were,O
measured,O
.,O
Tissue,O
sections,O
were,O
evaluated,O
with,O
light,O
and,O
electron,O
microscopy,O
.,O
Immunohistochemical,O
reactions,O
for,O
Anti,B
-,I
Proliferating,I
Cell,I
Nuclear,I
Antigen,I
(,I
PCNA,I
),I
were,O
performed,O
.,O
In,O
rats,O
of,O
the,O
experimental,O
group,O
",",O
the,O
mean,O
concentration,O
of,O
:,O
PRL,B
was,O
more,O
than,O
twice,O...O
expression,O
.,O
Electron,O
microscopy,O
revealed,O
changes,O
in,O
columnar,O
epithelial,O
cells,O
",",O
concerning,O
organelles,O
",",O
engaged,O
in,O
protein,O
synthesis,O
and,O
secretion,O
.,O
Relation,O
of,O
perfusion,O
defects,O
observed,O
with,O
myocardial,O
contrast,O
echocardiography,O
to,O
the,O
severity,O
of,O
coronary,O
stenosis,O
:,O
correlation,O
with,O
thallium,B
-,I
201,I
single,O
-,O
photon,O
emission,O
tomography,O
.,O
It,O
has,O
been,O
previously,O
shown,O
that,O
myocardial,B
contrast,I
echocardiography,I
is,O
a,O
valuable,O
technique,O
for,O
delineating,O
regions,O
of,O
myocardial,B
underperfusion,I
secondary,O
to,O
coronary,B
occlusion,I
and,O
to,O
critical,O
coronary,B
stenoses,I
in,O
the,O
presence,O
of,O
hyperemic,O
stimulation,O
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
determine,O
whether,O
myocardial,B
contrast,I
echocardiography,I
performed,O
with,O
a,O
stable,O
solution,O
of,O
sonicated,O
albumin,O
could,O
detect,O
regions,O
of,O
myocardial,B
underperfusion,I
resulting,O
from,O
various,O
degrees,O
of,O
coronary,B
stenosis,I
.,O
The,O
perfusion,O
defect,O
produced,O
in,O
16,O
open,O
chest,O
dogs,O
was,O
compared,O
with,O
the,O
anatomic,O
area,O
at,O
risk,O
measured,O
by,O
the,O
postmortem,O
dual,B
-,I
perfusion,I
technique,I
and,O
with,O
thallium,B
-,I
201,I
single,I
-,I
photon,I
emission,I
tomography,I
(,O
SPECT,B
),O
.,O
During,O
a,O
transient,O
(,O
20,O
-,O
s,O
),O
coronary,O
occlusion,O
",",O
a,O
perfusion,O
defect,O
was,O
observed,O
with,O
contrast,O
echocardiography,O
in,O
14,O
of,O
the,O
15,O
dogs,O
in,O
which,O
the,O
occlusion,O
was,O
produced,O
.,O
The,O
perfusion,O
defect,O
correlated,O
significantly,O
with,O
the,O
anatomic,O
area,O
at,O
risk,O
(,O
r,O
=,O
0,O
.,O
74,O
;,O
p,O
less,O
than,O
0,O
.,O
002,O
),O
.,O
During,O
dipyridamole,B
-,I
induced,I
hyperemia,I
",",O
12,O
of,O
the,O
16,O
dogs,O
with,O
a,O
partial,O
coronary,O
stenosis,O
had,O
a,O
visible,O
area,O
of,O
hypoperfusion,O
by,O
contrast,O
echocardiography,O
.,O
The,O
four,O
dogs,O
without,O
a,O
perfusion,O
defect,O
had,O
a,O
stenosis,O
that,O
resulted,O
in,O
a,O
mild,O
(,O
0,O
%,O
to,O
50,O
%,O
),O
reduction,O
in,O
dipyridamole,B
-,I
induced,I
hyperemia,I
.,O
The,O
size,O
of,O
the,O
perfusion,O
defect,O
during,O
stenosis,O
correlated,O
significantly,O
with,O
the,O
anatomic,O
area,O
at,O
risk,O
(,O
r,O
=,O
0,O
.,O
61,O
;,O
p,O
=,O
0,O
.,O
02,O
),O
.,O
Thallium,B
-,I
201,I
SPECT,I
demonstrated,O
a,O
perfusion,O
defect,O
in,O
all,O
14,O
dogs,O
analyzed,O
during,O
dipyridamole,B
-,I
induced,I
hyperemia,I
;,O
the,O
size,O
of,O
the,O
perfusion,O
defect,O
correlated,O
with,O
the,O
anatomic,O
area,O
at,O
risk,O
(,O
r,O
=,O
0,O
.,O
58,O
;,O
p,O
less,B
than,I
0,I
.,I
03,I
),O
and,O
with,O
the,O
perfusion,B
defect,I
by,O
contrast,O
echocardiography,B
(,O
r,O
=,O
0,O
.,O
58,O
;,O
p,O
less,B
than,I
0,I
.,I
03,I
),O
.,O
Thus,O
",",O
myocardial,O
contrast,B
echocardiography,I
can,O
be,O
used,O
to,O
visualize,O
and,O
quantitate,O
the,O
amount,O
of,O
jeopardized,O
myocardium,O
during,O
moderate,O
to,O
severe,O
degrees,O
of,O
coronary,O
stenosis,O
.,O
The,O
results,O
obtained,O
show,O
a,O
correlation,O
with,O
the,O
anatomic,O
area,O
at,O
risk,O
similar,O
to,O
that,O
obtained,O
with,O
thallium,B
-,I
201,I
SPECT,I
.,O
The,O
activation,O
of,O
spinal,O
N,B
-,I
methyl,I
-,I
D,I
-,I
aspartate,I
receptors,O
may,O
contribute,O
to,O
degeneration,O
of,O
spinal,O
motor,O
neurons,O
induced,O
by,O
neuraxial,O
morphine,O
after,O
a,O
noninjurious,O
interval,O
of,O
spinal,O
cord,O
ischemia,O
.,O
We,O
investigated,O
the,O
relationship,O
between,O
the,O
degeneration,O
of,O
spinal,O
motor,O
neurons,O
and,O
activation,O
of,O
N,B
-,I
methyl,I
-,I
d,I
-,I
aspartate,I
(,O
NMDA,B
),O
receptors,O
after,O
neuraxial,O
morphine,O
following,O
a,O
noninjurious,O
interval,O
of,O
aortic,O
occlusion,O
in,O
rats,O
.,O
Spinal,O
cord,O
ischemia,O
was,O
induced,O
by,O
aortic,B
occlusion,I
for,O
6,O
min,O
with,O
a,O
balloon,B
catheter,I
.,O
...Of,O
saline,B
(,O
group,B
C,I
;,O
n,O
=,O
8,O
),O
or,O
30,B
mug,I
of,I
morphine,I
(,O
group,B
SC,I
;,O
5,O
h,O
after,O
sham,O
operation,O
.,O
Microdialysis,O
samples,O
were,O
collected,O
preischemia,O
",",O
before,O
IT,O
injection,O
",",O
and,O
at,O
2,O
",",O
4,O
",",O
8,O
",",O
24,O
",",O
and,O
48,O
h,O
of,O
reperfusion,O
(,O
after,O
IT,O
injection,O
),O
.,O
Second,O
",",O
we,O
investigated,O
the,O
effect,O
of,O
IT,O
MK,B
-,I
801,I
(,O
30,O
mug,O
),O
on,O
the,O
histopathologic,O
changes,O
in,O
the,O
spinal,O
cord,O
after,O
morphine,O
-,I
induced,O
spastic,O
paraparesis,O
.,O
After,O
IT,O
morphine,B
",",O
the,O
cerebrospinal,O
fluid,O
(,O
CSF,O
),O
glutamate,O
concentration,O
was,O
increased,O
in,O
group,O
M,O
relative,O
to,O
both,O
baseline,O
and,O
group,O
C,O
(,O
P,O
<,O
0,O
.,O
05,O
),O
.,O
This,O
increase,O
persisted,O
for,O
8,O
hrs,O
.,O
IT,O
MK,O
-,O
801,O
significantly,O
reduced,O
the,O
number,O
of,O
dark,O
-,O
stained,O
alpha,O
-,O
motoneurons,O
after,O
morphine,B
-,O
induced,O
spastic,O
paraparesis,O
compared,O
with,O
the,O
saline,O
group,O
.,O
These,O
data,O
indicate,O
that,O
IT,O
morphine,B
induces,O
spastic,O
paraparesis,O
with,O
a,O
concomitant,O
increase,O
in,O
CSF,B
gl...iv,O
admin,O
##istration,O
of,O
am,O
##io,O
##dar,O
##one,O
:,O
a,O
report,O
of,O
two,O
cases,O
.,O
Amiodarone,B
represents,O
an,O
effective,O
antiarrhythmic,O
drug,O
for,O
cardioversion,O
of,O
recent,O
-,O
onset,O
atrial,O
fibrillation,O
(,O
AF,O
),O
and,O
maintenance,O
of,O
sinus,O
rhythm,O
.,O
We,O
briefly,O
describe,O
two,O
patients,O
suffering,O
from,O
recent,O
-,O
onset,O
atrial,O
fibrillation,O
",",O
who,O
experienced,O
an,O
acute,O
devastating,O
low,O
back,O
pain,O
a,O
few,O
minutes,O
after,O
initiation,O
of,O
intravenous,O
amiodarone,B
loading,O
.,O
Notably,O
",",O
this,O
side,O
effect,O
has,O
not,O
been,O
ever,O
reported,O
in,O
the,O
medical,O
literature,O
.,O
Clinicians,O
should,O
be,O
aware,O
of,O
this,O
reaction,O
since,O
prompt,O
termination,O
of,O
parenteral,O
administration,O
leads,O
to,O
complete,O
resolution,O
.,O
Quantitative,O
drug,B
levels,I
in,O
stimulant,O
psychosis,O
:,O
relationship,O
to,O
symptom,O
severity,O
",",O
catecholamines,O
and,O
hyperkinesia,O
.,O
To,O
examine,O
the,O
relationship,O
between,O
quantitative,O
stimulant,B
drug,I
levels,I
",",O
catecholamines,B
",",O
and,O
psychotic,O
symptoms,O
",",O
nineteen,O
patients,O
in,O
a,O
psychiatric,O
emergency,O
service,O
with,O
a,O
diagnosis,O
of,O
amphetamine,B
-,I
or,O
cocaine,B
-,I
induced,O
psychosis,O
were,O
interviewed,O
",",O
and,O
plasma,O
and,O
urine,O
were,O
collected,O
for,O
quantitative,O
assays,O
of,O
stimulant,B
drug,I
and,I
catecholamine,B
metabolite,I
levels,I
",",O
Methamphetamine,B
or,O
amphetamine,O
levels,O
were,O
related,O
to,O
several,O
psychopathology,O
scores,O
and,O
the,O
global,B
hyperkinesia,I
rating,O
.,O
HVA,B
levels,O
were,O
related,O
to,O
global,B
hyperkinesia,I
but,O
not,O
to,O
psychopathology,O
ratings,O
.,O
Although,O
many,O
other,O
factors,O
such,O
as,O
sensitization,O
may,O
play,O
a,O
role,O
",",O
intensity,O
of,O
stimulant,O
-,O
induced,O
psychotic,O
symptoms,O
and,O
stereotypies,O
appears,O
to,O
be,O
at,O
least,O
in,O
part,O
dose,O
-,O
related,O
.,O
Pheochromocytoma,B
unmasked,O
by,O
amisulpride,O
and,O
tiapride,O
.,O
OBJECTIVE,O
:,O
To,O
describe,O
the,O
unmasking,O
of,O
pheochromocyt...ent,O
with,O
amisulpride,O
100,O
mg,O
and,O
tiapride,O
100,O
mg,O
.,O
Both,O
drugs,O
were,O
immediately,O
discontinued,O
",",O
and,O
the,O
patient,O
recovered,O
after,O
subsequent,O
nicardipine,B
and,O
verapamil,B
treatment,O
.,O
Abdominal,O
ultrasound,O
showed,O
an,O
adrenal,O
mass,O
",",O
and,O
postoperative,O
histologic,O
examination,O
confirmed,O
the,O
diagnosis,O
of,O
pheochromocytoma,O
.,O
DISCUSSION,O
:,O
Drug,O
-,O
induced,O
symptoms,O
of,O
pheochromocytoma,O
are,O
often,O
associated,O
with,O
the,O
use,O
of,O
substituted,O
benzamide,O
drugs,O
",",O
but,O
the,O
underlying,O
mechanism,O
is,O
unknown,O
.,O
In,O
our,O
case,O
",",O
use,O
of,O
the,O
Naranjo,B
probability,I
scale,I
indicated,O
a,O
possible,O
relationship,O
between,O
the,O
hypertensive,O
crisis,O
and,O
amisulpride,B
and,O
tiapride,B
therapy,O
.,O
CONCLUSIONS,O
:,O
As,O
of,O
March,O
24,O
",",O
2005,O
",",O
this,O
is,O
the,O
first,O
reported,O
case,O
of,O
amisulpride,B
-,I
and,O
tiapride,B
-,I
induced,O
hypertensive,O
crisis,O
in,O
a,O
patient,O
with,O
pheochromocytoma,O
.,O
Physicians,O
and,O
other,O
healthcare,O
professionals,O
should,O
be,O
aware,O
of,O
this,O
potential,O
adverse,O
effect,O
of,O
The,
objective,
of,
this,
study,
was,
to,
assess,
minor,
neurological,
dysfunction,
",",
cognitive,
development,
",",
and,
somatic,
development,
after,
dexamethasone,
therapy,
in,
very,
-,
low,
-,
birthweight,
infants,
.,
Thirty,
-,
three,
children,
after,
dexamethasone,
treatment,
were,
matched,
to,
33,
children,
without,
dexamethasone,
treatment,
.,
Data,
were,
assessed,
at,
the,
age,
of,
3,
-,
7,
years,
.,
Dexamethasone,
was,
started,
between,
the,
7th,
and,
the,
28th,
day,
of,
life,
over,
7,
days,
with,
a,
total,
dose,
of,
2,
.,
35,
mg,
/,
kg,
/,
day,
.,
Exclusion,
criteria,
were,
asphyxia,
",",
malformations,
",",
major,
surgical,
interventions,
",",
small,
for,
gestational,
age,
",",
intraventricular,
haemorrhage,
grades,
III,
and,
IV,
",",
periventricular,
leukomalacia,
",",
and,
severe,
psychomotor,
retardation,
.,
Each,
child,
was,
examined,
by,
a,
neuropediatrician,
for,
minor,
neurological,
dysfunctions,
and,
tested,
by,
a,
psychologist,
for,
cognitive,
development,
with,
a,
Kaufman,
Assessment,
Battery,
for,
Children,
and,
a,
Draw,
-,
a,
-,
Man,
Test,
.,
There,
were,
no,
differences,
in,
demographic,
data,
",",
growth,
",",
and,
socio,
-,
economic,
status,
between,
the,
two,
groups,
.,
Fine,
motor,
skills,
and,
gross,
motor,
function,
were,
significantly,
better,
in,
the,
control,
group,
(,
p,
<,
0,
.,
01,
),
.,
In,
the,
Draw,
-,
a,
-,
Man,
Test,
",",
the,
control,
group,
showed,
better,
results,
(,
p,
<,
0,
.,
001,
),
.,
There,
were,
no,
differences,
in,
development,
of,
speech,
",",
social,
development,
",",
and,
the,
Kaufman,
Assessment,
Battery,
for,
Children,
.,
After,O
dexamethasone,B
treatment,O
",",O
children,O
showed,O
a,O
higher,O
rate,O
of,O
minor,O
neurological,O
dysfunctions,O
.,O
Neurological,B
development,O
was,O
affected,O
even,O
without,O
neurological,O
diagnosis,O
.,O
Further,O
long,O
-,O
term,O
follow,O
-,O
up,O
studies,O
will,O
be,O
necessary,O
to,O
fully,O
evaluate,O
the,O
impact,O
of,O
dexamethasone,B
on,O
neurological,O
and,O
cognitive,O
development,O
.,O
Valproic,B
acid,I
I,O
:,O
time,O
course,O
of,O
lipid,O
peroxidation,O
biomarkers,O
",",O
liver,O
toxicity,O
",",O
and,O
valproic,B
acid,I
metabolite,O
levels,O
in,O
rats,O
.,O
A,O
single,O
dose,O
of,O
valproic,B
acid,I
(,O
VPA,O
),O
",",O
which,O
is,O
a,O
widely,O
used,O
antiepileptic,O
drug,O
",",O
is,O
associated,O
with,O
oxidative,O
stress,O
in,O
rats,O
",",O
as,O
recently,O
demonstrated,O
by,O
elevated,O
levels,O
of,O
15,O
-,O
F,O
(,O
2t,O
),O
-,O
isoprostane,O
(,O
15,O
-,O
F,O
(,O
2t,O
),O
-,O
IsoP,O
),O
.,O
To,O
determine,O
whether,O
there,O
was,O
a,O
temporal,O
relationship,O
between,O
VPA,B
-,I
associated,I
oxidative,I
stress,I
and,O
hepatotoxicity,O
",",O
adult,O
male,O
Sprague,O
-,O
Dawley,O
rats,O
were,O
treated,O
ip,O
with,O
VPA,B
(,O
500,O
mg,O
/,O
kg,O
),O
or,O
0,O
.,O
9,O
%,O
saline,O
(,O
vehicle,O
),O
once,O
daily,O
for,O
2,O
",",O
4,O
",",O
7,O
",",O
10,O
",",O
or,O
14,O
days,O
.,O
Oxidative,B
stress,I
was,O
assessed,O
by,O
determining,O
plasma,O
and,O
liver,O
levels,O
of,O
15,B
-,I
F,I
(,I
2t,I
),I
-,I
IsoP,I
",",O
lipid,O
hydroperoxides,O
(,O
LPO,O
),O
",",O
and,O
thiobarbituric,B
acid,I
reactive,I
substances,I
(,I
TBARs,I
),I
.,O
Plasma,O
and,O
liver,O
15,B
-,I
F,I
(,O
2t,B
),I
-,I
IsoP,I
were,O
elevated,O
and,O
reached,O
a,O
plateau,O
05,O
),O
.,O
Liver,O
toxicity,O
was,O
evaluated,O
based,O
on,O
serum,O
levels,O
of,O
alpha,B
-,I
glutathione,I
S,I
-,I
transferase,I
(,O
alpha,B
-,I
GST,I
),O
and,O
by,O
histology,O
.,O
Serum,O
alpha,B
-,I
GST,I
levels,O
were,O
significantly,O
elevated,O
by,O
day,O
4,O
",",O
which,O
corresponded,O
to,O
hepatotoxicity,O
as,O
shown,O
by,O
the,O
increasing,O
incidence,O
of,O
inflammation,O
of,O
the,O
liver,O
capsule,O
",",O
necrosis,O
",",O
and,O
steatosis,O
throughout,O
the,O
study,O
.,O
The,O
liver,O
levels,O
of,O
beta,O
-,O
oxidation,O
metabolites,O
of,O
VPA,B
were,O
decreased,O
by,O
day,O
14,O
",",O
while,O...
steatosis,O
",",O
and,O
elevated,O
levels,O
of,O
serum,O
alpha,O
-,O
GST,O
.,O
Assessment,O
of,O
perinatal,O
hepatitis,B
and,B
rubella,B
prevention,O
in,O
New,O
Hampshire,O
delivery,O
hospitals,O
.,O
OBJECTIVE,O
:,...O
the,O
year,O
2000,O
birth,O
cohort,O
in,O
New,O
Hampshire,O
',O
s,O
25,O
delivery,O
hospitals,O
.,O
Assessment,
was,
done,
on,
the,
following,
:,
prenatal,
screening,
for,
hepatitis,
B,
and,
rubella,
",",
administration,
of,
the,
hepatitis,
B,
vaccine,
birth,
dose,
to,
all,
infants,
",",
administration,
of,
hepatitis,
B,
immune,
globulin,
to,
infants,
who,
were,
born,
to,
hepatitis,
B,
surface,
antigen,
-,
positive,
mothers,
",",
rubella,
immunity,
",",
and,
administration,
of,
in,
-,
hospital,
postpartum,
rubella,
vaccine,
to,
rubella,
nonimmune,
women,
.,
RESULTS,O
:,O
Prenatal,O
screening,O
rates,O
for,O
The,O
proportion,O
of,O
infants,O
who,O
were,O
vaccinated,O
in,O
January,O
and,O
February,O
2000,O
(,O
48,B
.,B
5,I
%,I
and,O
67,B
.,B
5,I
%,I
",",O
respectively,O
),O
was,O
less,O
than,O
any,O
other,O
months,O
",",O
whereas,O
the,O
proportion,O
who,O
were,O
vaccinated,O
in,O
December,O
2000,O
(,O
88,B
.,B
2,I
%,I
),O
was,O
the,O
highest,O
.,O
Women,O
who,O
were,O
born,O
between,O
1971,O
and,O
1975,O
had,O
the,O
highest,O
rate,O
of,O
rubella,O
nonimmunity,O
(,O
9,B
.,B
5,I
.,B
.,B
5,
%,
),
.,
In,
-,
hospital,
postpartum,
rubella,
vaccine,
administration,
was,
documented,
for,
75,
.,
6,
%,
of,
nonimmune,
women,
.,
CONCLUSION,
:,
This,
study,
documents,
good,
compliance,
in,
New,
Hampshire,
',
s,
birthing,
hospitals,
with,
national,
guidelines,
for,
perinatal,
hepatitis,
B,
and,
rubella,
prevention,
and,
highlights,
potential,
areas,
for,
improvement,
.,
Succinylcholine,B-Chemical
-,O
induced,O
masseter,O
muscle,O
rigidity,O
during,O
bronchoscopic,O
removal,O
of,O
a,O
tracheal,O
foreign,O
body,O
.,O
Masseter,O
muscle,O
rigidity,O
during,O
general,O
anesthesia,O
is,O
considered,O
an,O
early,O
warning,O
sign,O
of,O
a,O
possible,O
episode,O
of,O
malignant,O
hyperthermia,O
.,O
The,O
decision,O
whether,O
to,O
continue,O
or,O
discontinue,O
the,O
procedure,O
depends,O
on,O
the,O
urgency,O
of,O
the,O
surgery,O
and,O
severity,O
of,O
masseter,O
muscle,O
rigidity,O
.,O
Here,O
",",O
we,O
describe,O
a,O
case,O
of,O
severe,O
masseter,O
muscle,O
rigidity,O
(,O
jaw,O
of,O
steel,O
),O
after,O
suc...ance,O
were,O
available,O
to,O
detect,O
and,O
treat,O
malignant,O
hyperthermia,O
.,O
Dexrazoxane,
protects,
against,
myelosuppression,
from,
the,
DNA,
cleavage,
-,
enhancing,
drugs,
etoposide,
and,
daunorubicin,
but,
not,
doxorubicin,
.,
PURPOSE,
:,
The,
anthracyclines,
daunorubicin,
and,
doxorubicin,
and,
the,
epipodophyllotoxin,
etoposide,
are,
potent,
DNA,
cleavage,
-,
enhancing,
drugs,
that,
are,
widely,
used,
in,
clinical,
oncology,
;,
however,
",",
myelosuppression,
and,
cardiac,
toxicity,
limit,
their,
use,
.,
Dexrazoxane,B
(,O
ICRF,B
-,I
187,I
),O
is,O
recommended,O
for,O
protection,O
against,O
anthracycline,O
-,O
induced,O
cardiotoxicity,O
.,O
EXPERIMENTAL,O
DESIGN,O
:,O
Because,O
of,O
their,O
widespread,O
use,O
",",O
the,O
hematologic,O
toxicity,O
following,O
coadministration,O
of,O
dexrazoxane,B
and,O
these,O
three,O
structurally,O
different,O
DNA,O
cleavage,O
enhancers,O
was,O
investigated,O
:,O
Sensitivity,O
of,O
human,O
and,O
murine,O
blood,O
progenitor,O
cells,O
to,O
etoposide,O
",",O
daunorubicin,O
",",O
and,O
doxorubicin,O
+,O
/,O
-,O
dexrazoxane,B
was,O
determined,O
in,O
granulocyte,O
-,O
macrophage,O
colony,O
forming,O
assays,O
.,O
Likewise,O
",",O
in,O
vivo,O
",",O
B6D2F1,O
mice,O
were,O
treated,O
with,O
etoposide,B
",",O
daunorubicin,B
",",O
and,O
doxorubicin,B
",",O
with,O
or,O
without,O
dexrazoxane,B
over,O
a,O
wide,O
range,O
of,O
doses,O
:,O
posttreatment,O
",",O
a,O
full,O
hematologic,O
evaluation,O
was,O
done,O
.,O
RESULTS,O
:,O
Nontoxic,O
doses,O
of,O
dexrazoxane,B
reduced,O
myelosuppression,O
and,O
weight,O
loss,O
from,O
daunorubicin,B
and,O
etoposide,B
in,O
mice,O
and,O
antagonized,O
their,O
antiproliferative,O
effects,O
in,O
the,O
colony,O
assay,O
;,O
however,O
",",O
dexrazoxane,B
neither,O
reduced,O
myelosuppression,O
",",O
weight,O
loss,O
",",O
nor,O
the,O
in,O
vitro,O
cytotoxicity,O
from,O
doxorubicin,B
.,O
CONCLUSION,O
:,O
Although,O
our,O
findings,O
support,O
the,O
observation,O
that,O
dexrazoxane,B
reduces,O
neither,O
hematologic,O
activity,O
Our,O
data,O
also,O
suggest,O
that,O
significant,O
etoposide,B
dose,O
escalation,O
is,O
perhaps,O
possible,O
by,O
the,O
use,O
of,O
dexrazoxane,B
.,O
Clinical,O
trials,O
in,O
patients,O
with,O
brain,O
metastases,O
combining,O
dexrazoxane,O
and,O
high,O
doses,O
of,O
etoposide,B
is,O
ongoing,O
with,O
the,O
aim,O
of,O
improving,O
efficacy,O
without,O
aggravating,O
hematologic,O
toxicity,O
.,O
If,O
successful,O
",",O
this,O
represents,O
an,O
exciting,O
mechanism,O
for,O
pharmacologic,O
regulation,O
of,O
side,O
effects,O
from,O
cytotoxic,B
chemotherapy,I
.,O
Assessment,O
of,O
the,O
onset,O
and,O
persistence,O
of,O
amnesia,O
during,O
procedural,O
sedation,O
with,O
propofol,B
.,O
OBJECTIVES,O
:,O
To,O
assess,O
patients,O
',O
ability,O
to,O
repeat,O
and,O
recall,O
words,O
presented,O
to,O
them,O
while,O
undergoing,O
procedural,O
sedation,O
with,O
propofol,B
",",O
and,O
correlate,O
their,O
recall,O
with,O
their,O
level,O
of,O
awareness,O
as,O
measured,O
by,O
bispectral,O
index,O
(,O
BIS,O
),O
monitoring,O
.,O
METHODS,O
:,O
This,O
was,O
a,O
prospective,O
",",O
single,O
-,O
intervention,O
study,O
of,O
consenting,O
adult,O
patients,O
undergoin...,O
and,O
continuing,O
until,O
the,O
patient,O
had,O
regained,O
baseline,O
mental,O
status,O
.,O
At,O
1,O
-,O
minute,O
intervals,O
during,O
the,O
procedural,O
sedation,O
",",O
until,O
the,O
patient,O
regained,O
baseline,O
mental,O
status,O
at,O
the,O
end,O
of,O
the,O
procedure,O
",",O
a,O
word,O
from,O
a,O
standardized,O
list,O
was,O
read,O
aloud,O
",",O
and,O
the,O
patient,O
was,O
asked,O
to,O
immediately,O
repeat,O
the,O
word,O
to,O
the,O
investigator,O
.,O
The,O
BIS,O
score,O
at,O
the,O
time,O
the,O
word,O
was,O
read,O
and,O
the,O
patient,O
',O
s,O
ability,O
to,O
repeat,O
the,O
word,O
were,O
recorded,O
.,O
After,
the,
procedure,
",",
the,
patient,
was,
asked,
to,
state,
all,
of,
the,
words,
from,
the,
list,
that,
he,
or,
she,
could,
recall,
",",
and,
to,
identify,
the,
last,
word,
recalled,
from,
prior,
to,
the,
start,
of,
the,
procedure,
and,
the,
first,
word,
recalled,
from,
after,
the,
procedure,
was,
completed,
.,
RESULTS,
:,
Seventy,
-,
five,
consenting,
patients,
were,
enrolled,
;,
one,
patient,
was,
excluded,
from,
data,
analysis,
for,
a,
protocol,
violation,
.,
No,O
serious,O
adverse,O
events,O
were,O
noted,O
during,O
the,O
procedural,O
sedations,O
.,O
The,O
mean,O
(,O
+,O
/,O
-,O
standard,O
deviation,O
),O
time,O
of,O
data,O
collection,O
was,O
16,O
.,O
4,O
minutes,O
(,O
+,O
/,O
-,O
7,O
.,O
1,O
;,O
range,O
5,O
to,O
34,O
minutes,O
),O
.,O
The,O
mean,O
initial,O
(,O
preprocedure,O
),O
BIS,B
score,I
was,O
97,O
.,O
1,O
(,O
+,O
/,O
-,O
2,O
.,O
3,O
;,O
range,O
92,O
to,O
99,O
),O
.,O
The,O
mean,O
lowest,O
BIS,B
score,I
occurring,O
during,O
these,O
procedural,O
sedations,O
was,O
66,O
.,O
9,O
(,O
+,O
/,O
-,O
14,O
.,O
4,O
;,O
range,O
33,O
to,O
91,O
),O
.,O
The,O
mean,O
lowest,O
BIS,O
sco...to,O
repeat,O
words,O
was,O
81,O
.,O
5,O
(,O
95,O
%,O
CI,O
=,O
78,O
.,O
1,O
to,O
84,O
.,O
0,O
),O
8,O
),O
.,O
The,O
mean,O
BIS,B
score,I
corresponding,O
to,O
the,O
last,O
word,O
recalled,O
from,O
prior,O
to,O
the,O
The,O
mean,O
lowest,O
BIS,B
score,O
for,O
any,O
recalled,O
word,O
was,O
91,O
.,O
5,O
(,O
+,O
/,O
-,O
11,O
.,O
1,O
;,O
range,O
79,O
to,O
98,O
),O
",",O
and,O
no,O
words,O
were,O
recalled,O
when,O
the,O
corresponding,O
BIS,B
score,O
was,O
less,O
than,O
90,O
.,O
CONCLUSIONS,O
:,O
There,O
is,O
a,O
range,O
of,O
BIS,B
scores,O
during,O
which,O
sedated,O
patients,O
are,O
able,O
to,O
repeat,O
words,O
read,O
to,O
them,O
but,O
are,O
not,O
able,O
to,O
subsequently,O
recall,O
these,O
words,O
.,O
Furthermore,O
",",O
patients,O
had,O
no,O
recall,O
of,O
words,O
repeated,O
prior,O
to,O
procedural,O
sedation,O
in,O
BIS,B
ranges,I
associated,O
with,O
recall,O
after,O
procedural,O
sedation,O
",",O
suggestive,O
of,O
retrograde,O
amnesia,O
.,O
Amiodarone,B
pulmonary,I
toxicity,I
.,O
Amiodarone,B
is,O
an,O
effective,O
antiarrhythmic,O
agent,O
whose,O
utility,O
is,O
limited,O
by,O
many,O
side,O
-,O
effects,O
",",O
the,O
most,O
problematic,O
being,O
pneumonitis,O
.,O
The,O
pulmonary,O
toxicity,O
of,O
amiodarone,B
is,O
thought,O
to,O
result,O
from,O
direct,O
injury,O
related,O
to,O
the,O
intracellul...y,O
toxicity,O
are,O
characteristic,O
but,O
nonspecific,O
.,O
The,
diagnosis,
depends,
on,
exclusion,
of,
other,
entities,
",",
such,
as,
heart,
failure,
",",
infection,
",",
and,
malignancy,
.,
While,
withdrawal,
of,
amiodarone,
leads,
to,
clinical,
improvement,
in,
majority,
of,
cases,
",",
this,
is,
not,
always,
possible,
or,
advisable,
.,
Dose,
reduction,
or,
concomitant,
steroid,
therapy,
may,
have,
a,
role,
in,
selected,
patients,
.,
Two,O
prodrugs,O
of,O
potent,O
and,O
selective,O
GluR5,B
kainate,I
receptor,I
antagonists,I
actives,O
in,O
three,O
animal,O
models,O
of,O
pain,O
.,O
Amino,B
acids,I
5,I
and,I
7,I
",",O
two,O
potent,O
and,O
selective,O
competitive,O
GluR5,B
KA,I
receptor,I
antagonists,I
",",O
exhibited,O
high,O
GluR5,B
receptor,I
affinity,I
over,O
other,O
glutamate,O
receptors,O
.,O
Their,O
ester,O
prodrugs,O
6,I
and,I
8,I
were,O
orally,O
active,O
in,O
three,O
models,O
of,O
pain,O
:,O
reversal,O
of,O
formalin,O
-,O
induced,O
paw,O
licking,O
",",O
carrageenan,O
-,O
induced,O
thermal,O
hyperalgesia,O
",",O
and,O
capsaicin,O
-,O
induced,O
mechanical,O
hyperalgesia,O
.,O
Possible,O
azithromycin,B
-,I
associated,O
hiccups,O
.,O
OBJECTIVE,O
:,O
To,O
report,O
a,O
case,O
of,O
persistent,O
hiccups,O
assoc...zithromycin,O
for,O
the,O
treatment,O
of,O
pharyngitis,O
.,O
Hiccups,O
were,O
persistent,O
and,O
exhausting,O
.,O
Discontinuation,O
of,O
azithromycin,B
and,O
therapy,O
with,O
baclofen,O
finally,O
resolved,O
hiccups,O
.,O
No,O
organic,O
cause,O
of,O
hiccups,O
was,O
identified,O
despite,O
extensive,O
investigation,O
.,O
DISCUSSION,O
:,O
Pharmacotherapeutic,O
agents,O
have,O
been,O
uncommonly,O
associated,O
with,O
hiccups,O
.,O
Corticosteroids,B
(,O
dexamethasone,B
and,O
methylprednisolone,I
),O
",",O
benzodiazepines,B
(,O
midazolam,I
),O
and,O
general,O
anaesthesia,O
have,O
been,O
the,O
specific,O
agents,O
mentioned,O
most,O
frequently,O
in,O
the,O
literature,O
as,O
being,O
associated,O
with,O
the,O
development,O
of,O
hiccups,O
.,O
Few,O
cases,O
of,O
drug,O
-,O
induced,O
hiccups,O
have,O
been,O
reported,O
related,O
to,O
macrolide,B
antimicrobials,I
.,O
Using,Ellipsis
reaction,O
with,O
other,O
macrolides,O
and,O
the,O
absence,O
of,O
any,O
alternative,O
explanation,O
for,O
hiccups,O
.,O
Our,O
hypothesis,O
is,O
that,O
a,O
vagal,B
mechanism,O
mediated,O
by,O
azithromycin,B
could,O
be,O
the,O
pathogenesis,O
of,O
hiccups,O
in,O
our,O
patient,O
.,O
CONCLUSIONS,O
:,O
Diagnosis,O
of,O
drug,O
-,O
induced,O
hiccups,O
is,O
difficult,O
and,O
often,O
achieved,O
only,O
by,O
a,O
process,O
of,O
elimination,O
.,O
However,O
",",O
macrolide,O
antimicrobials,O
have,O
been,O
reported,O
to,O
be,O
associated,O
with,O
hiccups,O
and,O
vagal,B
mechanism,O
could,O
explain,O
the,O
development,O
of,O
this,O
side,O
-,O
effect,O
.,O
Calcium,B
carbonate,I
toxicity,I
:,O
the,O
updated,O
milk,B
-,I
alkali,I
syndrome,I
;,O
report,O
of,O
3,O
cases,O
and,O
...,O
milk,B
-,I
alkali,I
syndrome,I
.,O
METHODS,O
:,O
We,O
report,O
the,O
clinical,O
and,O
laboratory,O
data,O
in,O
3,O
patients,O
who,O
presented,O
with,O
severe,O
hypercalcemia,O
(,O
corrected,O
serum,O
calcium,O
>,O
or,O
=,O
14,O
mg,O
/,O
dL,O
),O
and,O
review,O
the,O
pertinent,O
literature,O
on,O
milk,B
-,I
alkali,I
syndrome,I
.,O
RESULTS,
:,
The,
3,
patients,
had,
acute,
renal,
insufficiency,
",",
relative,
metabolic,
alkalosis,
",",
and,
low,
parathyroid,
hormone,
(,
PTH,
),
",",
PTH,
-,
related,
peptide,
",",
and,
1,
",",
25,
-,
dihydroxyvitamin,
D,
concentrations,
.,
No,
malignant,
lesion,
was,
found,
.,
Treatment,
included,
aggressive,
hydration,
and,
varied,
amounts,
of,
furosemide,
.,
The,
2,
patients,
with,
the,
higher,
serum,
calcium,
concentrations,
received,
pamidronate,
intravenously,
(,
60,
and,
30,
mg,
",",
respectively,
),
",",
which,
caused,
severe,
hypocalcemia,
.,
Of,
the,
3,
patients,
",",
2,
were,
ingesting,
acceptable,
doses,
of,
elemental,
calcium,
(,
1,
g,
and,
2,
g,
daily,
",",
respectively,
),
in,
the,
form,
of,
calcium,
carbonate,
.,
In,O
addition,O
to,O
our,O
highlighted,O
cases,O
",",O
we,O
review,O
the,O
history,O
",",O
classification,O
",",O
pathophysiologic,O
featur...n,O
of,O
orally,O
ingested,O
calcium,B
carbonate,I
in,O
susceptible,O
persons,O
.,O
Treatment,O
with,O
hydration,B
",",O
furosemide,B
",",O
and,O
discontinuation,O
of,O
the,O
calcium,B
and,O
vitamin,B
D,I
source,O
is,O
adequate,O
.,O
Pamidronate,B
treatment,O
is,O
associated,O
with,O
considerable,O
risk,O
for,O
hypocalcemia,B
",",O
even,O
in,O
cases,O
of,O
initially,O
severe,O
hypercalcemia,O
.,O
Warfarin,B
-,I
induced,I
leukocytoclastic,I
vasculitis,I
.,O
Skin,O
reactions,O
associated,O
with,O
oral,O
coumarin,B
-,I
derived,I
anticoagulants,I
are,O
an,O
uncommon,O
occurrence,O
.,O
Leukocytoclastic,O
vasculitis,O
(,O
LV,O
),O
is,O
primarily,O
a,O
cutaneous,O
small,O
vessel,O
vasculitis,O
",",O
though,O
systemic,O
The,O
results,O
of,O
skin,O
lesion,O
biopsies,O
were,O
available,O
in,O
3,O
patients,O
",",O
confirming,O
LV,B
Cutaneous,B
lesions,B
resolved,O
in,O
all,O
patients,O
after,O
warfarin,O
was,O
discontinued,O
.,O
In,O
2,O
of,O
the,O
4,O
patients,O
",",O
rechallenge,O
with,O
warfarin,O
led,O
to,O
recurrence,O
of,O
the,O
lesions,O
.,O
LV,B
may,O
be,O
a,O
late,O
-,O
onset,O
adverse,O
reaction,O
associated,O
with,O
warfarin,O
therapy,O
.,O
Cocaine,B
-,I
induced,O
brainstem,B
seizures,O
and,O
behavior,O
.,O
A,O
variety,O
of,O
abnormal,O
sensory,O
/,O
motor,O
behaviors,O
associated,O
with,O
electrical,O
discharges,O
recorded,O
from,O
the,O
bilateral,O
brainstem,B
were,O
induced,O
in,O
adult,O
WKY,O
rats,O
by,O
mechanical,O
(,O
electrode,O
implants,O
),O
and,O
DC,O
electrical,O
current,O
stimulations,O
and,O
by,O
acute,O
and,O
chronic,O
administration,O
of,O
cocaine,B
.,O
The,O
electrode,O
implant,O
implicated,O
one,O
side,O
or,O
the,O
other,O
of,O
the,O
reticular,B
system,I
of,I
the,I
brainstem,I
but,O
subjects,O
were,O
not,O
incapacitated,O
by,O
the,O
stimulations,O
.,O
Cocaine,B
(,I
40,I
mg,I
/,I
kg,I
),I
was,O
injected,O
subcutaneously,O
for,O
an,O
acute,O
experiment,O
and,O
subsequent,O
20,I
mg,I
/,I
kg,I
doses,O
twice,O
daily,O
for,O
3,I
days,I
in,O
a,O
chronic,O
study,O
.,O
Cocaine,B
generated,O
more,O
abnormal,O
behaviors,O
in,O
the,O
brainstem,O
perturbation,O
group,O
",",O
especially,O
the,O
electrically,O
Shifts,O
in,O
the,O
power,O
frequency,O
spectra,O
of,O
the,O
discharge,O
patterns,O
were,O
noted,O
between,O
quiet,O
and,O
pacing,O
behavioral,O
states,O
.,O
Hypersensitivity,O
to,O
various,O
auditory,B
",",O
tactile,B
",",O
and,O
visual,B
stimulation,O
was,O
present,O
and,O
shifts,O
in,O
the,O
brainstem,O
ambient,O
power,O
spectral,O
frequency,O
occurred,O
in,O
response,O
to,O
tactile,O
stimulation,O
.,O
These,O
findings,O
suggest,O
that,O
the,O
brainstem,O
generates,O
and,O
propagates,O
pathological,O
discharges,O
that,O
can,O
be,O
elicited,O...
to,O
which,O
the,O
discharge,O
propagates,O
.,O
Cocaine,B
was,O
found,O
to,O
activate,O
the,O
discharge,O
system,O
and,O
thus,O
Cognitive,O
functions,O
may,O
also,O
be,O
involved,O
since,O
dopaminergic,B
and,O
serotonergic,B
cellular,O
elements,O
at,O
the,O
brainstem,Ellipsis
are,O
also,O
implicated,O
.,O
rTMS,O
of,O
supplementary,O
motor,O
area,O
modulates,O
therapy,O
-,O
induced,O
dyskinesias,O
in,O
Using,O
repetitive,O
transcranial,O
magnetic,O
stimulation,O
(,O
rTMS,B
),O
over,O
the,O
supplementary,O
motor,O
area,O
SMA,B
),O
in,O
a,O
group,O
of,O
patients,O
with,O
advanced,O
Parkinson,O
disease,O
",",O
the,O
authors,O
investigated,O
whether,O
modulation,O
of,O
SMA,B
excitability,O
may,O
result,O
in,O
a,O
modification,O
of,O
a,O
dyskinetic,O
state,O
induced,O
by,O
continuous,O
apomorphine,O
infusion,O
.,O
rTMS,O
at,O
1,O
Hz,O
was,O
observed,O
to,O
markedly,O
reduce,O
drug,B
-,I
induced,I
dyskinesias,I
",",O
whereas,O
5,O
-,I
Hz,I
rTMS,O
induced,O
a,O
slight,O
but,O
not,O
significant,O
increase,O
.,O
Intracavitary,O
chemotherapy,O
(,O
paclitaxel,B
/,I
carboplatin,I
liquid,I
crystalline,I
cubic,I
phases,I
),O
for,O
recurrent,O
glioblastoma,O
-,O
-,O
clinical,O
observations,O
.,O
Human,O
malignant,O
brain,O
tumors,O
have,O
a,O
poor,O
prognosis,O
in,O
spite,O
of,O
surgery,O
and,O
radiation,O
therapy,O
.,O
Cubic,B
phases,I
consist,O
of,O
curved,O
biocontinuous,O
lipid,O
bilayers,O
",",O
separating,O
two,O
congruent,O
networks,O
of,O
water,O
channels,O
.,O
Used,O
as,O
a,O
host,O
for,O
cytotoxic,O
drugs,O
",",O
the,O
gel,O
-,O
like,O
matrix,O
can,O
easily,O
be,O
applied,O
to,O
the,O
walls,O
of,O
a,O
surgical,O
resection,O
cavity,O
.,O
For,O
human,O
glioblastoma,O
recurrences,O
",",O
the,O
feasibility,O
",",O
safety,O
",",O
and,O
short,O
-,O
term,O
effects,O
of,O
a,O
surgical,O
intracavitary,O
application,O
of,O
paclitaxel,B
and,O
carboplatin,B
encapsulated,O
by,O
liquid,O
crystalline,O
cubic,B
phases,I
are,O
examined,O
in,O
a,O
pilot,O
study,O
.,O
A,O
total,O
of,O
12,O
patients,O
with,O
a,O
recurrence,O
of,O
a,O
glioblastoma,B
multiforme,I
underwent,O
re,O
-,O
resection,O
and,O
received,O
an,O
intracavitary,O
application,O
of,O
paclitaxel,B
and,O
carboplatin,B
cubic,I
phases,I
in,O
different,O
dosages,O
.,O
Six,O
of,O
the,O
patients,O
received,O
more,O
than,O
15,O
mg,O
paclitaxel,O
and,O
suffered,O
from,O
moderate,O
to,O
severe,O
brain,O
edema,O
",",O
while,O
the,O
remaining,O
patients,O
received,O
only,O
a,O
total,O
of,O
15,O
mg,O
paclitaxel,O
.,O
In,O
the,O
latter,O
group,O
",",O
brain,B
edema,I
was,O
markedly,O
reduced,O
and,O
dealt,O
medically,O
.,O
Intracavitary,O
Five,O
patients,O
with,O
idiopathic,B
generalized,I
epilepsies,I
(,O
IGE,O
),O
treated,O
with,O
lamotrigine,B
(,O
LTG,O
),O
experie...ted,O
MJ,B
in,O
a,O
dose,O
-,O
dependent,O
manner,O
with,O
early,O
aggravation,O
during,O
titration,O
.,O
MJ,B
disappeared,O
when,O
LTG,B
dose,O
was,O
decreased,O
by,O
25,O
to,O
50,O
%,O
In,O
two,O
patients,O
",",O
LTG,B
exacerbated,O
MJ,B
in,O
a,O
delayed,O
but,O
more,O
severe,O
manner,O
",",O
with,O
myoclonic,O
status,O
that,O
only,O
ceased,O
after,O
LTG,B
withdrawal,O
.,O
Absence,O
of,O
acute,O
cerebral,O
vasoconstriction,O
after,O
cocaine,B
-,I
associated,I
subarachnoid,I
hemorrhage,I
.,O
INTRODUCTION,O
:,O
Cocaine,B
use,O
has,O
been,O
associated,O
with,O
neurovascular,O
complications,O
",",O
including,O
arterial,O
vasoconstriction,O
and,O
vasculitis,O
.,O
However,O
",",O
there,O
are,O
few,O
studies,O
of,O
angiographic,O
effects,O
of,O
cocaine,B
on,O
human,O
cerebral,O
arteries,O
.,O
Information,O
on,O
these,O
effects,O
could,O
be,O
obtained,O
from,O
angiograms,O
of,O
patients,O
with,O
cocaine,B
-,I
associated,I
subarachnoid,I
hemorrhage,I
(,O
SAH,I
),O
who,O
underwent,O
angiography,O
shortly,O
after,O
cocaine,B
use,O
.,O
METHODS,O
:,O
We,O
screened,O
patients,O
with,O
SAH,B
retrospectively,O
and,O
identified,O
those,O
with,O
positive,O
urine,O
toxicology,O
for,O
cocaine,B
or,O
its,O
metabolites,O
.,O
Quantitative,
arterial,
diameter,
measurements,
from,
angiograms,
of,
these,
patients,
were,
compared,
to,
measurements,
from,
control,
patients,
with,
SAH,
who,
were,
matched,
for,
factors,
known,
to,
influence,
arterial,
diameter,
.,
Qualitative,
comparisons,
of,
small,
artery,
changes,
also,
were,
made,
.,
RESULTS,
:,
Thirteen,
patients,
with,
positive,
cocaine,
toxicology,
were,
compared,
to,
26,
controls,
.,
There,O
were,O
no,O
significant,O
differences,O
between,O
groups,O
in,O
the,O
mean,O
diameters,O
of,O
the,O
intradural,O
internal,B
carotid,I
",",O
sphenoidal,B
segment,I
of,I
the,I
middle,I
cerebral,I
",",O
precommunicating,B
segment,I
of,I
the,I
anterior,I
cerebral,I
",",O
or,O
basilar,B
arteries,I
(,O
p,O
greater,O
than,O
0,O
.,O
05,O
for,O
all,O
comparisons,O
",",O
unpaired,O
t,O
-,O
tests,O
),O
.,O
There,O
also,O
were,O
no,O
significant,O
differences,O
between,O
groups,O
when,O
expressing,O
diameters,O
as,O
the,O
sum,O
of,O
the,O
precommunicating,B
segment,I
of,I
the,I
anterior,I
cerebral,I
+,O
sphenoidal,B
segment,I
of,I
the,I
middle,I
cerebral,I
+,O
supraclinoid,B
internal,I
carotid,I
artery,I
+,O
basilar,B
artery,I
divided,O
by,O
the,O
diameter,O
of,O
the,O
petrous,O
internal,B
carotid,I
artery,I
(,O
p,O
greater,O
than,O
0,O
.,O
05,O
",",O
unpaired,O
t,O
-,O
tests,O
),O
.,O
Qualitative,O
assessments,O
showed,O
two,O
arterial,O
irregularities,O
in,O
the,O
distal,O
vasculature,O
in,O
each,O
group,O
.,O
CONCLUSION,O
:,O
No,O
quantitative,O
evidence,O
for,O
narrowing,O
of,O
large,O
cerebral,O
arteries,O
or,O
qualitative,O
angiographic,O
evidence,O
for,O
distal,O
narrowing,O
or,O
vasculitis,O
could,O
be,O
found,O
in,O
patients,O
who,O
underwent,O
angiography,O
after,O
aneurysmal,O
SAH,O
associated,O
with,O
cocaine,B
use,O
.,O
Methamphetamine,B
causes,O
alterations,O
in,O
the,O
MAP,O
kinase,O
-,O
related,O
pathways,O
in,O
the,O
brains,O
of,O
mice,O
that,O
display,O
increased,O
aggressiveness,O
.,O
Aggressive,O
behaviors,O
have,O
been,O
reported,O
in,O
patients,O
who,O
suffer,O
from,O
some,O
psychiatric,O
disorders,O
",",O
and,O
are,O
common,O
in,O
methamphetamine,O
(,O
METH,B
),O
abusers,O
.,O
Herein,O
",",O
we,O
report,O
that,O
multiple,O
(,O
but,O
not,O
single,O
),O
injections,O
of,O
METH,O
significantly,O
increased,O
aggressiveness,O
in,O
male,O
CD,O
-,O
1,O
mice,O
.,O
This,O
increase,O
in,O
aggressiveness,O
was,O
not,O
secondary,O
to,O
METH,B
-,O
induced,O
hyperactivity,O
.,O
Analysis,O
of,O
protein,O
expression,O
using,O
antibody,O
microarrays,O
and,O
Western,O
blotting,O
revealed,O
differential,O
changes,O
in,O
MAP,O
kinase,O
-,O
related,O
pathways,O
after,O
multiple,O
and,O
single,O
METH,B
injections,O
.,O
There,O
were,O
statistically,O
significant,O
(,O
p,O
<,O
0,O
.,O
05,O
),O
decreases,O
in,O
MEK1,B-Chemical
",",O
Erk2p,B-Chemical
",",O
GSK3alpha,B-Chemical
",",O
14,B-Chemical
-,I-Chemical
3,I-Chemical
-,I-Chemical
3e,I-Chemical
",",O
and,O
MEK7,B-Chemical
in,O
the,O
striata,O
of,O
mice,O
after,O
multiple,O
injections,O
of,O
METH,B-Chemical
.,O
MEK1,B-Chemical
was,O
significantly,O
decreased,O
also,O
after,O
a,O
single,O
injection,O
of,O
METH,B-Chemical
",",O
but,O
to,O
a,O
much,O
lesser,O
degree,O
than,O
after,O
multiple,O
injections,O
of,O
METH,B-Chemical
.,O
In,O
the,O
frontal,O
cortex,O
",",O
there,O
was,O
a,O
statistically,O
significant,O
decrease,O
in,O
GSK3alpha,B-Chemical
after,O
multiple,O
(,O
but,O
not,O
single,O
),O
injections,O
of,O
METH,B-Chemical
.,O
These,O
findings,O
suggest,O
that,O
alterations,O
in,O
MAP,B
kinase,I
-,I
related,I
pathways,I
in,I
the,I
prefronto,I
-,I
striatal,I
circuitries,I
might,O
be,O
involved,O
in,O
the,O
manifestation,O
of,O
aggressive,O
behaviors,O
in,O
mice,O
.,O
Amisulpride,B
related,O
tic,B
-,I
like,I
symptoms,I
in,I
an,I
adolescent,I
schizophrenic,I
.,I
Tic,B
disorders,I
can,O
be,O
effectively,O
treated,O
by,O
atypical,O
antipsychotics,O
such,O
as,O
risperidone,B
",",O
olanzapine,B
and,O
ziprasidone,B
.,O
However,O
",",O
there,O
are,O
two,O
case,O
reports,O
that,O
show,O
tic,O
-,O
like,O
symptoms,O
",",O
including,O
motor,B
and,I
phonic,I
variants,I
",",O
occurring,O
during,O
treatment,O
with,O
quetiapine,B
or,I
clozapine,I
.,O
We,O
present,O
a,O
15,O
-,O
year,O
-,O
old,O
girl,O
schizophrenic,O
who,O
developed,O
frequent,O
involuntary,O
eye,O
-,O
blinking,O
movements,O
after,O
5,O
months,O
of,O
amisulpride,B
treatment,I
(,O
1000,O
mg,O
per,O
day,O
),O
.,O
The,O
tic,O
-,O
like,O
symptoms,O
resolved,O
completely,O
after,O
we,O
reduced,O
the,O
dose,O
of,O
amisulpride,B
down,O
to,O
800,O
mg,O
per,O
day,O
.,O
However,O
",",O
her,O
psychosis,O
recurred,O
after,O
the,O
dose,O
reduction,O
.,O
We,O
then,O
placed,O
her,O
on,O
an,O
additional,O
100,O
mg,O
per,O
day,O
of,O
quetiapine,B
.,O
She,O
has,O
been,O
in,O
complete,O
remission,O
under,O
the,O
combined,O
medications,O
for,O
more,O
than,O
one,O
year,O
and,O
maintains,O
a,O
fair,O
role,O
function,O
.,O
No,O
more,O
tic,O
-,O
like,O
symptoms,O
or,O
other,O
side,O
effects,O
have,O
been,O
reported,O
.,O
Together,O
with,O
previously,O
reported,O
cases,O
",",O
our,O
patient,O
suggests,O
that,O
tic,O
-,O
like,O
symptoms,O
might,O
occur,O
in,O
certain,O
vulnerable,O
individuals,O
during,O
treatment,O
with,O
atypical,B
antipsychotics,I
such,O
as,O
quetiapine,B
",",O
clozapine,B
",",O
or,O
amisulpride,B
.,O
Chloroquine,B
related,O
complete,O
heart,O
block,O
with,O
blindness,O
:,O
case,O
report,O
.,O
A,O
27,O
-,O
year,O
old,O
African,O
woman,O
with,O
history,O
of,O
regular,O
chloroquine,B
ingestion,O
presented,O
with,O
The,O
heart,B
block,I
was,O
treated,O
by,O
pacemaker,O
insertion,O
and,O
the,O
heart,B
failure,I
resolved,O
spontaneously,O
following,O
chloroquine,B
discontinuation,I
.,O
She,O
however,O
remains,O
blind,O
.,O
Effects,O
of,O
suprofen,B
on,O
the,O
isolated,O
perfused,O
rat,O
kidney,O
.,O
Although,O
suprofen,O
has,O
been,O
associated,O
with,O
the,O
development,O
of,O
acute,O
renal,O
failure,O
in,O
greater,O
than,O
100,O
subjects,O
",",O
the,O
mechanism,O
of,O
damage,O
remains,O
unclear,O
.,O
The,O
direct,O
nephrotoxic,O
effects,O
of,O
a,O
single,O
dose,O
of,O
15,O
mg,O
of,O
suprofen,B
were,O
compared,O
in,O
the,Ellipsis
control,O
groups,O
.,O
In,
contrast,
",",
a,
significant,
decline,
in,
glomerular,
filtration,
rate,
was,
found,
after,
the,
introduction,
of,
suprofen,
to,
the,
kidney,
perfused,
with,
uric,
acid,
;,
no,
changes,
were,
found,
with,
suprofen,
in,
the,
absence,
of,
uric,
acid,
.,
A,
significant,
decrease,
in,
the,
baseline,
excretion,
rate,
of,
uric,
acid,
was,
found,
in,
rats,
given,
suprofen,
",",
compared,
with,
drug,
-,
free,
controls,
.,
However,O
",",O
the,O
fractional,O
excretion,O
of,O
uric,B
acid,I
was,O
unchanged,O
between,O
the,O
groups,O
over,O
the,O
experimental,O
period,O
.,O
In,O
summary,O
",",O
suprofen,O
causes,O
acute,O
declines,O
in,O
renal,O
function,O
",",O
most,O
likely,O
by,O
directly,O
altering,O
the,O
intrarenal,O
distribution,O
of,O
uric,B
acid,I
.,O
Microinjection,O
of,O
ritanserin,O
into,O
the,O
CA1,O
region,O
of,O
hippocampus,O
improves,O
scopolamine,O
-,O
induced,O
amnesia,O
in,O
adult,O
male,O
rats,O
.,O
The,
effect,
of,
ritanserin,
(,
5,
-,
HT2,
antagonist,
),
on,
scopolamine,
(,
muscarinic,
cholinergic,
antagonist,
),
-,
induced,
amnesia,
in,
Morris,
water,
maze,
(,
MWM,
),
was,
investigated,
.,
Rats,
were,
divided,
into,
eight,
groups,
and,
bilaterally,
cannulated,
into,
CA1,
region,
of,
the,
hippocampus,
.,
One,
week,
later,
",",
they,
received,
repeatedly,
vehicles,
(,
saline,
",",
DMSO,
",",
saline,
+,
DMSO,
),
",",
scopolamine,
(,
2,
microg,
/,
0,
.,
5,O
microl,B
saline,I
/,O
side,O
;,O
30,O
min,O
before,O
training,O
),O
",",O
ritanserin,B
(,O
2,O
",",O
4,O
and,O
8,O
microg,O
/,O
0,O
.,O
5,O
microl,O
DMSO,O
/,O
side,O
;,O
20,O
min,O
before,O
training,O
),O
and,O
scopolamine,B
(,O
2,O
microg,O
/,O
0,O
.,O
5,O
microl,O
;,O
30,O
min,O
before,O
ritanserin,O
injection,O
),O
+,O
ritanserin,B
(,O
4,O
microg,O
/,O
0,O
.,O
5,O
microl,O
DMSO,O
),O
through,O
cannulae,O
each,O
day,O
.,O
Animals,O
were,O
tested,O
for,O
four,O
consecutive,O
days,O
(,O
4,O
trial,O
/,O
day,O
),O
in,O
MWM,O
during,O
which,O
the,O
position,O
of,O
hidden,O
platform,O
was,O
unchanged,O
.,O
In,O
the,O
fifth,O
day,O
",",O
the,O
platform,O
was,O
elevated,O
above,O
the,O
water,O
surface,O
in,O
another,O
position,O
t...nce,O
to,O
find,O
platform,O
in,O
scopolamine,B
-,I
treated,I
group,I
as,O
compared,O
to,O
saline,B
group,I
.,O
Ritanserin,B
-,I
treated,O
rats,O
(,O
4,O
microg,O
/,O
0,O
.,O
5,O
microl,O
/,O
side,O
),O
showed,O
a,O
significant...tant,O
decrease,O
in,O
escape,O
latencies,O
and,O
traveled,O
distances,O
as,O
compared,O
to,O
the,O
scopolamine,B
-,I
treated,O
rats,O
.,O
Our,O
findings,O
show,O
that,O
microinjection,O
of,O
ritanserin,B
into,O
the,O
CA1,O
region,O
of,O
the,O
hippocampus,O
improves,O
th...,O
causes,O
",",O
including,O
infectious,O
and,O
autoimmune,O
processes,O
.,O
A,O
rare,O
cause,O
",",O
drug,O
-,O
induced,O
vasculitis,O
",",O
may,O
result,O
from,O
the,O
production,O
of,O
antineutrophil,B
cytoplasmic,I
antibodies,I
(,O
ANCAs,O
),O
in,O
response,O
to,O
a,O
medication,O
.,O
We,O
report,O
a,O
girl,O
Subsequent,O
treatment,O
of,O
persistent,O
hyperthyroidism,O
with,O
radioablation,O
did,O
not,O
result,O
in,O
an,O
exacerbation,O
of,O
the,...
important,O
factor,O
in,O
the,O
treatment,O
of,O
Alzheimer,B
',I
s,I
disease,I
(,O
AD,B
),O
.,O
Methanolic,
extracts,
from,
Pueraria,
thunbergiana,
exhibited,
an,
activation,
effect,
(,
46,
%,
),
on,
ChAT,
in,
vitro,
.,
Via,
the,
sequential,
isolation,
of,
Pueraria,
thunbergiana,
",",
the,
active,
component,
was,
ultimately,
identified,
as,
daidzein,
(,
4,
',
",",
7,
-,
dihydroxy,
-,
isoflavone,
),
.,
In,
order,
to,
investigate,
the,
effects,
of,
daidzein,
from,
Pueraria,
thunbergiana,
on,
scopolamine,
-,
induced,
impairments,
of,
learning,
and,
memory,
",",
we,
conducted,
a,
series,
of,
in,
vivo,
tests,
.,
Administration,O
of,O
daidzein,B
(,O
4,O
.,O
5,O
mg,O
/,O
kg,O
body,O
weight,O
),O
to,O
mice,O
was,O
shown,O
By,O
way,O
of,O
contrast,O
",",O
mice,O
treated,O
with,O
daidzein,B-Chemical
prior,O
to,O
the,O
scopolamine,O
injections,O
were,O
noticeably,O
protected,O
from,O
this,O
performance,O
impairment,O
(,O
an,O
approximately,O
12,O
%,O
-,O
21,O
%,O
decrease,O
in,O
alternation,O
behavior,O
),O
.,O
These,O
results,O
indicate,O
that,O
daidzein,B-Chemical
might,O
play,O
a,O
role,O
in,O
acetylcholine,O
biosynthesis,O
as,O
a,O
ChAT,O
activator,O
",",O
and,O
that,O
it,O
also,O
ameliorates,O
scopolamine,O
-,O
induced,O
amnesia,O
.,O
Urinary,O
symptoms,O
and,O
quality,O
of,O
life,O
changes,O
in,O
Thai,O
women,O
with,O
overactive,O
bladder,O
after,O
tolterodine,B
treatment,O
.,O
OBJECTIVES,O
:,O
To,O
study,O
the,O
urinary,O
symptoms,O
and,O
quality,O
of,O
life,O
changes,O
in,O
Thai,O
women,O
with,O
overactive,O
bladder,O
(,O
OAB,O
),O
after,O
tolterodine,B
treatment,O
.,O
MATERIAL,O
AND,O
METHOD,O
:,O
Thirty,O
women,O
(,O
aged,O
30,O
-,O
77,O
years,O
),O
diagnosed,O
as,O
having,O
OAB,O
at,O
the,O
Gynecology,O
Clinic,O
",",O
King,O
Chulalongkorn,O
Memorial,O
Hospital,O
from,O
January,O
to,O
April,O
2004,O
were,O
included,O
in,O
the,O
present,O
study,O
.,O
Tolterodine,B
2,I
mg,I
",",O
twice,O
daily,O
was,O
given,O
.,O
After,O
8,O
weeks,O
treatment,O
",",O
changes,O
in,O
micturition,O
diary,O
variables,O
and,O
tolerability,O
were,O
determined,O
.,O
Short,O
form,O
36,B
(,I
SF36,I
),I
questionaires,O
(,O
Thai,O
version,O
),O
were,O
given,O
before,O
and,O
after,O
8,O
weeks,O
of,O
treatment,O
.,O
RESULTS,O
:,O
At,O
8,O
weeks,O
",",O
all,O
micturition,O
per,O
day,O
decreased,O
from,O
16,O
.,O
7,O
+,O
/,O
-,O
5,O
.,O
3,O
to,O
6,O
.,O
7,O
+,O
/,O
-,O
2,O
.,O
4,O
times,O
per,O
day,O
.,O
The,O
number,O
of,O
nocturia,O
episodes,O
decreased,O
from,O
5,O
.,O
4,O
+,O
/,O
-,O
4,O
.,O
2,O
to,O
1,O
.,O
1,O
+,O
/,O
-,O
1,O
.,O
0,O
times,O
per,O
night,O
.,O
The,O
most,O
common,O
side,O
effect,O
was,O
dry,O
month,O
in,O
5,O
cases,O
(,O
16,O
.,O
7,O
%,O
),O
with,O
2,O
cases,O
reporting,O
a,O
moderate,O
degree,O
and,O
1,O
case,O
with,O
severe,O
degree,O
.,O
Only,O
one,O
case,O
(,O
3,O
.,O
3,O
%,O
),O
withdrew,O
from,O
the,O
present,O
study,O
due,O
to,O
a,O
severe,O
dry,B
mouth,I
.,O
The,O
SF,B
-,I
36,I
scores,O
changed,O
significantly,O
in,O
the,O
domains,O
of,O
physical,O
functioning,O
",",O
role,O
function,O
emotional,O
",",O
social,O
function,O
and,O
mental,O
heath,O
.,O
CONCLUSION,O
:,O
Tolterodine,B
was,O
well,O
tolerated,O
and,O
its,O
effects,O
improved,O
the,O
quality,O
of,O
life,O
in,O
Thai,O
women,O
with,O
OAB,B
.,O
Remifentanil,B
pretreatment,O
reduces,O
myoclonus,O
after,O
etomidate,B
.,O
STUDY,O
OBJECTIVE,O
:,O
The,O
aim,O
of,O
the,O
study,O
was,O
to,O
compare,O
the,O
effect,O
of,O
pretreatment,O
with,O
remifentanil,B
1,O
microg,O
/,O
kg,O
and,O
the,O
effect,O
of,O
gender,O
on,O
the,O
incidence,O
of,O
myoclonus,O
after,O
anesthesia,O
induction,O
with,O
etomidate,B
.,O
DESIGN,O
:,O
This,O
was,O
a,O
randomized,O
",",O
double,O
-,O
blind,O
study,O
.,O
SETTING,
:,
The,
study,
was,
conducted,
at,
a,
university,
hospital,
.,
PATIENTS,
:,
Sixty,
patients,
were,
pretreated,
in,
a,
randomized,
double,
-,
blinded,
fashion,
with,
remifentanil,
1,
microg,
/,
kg,
or,
placebo,
.,
Two,
minutes,
after,
remifentanil,
or,
placebo,
injection,
",",
etomidate,
0,
.,
3,
mg,
/,
kg,
was,
given,
.,
MEASUREMENTS,
:,
Myoclonus,
was,
recorded,
with,
a,
scale,
of,
0,
to,
3,
.,
The,O
grade,O
of,O
sedation,O
(,O
none,B
",",O
mild,B
",",O
moderate,B
",",O
severe,B
),O
",",O
nausea,B
",",O
pruritus,B
",",Ellipsis
pruritus,B
after,O
injection,O
of,O
both,O
drugs,O
.,O
None,B
of,O
the,O
patients,O
experienced,O
sedation,O
",",O
apnea,B
",",O
nausea,B
",",O
or,O
pruritus,B
after,O
injection,O
of,O
both,O
drugs,O
.,O
In,O
the,O
placebo,O
group,O
",",O
male,O
patients,O
were,O
associated,O
with,O
significantly,O
increased,O
incidence,O
of,O
myoclonus,B
after,O
etomidate,O
administration,O
.,O
CONCLUSION,O
:,O
Pretreatment,O
with,O
remifentanil,B
1,O
microg,O
/,O
kg,O
reduced,O
myoclonus,O
after,O
etomidate,O
induction,O
without,O
side,O
effects,O
such,O
as,O
sedation,O
",",O
apnea,O
",",O
nausea,O
",",O
or,O
pruritus,O
.,O
Men,
experience,
increased,
incidence,
of,
myoclonus,
than,
women,
after,
etomidate,
administration,
.,
Memory,
function,
and,
serotonin,
transporter,
promoter,
gene,
polymorphism,
in,
ecstasy,
(,
MDMA,
),
users,
.,
Although,
3,
",",
4,
-,
methylenedioxymethamphetamine,
(,
MDMA,
or,
ecstasy,
),
has,
been,
shown,
to,
damage,
brain,
serotonin,
(,
5,
-,
HT,
),
neurons,
in,
animals,
and,
possibly,
humans,
",",
little,
is,
known,
about,
the,
long,
-,
term,
consequences,
of,
MDMA,
-,
induced,
5,
-,
HT,
neurotoxic,
lesions,
on,
functions,
in,
which,
5,
-,
HT,
is,
involved,
",",
such,
as,
cognitive,
function,
.,
Because,O
5,B
-,I
HT,I
transporters,O
play,O
a,O
key,O
element,O
in,O
the,O
regulation,O
of,O
synaptic,O
5,B
-,I
HT,I
transmission,O
it,O
may,O
be,O
important,O
to,O
control,O
for,O
the,O
potential,O
covariance,O
effect,O
of,O
a,O
polymorphism,O
in,O
the,O
5,B
-,I
HT,I
transporter,O
promoter,O
gene,O
region,O
(,O
5,B
-,I
HTTLPR,I
),O
when,O
studying,O
the,O
effects,O
of,O
MDMA,O
as,O
well,O
as,O
cognitive,O
functioning,O
.,O
The,O
aim,O
of,O
the,O
study,O
was,O
to,O
investigate,O
the,O
effects,O
of,O
moderate,B
and,O
heavy,B
MDMA,I
use,O
on,O
cognitive,O
function,O
",",O
as,O
well,O
as,O
the,O
effects,O
of,O
long,B
-,I
term,I
abstention,I
from,O
MDMA,B
",",O
in,O
subjects,O
genotyped,O
for,O
5,B
-,I
HTTLPR,I
.,O
A,O
second,O
aim,O
of,O
the,O
study,O
was,O
to,O
determine,O
whether,O
these,O
effects,O
differ,O
for,O
females,O
and,O
males,O
.,O
Fifteen,O
moderate,O
MDMA,B
users,O
(,O
<,O
55,O
lifetime,O
tablets,O
),O
",",O
22,O
heavy,O
MDMA,B
+,O
users,O
(,O
>,O
55,O
lifetime,O
tablets,O
),O
",",O
16,O
ex,O
-,O
MDMA,B
+,O
users,O
(,O
last,O
tablet,O
>,O
1,O
year,O
ago,O
),O
and,O
13,O
controls,O
were,O
compared,O
on,O
a,O
battery,O
of,O
neuropsychological,O
tests,O
.,O
DNA,O
from,O
peripheral,O
nuclear,O
blood,O
cells,O
was,O
genotyped,O
for,O
5,O
-,O
HTTLPR,B
using,O
standard,O
polymerase,O
chain,O
reaction,O
methods,O
.,O
A,O
significant,O
group,O
effect,O
was,O
observed,O
only,O
on,O
memory,O
function,O
tasks,O
(,O
p,O
=,O
0,O
.,O
04,O
),O
but,O
not,O
on,O
reaction,O
times,O
(,O
p,O
=,O
0,O
.,O
61,O
),O
or,O
attention,O
/,O
executive,O
functioning,O
(,O
p,O
=,O
0,O
.,O
59,O
),O
.,O
Heavy,O
and,O
ex,O
-,O
MDMA,B
+,I
users,I
performed,O
significantly,O
poorer,O
on,O
memory,O
tasks,O
than,O
controls,O
.,O
In,O
contrast,O
",",O
no,O
evidence,O
of,O
memory,O
impairment,O
was,O
observed,O
in,O
moderate,O
MDMA,B
users,O
.,O
No,O
significant,O
effect,O
of,O
5,O
-,O
HTTLPR,O
or,O
gender,O
was,O
observed,O
.,O
While,O
the,O
use,O
of,O
MDMA,B
Role,O
of,O
mangiferin,B
on,O
biochemical,O
alterations,O
and,O
antioxidant,O
status,O
in,O
isoproterenol,B
-,I
induced,I
myocardial,I
infarction,I
in,O
rats,O
.,O
The,O
current,O
study,O
dealt,O
with,O
the,O
protective,O
role,O
of,O
mangiferin,B
",",O
a,O
polyphenol,O
from,O
Mangifera,B
indica,I
Linn,I
.,I
(,I
Anacardiaceae,I
),I
",",O
on,O
isoproterenol,B
(,I
ISPH,I
),I
-,I
induced,I
myocardial,I
infarction,I
(,O
MI,O
),O
in,O
rats,O
through,O
its,O
antioxidative,O
mechanism,O
.,O
Subcutaneous,O
injection,O
of,O
ISPH,B
(,O
200,O
mg,O
/,O
kg,O
body,O
weight,O
in,O
1,O
ml,O
saline,O
),O
to,O
rats,O
for,O
2,O
consecutive,O
days,O
caused,O
myocardial,O
damage,O
in,O
rat,O
heart,O
",",O
which,O
was,O
determined,O
by,O
the,O
increased,O
activity,O
of,O
serum,O
lactate,B
dehydrogenase,I
(,I
LDH,I
),I
and,O
creatine,B
phosphokinase,I
isoenzymes,I
(,I
CK,I
-,I
MB,I
),I
",",O
increased,O
uric,O
acid,O
level,O
and,O
reduced,O
plasma,B
iron,I
binding,I
capacity,I
.,O
The,O
protective,O
role,O
of,O
mangiferin,B
was,O
analyzed,O
by,O
triphenyl,B
tetrazolium,I
chloride,I
(,O
TTC,B
),O
test,O
used,...I
altered,O
in,O
MI,B
rats,O
.,O
Upon,O
pretreatment,O
with,O
mangiferin,B
(,O
100,O
mg,O
/,O
kg,O
body,O
weight,O
suspended,O
in,O
2,O
ml,O
of,O
dimethyl,B
sulphoxide,I
),O
given,O
intraperitoneally,O
for,O
28,O
days,O
to,O
MI,O
rats,O
protected,O
the,O
above,O
-,O
mentioned,O
parameters,O
to,O
fall,O
from,O
the,O
normal,O
levels,O
.,O
Activities,O
of,O
heart,O
tissue,O
enzymic,O
antioxidants,O
and,O
serum,O
non,O
-,O
enzymic,O
antioxidants,O
levels,O
rose,O
significantly,O
upon,O
mangiferin,O
administration,O
as,O
compared,O
to,O
ISPH,O
-,O
induced,O
MI,O
rats,O
.,O
From,O
the,O
present,O
study,O
it,O
is,O
concluded,O
that,O
mangiferin,B
exerts,O
a,O
beneficial,O
effect,O
against,O
ISPH,B
-,I
induced,I
MI,I
due,O
to,O
its,O
antioxidant,O
potential,O
",",O
which,O
regulated,O
the,O
tissues,O
defense,O
system,O
against,O
cardiac,O
damage,O
.,O
Cardiovascular,O
risk,O
with,O
cyclooxygenase,O
inhibitors,O
:,O
general,O
problem,O
with,O
substance,O
specific,O
differences,O
?,O
Randomised,O
clinical,O
trials,O
and,O
observational,O
studies,O
have,O
shown,O
an,O
increased,O
risk,O
of,O
myocardial,O
infarction,O
",",O
stroke,O
",",O
hypertension,O
and,O
heart,O
failure,O
during,O
treatment,O
with,O
cyclooxygenase,O
inhibitors,O
.,O
Adverse,O
cardiovascular,O
effects,O
occurred,O
mainly,O
",",O
but,O
not,O
exclusively,O
",",O
in,O
patients,O
with,O
concomitant,O
risk,O
factors,O
.,O
Cyclooxygenase,B
inhibitors,I
cause,O
complex,O
changes,O
in,O
renal,O
",",O
vascular,O
and,O
cardiac,O
prostanoid,O
profiles,O
thereby,O
increasing,O
vascular,O
resistance,O
and,O
fluid,O
retention,O
.,O
The,O
incidence,O
of,O
cardiovascular,O
adverse,O
events,O
tends,O
to,O
increase,O
with,O
the,O
daily,O
dose,O
and,O
total,O
exposure,O
time,O
.,O
A,O
comparison,O
of,O
individual,O
selective,O
and,O
unselective,O
cyclooxygenase,O
inhibitors,O
suggests,O
substance,O
-,O
specific,O
differences,O
",",O
which,O
may,O
depend,O
on,O
differences,O
in,O
pharmacokinetic,O
parameters,O
or,O
inhibitory,O
potency,O
and,O
may,O
be,O
contributed,O
by,O
prostaglandin,O
-,O
independent,O
effects,O
.,O
Diagnostic,O
markers,O
such,O
as,O
N,B
-,I
terminal,I
pro,I
brain,I
natriuretic,I
peptide,I
(,O
NT,B
-,I
proBNP,I
),O
or,O
high,O
-,O
sensitive,O
C,B
-,I
reactive,I
protein,I
might,O
help,O
in,O
the,O
early,O
identification,O
of,O
patients,O
at,O
risk,O
",",O
thus,O
avoiding,O
the,O
occurrence,O
of,O
serious,O
cardiovascular,O
toxicity,O
.,O
Pilocarpine,B
seizures,O
cause,O
age,O
-,O
dependent,O
impairment,O
in,O
auditory,O
location,O
discrimination,O
.,O
Children,O
who,O
have,O
status,O
epilepticus,O
have,O
continuous,O
or,O
rapidly,O
repeating,O
seizures,O
that,O
may,O
be,O
life,O
-,O
threatening,O
and,O
may,O
cause,O
life,O
-,O
long,O
changes,O
in,O
brain,O
and,O
behavior,O
.,O
The,O
extent,O
to,O
which,O
status,O
epilepticus,O
causes,O
deficits,O
in,O
auditory,O
discrimination,O
is,O
unknown,O
.,O
A,
naturalistic,
auditory,
location,
discrimination,
method,
was,
used,
to,
evaluate,
this,
question,
using,
an,
animal,
model,
of,
status,
epilepticus,
.,
Male,
Sprague,
-,
Dawley,
rats,
were,
injected,
with,
saline,
on,
postnatal,
day,
(,
P,
),
20,
",",
or,
a,
convulsant,
dose,
of,
pilocarpine,
on,
P20,
or,
P45,
.,
Pilocarpine,
on,
either,
day,
induced,
status,
epilepticus,
;,
status,
epilepticus,
at,
P45,
resulted,
in,
CA3,
cell,
loss,
and,
spontaneous,
seizures,
",",
whereas,
P20,
rats,
had,
no,
cell,
loss,
or,
spontaneous,
seizures,
.,
Mature,O
rats,O
were,O
trained,O
with,O
sound,B
-,I
source,I
location,I
and,O
sound,B
-,I
silence,I
discriminations,I
.,O
Control,...
Status,
epilepticus,
in,
rat,
causes,
an,
age,
-,
dependent,
",",
long,
-,
term,
impairment,
in,
auditory,
discrimination,
.,
This,
impairment,
may,
explain,
one,
cause,
of,
impaired,
auditory,
location,
discrimination,
in,
humans,
.,
Nerve,
growth,
factor,
and,
prostaglandins,
in,
the,
urine,
of,
female,
patients,
with,
overactive,
bladder,
.,
PURPOSE,
:,
NGF,
and,
PGs,
in,
the,
bladder,
can,
be,
affected,
by,
pathological,
changes,
in,
the,
bladder,
and,
these,
changes,
can,
be,
detected,
in,
urine,
.,
We,O
investigated,O
changes,O
in,O
urinary,O
NGF,B
and,O
PGs,B
in,O
women,O
with,O
OAB,B
.,O
MATERIALS,O
AND,O
METHODS,O
:,O
The,O
study,O
groups,O
included,O
65,O
women,O
with,O
OAB,B
and,O
20,O
without,O
bladder,O
symptoms,O
who,O
served,O
as,O
controls,O
.,O
Evaluation,O
included,O
patient,O
history,O
",",O
urinalysis,O
",",O
a,O
voiding,O
diary,O
and,O
urodynamic,O
studies,O
.,O
Urine,O
samples,O
were,O
collected,O
.,O
NGF,B
",",O
PGE2,B
",",O
PGF2alpha,B
and,O
PGI2,B
were,O
measured,O
using,O
enzyme,O
-,O
linked,O
immunosorbent,O
assay,O
and,O
compared,O
between,O
the,O
groups,O
.,O
In,O
addition,O
",",O
correlations,O
between,O
urinary,O
NGF,B
and,O
PG,B
",",O
and,O
urodynamic,O
parameters,O
in,O
patients,O
with,O
OAB,O
were,O
examined,O
.,O
RESULTS,O
:,O
Urinary,O
NGF,B
",",O
PGE2,B
and,O
PGF2alpha,B
were,O
significantly,O
increased,O
in,O
patients,O
with,O
OAB,O
compared,O
with,O
controls,O
(,O
p,O
<,O
0,O
.,O
05,O
),O
.,O
However,O
",",O
urinary,O
PGI2,B
was,O
not,O
different,O
between,O
controls,O
and,O
patients,O
with,O
OAB,B
.,O
In,O
patients,O
with,O
OAB,B
urinary,O
PGE2,B
positively,O
correlated,O
with,O
volume,O
at,O
first,O
desire,O
to,O
void,O
and,O
maximum,O
cystometric,O
capacity,O
(,O
p,O
<,O
0,O
.,O
05,O
),O
.,O
Urinary,O
NGF,B
",",O
PGF2alpha,B
and,O
PGI2,B
did,O
not,O
correlate,O
with,O
urodynamic,O
parameters,O
in,O
patients,O
with,O
OAB,B
.,O
CONCLUSIONS,
:,
NGF,
and,
PGs,
have,
important,
roles,
in,
the,
development,
of,
OAB,
symptoms,
in,
female,
patients,
.,
Urinary,
levels,
of,
these,
factors,
may,
be,
used,
as,
markers,
to,
evaluate,
OAB,
symptoms,
.,
Definition,
and,
management,
of,
anemia,
in,
patients,
infected,
with,
hepatitis,
C,
virus,
.,
Chronic,
infection,
with,
hepatitis,
C,
virus,
(,
HCV,
),
can,
progress,
to,
cirrhosis,
",",
hepatocellular,
carcinoma,
",",
and,
end,
-,
stage,
liver,
disease,
.,
The,O
current,O
best,O
treatment,O
for,O
HCV,B
infection,O
is,O
combination,O
therapy,O
with,O
pegylated,O
interferon,O
and,O
ribavirin,B
.,O
Although,O
this,O
regimen,O
produces,O
sustained,O
virologic,O
responses,O
(,O
SVRs,O
),O
in,O
approximately,O
50,O
%,O
of,O
patients,O
",",O
it,O
can,O
be,O
associated,O
with,O
a,O
potentially,O
dose,O
-,O
limiting,O
hemolytic,O
anemia,O
.,O
Hemoglobin,O
concentrations,O
decrease,O
mainly,O
as,O
a,O
result,O
of,O
ribavirin,B
-,O
induced,O
hemolysis,O
",",O
and,O
this,O
anemia,O
can,O
be,O
problematic,O
in,O
patients,O
with,O
HCV,B
infection,O
",",O
especially,O
those,O
who,O
have,O
comorbid,O
renal,O
or,O
cardiovascular,O
disorders,O
.,O
In,O
general,O
",",O
anemia,B
can,O
increase,O
the,O
risk,O
of,O
morbidity,O
and,O
mortality,O
",",O
and,O
may,O
have,O
negative,O
effects,O
on,O
cerebral,O
function,O
and,O
quality,O
of,O
life,O
.,O
Although,O
ribavirin,B
-,I
associated,I
anemia,I
can,O
be,O
reversed,O
by,O
dose,O
reduction,O
or,O
discontinuation,O
",",O
this,O
approach,O
compromises,O
outcomes,O
by,O
significantly,O
decreasing,O
SVR,O
rates,O
.,O
Recombinant,O
human,O
erythropoietin,O
has,O
been,O
used,O
to,O
manage,O
ribavirin,B
-,I
associated,I
anemia,I
but,O
has,O
other,O
potential,O
disadvantages,O
.,O
Viramidine,B
",",O
a,O
liver,O
-,I
targeting,I
prodrug,I
of,I
ribavirin,I
",",O
has,O
the,O
potential,O
to,O
maintain,O
the,O
virologic,O
efficacy,O
of,O
ribavirin,O
while,O
decreasing,O
the,O
risk,O
of,O
hemolytic,O
anemia,O
in,O
patients,O
with,O
chronic,O
hepatitis,O
C,O
.,O
Impact,O
of,O
alcohol,B
exposure,I
after,O
pregnancy,O
recognition,O
on,O
ultrasonographic,O
fetal,O
growth,O
measures,O
.,O
BACKGROUND,O
:,O
More,O
than,O
3,O
decades,O
after,O
Jones,O
and,O
Smith,O
(,O
1973,O
),O
reported,O
on,O
the,O
devastation,O
caused,O
by,O
alcohol,B
exposure,I
on,O
fetal,O
development,O
",",O
the,O
rates,O
of,O
heavy,O
drinking,O
during,O
pregnancy,O
remain,O
relatively,O
unchanged,O
.,O
Early,O
identification,O
of,O
fetal,B
alcohol,I
exposure,I
and,O
maternal,O
abstinence,O
led,O
to,O
better,O
infant,O
outcomes,O
.,O
This,O
study,O
examined,O
the,O
utility,O
of,O
biometry,O
for,O
detecting,O
alcohol,B
-,I
related,I
fetal,B
growth,I
impairment,I
.,O
METHODS,O
:,O
We,O
obtained,O
fetal,B
ultrasound,I
measures,O
from,O
routine,O
ultrasound,O
examinations,O
for,O
167,O
pregnant,O
hazardous,O
drinkers,O
who,O
were,O
enrolled,O
in,O
a,O
brief,O
alcohol,O
intervention,O
study,O
.,O
The,O
fetal,O
measures,O
for,O
women,O
who,O
quit,O
after,O
learning,O
of,O
their,O
pregnancies,O
were,O
compared,O
with,O
measures...e,B
alcohol,I
consumers,O
.,O
Fetal,O
measures,O
from,O
the,O
heavy,O
-,O
exposed,O
fetuses,O
were,O
also,O
compared,O
with,O
measures,O
from,O
a,O
nondrinking,O
group,O
that,O
was,O
representative,O
of,O
normal,O
",",O
uncomplicated,O
pregnancies,O
from,O
our,O
clinics,O
.,O
Analyses,O
of,O
covariance,O
were,O
used,O
to,O
determine,O
whether,O
there,O
were,O
differences,O
between,O
groups,O
after,O
controlling,O
for,O
influences,O
of,O
gestational,O
age,O
and,O
drug,O
abuse,O
.,O
RESULTS,O
:,O
Nearly,O
half,O
of,O
the,O
pregnant,O
drinkers,O
abstained,O
after,O
learning,O
of,O
their,O
pregnancies,O
.,O
When,...
drinking,O
or,O
who,O
were,O
nondrinkers,O
.,O
Amphetamine,B
abuse,I
was,O
predictive,O
of,O
larger,O
cranial,O
to,O
body,O
growth,O
ratios,O
.,O
CONCLUSIONS,O
:,O
Alterations,O
Ethambutol,B
-,I
associated,I
optic,I
neuropathy,I
.,O
INTRODUCTION,O
:,O
Ethambutol,B
is,O
used,O
in,O
the,O
treatment,O
of,O
All,O
3,O
patients,O
had,O
loss,O
of,O
central,B
visual,I
acuity,I
",",O
colour,O
vision,O
(,O
Ishihara,B
),O
and,O
visual,B
field,I
.,O
The,O
visual,B
field,I
loss,I
had,O
a,O
bitemporal,O
flavour,O
",",O
suggesting,O
involvement,O
of,O
the,O
optic,O
chiasm,O
.,O
TREATMENT,O
:,O
Despite,O
stopping,O
ethambutol,O
on,O
diagnosis,O
",",O
visual,O
function,O
continued,O
to,O
deteriorate,O
for,O
a,O
few,O
months,O
.,O
Subsequent,O
improvement,O
was,O
mild,O
in,O
2,O
cases,O
.,O
In,O
the,O
third,O
case,O
",",O
visual,B
acuity,I
and,O
colour,B
vision,I
normalised,O
but,O
the,O
optic,B
discs,I
were,O
pale,O
.,O
OUTCOME,O
:,O
All,O
3,O
patients,O
had,O
some,O
permanent,O
loss,O
of,O
visual,O
function,O
.,O
CONCLUSIONS,O
:,O
Ethambutol,B
usage,O
is,O
associated,O
with,O
permanent,O
visual,O
loss,O
and,O
should,O
be,O
avoided,O
if,O
possible,O
or,O
used,O
with,O
caution,O
and,O
proper,O
ophthalmological,O
follow,O
-,O
up,O
.,O
The,O
author,O
postulates,O
that,O
in,O
cases,O
of,O
ethambutol,B
associated,O
chiasmopathy,O
",",O
ethambutol,B
may,O
initially,O
affect,O
the,O
optic,O
nerves,O
and,O
subsequently,O
progress,O
to,O
involve,O
the,O
optic,O
chiasm,O
.,O
Possible,O
neuroleptic,O
malignant,O
syndrome,O
related,O
to,O
concomitant,O
treatment,O
with,O
paroxetine,O
and,O
alprazolam,O
.,O
A,O
74,O
-,O
year,O
-,O
old,O
man,O
with,O
depressive,O
symptoms,O
was,O
admitted,O
to,O
a,O
psychiatric,O
hospital,O
due,O
to,O
insomnia,O
",",O
loss,O
of,O
appetite,O
",",O
exhaustion,O
",",O
and,O
agitation,O
.,O
Medical,O
treatment,O
was,O
initiated,O
at,O
a,O
daily,O
dose,O
of,O
20,O
mg,B
paroxetine,I
and,O
1,O
.,O
2,O
mg,B
alprazolam,I
.,O
On,O
the,O
10th,O
day,O
of,O
paroxetine,B
and,O
alprazolam,B
treatment,I
",",O
the,O
patient,O
exhibited,O
marked,O
psychomotor,O
retardation,O
",",O
disorientation,O
",",O
and,O
severe,O
muscle,O
rigidity,O
with,O
tremors,O
.,O
The,O
patient,O
had,O
a,O
fever,O
(,O
38,O
.,O
2,O
degrees,O
C,O
),O
",",O
fluctuating,O
blood,O
pressure,O
(,O
between,O
165,O
/,O
90,O
and,O
130,O
/,O
70,O
mg,B
mm,I
Hg,I
),O
",",O
and,O
severe,O
extrapyramidal,O
symptoms,O
.,O
Laboratory,O
tests,O
showed,O
an,O
elevation,O
of,O
creatine,B
phosphokinase,I
(,O
2218,O
IU,O
/,O
L,O
),O
",",O
aspartate,B
aminotransferase,I
(,O
134,O
IU,O
/,O
L,O
),O
",",O
alanine,B
aminotransferase,I
(,O
78,O
IU,O
/,O
L,O
),O
",",O
and,O
BUN,B
(,O
27,O
.,O
9,O
mg,O
/,O
ml,O
),O
levels,O
.,O
The,O
patient,O
received,O
bromocriptine,O
and,O
diazepam,O
to,O
treat,O
his,O
symptoms,O
.,O
7,O
days,O
later,O
",",O
the,O
fever,O
disappeared,O
and,O
the,O
patient,O
',O
s,O
serum,O
CPK,B
levels,O
were,O
normalized,O
(,O
175,O
IU,O
/,O
L,O
),O
.,O
This,O
patient,O
presented,O
with,O
symptoms,O
of,O
neuroleptic,B
malignant,I
syndrome,I
(,O
NMS,B
),O
",",O
thus,O
demonstrating,O
The,O
involvement,O
of,O
physiologic,B
and,O
environmental,B
aspects,O
specific,O
to,O
this,O
patient,O
was,O
suspected,O
.,O
Several,O
risk,O
factors,O
for,O
NMS,B
should,O
be,O
noted,O
in,O
elderly,O
depressive,O
patients,O
whose,O
symptoms,O
often,O
include,O
dehydration,B
",",O
agitation,B
",",O
malnutrition,B
",",O
and,O
exhaustion,B
.,O
Careful,O
therapeutic,O
intervention,O
is,O
necessary,O
in,O
cases,O
involving,O
elderly,O
patients,O
who,O
suffer,O
from,O
depression,O
.,O
Down,O
-,O
regulation,O
of,O
norepinephrine,B
transporter,I
function,O
induced,O
by,O
chronic,O
administration,O
of,O
desipramine,O
linking,O
to,O
the,O
alteration,O
of,O
sensitivity,O
of,O
local,B
-,I
anesthetics,I
-,I
induced,O
convulsions,O
and,O
the,O
counteraction,O
by,O
co,O
-,O
administration,O
with,O
local,B
anesthetics,I
.,O
Alterations,O
of,O
norepinephrine,B
transporter,I
(,O
NET,O
),O
function,O
by,O
chronic,O
inhibition,O
of,O
NET,B
in,O
relation,O
to,O
sensitization,O
to,O
seizures,O
induce,O
by,O
cocaine,O
and,O
local,B
anesthetics,I
were,O
studied,O
in,O
mice,O
.,O
Daily,O
administration,O
of,O
desipramine,B
",",O
an,O
inhibitor,O
of,O
the,O
NET,B
",",O
for,O
5,O
days,O
decreased,O
[,O
(,O
3,O
),O
H,O
],O
norepinephrine,O
uptake,O
in,O
the,O
P2,B
fractions,O
of,O
hippocampus,O
but,O
not,O
cortex,O
",",O
striatum,O
or,O
amygdalae,O
.,O
Co,O
-,O
administration,O
of,O
lidocaine,B
",",O
bupivacaine,B
or,O
tricaine,B
with,O
desipramine,O
reversed,O
this,O
effect,O
.,O
Daily,O
treatment,O
of,O
cocaine,B
increased,O
[,O
(,O
3,O
),O
H,O
],O
norepinephrine,O
uptake,O
into,O
the,O
hippocampus,O
.,O
Daily,O
administration,O
of,O
desipramine,B
increased,O
the,O
incidence,O
of,O
appearance,O
of,O
lidocaine,B
-,I
induced,I
convulsions,I
and,O
decreased,O
that,O
of,O
cocaine,B
-,I
induced,I
convulsions,I
.,O
Co,O
-,O
administration,O
of,O
lidocaine,B
with,O
desipramine,B
reversed,O
the,O
changes,O
of,O
convulsive,O
activity,O
of,O
lidocaine,B
and,O
cocaine,B
induced,I
by,O
repeated,O
administration,O
of,O
desipramine,B
.,O
These,O
results,O
suggest,O
that,O
down,O
-,O
regulation,O
of,O
hippocampal,O
NET,B
induced,O
by,O
chronic,O
administration,O
of,O
desipramine,B
may,O
be,O
relevant,O
to,O
desipramine,O
-,O
induced,O
sensitization,O
of,O
lidocaine,B
convulsions,O
.,O
Inhibition,O
of,O
Na,B
(,O
+,O
),O
channels,O
by,O
local,O
anesthetics,O
may,O
regulate,O
desipramine,O
-,O
induced,O
down,O
-,O
regulation,O
of,O
NET,B
function,O
.,O
Repeated,O
administration,O
of,O
cocaine,B
induces,O
up,O
-,O
regulation,O
of,O
hippocampal,O
NET,B
function,O
.,O
Desipramine,B
-,I
induced,I
sensitization,I
of,I
lidocaine,B
seizures,I
may,O
have,O
a,O
mechanism,O
distinct,O
from,O
kindling,O
resulting,O
from,O
repeated,O
administration,O
of,O
cocaine,B
.,O
Atorvastatin,B
prevented,O
and,O
reversed,O
dexamethasone,B
-,I
induced,I
hypertension,I
in,O
the,O
rat,O
.,O
To,O
assess,O
the,O
antioxidant,O
effects,O
of,O
atorvastatin,B
(,O
atorva,O
),O
on,O
dexamethasone,B
(,O
dex,O
),O
-,O
i...on,O
SBP,O
),O
from,O
109,O
+,O
/,O
-,O
1,O
.,O
8,O
to,O
135,O
+,O
/,O
-,O
0,O
.,O
6,O
mmHg,O
9,O
saline,O
",",O
7931,O
+,B
/,I
-,I
392,I
.,I
8,I
U,I
/,I
ml,I
dex,I
",",O
P,O
<,O
0,O
.,O
001,O
...,O
mmHg,O
",",O
but,O
this,O
was,O
significantly,O
lower,O
than,O
in,O
the,O
dex,O
-,O
only,O
group,O
(,O
P,O
',O
<,O
0,O
.,O
05,O
),O
.,O
Atorva,O
reversed,O
dex,O
-,O
induced,O
hypertension,O
(,O
129,O
+,O
/,O
-,O
0,O
.,O
6,O
mmHg,B
",",O
vs,O
.,O
135,B
+,I
/,I
-,I
0,I
.,I
6,I
mmHg,B
P,O
',O
<,O
0,O
.,O
05,B
),O
and,O
decreased,O
plasma,O
superoxide,B
(,O
7931,B
+,I
/,I
-,I
392,I
.,I
8,I
dex,B
",",O
1187,B
+,I
/,I
-,I
441,I
.,I
2,I
atorva,B
+,I
dex,I
",",O
P,O
<,O
0,O
.,O
0001,B
),O
.,O
Plasma,O
nitrate,B
/,I
nitrite,I
(,I
NOx,I
),I
was,O
decreased,O
in,O
dex,O
-,O
treated,O
rats,O
compared,O
to,O
saline,O
-,O
treated,O
rats,O
(,O
11,B
.,I
2,I
+,I
/,I
-,I
1,I
.,I
08,I
microm,B
",",O
15,B
.,I
3,I
+,I
/,I
-,I
1,I
.,I
17,O
microm,O
",",O
respectively,O
",",O
P,O
<,O
0,O
.,O
05,O
),O
.,O
Atorva,B
affected,O
neither,O
plasma,O
NOx,B
nor,O
thymus,O
weight,O
.,O
Thus,O
",",O
atorvastatin,O
prevented,O
and,O
reversed,O
dexamethasone,O
-,O
induced,O
hypertension,O
in,O
the,O
rat,O
.,O
Peripheral,O
neuropathy,O
caused,O
by,O
high,O
-,O
dose,O
cytosine,B
arabinoside,I
treatment,O
in,O
a,O
patient,O
with,O
acute,O
myeloid,O
leukemia,O
.,O
The,O
central,O
nervous,O
system,O
toxicity,O
of,O
high,O
-,O
dose,O
cytosine,B
arabinoside,I
is,O
well,O
recognized,O
",",O
but,Ellipsis
20,O
g,O
/,O
m2,O
),O
as,O
consolidation,O
therapy,O
.,O
The,O
first,O
course,O
of,O
high,O
-,O
dose,O
cytosine,B
arabinoside,I
resulted,O
in,O
no,O
unusual,O
symptoms,O
",",O
but,O
o...ted,O
to,O
methylprednisolone,B
.,O
Although,O
the,O
mechanisms,O
of,O
peripheral,B
neuropathy,I
are,O
still,O
unclear,O
",",O
high,O
-,O
dose,O
cytosine,B
arabinoside,I
is,O
a,O
therapy,O
that,O
is,O
potentially,O
toxic,O
to,O
the,O
peripheral,B
nervous,I
system,I
",",O
and,O
auto,O
/,O
alloimmunity,O
may,O
play,O
an,O
important,O
role,O
in,O
these,O
mechanisms,O
.,O
Effect,O
of,O
alpha,O
-,O
tocopherol,O
and,O
deferoxamine,O
on,O
methamphetamine,B
-,I
induced,I
neurotoxicity,I
.,O
Methamphetamine,B
(,O
MA,B
),O
-,O
induced,O
dopaminergic,O
neurotoxicity,O
is,O
believed,O
to,O
be,O
associated,O
with,O
the,O
in...oxamine,B
(,O
DFO,B
),O
",",O
an,O
iron,O
chelator,O
",",O
on,O
the,O
MA,B
-,O
induced,O
neurotoxicity,O
.,O
Male,O
rats,O
were,O
treated,O
with,O
MA,B
(,O
10,B
mg,I
/,I
kg,I
",",O
every,O
2,O
h,O
for,O
four,O
injections,O
),O
.,O
The,O
rat,O
received,O
either,O
alpha,B
-,I
TC,I
(,O
20,B
mg,I
/,I
kg,I
),O
intraperitoneally,O
for,O
3,O
days,O
and,O
30,O
min,O
prior,O
to,O
MA,B
administration,O
or,O
DFO,B
(,O
50,B
mg,I
/,I
kg,I
),O
subcutaneously,O
30,O
min,O
before,O
MA,B
administration,O
.,O
The,O
concentrations,O
of,O
dopamine,B
(,O
DA,I
),O
",",O
serotonin,O
and,O
their,O
metabolites,O
decreased,O
significantly,O
after,O
MA,B
administration,O
",",O
which,O
was,O
inhibited,O
by,O
the,O
alpha,B
-,I
TC,I
and,O
DFO,B
pretreatment,O
.,O
alpha,O
-,O
TC,B
and,O
DFO,B
attenuated,O
the,O
MA,B
-,O
induced,O
hyperthermia,O
as,O
well,O
as,O
the,O
alterations,O
in...luted,O
by,O
alpha,O
-,O
TC,B
and,O
DFO,B
.,O
This,O
suggests,O
that,O
alpha,B
-,I
TC,I
and,O
DFO,B
ameliorate,O
the,O
MA,B
-,I
induced,I
neuronal,O
damage,O
by,O
decreasing,O
the,O
level,O
of,O
oxidative,O
stress,O
.,O
Blockade,O
of,O
both,O
D,B
-,I
1,I
and,O
D,B
-,I
2,I
dopamine,O
receptors,O
may,O
induce,O
catalepsy,O
in,O
mice,O
.,O
1,B
.,O
The,O
catalepsy,O
induced,O
by,O
dopamine,O
antagonists,O
has,O
been,O
tested,O
and,O
the,O
possible,O
dopamine,O
subtypes,O
involved,O
in,O
catalepsy,O
was,O
determined,O
.,O
2,O
.,O
Dopamine,B
antagonist,O
fluphenazine,B
",",O
D,B
-,I
1,I
antagonist,O
SCH,B
23390,I
or,O
D,B
-,I
2,I
antagonist,O
sulpiride,B
induced,O
catalepsy,O
.,O
The,O
effect,O
of,O
fluphenazine,B
and,O
sulpiride,B
was,O
dose,O
-,O
dependent,O
.,O
Combination,O
of,O
SCH,B
23390,I
with,O
sulpiride,B
did,O
not,O
induce,O
catalepsy,O
potentiation,O
.,O
3,O
.,O
D,B
-,I
1,I
agonist,O
SKF,B
38393,I
or,O
D,B
-,I
2,I
agonist,O
quinpirole,B
decreased,O
the,O
catalepsy,O
induced,O
by,O
fluphenazine,B
",",O
SCH,B
23390,I
or,O
sulpiride,B
.,O
4,O
.,O
Combination,O
of,O
SKF,B
38393,I
with,O
quinpirole,O
did,O
not,O
cause,O
potentiated,O
inhibitory,O
effect,O
on,O
catalepsy,O
induced,O
by,O
dopamine,O
antagonists,O
.,O
5,O
.,O
The,O
data,O
may,O
indicate,O
that,O
although,O
D,O
-,O
2,O
receptor,O
blockade,O
is,O
involved,O
in,O
catalepsy,O
",",O
the,O
D,O
-,O
1,O
receptor,O
may,O
plan,O
a,O
role,O
.,O
Sustained,O
clinical,O
improvement,O
of,O
a,O
patient,O
with,O
decompensated,O
hepatitis,O
B,B
virus,I
-,O
related,O
cirrhosis,O
after,O
treatment,O
with,O
lamivudine,B
monotherapy,I
.,O
Hepatitis,
B,
virus,
(,
HBV,
),
infection,
",",
which,
causes,
liver,
cirrhosis,
and,
hepatocellular,
carcinoma,
",",
remains,
a,
major,
health,
problem,
in,
Asian,
countries,
.,
Recent,
development,
of,
vaccine,
for,
prevention,
is,
reported,
to,
be,
successful,
in,
reducing,
the,
size,
of,
chronically,
infected,
carriers,
",",
although,
the,
standard,
medical,
therapies,
have,
not,
been,
established,
up,
to,
now,
.,
In,O
this,O
report,O
",",O
we,O
encountered,O
a,O
patient,O
with,O
decompensated,O
HBV,B
-,I
related,O
cirrhosis,O
who,O
exhibited,O
However,O
",",O
the,O
administration,O
of,O
lamivudine,B-Chemical
",",O
a,O
reverse,O
transcriptase,B-Chemical
inhibitor,O
",",O
for,O
23,O
month...ent,O
was,O
discontinued,O
.,O
Moreover,O
",",O
both,O
hepatitis,B
surface,B
antigen,I
and,O
e,B
antigen,I
were,O
observed,O
to,O
have,O
disappeared,O
in,O
Antiarrhythmic,O
effects,O
of,O
optical,O
isomers,O
of,O
cibenzoline,B
on,O
canine,O
ventricular,O
arrhythmias,O
.,O
Antiarrhythmic,O
effects,O
of,O
(,O
+,O
),O
-,O
cibenzoline,B
and,O
(,O
-,O
),O
-,O
cibenzoline,B
were,O
examined,O
using,O
two,O
canine,O
ventricular,O
arrhythmia,O
models,O
.,O
Digitalis,O
arrhythmia,O
",",O
which,O
is,O
suppressed,O
by,O
Na,O
channel,O
blockers,O
",",O
was,O
induced,O
by,O
intermittent,O
intravenous,O
(,O
i,O
.,O
v,O
.,O
),O
injection,O
of,O
ouabain,B
in,O
pentobarbital,O
-,O
anesthetized,O
dogs,O
.,O
Adrenaline,B
arrhythmia,O
",",O
which,O
is,O
suppressed,O
by,O
Ca,B
channel,I
blockers,I
",",O
was,O
induced,O
by,O
adrenaline,B
infusion,O
in,O
halothane,O
-,O
anesthetized,O
dogs,O
.,O
Ten,O
and,O
5,O
mg,O
/,O
kg,O
i,O
.,O
v,O
.,O
(,O
+,O
),O
-,O
cibenzoline,B
suppressed,O
digitalis,B
-,O
and,O
adrenaline,B
-,O
induced,O
arrhythmias,O
",",O
respectively,O
.,O
The,O
minimum,O
effective,O
plasma,O
concentrations,O
of,O
(,O
+,O
),O
-,O
cibenzoline,B
for,O
digitalis,B
-,I
and,O
adrenaline,B
-,I
induced,O
arrhythmias,O
were,O
1,O
.,O
4,O
+,O
/,O
-,O
0,O
.,O
4,O
and,O
2,O
.,O
0,O
+,O
/,O
-,O
0,O
.,O
6,O
micrograms,O
/,O
ml,O
",",O
respectively,O
(,O
mean,O
+,O
/,O
-,O
SD,O
",",O
n,O
=,O
6,O
),O
.,O
A,O
lower,O
dose,O
of,O
1,O
mg,O
/,O
kg,O
i,O
.,O
v,O
.,O
of,O
(,O
-,O
),O
-,O
cibenzoline,B
suppressed,O
the,O
digitalis,B
-,I
induced,O
arrhythmia,O
",",O
whereas,O
5,O
mg,O
/,O
kg,O
i,O
.,O
v,O
.,O
was,O
needed,O
to,O
suppress,O
adrenaline,B
-,I
induced,O
arrhythmias,O
.,O
The,O
minimum,O
effective,O
plasma,O
concentrat... nearly,O
5,O
-,O
20,O
times,O
stronger,O
in,O
suppressing,O
Na,O
channels,O
",",O
but,O
effects,O
of,O
both,O
drugs,O
on,O
Ca,O
channels,O
may,O
be,O
almost,O
equipotent,O
.,O
Passage,O
of,O
mannitol,B
into,O
the,O
brain,O
around,O
gliomas,O
:,O
a,O
potential,O
cause,O
of,O
rebound,O
phenomenon,O
.,O
A,O
study,O
on,O
21,O
patients,O
.,O
AIM,O
:,O
Widespread,O
use,O
of,O
mannitol,B
to,O
reduce,O
brain,O
edema,O
and,O
lower,O
elevated,O
ICP,O
in,O
brain,O
tumor,O
patients,O
continues,O
to,O
be,O
afflicted,O
by,O
the,O
so,O
-,O
called,O
rebound,O
phenomenon,O
.,O
Leakage,O
of,O
mannitol,B
into,O
the,O
brain,O
parenchyma,O
through,O
an,O
altered,O
BBB,O
and,O
secondary,O
reversal,O
of,O
osmotic,O
gradient,O
is,O
considered,O
the,O
major,O
cause,O
of,O
rebound,O
.,O
This,
has,
only,
been,
demonstrated,
experimentally,
in,
animals,
.,
As,
a,
contribution,
to,
this,
issue,
we,
decided,
to,
research,
the,
possible,
passage,
of,
mannitol,
into,
the,
brain,
after,
administration,
to,
21,
brain,
tumor,
patients,
.,
METHODS,
:,
Mannitol,
(,
18,
%,
solution,
;,
1,
g,
/,
kg,
),
was,
administered,
as,
a,
bolus,
to,
patients,
(,
ten,
had,
malignant,
glioma,
",",
seven,
brain,
metastases,
and,
four,
meningioma,
),
about,
30,
minutes,
before,
craniotomy,
.,
During,O
resection,O
",",O
a,O
sample,O
of,O
the,O
surrounding,O
edematous,O
white,B
matter,I
was,O
taken,O
at,O
the,O
same,O
5,
times,
),
.,
In,
meningioma,
and,
metastases,
patients,
plasma,
concentrations,
of,
mannitol,
were,
higher,
than,
white,
matter,
concentrations,
except,
in,
three,
cases,
with,
infiltration,
by,
neoplastic,
cells,
.,
CONCLUSIONS,
:,
The,
results,
of,
our,
study,
show,
that,
even,
after,
a,
single,
bolus,
",",
mannitol,
may,
leak,
through,
the,
altered,
BBB,
near,
gliomas,
",",
reversing,
the,
initial,
plasma,
-,
to,
-,
blood,
osmotic,
gradient,
",",
aggravating,
peritumoral,
edema,
and,
promoting,
rebound,
of,
ICP,
.,
Placebo,O
-,O
level,O
incidence,O
of,O
extrapyramidal,O
symptoms,O
(,O
EPS,B
),O
with,O
quetiapine,O
in,O
controlled,O
studies,O
of,O
patients,O
with,O
bipolar,O
mania,O
.,O
OBJECTIVES,O
:,O
To,O
evaluate,O
extrapyramidal,O
symptoms,O
(,O
EPS,B
),O
",",O
including,O
akathisia,O
",",O
with,O
quetiapine,O
in,O
patients,O
with,O
bipolar,O
mania,O
.,O
METHODS,O
:,O
Data,O
were,O
analyzed,O
from,O
four,O
similarly,O
designed,O
",",O
randomized,O
",",O
double,O
-,O
blind,O
",",O
3,O
-,O
to,O
12,O
-,O
week,O
studies,O
.,O
Two,
studies,
evaluated,
quetiapine,
monotherapy,
(,
up,
to,
800,
mg,
/,
day,
),
(,
n,
=,
209,
),
versus,
placebo,
(,
n,
=,
198,
),
",",
with,
lithium,
or,
haloperidol,
monotherapy,
as,
respective,
active,
controls,
.,
Two,
studies,
evaluated,
quetiapine,
(,
up,
to,
800,
mg,
/,
day,
),
in,
combination,
with,
a,
mood,
stabilizer,
(,
lithium,
or,
divalproex,
",",
QTP,
+,
Li,
/,
DVP,
),
(,
n,
=,
196,
),
compared,
to,
placebo,
and,
mood,
stabilizer,
(,
PBO,
+,
Li,
/,
DVP,
),
(,
n,
=,
203,
),
.,
Extrapyramidal,B
symptoms,I
were,O
evaluated,O
using,O
the,O
Simpson,B
-,I
Angus,I
Scale,I
(,O
SAS,B
),O
",",O
the,O
Barnes,B
Akathisia,I
Rating,I
Scale,I
(,O
BARS,B
),O
",",O
adverse,B
event,I
reports,I
and,O
anticholinergic,B
drug,I
usage,I
.,O
RESULTS,O
:,O
The,O
incidence,O
of,O
EPS,B
-,I
related,O
adverse,O
events,O
",",O
including,O
akathisia,B
",",O
was,O
no,O
different,O
with,O
quetiapine,O
monotherapy,O
(,O
12,O
.,O
9,O
%,O
),O
than,O
with,O
placebo,O
(,O
13,O
.,O
1,O
%,O
),O
.,O
Similarly,O
",",O
EPS,B
-,I
related,I
adverse,I
events,I
with,O
QTP,B
+,I
Li,I
/,I
DVP,I
(,O
21,O
.,O
4,O
%,O
),O
were,O
no,O
different,O
than,O
with,O
PBO,B
+,I
Li,I
/,I
DVP,I
(,O
19,O
.,O
2,O
%,O
),O
.,O
Adverse,O
events,O
related,O
to,O
EPS,B
occurred,O
in,O
59,O
.,O
6,O
%,O
of,O
patients,O
treated,O
with,O
haloperidol,B
(,O
n,O
=,O
99,O
),O
monotherapy,O
",",O
whereas,O
26,O
.,O
5,O
%,O
of,O
patients,O
treated,O
with,O
lithium,B
(,O
n,O
=,O
98,O
),O
monotherapy,O
experienced,O
adverse,O
events,O
related,O
to,O
EPS,B
.,O
The,
incidence,
of,
akathisia,
was,
low,
and,
similar,
with,
quetiapine,
monotherapy,
(,
3,
.,
3,
%,
),
and,
placebo,
(,
6,
.,
1,
%,
),
",",
and,
with,
QTP,
+,
Li,
/,
DVP,
(,
3,
.,
6,
%,
),
and,
PBO,
+,
Li,
/,
DVP,
(,
4,
.,
9,
%,
),
.,
Lithium,
was,
associated,
with,
a,
significantly,
higher,
incidence,
(,
p,
<,
0,
.,
05,
),
of,
tremor,
(,
18,
.,
4,
%,
),
than,
quetiapine,
(,
5,
.,
6,
%,
),
;,
cerebellar,
tremor,
",",
which,
is,
a,
known,
adverse,
effect,
of,
lithium,
",",
may,
have,
contributed,
to,
the,
elevated,
rate,
of,
tremor,
in,
patients,
receiving,
lithium,
therapy,
.,
Haloperidol,
induced,
a,
significantly,
higher,
incidence,
(,
p,
<,
0,
.,
001,
),
of,
akathisia,
(,
33,
.,
3,
%,
versus,
5,
.,
9,
%,
),
",",
tremor,
(,
30,
.,
3,
%,
versus,
7,
.,
8,
%,
),
",",
and,
extrapyramidal,
syndrome,
(,
35,
.,
4,
%,
versus,
5,
.,
9,
%,
),
than,
quetiapine,
.,
No,
significant,
differences,
were,
observed,
between,
quetiapine,
and,
placebo,
on,
SAS,
and,
BARS,
scores,
.,
Anticholinergic,O
use,O
was,O
low,O
and,O
similar,O
with,O
quetiapine,O
or,O
placebo,O
.,O
CONCLUSIONS,O
:,O
In,O
bipolar,O
mania,O
",",O
the,O
incidence,O
of,O
EPS,B
",",I
including,I
akathisia,I
",",O
with,O
quetiapine,O
therapy,O
is,O
similar,O
to,O
that,O
with,O
placebo,O
.,O
Is,O
phenytoin,O
administration,O
safe,O
in,O
a,O
hypothermic,O
child,O
?,O
A,O
male,O
neonate,O
with,O
a,O
Chiari,B
malformation,I
and,O
a,O
leaking,O
myelomeningocoele,B
underwent,O
ventriculoperitoneal,O
shunt,O
insertion,O
followed,O
by,O
repair,O
of,O
myelomeningocoele,B
.,O
During,O
anaesthesia,O
and,O
surgery,O
",",O
he,O
inadvertently,O
became,O
moderately,O
hypothermic,O
.,O
Intravenous,O
phenytoin,B
was,O
administered,O
during,O
the,O
later,O
part,O
of,O
the,O
surgery,O
for,O
seizure,O
prophylaxis,O
.,O
Following,O
phenytoin,B
administration,O
",",O
the,O
patient,O
developed,O
acute,O
severe,O
bradycardia,O
",",O
refractory,O
to,O
atropine,O
and,O
adrenaline,O
.,O
The,O
cardiac,O
depressant,O
actions,O
of,O
phenytoin,B
and,O
hypothermia,B
can,O
be,O
additive,O
.,O
Administration,O
of,O
phenytoin,B
in,O
the,O
presence,O
of,O
hypothermia,B
may,O
lead,O
to,O
an,O
adverse,O
cardiac,O
event,O
in,O
children,O
.,O
As,O
phenytoin,B
is,O
a,O
commonly,O
used,O
drug,O
",",O
clinicians,O
need,O
to,O
be,O
aware,O
of,O
this,O
interaction,O
.,O
Valproate,B
-,I
induced,I
chorea,I
and,I
encephalopathy,I
in,I
atypical,I
nonketotic,I
hyperglycinemia,I
.,O
Nonketotic,B
hyperglycinemia,I
is,O
a,O
disorder,O
of,O
amino,O
acid,O
metabolism,O
in,O
which,O
a,O
defect,O
in,O
the,O
glycine,B
cleavage,O
system,O
leads,O
to,O
an,O
accumulation,O
of,O
glycine,B
in,O
the,O
brain,O
and,O
other,O
body,O
compartments,O
.,O
In,O
the,O
classical,O
form,O
it,O
presents,O
as,O
neonatal,O
apnea,O
",",O
intractable,O
seizures,O
",",O
and,O
hypotonia,O
",",O
followed,O
by,O
significant,O
psychomotor,O
retardation,O
.,O
An,O
important,O
subset,O
of,O
children,O
with,O
nonketotic,B
hyperglycinemia,I
are,O
atypical,O
variants,O
who,O
present,O
in,O
a,O
hete...te,O
therapy,O
.,O
Delayed,O
institution,O
of,O
hypertension,O
during,O
focal,O
cerebral,O
ischemia,O
:,O
effect,O
on,O
brain,O
edema,O
.,O
The,O
effect,O
of,O
induced,O
hypertension,O
instituted,O
after,O
a,O
2,O
-,O
h,O
delay,O
following,O
middle,O
cerebral,O
artery,O
occlusion,O
(,O
MCAO,B
),O
on,O
brain,O
edema,O
formation,O
and,O
histochemical,O
injury,O
was,O
studied,O
.,O
Under,O
isoflurane,O
anesthesia,O
",",O
the,O
MCA,O
of,O
14,O
spontaneously,O
hypertensive,O
rats,O
was,O
occluded,O
.,O
In,O
the,O
control,O
group,O
(,O
n,O
=,O
7,O
),O
",",O
the,O
mean,O
arterial,O
pressure,O
(,O
MAP,O
),O
was,O
not...able,O
.,O
The,O
brains,O
were,O
sectioned,O
along,O
coronal,O
planes,O
spanning,O
the,O
distribution,O
of,O
ischemia,O
produced,O
by,O
MCAO,O
.,O
Specific,
gravity,
(,
SG,
),
was,
determined,
in,
the,
subcortex,
and,
in,
two,
sites,
in,
the,
cortex,
(,
core,
and,
periphery,
of,
the,
ischemic,
territory,
),
.,
The,
extent,
of,
neuronal,
injury,
was,
determined,
by,
2,
",",
3,
",",
5,
-,
triphenyltetrazolium,
staining,
.,
In,
the,
ischemic,
core,
",",
there,
was,
no,
difference,
in,
SG,
in,
the,
subcortex,
and,
cortex,
in,
the,
two,
groups,
.,
In,O
the,O
periphery,O
of,O
the,O
ischemic,B
territory,I
",",O
SG,B
in,O
the,O
cortex,O
was,O
greater,O
(,O
less,O
edema,O
accumulation,O
),O
in,O
the,O
hypertensive,O
group,O
(,O
1,O
.,O
041,O
+,O
/,O
-,O
0,O
.,O
001,O
vs,O
1,O
.,O
039,O
+,O
/,O
-,O
0,O
.,O
001,O
",",O
P,O
less,O
than,O
0,O
.,O
05,O
),O
.,O
The,O
area,O
of,O
histochemical,O
injury,O
(,O
as,O
a,O
percent,O
of,O
the,O
cross,O
-,O
sectional,O
area,O
of,O
the,O
hemisphere,O
),O
was,O
less,O
in,O
the,O
hypertensive,O
group,O
(,O
33,O
+,O
/,O
-,O
3,O
%,O
vs,O
21,O
+,O
/,O
-,O
2,O
%,O
",",O
P,O
less,O
than,O
0,O
.,O
05,O
),O
.,O
The,O
data,O
indicate,O
that,O
phenylephrine,B
-,I
induced,I
hypertension,I
instituted,O
2,O
h,O
after,O
MCAO,O
does,O
not,O
aggravate,O
edema,O
in,O
the,O
ischemic,O
core,O
",",O
that,O
it,O
improves,O
edema,O
in,O
the,O
periphery,O
of,O
the,O
ischemic,O
territory,O
",",O
and,O
that,O
it,O
reduces,O
the,O
area,O
of,O
histochemical,O
neuronal,O
dysfunction,O
.,O
Behavioral,O
effects,O
of,O
pubertal,O
anabolic,O
androgenic,O
steroid,O
exposure,O
in,O
male,O
rats,O
with,O
low,O
serotonin,O
.,O
The,O
goal,O
of,O
this,O
study,O
was,O
to,O
assess,O
the,O
interactive,O
effects,O
of,O
chronic,O
anabolic,O
androgenic,O
steroid,...
depleted,O
beginning,O
on,O
postnatal,O
day,O
26,O
with,O
parachlorophenylalanine,B
(,I
PCPA,I
100,I
mg,I
/,I
kg,I
",",I
every,I
other,I
day,I
),I
;,I
controls,O
received,O
saline,O
.,O
At,O
puberty,O
(,O
P40,O
),O
",",O
half,O
the,O
PCPA,B
-,I
treated,O
rats,O
and,O
half,O
the,O
saline,B
-,I
treated,O
rats,O
began,O
treatment,O
with,O
testosterone,B
(,O
T,O
",",O
5,O
mg,O
/,O
kg,O
",",O
5,O
days,O
/,O
week,O
),O
.,O
Behavioral,O
measures,O
included,O
locomotion,O
",",O
irritability,O
",",O
copulation,O
",",O
partner,O
preference,O
",",O
and,O
aggression,O
.,O
Animals,O
were,O
tested,O
for,O
aggression,O
in,O
their,O
home,O
cage,O
",",O
both,O
with,O
and,O
without,O
physical,O
provocation,O
(,O
mild,O
tail,O
pinch,O
),O
.,O
Brain,O
levels,O
of,O
5,B
-,I
HT,I
and,O
its,O
metabolite,O
",",O
5,B
-,I
hydroxyindoleacetic,I
acid,I
(,O
5,B
-,I
HIAA,I
),O
",",O
were,O
determined,O
using,O
HPLC,O
.,O
PCPA,O
significantly,O
and,O
substantially,O
depleted,O
5,B
-,I
HT,I
and,O
5,B
-,I
HIAA,I
in,O
all,O
brain,O
regions,O
examined,O
.,O
Chronic,O
T,O
treatment,O
significantly,O
decreased,O
5,B
-,I
HT,I
and,O
5,B
-,I
HIAA,I
in,O
certain,O
brain,O
areas,O
",",O
but,O
to,O
a,O
much,O
lesser,O
extent,O
than,O
PCPA,O
.,O
Chronic,O
exposure,O
to,O
PCPA,B
alone,O
significantly,O
decreased,O
locomotor,O
activity,O
and,O
increased,O
irritability,O
but,O
had,O
Based,
on,
these,
data,
",",
it,
can,
be,
speculated,
that,
pubertal,
AAS,
users,
with,
low,
central,
5,
-,
HT,
may,
be,
especially,
prone,
to,
exhibit,
aggressive,
behavior,
.,
Effects,
of,
UMB24,
and,
(,
+,
/,
-,
),
-,
SM,
21,
",",
putative,
sigma2,
-,
preferring,
antagonists,
",",
on,
behavioral,
toxic,
and,
stimulant,
effects,
of,
cocaine,
in,
mice,
.,
Earlier,
studies,
have,
demonstrated,
that,
antagonism,
of,
sigma1,
receptors,
attenuates,
the,
convulsive,
",",
lethal,
",",
locomotor,
stimulatory,
and,
rewarding,
actions,
of,
cocaine,
in,
mice,
.,
In,
contrast,
",",
the,
contribution,
of,
sigma2,
receptors,
is,
unclear,
because,
experimental,
tools,
to,
selectively,
target,
this,
subtype,
are,
unavailable,
.,
To,
begin,
addressing,
this,
need,
",",
we,
characterized,
UMB24,
(,
1,
-,
(,
2,
-,
phenethyl,
),
-,
4,
-,
(,
2,
-,
pyridyl,
),
-,
piperazine,
),
and,
(,
+,
/,
-,
),
-,
SM,
21,
(,
3alpha,
-,
tropanyl,
-,
2,
-,
(,
4,
-,
chorophenoxy,
),
butyrate,
),
in,
receptor,
binding,
and,
behavioral,
studies,
.,
Receptor,O
binding,O
studies,O
confirmed,O
that,O
UMB24,B
and,O
(,O
+,O
/,O
-,O
),O
-,O
SM,B
21,I
display,O
preferential,O
affinity,O
for,O
sigma2,O
over,O
sigma1,O
receptors,O
.,O
In,O
behavioral,O
studies,O
",",O
pretreatment,O
of,O
Swiss,O
Webster,O
mice,O
with,O
UMB24,B
or,O
(,O
+,O
/,O
-,O
),O
-,O
SM,B
21,I
significantly,O
attenuated,O
cocaine,O
-,O
induced,O
convulsions,O
and,O
locomotor,O
activity,O
",",O
but,O
not,O
lethality,O
.,O
When,
administered,
alone,
",",
(,
+,
/,
-,
),
-,
SM,
21,
produced,
no,
significant,
effects,
compared,
to,
control,
injections,
of,
saline,
",",
but,
UMB24,
had,
locomotor,
depressant,
actions,
.,
Together,
",",
the,
data,
suggest,
that,
sigma2,
receptor,
antagonists,
have,
the,
potential,
to,
attenuate,
some,
of,
the,
behavioral,
effects,
of,
cocaine,
",",
and,
further,
development,
of,
more,
selective,
",",
high,
affinity,
ligands,
are,
warranted,
.,
Cardiac,
arrest,
in,
a,
child,
with,
cerebral,
palsy,
undergoing,
sevoflurane,
induction,
of,
anesthesia,
after,
preoperative,
clonidine,
.,
Clonidine,
is,
a,
frequently,
administered,
alpha2,
-,
adrenergic,
agonist,
which,
can,
decrease,
heart,
rate,
and,
blood,
pressure,
.,
We,
present,
a,
case,
of,
a,
5,
-,
year,
-,
old,
child,
with,
cerebral,
palsy,
and,
seizure,
disorder,
",",
receiving,
clonidine,
for,
restlessness,
",",
who,
presented,
for,
placement,
of,
a,
baclofen,
pump,
.,
Without,O
the,O
knowledge,O
of,O
the,O
medical,O
personnel,O
",",O
the,O
patient,O
',O
s,O
mother,O
administered,O
three,O
doses,O
Angiotensin,B-chemical
-,I-chemical
converting,I-chemical
enzyme,I-chemical
(,O
ACE,O
),O
inhibitor,O
-,O
associated,O
angioedema,O
of,O
the,O
stomach,O
and,O
small,O
intestine,O
:,O
a,O
case,O
report,O
.,O
This,O
is,O
a,O
case,O
report,O
on,O
a,O
45,O
-,O
year,O
old,O
African,O
-,O
American,O
female,O
with,O
newly,O
diagnosed,O
hypertension,O
",",O
who,O
was,O
started,O
on,O
a,O
combination,O
pill,O
of,O
amlodipine,B-chemical
/,O
benazapril,B-chemical
10,I-chemical
/,I-chemical
5,I-chemical
mg,I-chemical
.,O
The,
very,
next,
day,
",",
she,
presented,
at,
the,
emergency,
room,
(,
ER,
),
with,
abdominal,
pain,
",",
nausea,
and,
vomiting,
.,
Physical,
exam,
",",
complete,
metabolic,
panel,
",",
and,
hemogram,
were,
in,
the,
normal,
range,
.,
She,
was,
discharged,
from,
the,
ER,
after,
a,
few,
hours,
of,
treatment,
with,
fluid,
and,
analgesics,
.,
However,
",",
she,
returned,
to,
the,
ER,
the,
next,
day,
with,
the,
same,
complaints,
.,
This,O
time,O
the,O
physical,O
exam,O
was,O
significant,O
for,O
a,O
distended,O
abdomen,O
with,O
dullness,O
to,O
percussion,O
.,O
CT,O
scan,O
of,O
the,O
abdomen,O
revealed,O
markedly,O
thickened,O
antrum,O
of,O
the,O
stomach,O
",",O
duodenum,O
and,O
jejunum,O
",",O
along,O
with,O
fluid,O
in,O
the,O
abdominal,O
and,O
pelvic,O
cavity,O
.,O
Angiotensin,B
-,I
converting,I
enzyme,I
inhibitor,I
(,I
ACEI,I
),I
-,I
induced,I
angioedema,I
was,O
suspected,O
",",O
and,O
anti,O
-,O
hypertensive,O
medications,O
were,O
discontinued,O
.,O
Her,O
symptoms,O
improved,O
within,O
the,O
next,O
24,O
hours,O
",",O
and,O
repeat,O
CT,O
after,O
72,O
hours,O
revealed,O
marked,O
improvement,O
in,O
stomach,O
and,O
small,O
bowel,O
thickening,O
and,O
resolution,O
of,O
ascites,O
.,O
The,O
recognition,O
of,O
angiotensin,B
-,I
converting,I
enzyme,I
(,O
ACE,B
),O
and,O
angiotensin,B
receptor,I
blocker,I
(,O
ARB,B
),O
intestinal,O
angioedema,O
constitutes,O
a,O
challenge,O
to,O
primary,O
care,O
physicians,O
",",O
internists,O
",",O
emergency,O
room,O
personal,O
and,O
Carbamazepine,
-,
induced,
cardiac,
dysfunction,
.,
Characterization,
of,
two,
distinct,
clinical,
syndromes,
.,
A,
patient,
with,
sinus,
bradycardia,
and,
atrioventricular,
block,
",",
induced,
by,
carbamazepine,
",",
prompted,
an,
extensive,
literature,
review,
of,
all,
previously,
reported,
cases,
.,
From,
the,
analysis,
of,
these,
cases,
",",
two,
distinct,
forms,
of,
carbamazepine,
-,
associated,
cardiac,
dysfunction,
emerged,
.,
One,
patient,
group,
developed,
sinus,
tachycardias,
in,
the,
setting,
of,
a,
massive,
carbamazepine,
overdose,
.,
The,
second,
group,
consisted,
almost,
exclusively,
of,
elderly,
women,
who,
developed,
potentially,
life,
-,
threatening,
bradyarrhythmias,
or,
atrioventricular,
conduction,
delay,
",",
associated,
with,
either,
therapeutic,
or,
modestly,
elevated,
carbamazepine,
serum,
levels,
.,
Because,O
carbamazepine,B
is,O
widely,O
used,O
in,O
the,O
treatment,O
of,O
many,O
neurologic,O
and,O
psychiatric,O
conditions,O
",",O
the,O
recognition,O
of,O
the,O
latter,O
syndrome,O
has,O
important,O
implications,O
for,O
the,O
use,O
of,O
this,O
drug,O
in,O
elderly,O
patients,O
.,O
Detection,O
of,O
abnormal,O
cardiac,O
adrenergic,O
neuron,O
activity,O
in,O
adriamycin,B
-,I
induced,I
cardiomyopathy,I
with,O
iodine,B
-,I
125,I
-,I
metaiodobenzylguanidine,I
.,O
Radiolabeled,
metaiodobenzylguanidine,
(,
MIBG,
),
",",
an,
analog,
of,
norepinephrine,
(,
NE,
),
",",
serves,
as,
an,
index,
of,
adrenergic,
neuron,
integrity,
and,
function,
.,
Using,
a,
rat,
model,
of,
adriamycin,
-,
induced,
cardiomyopathy,
",",
we,
tested,
the,
hypothesis,
that,
abnormal,
cardiac,
adrenergic,
neuron,
activity,
may,
appear,
and,
be,
exacerbated,
dose,
-,
dependently,
in,
adriamycin,
cardiomyopathy,
.,
The,O
degree,O
of,O
vacuolar,O
degeneration,O
of,O
myocardial,O
cells,O
was,O
analyzed,O
in,O
relation,O
to,O
the,O
duration,O
of,O
adriamycin,B
treatment,O
(,O
2,O
mg,O
/,O
kg,O
",",O
once,O
a,O
week,O
),O
.,O
There,O
were,O
no,O
abnormalities,O
or,O
only,O
isolated,O
degeneration,O
in,O
the,O
1,O
-,O
or,O
2,O
-,O
wk,O
treatment,O
groups,O
",",O
isolated,O
or,O
scattered,O
degeneration,O
in,O
half,O
of,O
the,O
3,O
-,O
wk,O
group,O
",",O
frequent,O
scattered,O
degeneration,O
in,O
the,O
4,O
-,O
wk,O
group,O
",",O
scattered,O
or,O
focal,O
degeneration,O
in,O
the,O
5,O
-,O
wk,O
group,O
",",O
and,O
extensive,O
degeneration,O
in,O
the,O
8,O
-,O
wk,O
group,O
.,O
Myocardial,O
accumulation,O
of,O
[,O
125I,B-chemical
],O
MIBG,I-chemical
4,O
hr,O
after,O
intravenous,O
injection,O
did,O
not,O
differ,O
between,O
the,O
controls,O
and,O
the,O
groups,O
treated,O
3,O
wk,O
or,O
less,O
.,O
However,O
",",O
the,O
4,O
-,O
wk,O
group,O
had,O
a,O
slightly,O
lower,O
accumulation,O
in,O
the,O
right,O
ventricular,O
wall,O
(,O
82,O
%,O
of,O
the,O
control,O
),O
and,O
significantly,O
lower,O
accumulation,O
in,O
the,O
left,O
ventricular,O
wall,O
(,O
about,O
66,O
%,O
of,O
the,O
control,O
:,O
p,O
less,O
than,O
0,O
.,O
05,O
),O
.,O
In,O
the,O
5,O
-,O
wk,O
group,O
",",O
MIBG,B
accumulation,O
in,O
the,O
right,O
and,O
left,O
ventricular,O
wall,O
was,O
35,O
%,O
and,O
27,O
%,O
of,O
that,O
in,O
controls,O
",",O
respectively,O
(,O
p,O
less,O
than,O
0,O
.,O
001,O
),O
.,O
In,O
the,O
8,O
-,O
wk,O
group,O
",",O
MIBG,B
accumulation,O
in,O
the,O
right,O
and,O
left,O
ventricular,O
wall,O
was,O
18,O
%,O
and,O
14,O
%,O
of,O
that,O
in,O
controls,O
",",O
respectively,O
(,O
p,O
less,O
than,O
0,O
.,O
001,O
),O
.,O
Thus,O
",",O
MIBG,B
accumulation,O
in,O
the,O
myocardium,O
decreased,O
in,O
an,O
adriamycin,O
dose,O
-,O
dependent,O
manner,O
.,O
The,O
appearance,O
of,O
impaired,O
cardiac,O
adrenergic,O
neuron,O
activity,O
in,O
the,O
presence,O
of,O
slight,O
myocardial,O
impairment,O
(,O
scattered,O
or,O
focal,O
vacuolar,O
degeneration,O
),O
indicates,O
that,O
MIBG,B
scintigraphy,O
may,O
be,O
a,O
useful,O
method,O
for,O
detection,O
of,O
adriamycin,O
-,O
induced,O
cardiomyopathy,O
.,O
Syncope,O
and,O
QT,O
prolongation,O
among,O
patients,O
treated,O
with,O
methadone,B
for,O
heroin,O
dependence,O
in,O
the,O
city,O
of,O
Copenhagen,O
.,O
BACKGROUND,O
:,O
Methadone,B
is,O
prescribed,O
to,O
heroin,B
addicts,O
to,O
decrease,O
illicit,O
opioid,O
use,O
.,O
Prolongation,O
of,O
the,O
QT,O
interval,O
in,O
the,O
ECG,O
of,O
patients,O
with,O
torsade,O
de,I
pointes,I
(,I
TdP,I
),I
has,O
been,O
reported,O
in,O
methadone,B
users,O
.,O
As,O
heroin,B
addicts,I
sometimes,O
faint,O
while,O
using,O
illicit,O
drugs,O
",",O
doctors,O
might,O
attribute,O
too,O
many,O
episodes,O
of,O
syncope,O
to,O
illicit,O
drug,O
use,O
and,O
thereby,O
underestimate,O
the,O
incidence,O
of,O
TdP,B
in,I
this,I
special,I
population,I
",",O
and,O
the,O
high,O
mortality,O
in,O
this,O
population,O
may,O
",",O
in,O
part,O
",",O
be,O
caused,O
by,O
the,O
proarrhythmic,O
effect,O
of,O
methadone,B
.,O
METHODS,O
:,O
In,O
this,O
cross,O
-,O
sectional,O
study,O
interview,O
",",O
ECGs,O
and,O
blood,O
samples,O
were,O
collected,O
The,O
QT,B
interval,I
was,O
estimated,O
from,O
12,O
lead,O
ECGs,O
.,O
All,O
participants,O
were,O
interviewed,O
about,O
any,O
experience,O
of,O
syncope,O
.,O
The,O
association,O
between,O
opioid,O
dose,O
and,O
QT,B
",",O
and,O
methadone,B
dose,I
and,O
reporting,O
of,O
syncope,O
was,O
assessed,O
using,O
multivariate,O
linear,O
regression,O
and,O
logistic,O
regression,O
",",O
respectively,O
.,O
RESULTS,O
:,O
Methadone,B
dose,I
was,O
associated,O
with,O
longer,O
QT,B
interval,I
of,O
0,O
.,O
140,O
ms,O
/,O
mg,O
(,O
p,O
=,O
0,O
.,O
002,O
),O
.,O
No,O
association,O
between,O
buprenorphine,B
and,O
QTc,Ellipsis
higher,O
methadone,B
dose,O
was,O
associated,O
with,O
a,O
1,O
.,O
440,O
s,O
(,O
(,O
1,O
/,O
2,O
),O
),O
2,O
(,O
95,O
%,O
CI,O
1,O
.,O
1,O
to,O
1,O
.,O
4,O
),O
times,O
higher,O
odds,O
for,O
syncope,O
.,O
CONCLUSIONS,O
:,O
Methadone,B
is,O
associated,O
with,O
QT,B
prolongation,I
and,O
higher,O
reporting,O
of,O
syncope,O
in,O
a,O
population,O
of,O
heroin,B
addicts,O
.,O
Neuroleptic,B
malignant,I
syndrome,I
induced,O
by,O
ziprasidone,O
on,O
the,O
second,O
day,O
of,O
treatment,O
.,O
Neuroleptic,B
malignant,I
syndrome,I
(,O
NMS,O
),O
is,O
the,O
rarest,O
and,O
most,O
serious,O
of,O
the,O
neuroleptic,O
-,O
induced,O
movement,O
disorders,O
.,O
We,
describe,
a,
case,
of,
neuroleptic,
malignant,
syndrome,
(,
NMS,
),
associated,
with,
the,
use,
of,
ziprasidone,
.,
Although,
conventional,
neuroleptics,
are,
more,
frequently,
associated,
with,
NMS,
",",
atypical,
antipsychotic,
drugs,
like,
ziprasidone,
may,
also,
be,
a,
cause,
.,
The,
patient,
is,
a,
24,
-,
year,
-,
old,
male,
with,
a,
history,
of,
schizophrenia,
who,
developed,
signs,
and,
symptoms,
of,
NMS,
after,
2,
days,
of,
treatment,
with,
an,
80,
-,
mg,
/,
day,
dose,
of,
orally,
administrated,
ziprasidone,
.,
This,
case,
is,
the,
earliest,
(,
second,
day,
of,
treatment,
),
NMS,
due,
to,
ziprasidone,
reported,
in,
the,
literature,
.,
Peripheral,
iron,
dextran,
induced,
degeneration,
of,
dopaminergic,
neurons,
in,
rat,
substantia,
nigra,
.,
Iron,
accumulation,
is,
considered,
to,
be,
involved,
in,
the,
pathogenesis,
of,
Parkinson,
',
s,
disease,
.,
To,
demonstrate,
the,
relationship,
between,
peripheral,
iron,
overload,
and,
dopaminergic,
neuron,
loss,
in,
rat,
substantia,
nigra,
(,
SN,
),
",",
in,
the,
present,
study,
we,
used,
fast,
cyclic,
voltammetry,
",",
tyrosine,
hydroxylase,
(,
TH,
),
immunohistochemistry,
",",
Perls,
',
iron,
staining,
",",
and,
high,
performance,
liquid,
chromatography,
-,
electrochemical,
detection,
to,
study,
the,
degeneration,
of,
dopaminergic,
neurons,
and,
increased,
iron,
content,
in,
the,
SN,
of,
iron,
dextran,
overloaded,
animals,
.,
The,O
findings,O
showed,O
that,O
peripheral,O
iron,B
dextran,I
overload,I
increased,O
the,O
iron,B
staining,I
positive,I
cells,I
and,O
These,O
results,O
suggest,O
that,O
peripheral,O
iron,B
dextran,O
can,O
increase,O
the,O
iron,B
level,O
in,O
the,O
SN,O
",",O
where,O
excessive,O
iron,O
causes,O
the,O
degeneration,O
of,O
dopaminergic,O
neurons,O
.,O
The,O
chronic,O
iron,B
overload,O
may,O
be,O
more,O
destructive,O
to,O
dopaminergic,O
neurons,O
than,O
the,O
acute,O
iron,B
overload,O
.,O
Attenuated,O
disruption,O
of,O
prepulse,O
inhibition,O
by,O
dopaminergic,O
stimulation,O
after,O
maternal,O
deprivation,O
and,O
adolescent,O
corticosterone,O
treatment,O
in,O
rats,O
.,O
The,O
development,O
of,O
schizophrenia,O
may,O
include,O
an,O
early,B
neurodevelopmental,I
stress,I
component,O
which,O
increases,O
vulnerability,O
to,O
later,O
stressful,O
life,O
events,O
",",O
in,O
combination,O
leading,O
to,O
overt,O
disease,O
.,O
We,O
investigated,O
the,O
effect,O
of,O
an,O
early,B
stress,I
",",O
in,O
the,O
form,O
of,O
maternal,O
deprivation,O
",",O
combined,O
with,O
a,O
later,O
stress,B
",",O
simulated,O
by,O
chronic,O
periadolescent,O
corticosterone,O
treatment,O
",",O
on,O
behaviour,O
in,O
rats,O
.,O
Acute,
treatment,
with,
apomorphine,
caused,
disruption,
of,
prepulse,
inhibition,
(,
PPI,
),
in,
controls,
and,
in,
rats,
that,
had,
undergone,
either,
maternal,
deprivation,
or,
corticosterone,
treatment,
",",
but,
was,
surprisingly,
absent,
in,
rats,
that,
had,
undergone,
the,
combined,
early,
and,
late,
stress,
.,
Amphetamine,
treatment,
significantly,
disrupted,
PPI,
in,
both,
non,
-,
deprived,
groups,
",",
but,
was,
absent,
in,
both,
maternally,
deprived,
groups,
.,
The,O
serotonin,B
-,I
1A,I
receptor,I
agonist,I
",",O
8,B
-,I
OH,I
-,I
DPAT,I
",",O
induced,O
a,O
significant,O
disruption,O
The,O
altered,O
effects,O
of,O
apomorphine,B
and,O
amphetamine,B
could,O
indicate,O
differential,O
changes,O
in,O
dopamine,O
receptor,O
signalling,O
leading,O
to,O
functional,O
desensitisation,O
",",O
or,O
altered,O
modulation,O
of,O
sensory,O
gating,O
in,O
the,O
nucleus,O
accumbens,O
by,O
limbic,O
structures,O
such,O
as,O
the,O
hippocampus,O
.,O
An,O
extremely,O
rare,O
case,O
of,O
delusional,O
parasitosis,O
in,O
a,O
chronic,O
hepatitis,O
C,O
patient,O
during,O
pegylated,O
interferon,O
alpha,O
-,O
2b,O
and,O
ribavirin,O
treatment,O
.,O
During,O
treatment,O
of,O
chronic,O
hepatitis,O
C,O
patients,O
with,O
interferon,B
and,O
ribavirin,B
",",O
a,O
lot,O
of,O
side,O
effects,O
are,O
described,O
.,O
Twenty,O
-,O
three,O
percent,O
to,O
44,O
%,O
of,O
patients,O
develop,O
depression,O
.,O
A,O
minority,O
of,O
patients,O
evolve,O
to,O
psychosis,O
.,O
To,O
the,O
best,O
of,O
our,O
knowledge,O
",",O
no,O
cases,O
of,O
psychogenic,O
parasitosis,O
occurring,O
during,O
interferon,O
therapy,O
have,O
been,O
described,O
in,O
the,O
literature,O
.,O
We,O
present,O
a,O
49,O
-,O
year,O
-,O
old,O
woman,O
who,O
developed,O
a,O
delusional,O
parasitosis,O
during,O
treatment,O
wi...n,O
alpha,B
-,I
2b,I
and,O
reappeared,O
after,O
restarting,O
it,O
.,O
She,O
had,O
a,O
complete,O
sustained,O
viral,O
response,O
.,O
Hepatonecrosis,B-Chemical
and,O
cholangitis,B-Chemical
related,O
to,O
long,O
-,O
term,O
phenobarbital,B-Chemical
therapy,O
:,O
an,O
autopsy,O
report,O
of,O
two,O
patients,O
.,O
Phenobarbital,B-Chemical
(,O
PB,B-Chemical
),O
has,O
a,O
reputation,O
for,O
safety,O
",",O
and,O
it,O
is,O
commonly,O
believed,O
that,O
PB,B-Chemical
-,O
related,O
increases,O
in,O
serum,O
aminotransferase,O
levels,O
do,O
not,O
indicate,O
or,O
predict,O
the,O
development,O
of,O
significant,O
chronic,O
liver,O
disease,O
.,O
Here,
we,
report,
of,
two,
adult,
patients,
with,
a,
long,
history,
of,
epilepsy,
treated,
with,
PB,
who,
died,
suddenly,
:,
one,
as,
consequence,
of,
cardiac,
arrest,
",",
the,
other,
of,
acute,
bronchopneumonia,
.,
At,
autopsy,
",",
analysis,
of,
liver,
parenchyma,
revealed,
rich,
portal,
inflammatory,
infiltrate,
",",
which,
consisted,
of,
mixed,
eosinophil,
and,
monocyte,
cells,
",",
associated,
with,
several,
foci,
of,
necrosis,
surrounded,
by,
a,
hard,
ring,
of,
non,
-,
specific,
granulomatous,
tissue,
.,
Inflammatory,O
reactions,O
of,O
internal,O
and,O
external,O
hepatic,B
biliary,I
ducts,I
were,O
also,O
seen,O
.,O
Our,O
findings,O
il...rectly,O
related,O
asymptomatic,O
chronic,B
hepatic,I
enzyme,I
dysfunction,I
.,O
Delayed,O
leukoencephalopathy,O
with,O
stroke,O
-,O
like,O
presentation,O
in,O
chemotherapy,O
recipients,O
.,O
BACKGROUND,O
:,O
A,O
transient,O
leukoencephalopathy,O
mimicking,O
cerebrovascular,O
accident,O
has,O
been,O
described,O
as,O
a,O
complication,O
of,O
chemotherapy,O
",",O
most,O
commonly,O
in,O
recipients,O
of,O
intrathecal,B
methotrexate,I
for,O
childhood,O
leukaemia,O
.,O
Recently,O
published,O
neuroimaging,O
data,O
suggest,O
a,O
common,O
pathophysiology,O
associated,O
with,O
a,O
variety,O
of,O
chemotherapy,B
agents,O
and,O
modes,O
of,O
administration,O
.,O
METHODS,O
:,O
We,O
reviewed,O
the,O
medical,O
literature,O
for,O
single,O
reports,O
and,O
case,O
series,O
of,O
patients,O
presenting,O
with,O
stroke,O
-,O
like,O
episodes,O
while,O
receiving,O
systemic,O
or,O
intrathecal,O
chemotherapy,B
.,O
We,O
only,O
included,O
studies,O
providing,O
detailed,O
neuroimaging,O
data,O
.,O
Patients,O
with,O
cerebrovascular,O
accidents,O
were,O
excluded,O
.,O
RESULTS,O
:,O
We,O
identified,O
27,O
reports,O
of,O
toxic,O
leukoencephalopathy,B
in,O
patients,O
treated,O
with,O
methotrexate,B
(,O
intrathecal,I
",",O
systemic,I
),O
",",O
5,O
-,O
fluorouracil,B
and,O
its,O
derivative,O
carmofur,B
",",O
and,O
capecitabine,B
.,O
Diffusion,O
weighted,O
imaging,O
(,O
DWI,O
),O
of,O
all,O
patients,O
revealed,O
well,O
demarcated,O
hyperintense,O
lesions,O
within,O
Lesions,
exceeded,
the,
confines,
of,
adjacent,
vascular,
territories,
.,
Complete,
resolution,
of,
symptoms,
within,
1,
-,
4,
days,
was,
accompanied,
by,
normalisation,
of,
ADC,
abnormalities,
.,
However,
",",
fluid,
attenuated,
inversion,
recovery,
(,
FLAIR,
),
sequences,
frequently,
revealed,
persistent,
white,
matter,
abnormalities,
.,
CONCLUSIONS,
:,
Several,
pathophysiological,
models,
of,
delayed,
leukoencephalopathy,
after,
exposure,
to,
intrathecal,
or,
systemic,
chemotherapy,
have,
been,
proposed,
.,
DWI,O
findings,O
in,O
this,O
cohort,O
are,O
indicative,O
of,O
cytotoxic,B
oedema,I
within,O
cerebral,O
white,O
matter,O
and,O
lend,O
support,O
to,O
an,O
at,O
least,O
partially,O
reversible,O
metabolic,O
derangement,O
as,O
the,O
basis,O
for,O
this,O
syndrome,O
.,O
Prenatal,O
exposure,O
to,O
fluoxetine,B
induces,O
fetal,O
pulmonary,O
hypertension,O
in,O
the,O
rat,O
.,O
RATIONALE,O
:,O
Fluoxetine,B
is,O
a,O
selective,O
serotonin,O
reuptake,O
inhibitor,O
antidepressant,O
widely,O
used,O
by,O
pregnant,O
women,O
.,O
Epidemiological,O
data,O
suggest,O
that,O
fluoxetine,B
exposure,O
prenatally,O
increases,O
the,O
prevalence,O
of,O
persistent,O
pulmonary,O
hypertens...effect,O
in,O
adult,O
rodents,O
.,O
OBJECTIVES,O
:,O
To,O
evaluate,O
the,O
fluoxetine,B
effect,O
on,O
fetal,O
rat,O
pulmonary,O
vascular,O
smooth,O
muscle,O
mechanical,O
properties,O
and,O
cell,O
proliferation,O
rate,O
.,O
METHODS,O
:,O
Pregnant,O
rats,O
were,O
treated,O
with,O
fluoxetine,B
(,O
10,O
mg,O
/,O
kg,O
),O
from,O
Day,O
11,O
through,O
Day,O
21,O
of,O
gestation,O
.,O
MEASUREMENTS,O
AND,O
MAIN,O
RESULTS,O
:,O
Fetuses,O
were,O
delivered,O
by,O
cesarean,O
section,O
.,O
As,O
compared,O
with,O
controls,O
",",O
fluoxetine,B
exposure,O
resulted,O
in,O
fetal,O
pulmonary,O
hypertension,O
as,O
evidenced,O
by,O
an,O
increase,O
in,O
the,O
weight,O
ratio,O
of,O
the,O
right,O
ventricle,O
to,O
the,O
left,O
ventricle,O
plus,O
septum,O
(,O
P,O
=,O
0,O
.,O
02,O
),O
and,O
by,O
an,O
increase,O
in,O
pulmonary,O
arterial,O
medial,O
thickness,O
(,O
P,O
<,O
0,O
.,O
01,O
),O
.,O
Postnatal,O
mortality,O
was,O
increased,O
among,O
experimental,O
animals,O
",",O
and,O
arterial,O
oxygen,O
saturation,O
was,O
96,O
+,O
/,O
-,O
1,O
%,O
in,O
1,O
-,O
day,O
-,O
old,O
control,O
animals,O
and,O
significantly,O
lower,O
(,O
P,O
<,O
0,O
.,O
01,O
),O
in,O
fluoxetine,B
-,I
exposed,O
pups,O
(,O
79,O
+,O
/,O
-,O
2,O
%,O
),O
.,O
In,O
vitro,O
",",O
fluoxetine,O
induced,O
pulmonary,O
arterial,O
muscle,O
contraction,O
in,O
fetal,O
",",O
but,O
not,O
adult,O
",",O
animals,O
(,O
P,O
<,O
0,O
.,O
01,O
),O
and,O
reduced,O
serotonin,O
-,O
induced,O
contraction,O
at,O
both,O
ages,O
(,O
P,O
<,O
0,O
.,O
01,O
),O
.,O
After,O
in,O
utero,O
exposure,O
to,O
a,O
low,O
fluoxetine,O
concentration,O
the,O
pulmonary,O
arterial,O
smooth,O
muscle,O
cell,O
proliferation,O
rate,O
was,O
significantly,O
increased,O
in,O
fetal,O
",",O
but,O
not,O
adult,O
",",O
cells,O
(,O
P,O
<,O
0,O
.,O
01,O
),O
.,O
CONCLUSIONS,O
:,O
In,O
contrast,O
to,O
the,O
adult,O
",",O
fluoxetine,B
exposure,O
in,O
utero,O
induces,O
pulmo...,B
-,I
induced,I
transient,I
optic,I
and,I
peripheral,I
neuropathy,I
:,O
a,O
case,O
report,O
.,O
AIM,O
:,O
To,O
report,O
a,O
case,O
of,O
optic,B
and,O
peripheral,B
neuropathy,I
after,O
chronic,O
use,O
of,O
disulfiram,B
for,O
alcohol,O
dependence,O
management,O
.,O
MATERIALS,O
AND,O
METHODS,O
:,O
A,O
case,O
report,O
.,O
RESULTS,O
:,O
A,O
57,O
-,O
year,O
-,O
old,O
male,O
presented,O
with,O
gradual,O
loss,O
of,O
vision,O
in,O
both,O
eyes,O
with,O
intermittent,O
headaches,O
for,O
2,O
months,O
.,O
He,O
also,O
complained,O
of,O
paraesthesia,O
with,O
numbness,O
in,O
both,O
feet,O
.,O
His,O
vision,O
was,O
6,O
/,O
15,O
and,O
2,O
/,O
60,O
in,O
the,O
right,O
and,O
left,O
eyes,O
",",O
respectively,O
.,O
Fundoscopy,O
revealed,O
bilaterally,O
swollen,O
optic,B
nerve,I
heads,I
.,O
Visual,O
field,O
testing,O
confirmed,O
bilateral,O
central,O
-,O
caecal,O
scotomata,O
.,O
He,O
had,O
been,O
taking,O
disulfiram,B
for,O
alcohol,O
dependence,O
for,O
the,O
preceding,O
3,O
years,O
.,O
Disulfiram,B
discontinuation,O
lead,O
to,O
an,O
immediate,O
symptomatic,O
improvement,O
.,O
CONCLUSION,
:,
Physicians,
initiating,
long,
-,
term,
disulfiram,
therapy,
should,
be,
aware,
of,
these,
adverse,
effects,
.,
They,
should,
recommend,
annual,
ophthalmic,
reviews,
with,
visual,
field,
testing,
.,
Patients,
should,
be,
reassured,
with,
respect,
to,
the,
reversibility,
of,
these,
adverse,
effects,
.,
Intraocular,
pressure,
in,
patients,
with,
uveitis,
treated,
with,
fluocinolone,
acetonide,
implants,
.,
OBJECTIVE,O
:,O
To,O
report,O
the,O
incidence,O
and,O
management,O
of,O
elevated,O
intraocular,O
pressure,O
(,O
IOP,B
),O
in,O
patients,O
with,O
uveitis,O
treated,O
with,O
the,O
fluocinolone,B
acetonide,I
(,O
FA,B
),O
intravitreal,O
implant,O
.,O
DESIGN,B
:,O
Pooled,O
data,O
from,O
3,O
multicenter,O
",",O
double,O
-,O
masked,O
",",O
randomized,O
",",O
controlled,O
",",O
phase,O
2b,O
/,O
3,O
clinical,O
trials,O
evaluating,O
the,O
safety,O
and,O
efficacy,O
of,O
the,O
0,O
.,O
59,O
-,O
mg,B
or,O
2,O
.,O
1,O
-,O
mg,B
FA,B
intravitreal,O
implant,O
or,O
standard,O
therapy,O
were,O
analyzed,O
Topical,O
IOP,B
-,I
lowering,I
medication,I
was,O
administered,O
in,O
74,O
.,O
8,O
%,O
of,O
implanted,O
eyes,O
",",O
and,O...
additional,O
IOP,B
-,I
lowering,I
medication,I
),O
in,O
85,O
.,O
.,O
.,O
1,O
%,O
of,O
eyes,O
at,O
1,O
year,O
.,O
The,O
rate,O
of,O
hypotony,B
(,O
IOP,B
<,I
/,I
=,I
5,I
mm,I
Hg,I
),O
following,O
IOP,B
-,I
lowering,I
surgery,I
(,O
42,O
.,O
5,O
%,O
),O
was,O
not,O
different,O
from,O
that,O
of,O
implanted,O
eyes,O
not,O
subjected,O
to,O
surgery,O
(,O
35,O
.,O
4,O
%,O
),O
(,O
P,O
=,O
.,O
09,O
),O
.,O
CONCLUSION,O
:,O
Elevated,O
IOP,B
is,O
a,O
significant,O
complication,O
with,O
the,O
FA,O
intravitreal,O
implant,O
but,O
may,O
be,O
controlled,O
with,O
medication,O
and,O
surgery,O
.,O
Myocardial,B
Fas,I
ligand,I
expression,O
increases,O
susceptibility,O
to,O
AZT,B
-,I
induced,O
cardiomyopathy,O
.,O
BACKGROUND,O
:,O
METHODS,O
AND,O
RESULTS,O
:,O
In,O
order,O
to,O
investigate,O
whether,O
the,O
HAART,O
component,O
zidovudine,B-Chemical
(,B-Chemical
3,I-Chemical
',I-Chemical
-,I-Chemical
azido,I-Chemical
-,I-Chemical
2,I-Chemical
',I-Chemical
",",I-Chemical
3,I-Chemical
',I-Chemical
-,I-Chemical
deoxythymidine,I-Chemical
;,I-Chemical
AZT,I-Chemical
),I-Chemical
triggers,O
the,O
Fas,O
-,O
dependent,O
cell,O
-,O
death,O
pathway,O
and,O
cause,O
cytoskeletal,O
disruption,O
in,O
a,O
murine,O
model,O
of,O
DCM,O
",",O
8,O
-,O
week,O
-,O
old,O
transgenic,O
(,O
expressing,O
Fas,O
ligand,O
in,O
the,O
myocardium,O
:,O
FasL,O
Tg,O
),O
and,O
non,O
-,O
transgenic,O
(,O
NTg,O
),O
mice,O
received,O
water,O
ad,O
libitum,O
containing,O
different,O
concentrations,O
of,O
AZT,B-Chemical
(,I-Chemical
0,I-Chemical
",",I-Chemical
0,I-Chemical
.,I-Chemical
07,O
",",O
0,O
.,O
2,O
",",O
and,O
0,O
.,O
7,O
mg,O
/,O
ml,O
),O
.,O
After,O
6,O
weeks,O
",",O
cardiac,O
function,O
was,O
assessed,O
by,O
echocardiography,O
and,O
morphology,O
was,O
assessed,O
by,O
histopathologic,O
and,O
immunohistochemical,O
methods,O
.,O
NTg,O
and,O
untreated,O
FasL,O
Tg,O
mice,O
showed,O
little,O
or,O
no,O
change,O
in,O
cardiac,O
structure,O
or,O
function,O
.,O
In,O
contrast,O
",",O
AZT,B
-,I
treated,O
FasL,O
Tg,O
mice,O
developed,O
cardiac,O
dilation,O
and,O
depressed,O
cardiac,O
function,O
in,O
a,O
dose,O
-,O
dependent,O
manner,O
",",O
with,O
concomitant,O
inflammatory,O
infiltration,O
of,O
both,O
ventricles,O
.,O
These,
changes,
were,
associated,
with,
an,
increased,
sarcolemmal,
expression,
of,
Fas,
and,
FasL,
",",
as,
well,
as,
increased,
activation,
of,
caspase,
3,
",",
translocation,
of,
calpain,
1,
to,
the,
sarcolemma,
and,
sarcomere,
",",
and,
increased,
numbers,
of,
cells,
undergoing,
apoptosis,
.,
These,
were,
associated,
with,
changes,
in,
dystrophin,
and,
cardiac,
troponin,
I,
localization,
",",
as,
well,
as,
loss,
of,
sarcolemmal,
integrity,
.,
CONCLUSIONS,O
:,O
The,O
expression,O
of,O
Fas,B
ligand,I
in,O
the,O
myocardium,O
",",O
as,O
identified,O
in,O
HIV,O
-,O
positive,O
patients,O
",",O
might,O
increase,O
the,O
susceptibility,O
to,O
HAART,O
-,O
induced,O
cardiomyopathy,O
due,O
to,O
activation,O
of,O
apoptotic,O
pathways,O
",",O
resulting,O
in,O
cardiac,O
dilation,O
and,O
dysfunction,O
.,O
Gastrointestinal,B
tolerability,I
of,O
etoricoxib,B
in,O
rheumatoid,O
arthritis,O
patients,O
:,O
results,O
of,O
the,O
etoricoxib,O
vs,O
diclofenac,O
sodium,O
gastrointestinal,O
tolerability,O
and,O
effectiveness,O
trial,O
(,O
EDGE,O
-,O
II,O
),O
.,O
OBJECTIVE,O
:,O
A,O
randomised,O
",",O
double,O
-,O
blind,O
study,O
to,O
compare,O
the,O
gastrointestinal,B
(,B
GI,I
),I
Use,O
of,O
gastroprotective,B
agents,O
and,O
low,O
-,O
dose,O
aspirin,B
was,O
allowed,O
.,O
The,O
prespecified,O
primary,O
end,O
point,O
consisted,O
of,O
the,O
cumulative,O
rate,O
of,O
patient,O
discontinuations,O
due,O
to,O
clinical,O
and,O
laboratory,O
GI,B
adverse,I
experiences,I
(,O
AEs,O
),O
.,O
General,O
safety,O
was,O
also,O
assessed,O
",",O
including,O
adjudicated,O
thrombotic,O
cardiovascular,O
event,O
data,O
.,O
Efficacy,O
was,O
evaluated,O
using,O
the,O
Patient,O
Global,O
Assessment,O
of,O
Disease,O
Status,O
(,O
PGADS,B
;,O
0,O
-,O
4,O
point,O
scale,O
),O
.,O
RESULTS,O
:,O
Mean,O
(,O
SD,O
;,O
maximum,O
),O
duration,O
of,O
treatment,O
was,O
19,O
.,O
3,O
(,O
10,O
.,O
3,O
;,O
32,O
.,O
9,O
),O
and,O
19,O
.,O
1,O
(,O
10,O
.,O
4,O
;,O
33,O
.,O
1,O
),O
months,O
in,O
the,O
etoricoxib,O
and,O
diclofenac,O
groups,O
",",O
respectively,O
.,O
The,O
cumulative,O
discontinuation,O
rate,O
due,O
to,O
GI,O
AEs,O
was,O
significantly,O
lower,O
with,O
etoricoxib,O
than,O
diclofenac,O
(,O
5,O
2,O
vs,O
8,O
.,O
5,O
events,O
per,O
100,O
patient,O
-,O
years,O
",",O
respectively,O
;,O
hazard,O
ratio,O
0,O
.,O
62,O
(,O
95,O
%,O
CI,O
:,O
0,O
.,O
47,O
",",O
0,O
.,O
81,O
;,O
p,O
<,O
or,O
=,O
0,O
.,O
001,O
),O
),O
.,O
The,O
incidence,O
of,O
discontinuations,O
for,O
hypertension,O
-,O
related,O
and,O
oedema,O
-,O
related,O
AEs,O
were,O
significantly,O
higher,O
with,O
etoricoxib,B
(,B
2,B
.,B
5,B
%,B
and,B
1,B
.,B
1,B
%,B
respectively,B
),O
compared,O
with,O
diclofenac,O
(,O
5,O
%,O
and,O
0,O
.,O
4,O
%,O
respectively,O
;,O
p,O
<,O
0,O
.,O
001,O
for,O
hypertension,O
and,O
p,O
<,O
0,O
.,O
01,O
for,O
oedema,O
),O
.,O
Etoricoxib,B
and,O
diclofenac,B
treatment,O
resulted,O
in,O
similar,O
efficacy,O
(,O
PGADS,O
mean,O
changes,O
from,O
baseline,O
-,O
0,O
.,O
62,O
vs,O
-,O
0,O
.,O
58,O
",",O
respectively,O
),O
.,O
CONCLUSIONS,O
:,O
Etoricoxib,B
90,O
mg,O
demonstrated,O
a,O
significantly,O
lower,O
risk,O
for,O
discontinuing,O
treatment,O
due,O
to,O
GI,B
AEs,O
compared,O
with,O
diclofenac,B
150,O
mg,O
.,O
Discontinuations,O
from,O
renovascular,B
AEs,O
",",O
although,O
less,O
common,O
than,O
discontinuations,O
from,O
GI,B
AEs,O
",",O
were,O
significantly,O
higher,O
with,O
etoricoxib,B
.,O
Anxiogenic,O
potential,O
of,O
ciprofloxacin,B
and,O
norfloxacin,B
in,O
rats,O
.,O
INTRODUCTION,O
:,O
The,O
possible,O
anxiogenic,O
effects,O
of,O
fluoroquinolones,O
",",O
namely,O
ciprofloxacin,B
and,O
norfloxacin,B
",",O
were,O
investigated,O
in,O
adult,O
Charles,O
Foster,O
albino,O
rats,O
of,O
either,O
sex,O
",",O
weighing,O
150,O
-,O
200,O
g,O
.,O
METHODS,O
:,O
The,O
drugs,O
were,O
given,O
orally,O
",",O
in,O
doses,O
of,O
50,B
mg,I
/,I
kg,I
for,O
five,B
consecutive,I
days,I
and,O
the,O
experiments,O
were,O
performed,O
on,O
the,O
fifth,B
day,I
.,O
The,O
tests,O
included,O
open,O
-,O
field,O
exploratory,O
behaviour,O
",",O
elevated,O
plus,O
maze,O
and,O
elevated,O
zero,O
maze,O
",",O
social,O
interaction,O
and,O
novelty,O
-,O
suppressed,O
feeding,O
latency,O
behaviour,O
.,O
RESULTS,O
:,O
The,O
results,O
indicate,O
that,O
ciprofloxacin,B
-,I
and,O
norfloxacin,B
-,I
treated,O
rats,O
showed,O
anxious,O
behaviour,O
in,O
comparison,O
to,O
control,O
rats,O
in,O
all,O
the,O
parameters,O
studied,O
.,O
However,O
",",O
ciprofloxacin,B
-,I
and,O
norfloxacin,B
-,I
treated,O
rats,O
did,O
not,O
differ,O
significantly,O
from,O
each,O
other,O
in,O
various,O
behavioural,O
parameters,O
.,O
CONCLUSION,O
:,O
The,O
present,O
experimental,O
findings,O
substantiate,O
the,O
clinically,O
observed,O
anxiogenic,O
potential,O
of,O
ciprofloxacin,B
and,O
norfloxacin,B
.,O
Reduction,O
of,O
pain,O
during,O
induction,O
with,O
target,O
-,O
controlled,O
propofol,O
and,O
remifentanil,O
.,O
BACKGROUND,O
:,O
Pain,O
on,O
injection,O
of,O
propofol,O
is,O
unpleasant,O
.,O
We,O
hypothesized,O
that,O
propofol,O
infusion,O
pain,O
might,O
be,O
prevented,O
by,O
infusing,O
remifentanil,O
before,O
starting,O
the,O
propofol,O
infusion,O
in,O
a,O
clinical,O
setting,O
where,O
target,O
-,O
controlled,O
infusions,O
(,O
TCI,O
),O
of,O
both,O
drugs,O
were,O
used,O
.,O
A,
prospective,
",",
randomized,
",",
double,
-,
blind,
",",
placebo,
-,
controlled,
trial,
was,
performed,
to,
determine,
the,
effect,
-,
site,
concentration,
(,
Ce,
),
of,
remifentanil,
to,
prevent,
the,
pain,
without,
producing,
complications,
.,
METHODS,
:,
A,
total,
of,
128,
patients,
undergoing,
general,
surgery,
were,
randomly,
allocated,
to,
receive,
normal,
saline,
(,
control,
),
or,
remifentanil,
to,
a,
target,
Ce,
of,
2,
ng,
ml,
(,
-,
1,
),
(,
R2,
),
",",
4,
ng,
ml,
(,
-,
1,
),
(,
R4,
),
",",
or,
6,
ng,
ml,
(,
-,
1,
),
(,
R6,
),
administered,
via,
TCI,
.,
After,O
the,O
target,O
Ce,B
was,O
achieved,O
",",O
the,O
infusion,O
of,O
propofol,B
was,O
started,O
.,O
Remifentanil,B
-,I
related,I
complications,O
were,O
assessed,O
during,O
the,O
remifentanil,O
infusion,O
",",O
and,O
pain,O
caused,O
by,O
propofol,B
was,O
evaluated,O
using,O
a,O
four,O
-,I
point,I
scale,I
during,O
the,O
propofol,B
infusion,O
.,O
RESULTS,O
:,O
The,O
incidence,O
of,O
pain,O
was,O
significantly,O
lower,O
in,O
Groups,O
R4,B
and,O
R6,B
than,O
in,O
the,O
control,O
and,O
R2,B
groups,O
(,O
12,O
/,O
32,O
and,O
6,O
/,O
31,O
vs,O
26,O
/,O
31,O
and,O
25,O
/,O
32,O
",",O
respectively,O
",",O
P,O
<,O
0,O
.,O
001,
),
.,
Pain,
was,
less,
severe,
in,
Groups,
R4,
and,
R6,
than,
in,
the,
control,
and,
R2,
groups,
(,
P,
<,
0,
.,
001,
),
.,
However,
",",
both,
incidence,
and,
severity,
of,
pain,
were,
not,
different,
between,
Groups,
R4,
and,
R6,
.,
No,
significant,
complications,
were,
observed,
during,
the,
study,
.,
CONCLUSIONS,
:,
During,
induction,
of,
anaesthesia,
with,
TCI,
of,
propofol,
and,
remifentanil,
",",
a,
significant,
reduction,
in,
propofol,
infusion,
pain,
was,
achieved,
without,
significant,
complications,
by,
prior,
administration,
of,
remifentanil,
at,
a,
target,
Ce,
of,
4,
ng,
ml,
(,
-,
1,
),
.,
Dexmedetomidine,B
and,O
cardiac,O
protection,O
for,O
non,O
-,O
cardiac,O
surgery,O
:,O
a,O
meta,O
-,O
analysis,O
of,O
randomised,O
controlled,O
trials,O
.,O
We,O
conducted,O
a,O
systematic,O
review,O
of,O
the,O
effects,O
of,O
dexmedetomidine,B
on,O
cardiac,O
outcomes,O
following,O
non,O
-,O
cardiac,O
surgery,O
.,O
We,O
included,O
prospective,O
",",O
randomised,O
peri,O
-,O
operative,O
studies,O
of,O
dexmedetomidine,B
that,O
reported,O
mortality,O
",",O
cardiac,O
morbidity,O
or,O
adverse,O
drug,O
events,O
.,O
A,O
PubMed,B
Central,I
and,O
EMBASE,B
search,O
was,O
conducted,O
up,O
to,O
July,O
2007,O
.,O
The,B
reference,I
lists,I
of,O
identified,O
papers,O
were,O
examined,O
for,O
further,O
trials,O
.,O
Of,O
425,O
studies,O
identified,O
",",O
20,O
were,O
included,O
in,O
the,O
meta,B
-,I
analysis,I
(,O
840,B
patients,I
),O
.,O
Dexmedetomidine,B
was,O
associated,O
with,O
a,O
trend,O
towards,O
improved,O
cardiac,O
outcomes,O
;,O
all,O
-,O
cause,O
mortality,O
(,O
OR,O
0,O
.,O
27,
",",
95,
%,
CI,
0,
.,
01,
-,
7,
.,
13,
",",
p,
=,
0,
.,
44,
),
",",
non,
-,
fatal,
myocardial,
infarction,
(,
OR,
0,
.,
26,
",",
95,
%,
CI,
0,
.,
04,
-,
1,
.,
60,
",",
p,
=,
0,
.,
14,
),
",",
and,
myocardial,
ischaemia,
(,
OR,
0,
.,
65,
",",
95,
%,
CI,
0,
.,
26,
-,
1,
.,
63,
",",
p,
=,
0,
.,
36,
),
.,
Peri,
-,
operative,
hypotension,
(,
26,
%,
",",
OR,
3,
.,
80,
",",
95,
%,
CI,
1,
.,
91,
-,
7,
.,
54,
",",
p,
=,
0,
.,
0001,
),
and,
bradycardia,
(,
17,
%,
",",
OR,
5,
.,
45,O
",",O
95,O
%,O
CI,B
2,I
.,I
98,I
-,I
9,I
.,I
95,I
",",O
p,O
<,O
0,O
.,O
00001,O
),O
BACKGROUND,
:,
Clomiphene,
citrate,
(,
CC,
),
is,
commonly,
prescribed,
for,
ovulation,
induction,
.,
It,
is,
considered,
safe,
",",
with,
minimal,
side,
effects,
.,
Thromboembolism,
is,
a,
rare,
but,
life,
-,
threatening,
complication,
that,
has,
been,
reported,
after,
ovulation,
induction,
with,
CC,
.,
Spontaneous,
coronary,
thrombosis,
or,
thromboembolism,
with,
subsequent,
clot,
lysis,
has,
been,
suggested,
as,
one,
of,
the,
most,
common,
causes,
of,
myocardial,
infarction,
(,
MI,
),
during,
pregnancy,
",",
with,
a,
subsequently,
normal,
coronary,
angiogram,
.,
CASE,
:,
A,
33,
-,
year,
-,
old,
woman,
with,
a,
5,
-,
week,
gestation,
had,
recently,
received,
CC,
for,
ovulation,
induction,
and,
presented,
with,
chest,
pain,
.,
An,
electrocardiogram,
showed,
a,
lateral,
and,
anterior,
wall,
myocardial,
infarction,
.,
Cardiac,
enzymes,
showed,
a,
peak,
rise,
in,
troponin,
I,
to,
9,
.,
10,
ng,
/,
mL,
.,
An,
initial,
exercise,
stress,
test,
was,
normal,
.,
At,O
the,O
time,O
of,O
admission,O
",",O
the,O
patient,O
was,O
at,O
high,O
risk,O
of,O
radiation,O
injury,O
to,O
the,O
fetus,O
",",O
so,O
a,O
coronary,O
angiogram,O
was,O
postponed,O
until,O
the,O
second,O
trimester,O
.,O
It,O
showed,O
normal,O
coronary,O
vessels,O
.,O
CONCLUSION,O
:,O
This,O
appears,O
to,O
be,O
the,O
first,O
reported,O
case,O
documenting,O
a,O
possible,O
association,O
between,O
CC,B
and,O
myocardial,O
infarction,O
.,O
Thrombosis,B-chemical
might,O
be,O
a,O
rare,O
but,O
hazardous,O
complication,O
of,O
CC,B-chemical
.,O
Given,O
this,O
life,O
-,O
threa...psyndrome,O
(,O
reverse,O
Takotsubo,O
cardiomyopathy,O
),O
in,O
a,O
young,O
woman,O
in,O
the,O
setting,O
of,O
amphetamine,B-chemical
use,O
.,O
Transient,O
left,O
ventricular,O
apical,O
ballooning,O
syndrome,O
was,O
first,O
described,O
in,O
Japan,O
as,O
Takotsubo,B
cardiomyopathy,O
.,O
This,O
syndrome,O
has,O
been,O
identified,O
in,O
many,O
other,O
countries,O
.,O
Many,O
variations,O
of,O
this,O
syndrome,O
have,O
been,O
recently,O
described,O
in,O
the,O
literature,O
.,O
One,O
of,O
the,O
rarest,O
is,O
the,O
reverse,O
type,O
of,O
this,O
syndrome,O
",",O
with,O
hyperdynamic,O
apex,O
and,O
complete,O
akinesia,O
of,O
the,O
base,O
(,O
as,O
opposed,O
to,O
the,O
classic,O
apical,O
ballooning,O
),O
.,O
In,O
this,O
article,O
",",O
we,O
report,O
an,O
interesting,O
case,O
of,O
a,O
young,O
woman,O
who,O
presented,O
with,O
this,O
rare,O
type,O
of,O
reverse,O
apical,O
ballooning,O
syndrome,O
occurring,O
after,O
amphetamine,B
use,O
.,O
This,O
report,O
is,O
followed,O
by,O
review,O
of,O
the,O
literature,O
.,O
Results,O
of,O
a,B
comparative,I
",",O
phase,O
III,O
",",O
12,O
-,O
week,O
",",O
multicenter,O
",",O
prospective,O
",",O
randomized,O
",",O
double,O
-,O
blind,O
assessment,O
of,O
the,O
efficacy,O
and,O
tolerability,O
of,O
a,O
fixed,O
-,O
dose,O
combination,O
of,O
telmisartan,B
and,O
amlodipine,B
versus,O
amlodipine,O
monotherapy,O
in,O
Indian,O
adults,O
with,O
stage,O
II,O
hypertension,O
.,O
OBJECTIVE,O
:,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
evaluate,O
the,O
efficacy,O
and,O
tolerability,O
of,O
a,O
new,O...
conducted,O
in,O
Indian,O
patients,O
aged,O
18,O
to,O
65,O
years,O
with,O
established,O
stage,O
II,O
hypertension,O
.,O
.,O
Patients,O
were,O
treated,O
with,O
oral,O
FDC,B
of,I
T,I
+,I
A,I
or,O
A,B
QD,I
before,O
breakfast,O
for,O
12,O
weeks,O
;,O
blood,O
pressure,O
(,O
BP,B
),O
and,O
heart,O
rate,O
were,O
measured,O
in,O
the,O
sitting,O
position,O
.,O
Primary,O
efficacy,O
end,O
points,O
were,O
reduction,O
in,O
clinical,O
systolic,O
BP,B
(,O
SBP,I
),O
/,O
diastolic,O
BP,B
(,O
DBP,I
),O
from,O
baseline,O
to,O
study,O
end,O
and,O
number,O
of,O
responders,O
(,O
ie,O
",",O
patients,O
who,O
achieved,O
target,O
SBP,B
/,O
DBP,B
<,O
130,O
/,O
<,O
80,O
mm,O
Hg,O
),O
at,O
end,O
of,O
study,O
.,O
Tolerability,
was,
assessed,
by,
treatment,
-,
emergent,
adverse,
events,
",",
identified,
using,
physical,
examination,
",",
laboratory,
analysis,
",",
and,
electrocardiography,
.,
RESULTS,
:,
A,
total,
of,
210,
patients,
were,
enrolled,
in,
the,
study,
;,
203,
patients,
(,
143,
men,
",",
60,
women,
),
completed,
the,
study,
while,
7,
were,
lost,
to,
follow,
-,
up,
(,
4,
patients,
in,
the,
T,
+,
A,
group,
and,
3,
in,
the,
A,
group,
),
and,
considered,
with,
-,
drawn,
.,
At,O
study,O
end,O
",",O
statistically,O
significant,O
percentage,O
reductions,O
from,O
baseline,O
within,O
groups,O
and,O
between,O
groups,O
were,O
observed,O
in,O
SBP,B
(,O
T,O
+,O
A,B
[,O
-,O
27,O
.,O
4,O
%,O
],O
;,O
A,B
[,O
-,O
16,O
.,O
6,O
%,O
],O
),O
and,O
DBP,B
(,O
T,O
+,O
A,B
[,O
-,O
20,O
.,O
1,O
%,O
],O
;,O
A,B
[,O
-,O
13,O
.,O
3,O
%,O
],O
),O
(,O
all,O
",",O
P,O
<,O
0,O
.,O
05,O
),O
.,O
Response,O
rates,O
were,O
87,O
.,O
3,O
%,O
(,O
89,O
/,O
102,O
),O
in,O
the,O
T,O
+,O
A,B
group,O
and,O
69,O
.,O
3,O
%,O
(,O
70,O
/,O
101,O
),O
in,O
the,O
A,O
group,O
(,O
P,O
<,O
0,O
.,O
05,O
),O
.,O
The,O
prevalences,O
of,O
adverse,O
events,O
were,O
not,O
significantly,O
different,O
between,O
the,O
2,O
treatment,O
groups,O
(,O
T,O
+,O
A,O
",",O
16,O
.,O
0,O
%,O
[,O
17,O
/,O
106,O
],O
;,O
A,O
",",O
15,O
.,O
4,O
%,O
[,O
16,O
/,O
104,O
],O
),O
.,O
Peripheral,B
edema,I
was,O
reported,O
in,O
8,O
.,O
5,O
%,O
patients,O
(,O
9,O
/,O
106,O
],O
in,O
the,O
T,O
+,O
A,O
group,O
compared,O
with,O
13,O
.,O
5,
%,
(,
14,
/,
104,
),
in,
the,
A,
group,
",",
and,
cough,
was,
reported,
in,
3,
.,
8,
%,
patients,
(,
4,
/,
106,
),
in,
the,
T,
+,
A,
group,
and,
1,
.,
0,
%,
(,
1,
/,
104,
),
patients,
in,
the,
A,
group,
;,
these,
differences,
did,
not,
reach,
statistical,
significance,
.,
The,
incidences,
of,
headache,
",",
dizziness,
",",
and,
diarrhea,
were,
similar,
between,
the,
2,
groups,
.,
CONCLUSIONS,
:,
Among,
these,
Indian,
patients,
with,
stage,
II,
hypertension,
",",
the,
FDC,
of,
T,
+,
A,
was,
found,
to,
be,
significantly,
more,
effective,
",",
with,
regard,
to,
BP,
reductions,
",",
than,
A,
",",
and,
both,
treatments,
were,
well,
tolerated,
.,
Increased,
mental,
slowing,
associated,
with,
the,
APOE,
epsilon4,
allele,
after,
trihexyphenidyl,
oral,
anticholinergic,
challenge,
in,
healthy,
elderly,
.,
OBJECTIVES,O
:,O
The,O
objectives,O
of,O
this,O
study,O
were,O
to,O
examine,O
the,O
relationship,O
between,O
APOE,B
epsilon4,I
and,O
subjective,O
effects,O
of,O
trihexyphenidyl,B
on,O
measures,O
reflecting,O
sedation,O
and,O
confusion,O
and,O
to,O
investigate,O
the,O
relationship,O
between,O
trihexyphenidyl,B
-,I
induced,O
subjective,O
effects,O
and,O
objective,O
memory,O
performance,O
.,O
METHODS,
:,
This,
study,
comprised,
24,
cognitively,
intact,
",",
health,
elderly,
adults,
(,
12,
APOE,
epsilon4,
carriers,
),
at,
an,
outpatient,
geriatric,
psychiatry,
research,
clinic,
.,
This,
was,
a,
randomized,
",",
double,
blind,
",",
placebo,
-,
controlled,
",",
three,
-,
way,
",",
crossover,
experimental,
design,
.,
All,
participants,
received,
1,
.,
0,
mg,
or,
2,
.,
0,O
mg,O
trihexyphenidyl,B
or,O
placebo,O
administered,O
in,O
counterbalanced,O
sequences,O
over,O
a,O
period,O
of,O
three,O
consecutive,O
weeks,O
.,O
Bond,O
and,O
Lader,O
',O
s,O
visual,O
analog,O
scales,O
and,O
alternate,O
versions,O
of,O
the,O
Buschke,O
Selective,O
Reminding,O
Test,O
were,O
administered,O
in,O
a,O
repeated,O
measures,O
design,O
at,O
baseline,O
",",O
1,O
",",O
2,O
.,O
5,O
",",O
and,O
5,O
hours,O
postdrug,O
administration,O
.,O
RESULTS,O
:,O
A,O
2,O
.,O
0,O
-,O
mg,O
oral,O
dose,O
of,O
trihexyphenidyl,B
resulted,O
in,O
increased,O
subjective,O
ratin...s,O
of,O
the,O
APOE,B
epsilon4,I
allele,I
only,O
.,O
Drug,O
effects,O
as,O
determined,O
by,O
difference,O
scores,O
between,O
However,O
",",O
no,O
significant,O
effects,O
were,O
found,O
with,O
other,O
visual,O
analog,O
scales,O
reflecting,O
subjective,O
sedation,O
and,O
clear,O
-,O
headedness,O
.,O
CONCLUSION,O
:,O
The,O
epsilon4,B
allele,O
in,O
healthy,O
elderly,O
was,O
associated,O
with,O
increased,O
subjective,O
mental,O
slowing,O
after,O
trihexyphenidyl,O
anticholinergic,O
challenge,O
.,O
An,O
evaluation,O
of,O
amikacin,B
nephrotoxicity,O
in,O
the,O
hematology,O
/,O
oncology,O
population,O
.,O
Amikacin,B
is,O
an,O
aminoglycoside,O
commonly,O
used,O
to,O
provide,O
empirical,O
double,O
gram,O
-,O
negative,O
treatment,O
for,O
...This,O
is,O
particularly,O
important,O
in,O
the,O
hematology,O
/,O
oncology,O
population,O
.,O
To,O
evaluate,O
amikacin,B
-,I
associated,I
nephrotoxicity,I
in,O
an,O
adult,O
hematology,O
/,O
oncology,O
population,O
",",O
a,O
pro...,I
that,O
required,O
treatment,O
with,O
an,O
aminoglycoside,O
were,O
randomized,O
to,O
either,O
conventional,O
or,O
extended,O
-,O
interval,O
amikacin,O
.,O
The,O
occurrence,O
of,O
nephrotoxicity,O
by,O
means,O
of,O
an,O
increase,O
in,O
serum,O
creatinine,B
and,O
evaluation,O
of,O
efficacy,O
via,O
amikacin,B
serum,O
concentrations,O
with,O
respective,O
pathogens,O
were,O
assessed,O
.,O
The,O
occurrence,O
of,O
nephrotoxicity,O
was,O
similar,O
between,O
the,O
conventional,O
and,O
extended,O
-,O
interval,O
groups,O
",",O
at,O
10,O
%,O
and,O
5,O
%,O
",",O
respectively,O
(,O
P,O
=,O
1,O
.,O
00,O
),O
.,O
Six,O
patients,O
in,O
the,O
conventional,O
group,O
had,O
a,O
positive,O
culture,O
",",O
compared,O
with,O
none,Ellipsis
was,O
variable,O
between,O
the,O
two,O
groups,O
.,O
Efficacy,O
could,O
not,O
be,O
assessed,O
.,O
High,O
dose,O
dexmedetomidine,B
as,O
the,O
sole,O
sedative,O
for,O
pediatric,O
MRI,O
.,O
OBJECTIVE,O
:,O
This,O
large,O
-,O
scale,O
retrospective,O
review,O
evaluates,O
the,O
sedation,O
profile,O
of,O
dexmedetomidine,B
.,O
AIM,O
:,O
To,O
determine,O
the,O
hemodynamic,O
responses,O
",",O
efficacy,O
and,O
adverse,O
events,O
associated,O
with,O
the,O
use,O
of,O
high,O
dose,O
dexmedetomidine,B
as,O
the,O
sole,O
sedative,O
for,O
magnetic,O
resonance,O
imaging,O
(,O
MRI,O
),O
studies,O
.,O
BACKGROUND,O
:,O
Dexmedetomidine,B
has,O
been,O
used,O
at,O
our,O
institution,O
since,O
2005,O
to,O
provide,O
sedation,O
for,O
pediatric,O
radiological,O
imaging,O
studies,O
.,O
Over,O
time,O
",",O
an,O
effective,O
protocol,O
utilizing,O
high,O
dose,O
dexmedetomidine,B
as,O
the,O
sole,O
sedative,O
agent,O
has,O
evolved,O
.,O
METHODS,O
/,O
MATERIALS,O
:,O
As,O
part,O
of,O
the,O
ongoing,O
Quality,O
Assurance,O
process,O
",",O
data,O
on,O
all,O
sedations,O
are,O
reviewed,O
monthly,O
and,O
protocols,O
modified,O
as,O
needed,O
.,O
Data,O
were,O
analyzed,O
from,O
all,O
747,O
consecutive,O
patients,O
who,O
received,O
dexmedetomidine,B
for,O
MRI,O
sedation,O
from,O
kg,O
(,O
-,O
1,O
),O
.,O
h,O
(,O
-,O
1,O
),O
.,O
The,O
current,O
sedation,O
protocol,O
progressively,O
increased,O
the,O
rate,O
of,O
successful,O
sedation,O
(,O
able,O
to,O
complete,O
the,O
imaging,O
study,O
),O
when,O
using,O
dexmedetomidine,B
alone,O
from,O
91,O
.,O
8,O
%,O
to,O
97,O
.,O
6,O
%,O
(,O
P,O
=,O
0,O
.,O
009,O
),O
",",O
reducing,O
the,O
requirement,O
for,O
adjuvant,O
pentobarbital,B
in,O
the,O
event,O
of,O
sedation,O
failure,O
with,O
dexmedetomidine,B
alone,O
and,O
decreased,O
the,O
mean,O
recovery,O
time,O
by,O
10,O
min,O
(,O
P,O
<,O
0,O
.,O
001,O
),O
.,O
Although,O
dexmedetomidine,B
sedation,O
was,O
associated,O
with,O
a,O
16,O
%,O
incidence,O
of,O
bradycardia,O
",",O
all,O
concomitant,O
mean,O
arterial,O
blood,O
pressures,O
were,O
within,O
20,O
%,O
of,O
age,O
-,O
adjusted,O
normal,O
range,O
and,O
oxygen,O
saturations,O
were,O
95,O
%,O
or,O
higher,O
.,O
CONCLUSION,O
:,O
Dexmedetomidine,B
in,O
high,O
doses,O
provides,O
adequate,O
sedation,O
for,O
pediatric,O
MRI,O
studies,O
.,O
While,
use,
of,
high,
dose,
dexmedetomidine,
is,
associated,
with,
decreases,
in,
heart,
rate,
and,
blood,
pressure,
outside,
the,
established,
',
awake,
',
norms,
",",
this,
deviation,
is,
generally,
within,
20,
%,
of,
norms,
",",
and,
is,
not,
associated,
with,
adverse,
sequelae,
.,
Dexmedetomidine,
is,
useful,
as,
the,
sole,
sedative,
for,
pediatric,
MRI,
.,
Hepatotoxicity,O
associated,O
with,O
sulfasalazine,B
in,O
inflammatory,O
arthritis,O
:,O
A,O
case,O
series,O
from,O
a,O
local,O
surveillance,O
of,O
serious,O
adverse,O
events,O
.,O
BACKGROUND,O
:,O
Spontaneous,O
reporting,O
systems,O
for,O
adverse,O
drug,O
reactions,O
(,O
ADRs,O
),O
are,O
handicapped,O
by,O
under,O
-,O
reporting,O
and,O
limited,O
detail,O
on,O
individual,O
cases,O
.,O
We,O
report,O
an,O
investigation,O
from,O
a,O
local,O
surveillance,O
for,O
serious,O
adverse,O
drug,O
reactions,O
associated,O
with,O
disease,O
modifying,O
anti,O
-,O
rheumatic,O
drugs,O
that,O
was,O
triggered,O
by,O
the,O
occurrence,O
of,O
liver,O
failure,O
in,O
two,O
of,O
our,O
patients,O
.,O
METHODS,O
:,O
Serious,O
ADR,O
reports,O
have,O
been,O
solicited,O
from,O
local,O
clinicians,O
by,O
regular,O
postcards,O
over,O
the,O
past,O
seven,O
years,O
.,O
Patients,O
',O
",",O
who,O
had,O
hepatotoxicity,B
on,O
sulfasalazine,B
and,O
met,O
a,O
definition,O
of,O
a,O
serious,O
ADR,O
",",O
were,O
identified,O
.,O
Two,O
clinicians,O
reviewed,O
structured,O
case,O
reports,O
and,O
assessed,O
causality,O
by,O
consensus,O
and,O
by,O
using,O
a,O
causality,O
assessment,O
instrument,O
.,O
The,
likely,
frequency,
of,
hepatotoxicity,
with,
sulfasalazine,
was,
estimated,
by,
making,
a,
series,
of,
conservative,
assumptions,
.,
RESULTS,
:,
Ten,
cases,
were,
identified,
:,
eight,
occurred,
during,
surveillance,
.,
Eight,
patients,
were,
hospitalised,
",",
two,
in,
hepatic,
failure,
-,
one,
died,
after,
a,
liver,
transplant,
.,
All,
but,
one,
event,
occurred,
within,
6,
weeks,
of,
treatment,
.,
Seven,O
patients,O
had,O
a,O
skin,O
rash,O
",",O
three,O
eosinophilia,B
and,O
one,O
interstitial,O
nephritis,O
.,O
Five,O
patients,O
were,O
of,O
Black,B
British,I
of,I
African,I
or,I
Caribbean,I
descent,I
.,O
Liver,O
enzymes,O
showed,O
a,O
hepatocellular,B
pattern,I
in,O
four,O
cases,O
and,O
a,O
mixed,B
pattern,I
in,O
six,O
.,O
Drug,O
-,O
related,O
hepatotoxicity,O
was,O
judged,O
probable,O
or,O
highly,O
probable,O
in,O
8,O
patients,O
.,O
The,O
likely,O
frequency,O
of,O
serious,O
hepatotoxicity,O
with,O
sulfasalazine,B
was,O
estimated,O
at,O
0,O
.,O
4,O
%,O
of,O
treated,O
patients,O
.,O
CONCLUSION,O
:,O
Serious,O
hepatotoxicity,O
associated,O
with,O
sulfasalazine,B
appears,O
to,O
be,O
under,O
-,O
appreciated,O
and,O
intensive,O
monitoring,O
and,O
vigilance,O
in,O
the,O
first,O
6,O
weeks,O
of,O
treatment,O
is,O
especially,O
important,O
.,O
Complete,O
atrioventricular,O
block,O
secondary,O
to,O
lithium,B
therapy,O
.,O
Sinus,O
node,O
dysfunction,O
has,O
been,O
reported,O
most,O
frequently,O
among,O
the,O
adverse,O
cardiovascular,O
effects,O
of,O
lithium,B
.,O
In,O
the,O
present,O
case,O
",",O
complete,O
atrioventricular,O
(,O
AV,O
),O
block,O
with,O
syncopal,O
attacks,O
developed,O
secondary,O
to,O
lithium,B
therapy,O
",",O
necessitating,O
permanent,O
pacemaker,O
implantation,O
.,O
Serum,O
lithium,B
levels,I
remained,O
under,O
or,O
within,O
the,O
therapeutic,O
range,O
during,O
the,O
syncopal,O
attacks,O
.,O
Lith...ly,O
in,O
patients,O
with,O
mild,O
disturbance,O
of,O
AV,O
conduction,O
.,O
Exaggerated,O
expression,O
of,O
inflammatory,O
mediators,O
Vasoactive,O
intestinal,O
polypeptide,O
(,O
VIP,B
),O
is,O
an,O
immunomodulatory,O
neuropeptide,O
distributed,O
in,O
micturition,O
pathways,O
.,O
VIP,B
(,O
-,O
/,O
-,O
),O
mice,O
exhibit,O
altered,O
bladder,O
function,O
and,O
neurochemical,O
properties,O
in,O
micturition,O
pathways,O
after,O
cyclophosphamide,O
(,O
CYP,B
),O
-,O
induced,O
cystitis,O
.,O
Given,O
VIP,B
',I
s,O
role,O
as,O
an,O
anti,O
-,O
inflammatory,O
mediator,O
",",O
we,O
hypothesized,O
that,O
VIP,B
(,O
-,O
/,O
-,O
),O
mice,O
would,O
exhibit,O
enhanced,O
inflammatory,O
mediator,O
expression,O
after,O
cystitis,O
.,O
A,O
mouse,O
inflammatory,B
cytokine,I
and,O
receptor,O
RT2,B
profiler,I
array,I
was,O
used,O
to,O
determine,O
regulated,O
The,
genes,
presented,
represent,
(,
1,
),
greater,
than,
1,
.,
5,
-,
fold,
change,
in,
either,
direction,
and,
(,
2,
),
the,
p,
value,
is,
less,
than,
0,
.,
05,
for,
the,
comparison,
being,
made,
.,
Several,
regulated,
genes,
were,
validated,
using,
enzyme,
-,
linked,
immunoassays,
including,
IL,
-,
1beta,
and,
CXCL1,
.,
CYP,
treatment,
significantly,
(,
p,
<,
or,
=,
0,
.,
001,
),
increased,
expression,
of,
CXCL1,
and,
IL,
-,
1beta,
in,
the,
urinary,
bladder,
of,
WT,
and,
VIP,
(,
-,
/,
-,
),
mice,
",",
but,
expression,
in,
VIP,
(,
-,
/,
-,
),
mice,
with,
CYP,
treatment,
was,
significantly,
(,
p,
<,
or,
=,
0,
.,
001,
),
greater,
(,
4,
.,
2,
-,
to,
13,
-,
fold,
increase,
),
than,
that,
observed,
in,
WT,
urinary,
bladder,
(,
3,
.,
6,
-,
to,
5,
-,
fold,
increase,
),
.,
The,O
data,O
suggest,O
that,O
in,O
VIP,B
(,O
-,O
/,O
-,O
),O
mice,O
with,O
bladder,O
inflammation,O
",",O
inflammatory,O
mediators,O
are,O
increased,O
above,O
that,O
observed,O
in,O
WT,B
with,O
CYP,B
.,O
This,O
shift,O
in,O
balance,O
may,O
Debrisoquine,O
phenotype,O
and,O
the,O
pharmacokinetics,O
and,O
beta,O
-,O
2,O
receptor,O
pharmacodynamics,O
of,O
metoprolol,B
and,O
its,O
enantiomers,O
.,O
The,O
metabolism,O
of,O
the,O
cardioselective,O
beta,O
-,O
blocker,O
metoprolol,B
is,O
under,O
genetic,O
control,O
of,O
the,O
debrisoquine,O
/,O
sparteine,O
type,O
.,O
The,O
two,O
metabolic,O
phenotypes,O
",",O
extensive,O
(,O
EM,O
),O
and,O
poor,O
metabolizers,O
(,O
PM,O
),O
",",O
show,O
different,O
stereoselective,O
metabolism,O
",",O
resulting,O
in,O
apparently,O
higher,O
beta,O
-,O
1,O
adrenoceptor,O
antagonistic,O
potency,O
of,O
racemic,O
metoprolol,B
in,O
EMs,O
.,O
We,O
investigated,O
if,O
the,O
latter,O
also,O
applies,O
to,O
the,O
beta,B
-,I
2,I
adrenoceptor,I
antagonism,I
by,O
metoprolol,B
.,O
The,O
drug,O
effect,O
studied,O
was,O
the,O
antagonism,O
by,O
metoprolol,B
of,O
terbutaline,B
-,I
induced,I
hypokalemia,I
.,O
By,O
using,O
pharmacokinetic,O
pharmacodynamic,O
modeling,O
the,O
pharmacodynamics,O
of,O
racemic,O
metoprolol,B
and,O
the,O
active,O
S,B
-,I
isomer,I
",",O
were,O
quantitated,O
in,O
EMs,O
and,O
PMs,O
in,O
terms,O
of,O
IC50,O
values,O
",",O
representing,O
metoprolol,O
plasma,O
concentrations,O
resulting,O
in,O
half,O
-,O
maximum,O
receptor,O
occupancy,O
.,O
Six,
EMs,
received,
0,
.,
5,
mg,
of,
terbutaline,
s,
.,
c,
.,
on,
two,
different,
occasions,
:,
1,
),
1,
hr,
after,
administration,
of,
a,
placebo,
and,
2,
),
1,
hr,
after,
150,
mg,
of,
metoprolol,
p,
.,
o,
.,
Five,
PMs,
were,
studied,
according,
to,
the,
same,
protocol,
",",
except,
for,
a,
higher,
terbutaline,
dose,
(,
0,
.,
75,
mg,
),
on,
day,
2,
.,
Blood,
samples,
for,
the,
analysis,
of,
plasma,
potassium,
",",
terbutaline,
",",
metoprolol,
(,
racemic,
",",
R,
-,
and,
S,
-,
isomer,
),
",",
and,
alpha,
-,
hydroxymetoprolol,
concentrations,
were,
taken,
at,
regular,
time,
intervals,
",",
during,
8,
hr,
after,
metoprolol,
.,
In,O
PMs,O
",",O
metoprolol,B
increased,O
the,O
terbutaline,B
area,O
under,O
the,O
plasma,O
concentration,O
vs,O
.,O
time,O
ml,
-,
1,
),
than,
EMs,
(,
42,
+,
/,
-,
8,
ng,
.,
ml,
-,
1,
",",
P,
less,
than,
.,
001,
),
.,
(,
ABSTRACT,
TRUNCATED,
AT,
250,
WORDS,
),
The,
hemodynamics,
of,
oxytocin,
and,
other,
vasoactive,
agents,
during,
neuraxial,
anesthesia,
for,
cesarean,
delivery,
:,
findings,
in,
six,
cases,
.,
Oxytocin,
is,
a,
commonly,
used,
uterotonic,
that,
can,
cause,
significant,
and,
even,
fatal,
hypotension,
",",
particularly,
when,
given,
as,
a,
bolus,
.,
The,O
resulting,O
hypotension,O
can,O
be,O
produced,O
by,O
a,O
decrease,O
in,O
systemic,O
vascular,O
resistance,O
or,O
cardiac,O
output,O
through,O
a,O
decrease,O
in,O
venous,O
return,O
.,O
Parturients,O
with,O
normal,O
volume,O
status,O
",",O
heart,O
valves,O
and,O
pulmonary,O
vasculature,O
most,O
often,O
respond,O
to,O
this,O
hypotension,O
with,O
a,O
compensatory,O
increase,O
in,O
heart,O
rate,O
and,O
stroke,O
volume,O
.,O
Oxytocin,B
-,I
induced,I
hypotension,I
at,O
cesarean,O
delivery,O
may,O
be,O
incorrectly,O
attributed,O
to,O
blood,O
loss,O
.,O
Pulse,O
power,O
analysis,O
(,O
also,O
called,O
pulse,O
contour,O
analysis,O
),O
of,O
an,O
arterial,O
pressure,O
wave,O
form,O
allows,O
continuous,O
evaluation,O
of,O
systemic,O
vascular,O
resistance,O
and,O
cardiac,O
output,O
in,O
real,O
time,O
",",O
thereby,O
elucidating,O
the,O
causative,O
factors,O
behind,O
changes,O
in,O
blood,O
pressure,O
.,O
Pulse,O
power,O
analysis,O
was,O
conducted,O
in,O
six,O
cases,O
of,O
cesarean,B-Chemical
delivery,I-Chemical
performed,O
under,O
neuraxial,O
anesthesia,O
.,O
Hypotension,O
in,O
response,O
to,O
oxytocin,B-Chemical
was,O
associated,O
with,O
a,O
decrease,O
in,O
systemic,O
vascular,O
resistance,O
and,O
a,O
compensatory,O
increase,O
in,O
stroke,O
volume,O
",",O
heart,O
rate,O
and,O
cardiac,O
output,O
.,O
Pulse,O
power,O
analysis,O
may,O
be,O
helpful,O
in,O
determining,O
the,O
etiology,O
of,O
and,O
treating,O
hypotension,O
during,O
cesarean,B-Chemical
delivery,I-Chemical
under,O
neuraxial,O
anesthesia,O
.,O
Protective,O
effects,O
of,O
antithrombin,B
on,O
puromycin,B
aminonucleoside,I
nephrosis,I
in,O
rats,O
.,O
We,O
investigated,O
the,O
effects,O
of,O
antithrombin,B
",",O
a,O
plasma,O
inhibitor,O
of,O
coagulation,O
factors,O
",",O
in,O
rats,O
with,O
puromycin,B
aminonucleoside,I
-,I
induced,I
nephrosis,I
",",O
which,O
is,O
an,O
experimental,O
model,O
of,O
human,O
nephrotic,O
syndrome,O
.,O
Antithrombin,B
(,O
50,O
or,O
500,O
IU,O
/,O
kg,O
/,O
i,O
.,O
v,O
.,O
),O
was,O
administered,O
to,O
rats,O
once,O
a,O
day,O
for,O
10,O
days,O
immediately,O
after,O
the,O
injection,O...
dysfunction,O
and,O
hyperlipidemia,O
were,O
also,O
suppressed,O
.,O
Histopathological,O
examination,O
revealed,O
severe,O
renal,B
damage,O
such,O
as,O
proteinaceous,O
casts,O
in,O
tubuli,O
and,O
tubular,O
expansion,O
in,O
the,O
kidney,O
of,O
control,O
rats,O
",",O
while,O
an,O
improvement,O
of,O
the,O
damage,O
was,O
seen,O
in,O
antithrombin,B
-,I
treated,O
rats,O
.,O
In,O
addition,O
",",O
antithrombin,B
treatment,O
markedly,O
suppressed,O
puromycin,O
aminonucleoside,O
-,O
induced,O
apoptosis,O
of,O
renal,B
tubular,O
epithelial,O
cells,O
.,O
Furthermore,O
",",O
puromycin,B
aminonucleoside,I
-,I
induced,I
increases,O
in,O
renal,O
cytokine,O
content,O
were,O
also,O
decreased,O
...onucleoside,I
-,I
induced,I
nephrotic,O
syndrome,O
.,O
Treatment,O
with,O
antithrombin,O
may,O
be,O
clinically,O
effective,O
in,O
patients,O
with,O
nephrotic,O
syndrome,O
.,O
Heparin,B
-,I
induced,O
thrombocytopenia,O
after,O
liver,O
transplantation,O
.,O
BACKGROUND,O
:,O
Unfractionated,O
heparin,O
sodium,O
(,O
UFH,B
),O
or,O
low,O
-,I
molecular,O
weight,O
heparin,O
(,O
LMWH,B
),O
is,O
used,O
in,O
anticoagulant,O
protocols,O
at,O
several,O
institutions,O
to,O
prevent,O
thrombosis,O
after,O
liver,O
transplantation,O
.,O
Heparin,B
-,I
induced,O
thrombocytopenia,O
(,O
HIT,B
),O
is,O
an,O
adverse,O
immune,O
-,I
mediated,O
reaction,O
to,O
heparin,O
",",O
resulting,O
in,O
platelet,O
count,O
decreases,O
of,O
more,O
than,O
50,O
%,O
.,O
The,O
frequencies,O
of,O
HIT,B
after,O
liver,O
transplantation,O
and,O
platelet,O
factor,O
4,O
/,O
heparin,O
-,O
reactive,O
The,O
dose,O
of,O
UFH,B
was,O
changed,O
according,O
to,O
the,O
activated,O
clotting,O
time,O
level,O
.,O
HIT,B
antibody,O
levels,O
were,O
measured,O
the,O
day,O
before,O
surgery,O
and,O
on,O
POD,O
7,O
and,O
14,O
.,O
Platelet,O
count,O
was,O
measured,O
daily,O
for,O
3,O
weeks,O
.,O
RESULTS,O
:,O
The,O
average,O
platelet,O
counts,O
preoperatively,O
",",O
and,O
on,O
POD,O
7,O
",",O
14,O
",",O
and,O
21,O
were,O
65,O
",",O
88,O
",",O
149,O
",",O
and,O
169,O
x,O
10,O
(,O
9,O
),O
/,O
L,O
",",O
respectively,O
.,O
Two,O
patients,O
developed,O
hepatic,B
artery,I
thrombosis,I
on,O
POD,O
11,O
and,O
19,O
",",O
respectively,O
",",O
although,O
they,O...
on,O
POD,O
7,O
to,O
33,O
x,O
10,O
(,O
9,O
),O
/,O
L,O
on,O
POD,O
9,O
",",O
respectively,O
.,O
The,O
heparin,B
-,I
induced,I
platelet,I
aggregation,I
test,I
was,O
negative,O
in,O
these,O
patients,O
.,O
The,O
percentage,O
of,Ellipsis
HIT,O
.,O
CONCLUSIONS,O
:,O
In,O
our,O
series,O
",",O
the,O
occurrence,O
of,O
HIT,B
after,O
liver,O
transplantation,O
was,O
uncommon,O
.,O
Doxorubicin,B
cardiomyopathy,I
-,I
induced,I
inflammation,I
and,O
apoptosis,O
are,O
attenuated,O
by,O
gene,O
deletion,O
of,O
the,O
kinin,O
B1,B
receptor,I
.,O
Clinical,O
use,O
of,O
the,O
anthracycline,O
doxorubicin,B
(,O
DOX,O
),O
is,O
limited,O
by,O
its,O
cardiotoxic,O
effects,O
",",O
which,O
are,O
attributed,O
to,O
the,O
induction,O
of,O
apoptosis,O
.,O
To,O
elucidate,O
the,O
possible,O
role,O
of,O
the,O
kinin,O
B1,B
receptor,I
(,O
B1R,O
),O
during,O
the,O
development,O
of,O
DOX,O
cardiomyopathy,O
",",O
we,O
studied,O
B1R,O
knockout,O
mice,O
(,O
B1R,O
(,O
-,O
/,O
-,O
),O
-,O
),O
),O
by,O
investigating,O
cardiac,O
inflammation,O
and,O
apoptosis,O
after,O
induction,O
of,O
DOX,O
-,O
induced,O
cardiomyopathy,O
.,O
DOX,B
control,O
mice,O
showed,O
cardiac,O
dysfunction,O
measured,O
by,O
pressure,O
-,O
volume,O
loops,O
in,O
vivo,O
.,O
This,...
the,O
proinflammatory,O
cytokine,O
interleukin,O
6,O
were,O
increased,O
in,O
the,O
cardiac,O
tissue,O
.,O
In,O
DOX,B
B1R,I
(,O
-,O
),O
mice,O
",",O
cardiac,O
dysfunction,O
was,O
improved,O
compared,O
to,O
DOX,O
control,O
mice,O
",",O
which,O
was,O
associated,O
with,O
normalization,O
of,O
the,O
bax,B
/,O
bcl,B
-,I
2,I
ratio,I
and,O
interleukin,O
6,O
",",O
as,O
well,O
as,O
AKT,O
activation,O
state,O
.,O
These,O
findings,O
suggest,O
that,O
B1R,O
is,O
detrimental,O
in,O
DOX,O
cardiomyopathy,O
in,O
that,O
it,O
mediates,O
the,O
inflammatory,O
response,O
and,O
apoptosis,O
.,O
These,O
insights,O
might,O
have,O
useful,O
implications,O
for,O
future,O
studies,O
utilizing,O
B1R,B
antagonists,O
for,O
treatment,O
of,O
human,O
DOX,B
cardiomyopathy,O
.,O
Detailed,O
spectral,O
profile,O
analysis,O
of,O
penicillin,B
-,I
induced,I
epileptiform,O
activity,O
in,O
anesthetized,O
rats,O
.,O
Penicillin,B
model,I
is,O
a,O
widely,O
used,O
experimental,O
model,O
for,O
epilepsy,O
research,O
.,O
In,O
the,O
present,O
study,O
we,O
aimed,O
to,O
portray,O
a,O
detailed,O
spectral,O
analysis,O
of,O
penicillin,B
-,I
induced,I
ep...ctivity,O
recording,O
",",O
epileptic,O
focus,O
was,O
induced,O
by,O
injecting,O
400IU,O
/,O
2,O
microl,O
penicillin,B
-,I
G,I
potassium,I
into,O
the,O
left,O
lateral,O
ventricle,O
while,O
the,O
cortical,O
activity,O
was,O
continuously,O
recorded,O
.,O
Basal,O
activity,O
",",O
latent,O
period,O
and,O
the,O
penicillin,B
-,I
induced,I
epileptiform,I
activity,I
periods,O
were,O
then,O
analyzed,O
using,O
both,O
conventional,O
methods,O
and,O
spectral,O
analysis,O
.,O
Spectral,O
analyses,O
were,O
conducted,O
by,O
dividing,O
the,O
whole,O
spectrum,O
into,O
different,O
frequency,O
bands,O
including,O
delta,B
",",O
theta,B
(,O
slow,O
and,O
fast,O
),O
",",O
alpha,B
-,I
sigma,I
",",O
beta,B
(,O
1,I
and,I
2,I
),O
and,O
gamma,B
(,O
1,I
and,I
2,I
),O
bands,O
.,O
Our,O
results,O
show,O
that,O
the,O
most,O
affected,O
frequency,O
bands,O
were,O
delta,B
",",O
theta,B
",",O
beta,B
-,I
2,I
and,O
gamma,B
-,I
2,I
bands,O
during,O
the,O
epileptiform,O
activity,O
and,O
there,O
were,O
marked,O
differences,O
in,O
terms,O
of,O
spectral,O
densities,O
between,O
three,O
investigated,O
episodes,O
(,O
basal,B
activity,B
",",O
latent,B
period,I
and,O
epileptiform,O
activity,O
),O
.,O
Our,O
results,O
may,O
help,O
to,O
analyze,O
novel,O
data,O
obtained,O
using,O
similar,O
experimental,O
models,O
and,O
the,O
simple,O
analysis,O
method,O
described,O
here,O
can,O
be,O
used,O
in,O
similar,O
studies,O
to,O
investigate,O
the,O
basic,O
neuronal,O
mechanism,O
of,O
this,O
or,O
other,O
types,O
of,O
experimental,O
epilepsies,O
.,O
High,O
fat,B
diet,I
-,O
fed,O
obese,O
rats,O
are,O
highly,O
sensitive,O
to,O
doxorubicin,B
-,O
induced,O
cardiotoxicity,O
.,O
Often,
",",
chemotherapy,
by,
doxorubicin,
(,
Adriamycin,
),
is,
limited,
due,
to,
life,
threatening,
cardiotoxicity,
in,
patients,
during,
and,
posttherapy,
.,
Recently,
",",
we,
have,
shown,
that,
moderate,
diet,
restriction,
remarkably,
protects,
against,
doxorubicin,
-,
induced,
cardiotoxicity,
.,
This,
cardioprotection,
is,
accompanied,
by,
decreased,
cardiac,
oxidative,
stress,
and,
triglycerides,
and,
increased,
cardiac,
fatty,
-,
acid,
oxidation,
",",
ATP,
synthesis,
",",
and,
upregulated,
JAK,
/,
STAT3,
pathway,
.,
In,
the,
current,
study,
",",
we,
investigated,
whether,
a,
physiological,
intervention,
by,
feeding,
40,
%,
high,
fat,
diet,
(,
HFD,
),
",",
which,
induces,
obesity,
in,
male,
Sprague,
-,
Dawley,
rats,
(,
250,
-,
275,
g,
),
",",
sensitizes,
to,
doxorubicin,
-,
induced,
cardiotoxicity,
.,
A,
LD,
(,
10,
),
dose,
(,
8,
mg,
doxorubicin,
/,
kg,
",",
ip,
),
administered,
on,
day,
43,
of,
the,
HFD,
feeding,
regimen,
led,
to,
higher,
cardiotoxicity,
",",
cardiac,
dysfunction,
",",
lipid,
peroxidation,
",",
and,
80,
%,
mortality,
in,
the,
obese,
(,
OB,
),
rats,
in,
the,
absence,
of,
any,
significant,
renal,
or,
hepatic,
toxicity,
.,
Doxorubicin,B
toxicokinetics,O
studies,O
revealed,O
no,O
change,O
in,O
accumulation,O
of,O
doxorubicin,B
and,O
doxorubicinol,I
(,O
toxic,O
9,
+,
/,
-,
14,
.,
0,
nmol,
/,
min,
/,
g,
heart,
in,
ND,
versus,
400,
.,
2,
+,
/,
-,
11,
.,
8,
nmol,
/,
min,
/,
g,
heart,
in,
OB,
),
",",
(,
5,
),
decreased,
mitochondrial,
AMP,
-,
alpha2,
protein,
kinase,
",",
and,
(,
6,
),
86,
%,
drop,
in,
cardiac,
ATP,
levels,
accompanied,
by,
decreased,
ATP,
/,
ADP,
ratio,
after,
doxorubicin,
administration,
.,
Decreased,
cardiac,
erythropoietin,
and,
increased,
SOCS3,
further,
downregulated,
the,
cardioprotective,
JAK,
/,
STAT3,
pathway,
.,
In,O
conclusion,O
",",O
HFD,B
-,I
induced,I
obese,I
rats,I
are,O
highly,O
sensitized,O
to,O
doxorubicin,B
-,I
induced,I
cardiotoxicity,I
by,O
substantially,O
downregulating,O
cardiac,O
mitochondrial,O
ATP,B
generation,I
",",O
increasing,O
oxidative,O
stress,O
and,O
downregulating,O
the,O
JAK,O
/,O
STAT3,O
pathway,O
.,O
Isoproterenol,B
induces,I
primary,I
loss,I
of,I
dystrophin,I
in,I
rat,I
hearts,I
:,O
correlation,O
with,O
myocardial,O
injury,O
.,O
The,O
mechanism,O
of,O
isoproterenol,B
-,I
induced,I
myocardial,I
damage,I
is,O
unknown,O
",",O
but,O
a,O
mismatch,O
of,O
oxygen...lia,I
of,I
cardiomyocytes,I
have,O
been,O
demonstrated,O
to,O
be,O
caused,O
by,O
isoproterenol,B
.,O
Taking,O
into,O
account,O
that,O
the,O
sarcolemmal,B
integrity,I
is,O
stabilized,O
by,O
the,O
dystrophin,B
-,I
glycoprotein,I
complex,I...B
changes,O
in,O
the,O
DGC,B
and,O
integrins,I
.,O
We,O
found,O
different,O
sensitivity,O
of,O
the,O
DGC,B
and,O
integrin,B
to,O
isoproterenol,B
subcutaneous,O
administration,O
.,O
Immunofluorescent,O
staining,O
revealed,O
that,O
dystrophin,B
is,O
the,O
most,O
sensitive,O
among,O
the,O
structures,O
connecting,O
the,O
actin,O
in,O
the,O
cardiomyocyte,O
cytoskeleton,O
and,O
the,O
extracellular,O
matrix,O
.,O
The,O
sarcomeric,O
actin,O
dissolution,O
occurred,O
after,O
the,O
reduction,O
or,O
loss,O
of,O
dystrophin,B
.,O
Subsequently,O
",",O
after,O
lysis,O
of,O
myofilaments,O
",",O
gamma,B
-,I
sarcoglycan,I
",",O
beta,B
-,I
dystroglycan,I
",",O
beta1,B
-,I
integrin,I
",",O
and,O
laminin,B
alpha,I
-,I
2,I
expressions,O
were,O
reduced,O
followed,O
by,O
their,O
breakdown,O
",",O
as,O
epiphenomena,O
of,O
the,O
myocytolytic,O
process,O
.,O
In,O
conclusion,O
",",O
administration,O
of,O
isoproterenol,O
to,O
rats,O
results,O
in,O
primary,O
loss,O
of,O
dystrophin,O
",",O
the,O
most,O
sensitive,O
among,O
the,O
structural,O
proteins,O
that,O
form,O
the,O
DGC,O
that,O
connects,O
the,O
extracellular,O
matrix,O
and,O
the,O
cytoskeleton,O
in,O
cardiomyocyte,O
.,O
These,O
changes,O
",",O
related,O
to,O
ischaemic,B
injury,B
",",O
explain,O
the,O
severe,O
alterations,O
in,O
the,O
structural,O
in...tements,O
.,O
Within,O
the,O
last,O
several,O
years,O
",",O
previously,O
rare,O
liver,O
tumors,O
have,O
been,O
seen,O
in,O
young,O
women,O
using,O
oral,O
contraceptive,O
steroids,O
.,O
The,O
Registry,O
for,O
Liver,O
Tumors,O
Associated,O
with,O
Oral,B
Contraceptives,I
at,O
the,O
University,O
of,O
California,O
",",O
I...romatoma,O
",",O
and,O
hepatoma,O
.,O
Significant,O
statistical,O
etiological,O
factors,O
include,O
prolonged,O
uninterrupted,O
usage,O
of,O
oral,B
contraceptive,I
steroids,I
.,O
Eight,O
deaths,O
and,O
liver,O
rupture,O
in,O
18,O
patients,O
attest,O
to,O
the,O
seriousness,O
of,O
this,O
new,O
potentially,O
lethal,O
adverse,O
phenomenon,O
.,O
Ifosfamide,B
continuous,I
infusion,I
without,O
mesna,B
.,O
A,O
phase,O
I,O
trial,O
of,O
a,O
14,O
-,O
day,O
cycle,O
.,O
Twenty,O
patients,O
received,O
27,O
courses,O
of,O
ifosfamide,B
administered,O
as,O
a,O
24,O
-,O
hour,O
continuous,O
infusion,O
fo...ivalent,O
bolus,O
or,O
short,O
-,O
term,O
infusions,O
administered,O
with,O
Mesna,B
.,O
Dose,O
escalations,O
proceeded,O
from,O
200,B
to,O
300,B
",",O
400,B
",",O
450,B
",",O
500,B
",",O
and,O
550,B
mg,I
/,Ellipsis
(,O
1,O
),O
",",O
nausea,O
(,O
1,O
),O
",",O
and,O
Grade,O
2,O
leukopenia,O
(,O
1,O
),O
.,O
The,O
recommended,O
dose,O
of,O
500,B
mg,I
/,I
m2,I
/,I
d,I
delivers,O
a,O
total,O
dose,O
of,O
7,B
g,I
/,I
m2,I
per,O
cycle,O
",",O
which,O
is,O
comparable,O
to,O
that,O
delivered,O
in,O
clinical,O
practice,O
for,O
bolus,O
or,O
short,O
-,O
term,O
infusion,O
.,O
Because,O
few,O
patients,O
received,O
multiple,O
courses,O
over,O
time,O
",",O
the,O
cumulative,O
effects,O
are,O
indeterminate,O
in,O
the,O
present,O
trial,O
.,O
The,
frequency,
and,
predictability,
of,
hematuria,
are,
not,
precise,
",",
and,
at,
least,
daily,
monitoring,
by,
urine,
Hematest,
is,
essential,
",",
adding,
Mesna,
to,
the,
infusate,
in,
patients,
with,
persistent,
hematuria,
.,
The,
protracted,
infusion,
schedule,
for,
ifosfamide,
permits,
convenient,
outpatient,
administration,
without,
Mesna,
and,
reduces,
the,
drug,
cost,
of,
clinical,
usage,
of,
this,
agent,
by,
up,
to,
890,
per,
cycle,
.,
Clinical,O
activity,O
was,O
demonstrated,O
in,O
a,O
single,O
patient,O
",",O
but,O
a,O
comparative,O
trial,O
of,O
standard,O
bolus,O
schedules,O
with,O
the,O
protracted,O
infusion,O
schedule,O
will,O
be,O
necessary,O
to,O
determine,O
if,O
the,O
clinical,O
effectiveness,O
of,O
the,O
drug,O
is,O
maintained,O
.,O
A,O
case,O
of,O
ventricular,B
tachycardia,I
related,O
to,O
caffeine,B
pretreatment,O
.,O
Suboptimal,O
seizure,O
duration,O
is,O
commonly,O
encountered,O
in,O
electroconvulsive,O
therapy,O
practice,O
",",O
especially,O
in,O
older,O
patients,O
with,O
higher,O
seizure,O
thresholds,O
.,O
Intravenous,O
caffeine,B
is,O
commonly,O
used,O
to,O
improve,O
seizure,O
duration,O
and,O
quality,O
in,O
such,O
patients,O
and,O
is,O
generally,O
well,O
tolerated,O
aside,O
from,O
occasional,O
reports,O
of,O
relatively,O
benign,O
ventricular,O
ectopy,O
.,O
We,O
describe,O
a,O
patient,O
with,O
no,O
previous,O
history,O
of,O
cardiac,O
disease,O
or,O
arrhythmia,O
who,O
developed,O
sustain...,O
the,O
potential,O
for,O
unpredictable,O
and,O
serious,O
ventricular,O
arrhythmias,O
.,O
Fatal,O
haemopericardium,O
and,O
gastrointestinal,O
haemorrhage,O
due,O
to,O
possible,O
interaction,O
of,O
cranberry,B
juice,O
with,O
warfarin,B
.,O
We,O
report,O
a,O
case,O
of,O
fatal,O
internal,O
haemorrhage,O
in,O
an,O
elderly,O
man,O
who,O
consumed,O
only,O
cranberry,B
juice,O
for,O
two,O
weeks,O
while,O
maintaining,O
his,O
usual,O
dosage,O
of,O
warfarin,B
.,O
We,O
propose,O
that,O
naturally,O
occurring,O
compounds,O
such,O
as,O
flavonoids,O
",",O
which,O
are,O
present,O
in,O
fruit,O
juices,O
",",O
may,O
increase,O
the,O
potency,O
of,O
warfarin,B
by,O
competing,O
for,O
the,O
enzymes,O
that,O
normally,O
inactivate,O
warfarin,O
.,O
While,O
traditionally,O
regarded,O
as,O
foodstuffs,O
",",O
consumption,O
of,O
fruit,O
juices,O
should,O
be,O
considered,O
when,O
patients,Ellipsis
and,O
incidence,O
of,O
bupropion,B
-,I
induced,I
seizures,I
.,O
BACKGROUND,O
:,O
It,O
is,O
not,O
known,O
if,O
there,O
This,O
is,O
important,O
",",O
since,O
different,O
controlled,O
release,O
formulations,O
of,O
bupropion,B
release,O
the,O
active,O
drug,O
at,O
different,O
rates,O
.,O
METHODS,O
:,O
We,O
investigated,O
the,O
effect,O
of,O
varying,O
the,O
intraperitoneal,O
infusion,O
rates,O
of,O
bupropion,B
HCl,I
120,I
mg,I
/,I
kg,I
",",O
a,O
known,O
convulsive,O
dose,O
50,O
(,O
CD50,O
),O
",",O
on,O
the,O
incidence,O
and,O
severity,O
of,O
bupropion,O
-,O
induced,O
convulsions,O
in,O
the,O
Swiss,O
albino,O
mice,O
.,O
A,
total,
of,
69,
mice,
",",
approximately,
7,
weeks,
of,
age,
",",
and,
weighing,
21,
.,
0,
to,
29,
.,
1,
g,
were,
randomly,
assigned,
to,
bupropion,
HCl,
120,
mg,
/,
kg,
treatment,
by,
intraperitoneal,
(,
IP,
),
administration,
in,
7,
groups,
(,
9,
to,
10,
animals,
per,
group,
),
.,
Bupropion,
HCl,
was,
infused,
through,
a,
surgically,
implanted,
IP,
dosing,
catheter,
with,
infusions,
in,
each,
group,
of,
0,
min,
",",
15,
min,
",",
30,
min,
",",
60,
min,
",",
90,
min,
",",
120,
min,
",",
and,
240,
min,
.,
The,O
number,O
",",O
time,O
of,O
onset,O
",",O
duration,O
and,O
the,O
intensity,O
of,O
the,O
convulsions,O
or,O
absence,O
of,O
convulsions,O
were,O
recorded,O
.,O
RESULTS,O
:,O
The,O
results,O
showed,O
that,O
IP,O
administration,O
of,O
bupropion,B
HCl,I
120,I
mg,I
/,I
kg,I
by,O
bolus,O
injection,O
induced,O
convulsions,O
in,O
6,O
out,O
of,O
10,O
mice,O
(,O
60,O
%,O
of,O
convulsing,O
mice,O
),O
in,O
group,O
1,O
.,O
Logistic,O
regression,O
analysis,O
revealed,O
that,O
infusion,O
time,O
was,O
significant,O
(,O
p,O
=,O
0,O
.,O
0004,O
;,O
odds,O
ratio,O
=,O
0,O
.,O
974,O
),O
and,O
increasing,O
the,O
IP,O
infusion,O
time,O
of,O
bupropion,B
HCl,I
120,B
mg,I
/,O
kg,I
was,O
associated,O
with,O
a,O
91,O
%,O
reduced,O
odds,O
of,O
convulsions,O
at,O
infusion,O
times,O
of,O
15,O
to,O
90,O
min,O
compared,O
to,O
bolus,O
injection,O
.,O
Further,O
increase,O
in,O
infusion,O
time,O
resulted,O
in,O
further,O
reduction,O
in,O
the,O
odds,O
of,O
convulsions,O
to,O
99,O
.,O
8,O
%,O
reduction,O
at,O
240,O
min,O
.,O
CONCLUSION,O
:,O
In,O
conclusion,O
",",O
the,O
demonstration,O
of,O
an,O
inverse,O
relationship,O
between,O
infusion,O
time,O
of,O
a,O
fixed,O
and,O
convulsive,O
dose,O
of,O
bupropion,B
and,O
the,O
risk,O
of,O
convulsions,O
in,O
a,O
prospective,O
study,O
is,O
novel,O
.,O
Graft,O
-V,O
ers,O
-host,O
disease,O
prophylaxis,O
with,O
everolimus,B
and,O
tacrolimus,B
is,O
associated,O
with,O
a,O
high,O
incidence,O
of,O
sinusoidal,O
obstruction,O
syndrome,O
and,O
microangiopathy,O
:,O
results,O
of,O
the,O
EVTAC,O
trial,O
.,O
A,O
calcineurin,B
inhibitor,O
combined,O
with,O
methotrexate,B
is,O
the,O
standard,O
prophylaxis,O
for,O
graft,O
-,O
versus,O
-,O
All,
patients,
engrafted,
",",
and,
only,
1,
patient,
experienced,
grade,
IV,
mucositis,
.,
Nine,
patients,
(,
37,
%,
),
developed,
acute,
grade,
II,
-,
IV,
GVHD,
",",
and,
11,
of,
17,
evaluable,
patients,
(,
64,
%,
),
developed,
chronic,
extensive,
GVHD,
.,
Transplantation,
-,
associated,
microangiopathy,
(,
TMA,
),
occurred,
in,
7,
patients,
(,
29,
%,
),
",",
with,
2,
cases,
of,
acute,
renal,
failure,
.,
The,O
study,O
was,O
terminated,O
prematurely,O
because,O
an,O
additional,O
6,O
patients,O
(,O
25,O
%,O
),O
developed,O
sinusoidal,...
seen,O
with,O
other,O
regimens,O
.,O
Longitudinal,O
assessment,O
of,O
air,O
conduction,O
audiograms,O
in,O
a,O
phase,O
III,O
clinical,O
trial,O
of,O
difluoromethylornithine,B
and,O
sulindac,B
for,O
prevention,O
of,O
sporadic,O
colorectal,O
adenomas,O
.,O
A,O
phase,O
III,O
clinical,O
trial,O
assessed,O
the,O
recurrence,O
of,O
adenomatous,O
polyps,O
after,O
treatment,O
for,O
36,O
months,O
with,O
difluoromethylornithine,B
(,O
DFMO,B
),O
plus,O
sulindac,B
or,O
matched,O
placebos,O
.,O
Temporary,O
hearing,O
loss,O
is,O
a,O
known,O
toxicity,O
of,O
treatment,O
with,O
DFMO,B
",",O
thus,O
a,O
comprehensive,O
approach,O
was,O
developed,O
to,O
analyze,O
serial,O
air,O
conduction,O
audiograms,O
.,O
The,O
generalized,O
estimating,O
equation,O
method,O
estimated,O
the,O
mean,O
difference,O
between,O
treatment,O
arms,O
with,O
regard,O
to,O
change,O
in,O
air,O
conduction,O
pure,O
tone,O
thresholds,O
while,O
accounting,O
for,O
within,O
-,O
subject,O
correlation,O
due,O
to,O
repeated,O
measurements,O
at,O
frequencies,O
.,O
Based,O
on,O
290,O
subjects,O
",",O
there,O
was,O
an,O
average,O
difference,O
of,O
0,O
.,O
50,O
dB,B
between,O
subjects,O
treated,O
with,O
DFMO,B
plus,O
sulindac,B
compared,O
with,O
those,O
treated,O
with,O
placebo,B
(,O
95,O
%,O
confidence,O
interval,O
",",O
-,O
0,O
.,O
64,O
to,O
1,O
.,O
63,O
dB,B
;,O
P,O
=,O
0,O
.,O
39,O
),O
",",O
adjusted,O
for,O
baseline,O
values,O
",",O
age,O
",",O
and,O
frequencies,O
.,O
In,O
the,O
normal,O
speech,O
range,O
of,O
500,O
to,O
3,O
",",O
000,O
Hz,B
",",O
an,O
estimated,O
difference,O
of,O
0,O
.,O
99,O
dB,O
(,O
-,O
0,O
.,O
17,O
to,O
2,O
.,O
14,O
dB,O
;,O
P,O
=,O
0,O
.,O
09,O
),O
was,O
detected,O
.,O
Dose,O
intensity,O
did,O
not,O
add,O
information,O
to,O
models,O
.,O
There,O
were,O
14,O
of,O
151,O
(,O
9,O
.,O
3,O
%,O
),O
in,O
the,O
DFMO,B
plus,I
sulindac,I
group,I
and,O
4,O
of,O
139,O
(,O
2,O
.,O
9,O
%,O
),O
in,O
the,O
placebo,B
group,I
who,O
experienced,O
at,O
least,O
15,O
dB,O
hearing,O
reduction,O
from,O
baseline,O
in,O
2,O
or,O
more,O
consecutive,O
frequencies,O
across,O
the,O
entire,O
range,O
tested,O
(,O
P,O
=,O
0,O
.,O
02,
),
.,
Follow,
-,
up,
air,
conduction,
done,
at,
least,
6,
months,
after,
end,
of,
treatment,
showed,
an,
adjusted,
mean,
difference,
in,
hearing,
thresholds,
of,
1,
.,
08,
dB,
(,
-,
0,
.,
81,
to,
2,
.,
96,
dB,
;,
P,
=,
0,
.,
26,
),
between,
treatment,
arms,
.,
There,
was,
no,
significant,
difference,
in,
the,
proportion,
of,
subjects,
in,
the,
DFMO,
plus,
sulindac,
group,
who,
experienced,
clinically,
significant,
hearing,
loss,
compared,
with,
the,
placebo,
group,
.,
The,
estimated,
attributable,
risk,
of,
ototoxicity,
from,
exposure,
to,
the,
drug,
is,
8,
.,
4,
%,
(,
95,
%,
confidence,
interval,
",",
-,
2,
.,
0,
%,
to,
18,
.,
8,
%,
;,
P,
=,
0,
.,
12,
),
.,
There,
is,
a,
<,
2,
dB,
difference,
in,
mean,
threshold,
for,
patients,
treated,
with,
DFMO,
plus,
sulindac,
compared,
with,
those,
treated,
with,
placebo,
.,
Proteinase,
3,
-,
antineutrophil,
cytoplasmic,
antibody,
-,
(,
PR3,
-,
ANCA,
),
positive,
necrotizing,
glomerulonephritis,
after,
restarting,
sulphasalazine,
treatment,
.,
A,O
59,O
-,O
year,O
-,O
old,O
woman,O
with,O
ulcerative,O
colitis,O
developed,O
red,O
eyes,O
",",O
pleural,O
effusion,O
...nephritis,B
without,O
deposition,O
of,O
immunoglobulin,O
or,O
complement,O
.,O
Proteinase,
3,
-,
antineutrophil,
cytoplasmic,
antibody,
(,
PR3,
-,
ANCA,
),
titer,
was,
elevated,
at,
183,
ELISA,
units,
(,
EU,
),
in,
sera,
(,
normal,
range,
less,
than,
10,
EU,
),
",",
myeloperoxidase,
-,
ANCA,
was,
negative,
.,
PR3,
-,
ANCA,
titer,
was,
250,
and,
1,
",",
070,
EU,
in,
pleural,
effusions,
on,
right,
and,
left,
side,
",",
respectively,
.,
Although,
cessation,
of,
sulphasalazine,
treatment,
resulted,
in,
improvements,
in,
fever,
",",
red,
eyes,
",",
chest,
pain,
",",
titer,
of,
C,
-,
reactive,
protein,
and,
volume,
of,
the,
pleural,
effusions,
",",
we,
initiated,
steroid,
therapy,
",",
because,
PR3,
-,
ANCA,
titer,
rose,
to,
320,
EU,
",",
eosinophil,
count,
increased,
to,
1,
",",
100,
cells,
/,
microl,
",",
and,
the,
pleural,
effusion,
remained,
.,
One,O
month,O
after,O
steroid,O
therapy,O
",",O
the,O
pleural,O
effusion,O
disappeared,O
",",O
and,O
PR3,B
-,I
ANCA,I
titer,O
normalized,O
3,O
months,O
later,O
.,O
This,O
case,O
suggests,O
that,O
sulphasalazine,O
can,O
induce,O
PR3,B
-,I
ANCA,I
-,I
positive,I
necrotizing,I
glomerulonephritis,I
.,O
Comparison,O
of,O
unilateral,O
pallidotomy,O
and,O
subthalamotomy,O
findings,O
in,O
advanced,O
idiopathic,O
Parkinson,O
',O
s,O
disease,O
.,O
A,O
prospective,O
",",O
randomized,O
",",O
double,O
-,O
blind,O
pilot,O
study,O
to,O
compare,O
the,O
results,O
of,O
stereotactic,O
unilateral,O
pallidotomy,B
and,O
subthalamotomy,B
in,O
advanced,O
idiopathic,O
Parkinson,B
',O
s,O
disease,O
(,O
PD,B
),O
refractory,O
to,O
medical,O
treatment,O
was,O
designed,O
.,O
Ten,O
consecutive,O
patients,O
(,O
mean,O
age,O
",",O
58,O
.,O
4,O
+,O
/,O
-,O
6,O
.,O
8,O
years,O
;,O
7,O
men,O
",",O
3,O
women,O
),O
with,O
similar,O
characteristics,O
at,O
the,O
duration,O
of,O
disease,O
(,O
mean,O
disease,O
time,O
",",O
8,O
.,O
4,O
+,O
/,-
3,O
.,O
5,O
years,O
),O
",",O
disabling,O
motor,O
fluctuations,O
(,B
Hoehn,I
_,I
Yahr,I
stage,I
3,O
Clinical,
evaluation,
included,
the,
use,
of,
the,
Unified,
Parkinson,
',
s,
Disease,
Rating,
Scale,
(,
UPDRS,
),
",",
Hoehn,
_,
Yahr,
score,
and,
Schwab,
England,
activities,
of,
daily,
living,
(,
ADL,
),
score,
in,
',
on,
',
-,
and,
',
off,
',
-,
drug,
conditions,
before,
surgery,
and,
6,
months,
after,
surgery,
.,
There,
was,
statistically,
significant,
improvement,
in,
all,
contralateral,
major,
parkinsonian,
motor,
signs,
in,
all,
patients,
followed,
for,
6,
months,
.,
Levodopa,B
equivalent,O
daily,O
intake,O
was,O
significantly,O
reduced,O
in,O
the,O
STN,B
group,O
.,O
Changes,O
in,O
UPDRS,B
",",O
Hoehn,B
_,I
Yahr,I
and,O
Schwab,B
England,I
ADL,I
scores,O
were,O
similar,O
in,O
both,O
groups,O
.,O
Cognitive,O
functions,O
were,O
unchanged,O
in,O
both,O
groups,O
.,O
Complications,O
were,O
observed,O
in,O
two,O
patients,O
:,O
one,O
had,O
a,O
left,O
homonymous,O
hemianopsia,O
after,O
pallidotomy,O
and,O
another,O
one,B
developed,O
left,O
hemiballistic,O
movements,O
3,O
days,O
after,O
subthalamotomy,O
which,O
partly,O
improved,O
within,O
1,O
month,O
with,O
Valproate,B
1000,O
mg,O
/,O
day,O
.,O
The,
findings,
of,
this,
study,
suggest,
that,
lesions,
of,
the,
unilateral,
STN,
and,
GPi,
are,
equally,
effective,
treatment,
for,
patients,
with,
advanced,
PD,
refractory,
to,
medical,
treatment,
.,
DSMM,
XI,
study,
:,
dose,
definition,
for,
intravenous,
cyclophosphamide,
in,
combination,
with,
bortezomib,
/,
dexamethasone,
for,
remission,
induction,
in,
patients,
with,
newly,
diagnosed,
myeloma,
.,
A,O
clinical,O
trial,O
was,O
initiated,O
to,O
evaluate,O
the,O
recommended,O
dose,O
of,O
cyclophosphamide,B
in,O
combination,O
with,O
bortezomib,B
and,O
dexamethasone,B
as,O
induction,O
treatment,O
before,O
stem,O
cell,O
transplantation,O
for,O
younger,O
patients,O
with,O
newly,O
diagnosed,O
multiple,O
myeloma,O
(,O
MM,B
),O
.,O
Thirty,O
patients,O
were,O
treated,O
with,O
three,O
21,O
-,O
day,O
cycles,O
of,O
bortezomib,B
1,O
.,O
3,
mg,
/,
m,
(,
2,
),
on,
days,
1,
",",
4,
",",
8,
",",
and,
11,
plus,
dexamethasone,
40,
mg,
on,
the,
day,
of,
bortezomib,
injection,
and,
the,
day,
after,
plus,
cyclophosphamide,
at,
900,
",",
1,
",",
200,
",",
or,
1,
",",
500,
mg,
/,
m,
(,
2,
),
on,
day,
1,
.,
The,
maximum,
tolerated,
dose,
of,
cyclophosphamide,
was,
defined,
as,
900,
mg,
/,
m,
(,
2,
),
.,
At,
this,
dose,
level,
",",
92,
%,
of,
patients,
achieved,
at,
least,
a,
partial,
response,
.,
The,O
overall,O
response,O
rate,O
[,O
complete,B
response,I
(,I
CR,I
),I
plus,O
partial,B
response,I
(,I
PR,I
),I
],O
across,O
all,O
dose,O
levels,O
was,O
77,O
%,O
",",O
with,O
a,O
10,O
%,O
CR,B
rate,O
.,O
No,O
patient,O
experienced,O
progressive,O
disease,O
.,O
The,O
most,O
frequent,O
adverse,O
events,O
were,O
hematological,B
and,O
gastrointestinal,B
toxicities,O
as,O
well,O
as,O
neuropathy,B
.,O
The,O
results,O
suggest,O
that,O
bortezomib,B
in,O
combination,O
with,O
cyclophosphamide,B
at,O
900,O
mg,O
/,O
m,O
(,O
2,O
),O
and,O
dexamethasone,O
is,O
an,O
effective,O
induction,O
treatment,O
for,O
patients,O
with,O
newly,O
diagnosed,O
MM,B
that,O
warrants,O
further,O
investigation,O
.,O
Naloxone,B
reversal,O
of,O
hypotension,O
due,O
to,O
captopril,B
overdose,O
.,O
The,O
hemodynamic,O
effects,O
of,O
captopril,B
and,O
other,O
angiotensin,O
-,O
converting,O
enzyme,O
inhibitors,O
may,O
be,O
mediated,O
by,O
the,O
endogenous,O
opioid,O
system,O
.,O
The,O
opioid,B
antagonist,O
naloxone,B
has,O
been,O
shown,O
to,O
block,O
or,O
reverse,O
the,O
hypotensive,O
actions,O
of,O
captopril,B
.,O
We,O
report,O
a,O
case,O
of,O
an,O
intentional,O
captopril,B
overdose,O
",",O
manifested,O
by,O
marked,O
hypotension,O
",",O
that,O
resolved,O
promptly,O
with,O
the,O
administration,O
of,O
naloxone,B
.,O
To,O
our,O
knowledge,O
",",O
this,O
is,O
the,O
first,O
reported,O
case,O
of,O
captopril,B
-,I
induced,I
hypotension,I
treated,O
with,O
naloxone,B
.,O
Our,O
experience,O
demonstrates,O
a,O
possible,O
role,O
of,O
naloxone,B
in,O
the,O
reversal,O
of,O
hypotension,O
resulting,O
from,O
captopril,B
.,O
Identification,O
of,O
a,O
simple,O
and,O
sensitive,O
microplate,O
method,O
for,O
the,O
detection,O
of,O
oversulfated,B-Chemical
chondroitin,I-Chemical
sulfate,I-Chemical
in,O
heparin,B-Chemical
products,O
.,O
Heparin,B-Chemical
is,O
a,O
commonly,O
implemented,O
anticoagulant,O
used,O
to,O
treat,O
critically,O
ill,O
patients,O
.,O
Recently,O
",",O
a,O
number,O
of,O
commercial,O
lots,O
of,O
heparin,B-Chemical
products,O
were,O
found,O
to,O
be,O
contaminated,O
with,O
an,O
oversulfated,B-Chemical
chondroitin,I-Chemical
sulfate,I-Chemical
(,O
OSCS,B-Chemical
),O
derivative,O
that,O
could,O
elicit,O
a,O
hypotensive,O
response,O
in,O
pigs,O
following,O
a,O
single,O
high,O
-,O
dose,O
infusion,O
.,O
Using,
both,
contaminated,
heparin,
products,
and,
the,
synthetically,
produced,
derivative,
",",
we,
showed,
that,
the,
OSCS,
produces,
dose,
-,
dependent,
hypotension,
in,
pigs,
.,
The,
no,
observed,
effect,
level,
(,
NOEL,
),
for,
this,
contaminant,
appears,
to,
be,
approximately,
1mg,
/,
kg,
",",
corresponding,
to,
a,
contamination,
level,
of,
approximately,
3,
%,
.,
We,O
also,O
demonstrated,O
that,O
OSCS,B
can,O
be,O
identified,O
in,O
heparin,O
products,O
using,O
a,O
simple,O
",",O
inexpensive,O
",",O
commercially,O
available,O
heparin,O
enzyme,O
immunoassay,O
(,O
EIA,B
),O
kit,O
that,O
has,O
a,O
limit,O
of,O
detection,O
of,O
approximately,O
0,O
.,O
1,O
%,O
",",O
well,O
below,O
the,O
NOEL,O
.,O
This,O
kit,O
may,O
provide,O
a,O
useful,O
method,O
to,O
test,O
heparin,O
products,O
for,O
contamination,O
with,O
oversulfated,O
GAG,B
derivatives,O
.,O
5,O
flourouracil,B
-,O
induced,O
apical,O
ballooning,O
syndrome,O
:,O
a,O
case,O
report,O
.,O
The,O
apical,O
ballooning,O
Cardiotoxicity,
is,
not,
an,
uncommon,
adverse,
effect,
of,
chemotherapeutic,
agents,
.,
However,
",",
there,
are,
no,
reports,
of,
ABS,
secondary,
to,
chemotherapeutic,
agents,
.,
We,
describe,
the,
case,
of,
a,
woman,
who,
developed,
the,
syndrome,
after,
chemotherapy,
for,
metastatic,
cancer,
.,
A,
79,
-,
year,
-,
old,
woman,
presented,
with,
typical,
ischemic,
chest,
pain,
",",
elevated,
cardiac,
enzymes,
with,
significant,
ST,
-,
segment,
abnormalities,
on,
her,
electrocardiogram,
.,
She,O
underwent,O
recent,O
chemotherapy,B
with,O
fluorouracil,B
for,O
metastatic,O
colorectal,O
cancer,O
.,O
Echocardiography,O
revealed,O
a,O
...vealed,O
no,O
obstructive,O
coronary,O
lesions,O
.,O
The,O
patient,O
was,O
stabilized,O
with,O
medical,O
therapy,O
.,O
Four,O
weeks,O
later,O
she,O
remained,O
completely,O
asymptomatic,O
.,O
Echocardiogram,O
revealed,O
a,O
normal,O
ejection,O
fraction,O
and,O
a,O
resolution,O
of,O
the,O
apical,O
akinesis,O
.,O
Pathogenetic,O
mechanisms,O
of,O
cardiac,O
complications,O
in,O
cancer,O
patients,O
undergoing,O
chemotherapy,O
include,O
coronary,B
vasospasm,I
",",O
endothelial,O
damage,O
and,O
consequent,O
thrombus,O
formation,O
.,O
In,O
our,O
patient,O
",",O
both,O
supraphysiologic,B
levels,I
of,I
plasma,I
catecholamines,I
and,O
stress,O
related,O
neuropeptides,O
Warfarin,B
-,O
associated,O
intracerebral,O
hemorrhage,O
(,O
W,B
-,I
ICH,I
),O
is,O
a,O
severe,O
type,O
of,O
stroke,O
.,O
There,O
is,O
no,O
consensus,O
on,O
the,O
optimal,O
treatment,O
for,O
W,B
-,I
ICH,I
.,O
Using,O
a,O
mouse,O
model,O
",",O
we,O
tested,O
whether,O
the,O
rapid,O
reversal,O
of,O
anticoagulation,O
using,O
human,O
prothrombin,O
complex,O
concentrate,O
(,O
PCC,B
),O
can,O
reduce,O
hemorrhagic,O
blood,O
volume,O
.,O
Male,
CD,
-,
1,
mice,
were,
treated,
with,
warfarin,
(,
2,
mg,
/,
kg,
over,
24,
h,
),
",",
resulting,
in,
a,
mean,
(,
+,
/,
-,
s,
.,
d,
.,
),
International,
Normalized,
Ratio,
of,
3,
.,
5,
+,
/,
-,
0,
.,
9,
.,
First,
",",
we,
showed,
that,
an,
intravenous,
administration,
of,
human,
PCC,
rapidly,
reversed,
anticoagulation,
in,
mice,
.,
Second,
",",
a,
stereotactic,
injection,
of,
collagenase,
was,
administered,
to,
induce,
hemorrhage,
in,
the,
right,
striatum,
.,
Forty,O
-,O
five,O
minutes,O
later,O
",",O
the,O
animals,O
were,O
randomly,O
treated,O
with,O
PCC,B-Chemical
(,O
100,O
U,O
/,O
kg,O
),O
or,O
saline,B-Chemical
i,O
.,O
v,O
.,O
(,O
n,O
=,O
12,O
per,O
group,O
),O
.,O
Twenty,O
-,O
four,O
hours,O
after,O
hemorrhage,O
induction,O
",",O
hemorrhagic,O
blood,O
volume,O
was,O
quantified,O
using,O
a,O
photometric,O
hemoglobin,O
assay,O
.,O
The,O
mean,O
hemorrhagic,O
blood,O
volume,O
was,O
reduced,O
in,O
PCC,B-Chemical
-,I
treated,I
animals,I
(,O
6,O
5,
+,
/,
-,
3,
.,
1,
microL,
),
compared,
with,
saline,
controls,
(,
15,
.,
3,
+,
/,
-,
11,
.,
2,
microL,
",",
P,
=,
0,
.,
015,
),
.,
In,
the,
saline,
group,
",",
45,
%,
of,
the,
mice,
developed,
large,
hematomas,
(,
i,
.,
e,
.,
",",
>,
15,
microL,
),
.,
In,
contrast,
",",
such,
extensive,
lesions,
were,
never,
found,
in,
the,
PCC,
group,
.,
We,
provide,
experimental,
data,
suggesting,
PCC,
to,
be,
an,
effective,
acute,
treatment,
for,
W,
-,
ICH,
in,
terms,
of,
reducing,
hemorrhagic,
blood,
volume,
.,
Future,O
studies,O
are,O
needed,O
to,O
assess,O
the,O
therapeutic,O
potential,O
emerging,O
from,O
our,O
finding,O
for,O
human,O
W,B
-,I
ICH,I
.,O
Long,O
term,O
hormone,O
therapy,O
for,O
perimenopausal,O
and,O
postmenopausal,O
women,O
.,O
BACKGROUND,O
:,O
Hormone,B
therapy,I
(,O
HT,B
),O
is,O
widely,O
used,O
for,O
controlling,O
menopausal,O
symptoms,O
and,O
has,O
also,O
been,O
used,O
for,O
the,O
management,O
and,O
prevention,O
of,O
cardiovascular,O
disease,O
",",O
osteoporosis,O
and,O
dementia,O
in,O
older,O
women,O
.,O
This,
is,
an,
updated,
version,
of,
the,
original,
Cochrane,
review,
first,
published,
in,
2005,
.,
OBJECTIVES,
:,
To,
assess,
the,
effect,
of,
long,
-,
term,
HT,
on,
mortality,
",",
cardiovascular,
outcomes,
",",
cancer,
",",
gallbladder,
disease,
",",
cognition,
",",
fractures,
and,
quality,
of,
life,
.,
SEARCH,
STRATEGY,
:,
We,
searched,
the,
following,
databases,
to,
November,
2007,
:,
Trials,
Register,
of,
the,
Cochrane,
Menstrual,
Disorders,
and,
Subfertility,
Group,
",",
Cochrane,
Central,
Register,
of,
Controlled,
Trials,
",",
MEDLINE,
",",
EMBASE,
",",
Biological,
Abstracts,
.,
Also,O
relevant,O
non,O
-,O
indexed,O
journals,O
and,O
conference,O
abstracts,O
.,O
SELECTION,O
CRITERIA,O
:,O
Randomised,O
double,O
-,O
blind,O
trials,O
of,O
HT,O
versus,O
placebo,O
",",O
taken,O
for,O
at,O
least,O
one,O
year,O
by,O
perimenopausal,O
or,O
postmenopausal,O
women,O
.,O
HT,B
included,O
oestrogens,B
",",O
with,O
or,O
without,O
progestogens,B
",",O
via,O
oral,O
",",O
transdermal,O
",",O
subcutaneous,O
or,O
transnasal,O
routes,O
.,O
DATA,O
COLLECTION,O
AND,O
ANALYSIS,O
:,O
Two,O
authors,O
independently,O
assessed,O
trial,O
quality,O
and,O
extracted,O
data,O
.,O
Long,O
-,O
term,O
oestrogen,B
-,I
only,I
HT,I
significantly,O
increased,O
the,O
risk,O
of,O
venous,B
thrombo,I
-,I
embolism,I
",",O
stroke,B
and,O
gallbladder,B
disease,I
(,O
after,O
one,O
to,O
two,O
years,O
",",O
three,O
years,O
and,O
seven,O
years,O
',O
use,O
respectively,O
),O
",",O
but,O
did,O
not,O
significantly,O
increase,O
the,O
risk,O
of,O
breast,B
cancer,I
.,O
The,O
only,O
statistically,O
significant,O
benefits,O
of,O
HT,B
were,O
a,O
decreased,O
incidence,O
of,O
fractures,B
and,O
(,O
for,O
combined,O
HT,I
),I
colon,O
cancer,I
",",O
with,O
long,O
-,O
term,O
use,O
.,O
Among,O
women,O
aged,O
over,O
65,O
who,O
were,O
relatively,O
healthy,O
(,O
i,O
.,O
e,O
.,O
generally,O
fit,O
",",O
without,O
overt,O
disease,O
),O
and,O
taking,O
continuous,O
combined,O
HT,B
",",O
there,O
was,O
a,O
statistically,O
significant,O
increase,O
in,O
the,O
incidence,O
of,O
dementia,O
.,O
Among,O
women,O
with,O
cardiovascular,O
disease,O
",",O
long,O
-,O
term,O
use,O
of,O
combined,O
continuous,O
HT,B
significantly,O
increased,O
the,O
risk,O
of,O
venous,O
thrombo,O
-,O
embolism,O
.,O
One,O
trial,O
analysed,O
subgroups,O
of,O
2839,O
relatively,O
healthy,O
50,B
to,O
59,B
year,I
old,I
women,I
taking,O
combined,O
continuous,O
HT,B
and,O
1637,O
taking,O
oestrogen,B
-,I
only,I
HT,I
",",O
versus,O
similar,O
-,O
sized,O
placebo,O
groups,O
.,O
The,O
only,O
significantly,O
increased,O
risk,O
reported,O
was,O
for,O
venous,O
thrombo,O
-,O
embolism,O
in,O
women,O
taking,O
combined,O
continuous,O
HT,B
:,O
their,O
absolute,O
risk,O
remained,O
low,O
",",O
at,O
less,O
than,O
1,O
/,O
500,O
.,O
However,O
",",O
this,O
study,O
was,O
not,O
powered,O
to,O
detect,O
differences,O
between,O
groups,O
of,O
younger,O
women,O
.,O
AUTHORS,O
',O
CONCLUSIONS,O
:,O
HT,O
is,O
not,O
indicated,O
for,O
the,O
routine,O
management,O
of,O
chronic,O
disease,O
.,O
We,O
need,O
more,O
evidence,O
on,O
the,O
safety,O
of,O
HT,O
for,O
menopausal,O
symptom,O
control,O
",",O
though,O
short,O
-,I
term,I
use,I
appears,O
to,O
be,O
relatively,O
safe,O
for,O
healthy,O
younger,O
women,O
.,O
Acute,O
renal,O
failure,O
in,O
patients,O
with,O
AIDS,O
on,O
tenofovir,B
while,O
receiving,O
prolonged,O
vancomycin,B
course,O
Vancomycin,B
nephrotoxicity,O
is,O
infrequent,O
but,O
may,O
result,O
from,O
coadministration,O
with,O
a,O
nephrotoxic,O
agent,O
.,O
Clinicians,O
should,O
be,O
aware,O
that,O
tenofovir,O
may,O
raise,O
the,O
risk,O
of,O
renal,O
failure,O
during,O
prolonged,O
administration,O
of,O
vancomycin,O
.,O
Recurrent,O
dysosmia,B
induced,O
by,O
pyrazinamide,B
.,O
Pyrazinamide,B
can,O
have,O
adverse,O
effects,O
such,O
as,O
hepatic,O
toxicity,O
",",O
hyperuricemia,O
or,O
digestive,O
disorders,O
.,O
In,O
rare,O
cases,O
",",O
alterations,O
in,O
taste,O
and,O
smell,O
function,O
have,O
been,O
reported,O
for,O
pyrazinamide,B
when,O
combined,O
with,O
other,O
drugs,O
.,O
We,O
report,O
a,O
case,O
of,O
reversible,O
olfactory,O
disorder,O
related,O
to,O
pyrazinamide,B
in,O
a,O
woman,O
",",O
with,O
a,O
positive,O
rechallenge,O
.,O
The,O
patient,O
presented,O
every,O
day,O
a,O
sensation,O
of,O
smelling,O
something,O
burning,O
15,O
min,O
after,O
drug,O
intake,O
.,O
Dysosmia,O
disappeared,O
completely,O
after,O
pyrazinamide,B
withdrawal,O
and,O
recurred,O
after,O
its,O
rechallenge,O
.,O
The,O
case,O
wa...loan,B
-,I
induced,I
polyuria,O
.,O
Cyclooxygenase,B
-,I
2,I
activity,O
is,O
required,O
for,O
the,O
development,O
of,O
lithium,O
However,O
",",O
the,O
involvement,O
of,O
a,O
specific,O
",",O
terminal,O
prostaglandin,B
(,I
PG,I
),I
isomerase,O
has,O
not,O
been,O
evaluated,O
.,O
The,O
present,O
study,O
was,O
undertaken,O
to,O
assess,O
lithium,O
-,O
induced,O
polyuria,O
in,O
mice,O
deficient,O
in,O
microsomal,B
prostaglandin,I
E,I
synthase,I
-,I
1,I
(,I
mPGES,I
-,I
1,I
),I
.,O
A,O
2,O
-,O
wk,O
administration,O
of,O
LiCl,O
(,I
4,I
mmol,I
.,I
kg,I
(,I
-1,I
),I
.,I
day,
(,
-,
1,
),
ip,
),
in,
mPGES,
-,
1,
+,
/,
+,
mice,
led,
to,
a,
marked,
polyuria,
with,
hyposmotic,
urine,
.,
This,
was,
associated,
with,
elevated,
renal,
mPGES,
-,
1,
protein,
expression,
and,
increased,
urine,
PGE,
(,
2,
),
excretion,
.,
In,
contrast,
",",
mPGES,
-,
1,
-,
/,
-,
mice,
were,
largely,
resistant,
to,
lithium,
-,
induced,
polyuria,
and,
a,
urine,
concentrating,
defect,
",",
accompanied,
by,
nearly,
complete,
blockade,
of,
high,
urine,
PGE,
(,
2,
),
and,
cAMP,
output,
.,
Immunoblotting,O
",",O
immunohistochemistry,O
",",O
and,O
quantitative,O
(,O
q,O
),O
RT,O
-,O
PCR,O
consistently,O
detected,O
a,O
si...C detected similar patterns of changes in,O
AQP2,B
mRNA,O
in,O
the,O
medulla,O
but,O
not,O
in,O
the,O
cortex,O
.,O
Similarly,O
",",O
the,O
total,O
protein,O
abundance,O
of,O
the,O
Na,B
-,I
K,I
-,I
2Cl,B
cotransporter,O
(,O
NKCC2,B
),O
in,O
the,O
medulla,O
but,O
not,O
in,O
the,O
cortex,O
of,O
the,O
+,O
/,O
+,O
mice,O
was,O
significantly,O
reduced,O
by,O
lithium,O
treatment,O
.,O
In,O
contrast,O
",",O
the,O
dowregulation,O
of,O
renal,O
medullary,O
NKCC2,B
expression,O
was,O
significantly,O
attenuated,O
in,O
the,O
-,O
/,O
-,O
mice,O
.,O
We,O
conclude,O
that,O
mPGES,B
-,I
1,I
-,I
derived,O
PGE,B
(,O
2,O
),O
mediates,O
lithium,O
-,O
induced,O
polyuria,O
likely,O
via,O
inhibition,O
of,O
AQP2,B
and,O
NKCC2,B
expression,O
.,O
Preservation,O
of,O
renal,O
blood,O
flow,O
during,O
hypotension,O
induced,O
with,O
fenoldopam,O
in,O
dogs,O
.,O
The,O
introduction,O
of,O
drugs,O
that,O
could,O
induce,O
hypotension,O
with,O
different,O
pharmacological,O
actions,O
would,O
be,O
advantageous,O
because,O
side,O
effects,O
unique,O
to,O
a,O
specific,O
drug,O
could,O
be,O
minimized,O
by,O
selecting,O
appropriate,O
therapy,O
.,O
Specific,O
dopamine,B-Chemical
-,I-Chemical
1,I-Chemical
",",O
(,O
DA1,B-Chemical
),O
and,O
dopamine,B-Chemical
-,I-Chemical
2,I-Chemical
(,O
DA2,B-Chemical
),O
receptor,O
agonists,O
are,O
now,O
under,O
clinical,O
investigation,O
.,O
Fenoldopam,B-Chemical
mesylate,I-Chemical
is,O
a,O
specific,O
DA1,B-Chemical
receptor,O
agonist,O
that,O
lowers,O
blood,O
pressure,O
by,O
vasodilatation,O
.,O
The,O
hypothesis,O
that,O
fenoldopam,B-Chemical
could,O
be,O
used,O
to,O
induce,O
hypotension,O
and,O
preserve,O
blood,O
flow,O
to,O
the,O
kidney,O
was,O
tested,O
.,O
Systemic,O
aortic,B
blood,I
pressure,I
and,O
renal,B
blood,I
flow,I
were,O
measured,O
continuously,O
with,O
a,O
carotid,B
arterial,I
Mean,O
arterial,O
pressure,O
was,O
decreased,O
30,O
+,O
/,O
-,O
8,O
per,O
cent,O
from,O
control,O
with,O
infusion,O
01,
),
.,
Sodium,
nitroprusside,
is,
a,
non,
-,
selective,
arteriolar,
and,
venous,
vasodilator,
that,
can,
produce,
redistribution,
of,
blood,
flow,
away,
from,
the,
kidney,
during,
induced,
hypotension,
.,
Fenoldopam,
is,
a,
selective,
dopamine,
-,
1,
(,
DA1,
),
receptor,
agonist,
that,
causes,
vasodilatation,
to,
the,
kidney,
and,
other,
organs,
with,
DA1,
receptors,
and,
preserves,
blood,
flow,
to,
the,
kidney,
during,
induced,
hypotension,
.,
Seizures,O
associated,O
with,O
levofloxacin,B
:,O
case,O
presentation,O
and,O
literature,O
review,O
.,O
PURPOSE,O
:,O
We,O
present,O
...,O
induced,O
seizures,O
.,O
METHODS,O
:,O
Several,O
biomedical,O
databases,O
were,O
searched,O
including,O
MEDLINE,B
",",O
Cochrane,B
and,O
Ovid,B
.,O
The,O
Drug,O
-,O
drug,O
interactions,O
related,O
to,O
the,O
inhibition,O
of,O
CYP1A2,B
by,O
levofloxacin,B
are,O
likely,O
involved,O
Dextran,B
-,O
etodolac,B
conjugates,O
:,O
synthesis,O
",",O
in,O
vitro,O
and,O
in,O
vivo,O
evaluation,O
.,O
Etodolac,B
(,O
E,O
),O
",",O
is,O
a,O
non,O
-,O
narcotic,O
analgesic,O
and,O
antiinflammatory,O
drug,O
.,O
A,O
biodegradable,O
polymer,O
dextran,B
has,O
been,O
utilized,O
as,O
a,O
carrier,O
for,O
synthesis,O
of,O
etodolac,O
-,O
dextran,O
conjugates,O
(,O
ED,O
),O
to,O
improve,O
its,O
aqueous,O
solubility,O
and,O
reduce,O
gastrointestinal,O
side,O
effects,O
.,O
An,O
activated,O
moiety,O
",",O
i,O
.,O
e,O
.,O
N,B
-,I
acylimidazole,I
derivative,I
of,O
etodolac,B
(,O
EAI,B
),O
",",O
was,O
condensed,O
with,O
the,O
polysaccharide,O
polymer,O
dextran,O
of,O
different,O
molecular,O
weights,O
(,O
40000,O
",",O
60000,O
",",O
110000,O
and,O
200000,O
),O
.,O
IR,O
spectral,O
data,O
confirmed,O
formation,O
of,O
ester,O
bonding,O
in,O
the,O
conjugates,O
.,O
Etodolac,O
contents,O
were,O
evaluated,O
by,O
UV,O
-,O
spectrophotometric,O
analysis,O
.,O
The,O
molecular,O
weights,O
were,O
determined,O
by,O
measuring,O
viscosity,O
using,O
the,O
Mark,B
-,I
Howink,I
-,I
Sakurada,I
equation,I
.,O
In,O
vitro,O
hydrolysis,O
of,O
ED,B
was,O
done,O
in,O
aqueous,O
buffers,O
(,O
pH,B
1,I
.,I
2,I
",",I
7,I
.,I
4,I
",",I
9,I
),I
and,O
in,O
80,O
%,O
(,O
v,B
/,I
v,I
),I
human,O
plasma,O
(,O
pH,B
7,I
.,I
4,I
),I
.,O
At,O
pH,B
9,I
",",I
a,O
higher,O
rate,O
of,O
etodolac,O
release,O
from,O
ED,B
was,O
observed,O
as,O
compared,O
to,O
aqueous,O
buffer,O
of,O
pH,B
7,I
.,I
4,O
and,O
80,O
%,O
human,O
plasma,O
(,O
pH,O
7,O
.,O
4,O
),O
",",O
following,O
first,O
-,O
order,O
kinetics,O
.,O
In,O
vivo,O
investigations,O
were,O
performed,O
in,O
animals,O
.,O
Acute,O
analgesic,O
and,O
antiinflammatory,O
activities,O
were,O
ascertained,O
using,O
acetic,B
acid,I
induced,O
writhing,O
model,O
(,O
mice,O
),O
and,O
carrageenan,O
-,O
induced,O
rat,O
paw,O
edema,O
model,O
",",O
respectively,O
.,O
In,O
comparison,O
to,O
control,O
",",O
E,B
and,O
ED1,B
-,I
ED4,I
showed,O
highly,O
significant,O
analgesic,O
and,O
antiinflammatory,O
activities,O
(,O
p,O
<,O
0,O
.,O
001,O
),O
.,O
Biological,O
evaluation,O
suggested,O
that,O
conjugates,O
(,O
ED1,B
-,I
ED4,I
),I
retained,O
comparable,O
analge...n,O
-,O
pilocarpine,O
on,O
animal,O
models,O
.,O
This,O
study,O
was,O
designed,O
to,O
evaluate,O
the,O
effects,O
of,O
pilocarpine,B-Chemical
and,O
explore,O
the,O
underlying,O
ionic,O
mechanism,O
",",O
using,O
both,O
aconitine,B-Chemical
-,O
induced,O
rat,O
and,O
ouabain,B-Chemical
-,O
induced,O
guinea,O
pig,O
arrhythmia,O
models,O
.,O
Confocal,O
microscopy,O
was,O
used,O
to,O
measure,O
intracellular,O
free,O
-,O
calcium,O
concentrations,O
(,O
[,O
C,a
(,O
2,O
+,O
),O
],O
(,O
i,O
),O
),O
in,O
isolated,O
myocytes,O
.,O
The,O
current,O
data,O
showed,O
that,O
pilocarpine,B
significantly,O
delayed,O
onset,O
of,O
arrhythmias,O
",",O
decreased,O
the,O
time,O
Moreover,O
",",O
M,B
(,O
3,I
),O
-,O
muscarinic,B
acetylcholine,I
receptor,I
(,O
mAChR,B
),O
antagonist,O
4,B
-,I
DAMP,I
(,O
4,B
-,I
diphenylacetoxy,I
-,I
N,I
-,I
methylpiperidine,I
-,I
methiodide,I
),O
partially,O
abolished,O
the,O
beneficial,O
effects,O
of,O
pilocarpine,O
.,O
These,O
data,O
suggest,O
that,O
pilocarpine,O
produced,O
antiarrhythmic,O
actions,O
on,O
arrhythmic,O
rat,O
and,O
guinea,O
pig,O
models,O
induced,O
by,O
aconitine,O
or,O
ouabain,O
via,O
stimulating,O
the,O
cardiac,O
M,B
(,O
3,I
),O
-,O
mAChR,B
.,O
The,O
mechanism,O
may,O
be,O
related,O
to,O
the,O
improvement,O
of,O
Ca,B
(,B
2,I
+,I
),I
handling,O
.,O
Effect,O
of,O
Hibiscus,B
rosa,I
sinensis,I
on,O
reserpine,O
-,O
induced,O
neurobehavioral,O
and,O
biochemical,O
alterations,O
in,O
rats,O
.,O
Effect,O
of,O
methanolic,O
extract,O
of,O
Hibiscus,B
rosa,I
sinensis,I
(,B
100,I
-,I
300,I
mg,I
/,I
kg,I
),I
was,O
studied,O
on,O
reserpine,O
-,O
induced,O
orofacial,O
dyskinesia,O
and,O
neurochemical,O
alterations,O
.,O
The,O
rats,O
were,O
treated,O
with,O
intraperitoneal,B
reserpine,I
(,O
1,B
mg,I
/,I
kg,I
",",O
ip,O
),O
for,O
3,B
days,I
every,O
other,O
day,O
.,O
On,O
day,O
5,B
",",O
vacuous,O
chewing,O
movements,O
and,O
tongue,O
protrusions,O
were,O
counted,O
for,O
5,B
min,I
.,O
Reserpine,O
treated,O
rats,O
significantly,O
developed,O
vacuous,O
chewing,O
movements,O
and,O
tongue,O
protrusions,O
however,O
",",O
coadministration,O
of,O
Hibiscus,B
rosa,I
sinensis,I
roots,I
extract,I
(,I
100,I
",",O
200,B
and,I
300,I
mg,I
/,I
kg,I
",",O
per,O
orally,O
),O
attenuated,O
the,O
effects,O
.,O
Biochemical,
analysis,
of,
brain,
revealed,
that,
the,
reserpine,
treatment,
significantly,
increased,
lipid,
peroxidation,
and,
decreased,
levels,
of,
superoxide,
dismutase,
(,
SOD,
),
",",
catalase,
(,
CAT,
),
and,
glutathione,
reductase,
(,
GSH,
),
",",
an,
index,
of,
oxidative,
stress,
process,
.,
Coadministration,
of,
extract,
significantly,
reduced,
the,
lipid,
peroxidation,
and,
reversed,
the,
decrease,
in,
brain,
SOD,
",",
CAT,
and,
GSH,
levels,
.,
The,O
results,O
of,O
the,O
present,O
study,O
suggested,O
that,O
Hibiscus,B
rosa,I
sinensis,I
had,O
a,O
protective,O
role,O
against,...
in,O
dynamic,O
responses,O
of,O
blood,O
vessels,O
The,
new,
approach,
to,
ex,
vivo,
blood,
vessel,
experiments,
in,
which,
not,
only,
the,
end,
points,
of,
vessels,
response,
within,
the,
time,
interval,
is,
considered,
",",
but,
also,
dynamics,
of,
this,
response,
",",
was,
used,
in,
this,
paper,
.,
Our,
results,
confirm,
the,
alteration,
in,
dynamic,
response,
of,
blood,
vessels,
during,
the,
change,
of,
pressure,
in,
gentamicin,
-,
treated,
animals,
.,
The,O
beneficial,O
effects,O
of,O
vitamin,B
C,I
administration,O
to,O
gentamicin,B
-,I
treated,I
animals,I
are,O
also,O
confirmed,O
...ute,O
pressure,O
change,O
in,O
gentamicin,B
-,I
treated,I
animals,I
(,O
8,O
.,O
07,O
+,O
/,O
-,O
1,O
.,O
7,O
s,O
vs,O
.,O
5,O
.,O
64,O
+,O
/,O
-,O
0,O
.,O
18,O
s,O
),O
.,O
Vitamin,B
C,I
administration,O
induced,O
slowdown,O
of,O
pressure,O
change,O
back,O
to,O
the,O
control,O
values,O
.,O
The,O
pressure,O
dynamic,O
properties,O
",",O
quantitatively,O
defined,O
by,O
comparative,O
pressure,O
dynamic,O
and,O
total,O
pressure,O
dynamic,O
",",O
confirm,O
the,O
alteration,O
in,O
dynamic,O
response,O
of,O
blood,O
vessels,O
during,O
the,O
change,O
of,O
pressure,O
in,O
gentamicin,O
-,O
treated,O
animals,O
and,O
beneficial,O
effects,O
of,O
vitamin,O
C,I
administration,O
.,O
Reversible,O
myocardial,B
hypertrophy,I
induced,O
by,O
tacrolimus,B
in,O
a,O
pediatric,O
heart,O
transplant,O
recipient,O
:,O
case,O
report,O
.,O
Tacrolimus,B
is,O
a,O
potent,O
immunosuppressant,O
that,O
is,O
frequently,O
used,O
in,O
organ,O
transplantation,O
.,O
However,O
",",O
adverse,O
effects,O
include,O
cardiac,B
toxicity,I
.,O
Herein,O
we,O
describe,O
transient,O
myocardial,B
hypertrophy,I
induced,O
by,O
tacrolimus,B
after,O
heart,O
transplantation,O
.,O
The,O
hypertrophy,O
caused,O
no,O
clinical,O
symptoms,O
but,O
was,O
noted,O
because,O
of,O
elevation,O
of,O
plasma,O
brain,O
The,O
blood,O
tacrolimus,B
concentration,O
was,O
higher,O
than,O
usual,O
at,O
that,O
time,O
;,O
thus,O
",",O
tacrolimus,B
dosage,O
was,O
reduced,O
.,O
Myocardial,O
hypertrophy,O
completely,O
resolved,O
upon,O
reducing,O
the,O
target,O
concentration,O
of,O
tacrolimus,B
and,O
did,O
not,O
recur,O
",",O
as,O
confirmed,O
at,O
echocardiography,O
and,O
myocardial,O
biopsy,O
.,O
Thus,O
",",O
we,O
conclude,O
that,O
tacrolimus,B
induces,O
reversible,O
myocardial,O
hypertrophy,O
.,O
In,O
patients,O
receiving,O
tacrolimus,B
therapy,O
",",O
blood,O
concentration,O
should,O
be,O
carefully,O
controlled,O
and,O
extreme,O
attention,O
paid,O
to,O
cardiac,O
involvement,O
.,O
Nimodipine,B
prevents,O
memory,O
impairment,O
caused,O
by,O
nitroglycerin,B
-,I
induced,I
hypotension,I
in,O
adult,O
mice,O
.,O
BACKGROUND,O
:,O
Hypotension,O
and,O
a,O
resultant,O
decrease,O
in,O
cerebral,O
blood,O
flow,O
have,O
been,O
implicated,O
in,O
the,O
development,O
of,O
cognitive,O
dysfunction,O
.,O
We,O
tested,O
the,O
hypothesis,O
that,O
nimodipine,B
(,O
NIMO,I
),O
administered,O
at,O
the,O
onset,O
of,O
nitroglycerin,B
(,O
NTG,I
),O
-,O
induced,O
hypotension,O
would,O
preserve,O
long,O
-,O
term,O
associative,O
memory,O
.,O
METHODS,O
:,O
The,O
passive,O
avoidance,O
(,O
PA,B
),O
paradigm,O
was,O
used,O
to,O
assess,O
memory,O
retention,O
.,O
For,O
PA,B
training,O
",",O
latencies,O
(,O
seconds,O
),O
were,O
recorded,O
for,O
entry,O
from,O
a,O
suspended,O
platform,O
into,O
a,O
Plexiglas,O
tube,O
where,O
a,O
shock,O
was,O
automatically,O
delivered,O
.,O
Latencies,O
were,O
recorded,O
48,O
h,O
later,O
for,O
a,O
testing,O
trial,O
.,O
Ninety,O
-,O
six,O
Swiss,O
-,O
Webster,O
RESULTS,O
:,O
All,O
groups,O
exhibited,O
similar,O
training,O
latencies,O
(,O
17,O
.,O
0,O
+,O
/,O
-,O
4,O
.,O
6,O
s,O
),O
.,O
Mice,O
subjected,O
to,O
hypotensive,O
episodes,O
showed,O
a,O
significant,O
decrease,O
in,O
latency,O
time,O
(,O
178,O
+,O
/,O
-,O
156,O
s,O
),O
compared,O
with,O
those,O
injected,O
with,O
saline,B
",",O
NTG,B
+,O
NIMO,B
",",O
or,O
delayed,B
NTG,I
(,O
580,O
+,O
/,O
-,O
81,O
s,O
",",O
557,O
+,O
/,O
-,O
67,O
s,O
",",O
and,O
493,O
+,O
/,O
-,O
146,O
s,O
",",O
respectively,O
),O
.,O
A,O
Kruskal,O
-,O
Wallis,O
1,O
-,O
way,O
analysis,O
of,O
variance,O
indicated,O
a,O
significant,O
difference,O
among,O
the,O
4,O
treatment,O
groups,O
(,O
H,O
=,O
15,O
.,O
34,O
;,O
P,O
<,O
0,O
.,O
001,O
),O
.,O
In,O
a,O
separate,O
group,O
of,O
mice,O
not,O
subjected,O
to,O
behavioral,O
studies,O
",",O
the,O
same,O
dose,O
of,O
NTG,B
(,O
n,O
=,O
3,O
),O
and,O
NTG,B
+,O
NIMO,B
(,O
n,O
=,O
3,O
),O
caused,O
mean,O
arterial,O
blood,O
pressure,O
to,O
decrease,O
from,O
85,O
.,O
9,O
+,O
/,O
-,O
3,O
.,O
8,O
mm,O
Hg,O
sem,O
to,O
31,O
.,O
6,O
+,O
/,O
-,O
0,O
.,O
8,O
mm,O
Hg,O
sem,O
and,O
from,O
86,O
.,O
2,O
+,O
/,O
-,O
3,O
.,O
7,O
mm,O
Hg,O
sem,O
",",O
respectively,O
.,O
Mean,O
arterial,O
blood,O
pressure,O
in,O
mice,O
treated,O
with,O
NIMO,B
alone,O
decreased,O
from,O
88,O
.,O
1,O
+,O
/,O
-,O
3,O
.,O
8,O
mm,O
Hg,O
to,O
80,O
.,O
0,O
+,O
/,O
-,O
2,O
.,O
9,O
mm,O
Hg,O
.,O
The,O
intergroup,O
difference,O
was,O
statistically,O
significant,O
(,O
P,O
<,O
0,O
.,O
05,
),
.,
PbtO,
(,
2,
),
decreased,
from,
51,
.,
7,
+,
/,
-,
4,
.,
5,
mm,
Hg,
sem,
to,
33,
.,
8,
+,
/,
-,
5,
.,
2,
mm,
Hg,
sem,
in,
the,
NTG,
group,
and,
from,
38,
.,
6,
+,
/,
-,
6,
.,
1,
mm,
Hg,
sem,
to,
25,
.,
4,
+,
/,
-,
2,
.,
0,
mm,
Hg,
sem,
in,
the,
NTG,
+,
NIMO,
groups,
",",
respectively,
.,
There,
were,
no,
significant,
differences,
among,
groups,
.,
CONCLUSION,
:,
In,
a,
PA,
retention,
paradigm,
",",
the,
injection,
of,
NTG,
immediately,
after,
learning,
produced,
a,
significant,
impairment,
of,
long,
-,
term,
associative,
memory,
in,
mice,
",",
whereas,
delayed,
induced,
hypotension,
had,
no,
effect,
.,
NIMO,
attenuated,
the,
disruption,
in,
consolidation,
of,
long,
-,
term,
memory,
caused,
by,
NTG,
but,
did,
not,
improve,
latency,
in,
the,
absence,
of,
hypotension,
.,
The,
observed,
effect,
of,
NIMO,
may,
have,
been,
attributable,
to,
the,
preservation,
of,
calcium,
homeostasis,
during,
hypotension,
",",
because,
there,
were,
no,
differences,
in,
the,
PbtO,
(,
2,
),
indices,
among,
groups,
.,
Metabotropic,
glutamate,
7,
receptor,
subtype,
modulates,
motor,
symptoms,
in,
rodent,
models,
of,
Parkinson,
',
s,
disease,
.,
Metabotropic,
glutamate,
(,
mGlu,
),
receptors,
modulate,
synaptic,
transmission,
in,
the,
central,
nervous,
system,
and,
represent,
promising,
therapeutic,
targets,
for,
symptomatic,
treatment,
of,
Parkinson,
',
s,
disease,
(,
PD,
),
.,
Among,O
the,O
eight,O
mGlu,B
receptor,I
subtypes,I
",",O
mGlu7,B
receptor,I
is,O
prominently,O
expressed,O
in,O
the,O
basal,O
ganglia,O
",",O
but,O
its,O
role,O
in,O
restoring,O
motor,O
function,O
in,O
animal,O
models,O
of,O
PD,B
is,O
not,O
known,O
.,O
The,O
effects,O
of,O
N,B
",",O
N,B
',I
-,I
dibenzhydrylethane,I
-,I
1,I
",",O
2,I
-,I
diamine,I
dihydrochloride,I
(,O
AMN082,B
),O
",",O
the,O
first,O
selective,O
allosteric,O
activator,O
of,O
mGlu7,B
receptors,I
",",O
were,O
thus,O
tested,O
in,O
different,O
rodent,O
models,O
of,O
PD,B
.,O
Here,
",",
we,
show,
that,
oral,
(,
5,
mg,
/,
kg,
),
or,
intrastriatal,
administration,
(,
0,
.,
1,
and,
0,
.,
5,
nmol,
),
of,
AMN082,
reverses,
haloperidol,
-,
induced,
catalepsy,
in,
rats,
.,
AMN082,
(,
2,
.,
5,
and,
5,
mg,
/,
kg,
),
reduces,
apomorphine,
-,
induced,
rotations,
in,
unilateral,
6,
-,
hydroxydopamine,
(,
6,
-,
OHDA,
),
-,
lesioned,
rats,
.,
In,
a,
more,
complex,
task,
commonly,
used,
to,
evaluate,
major,
akinetic,
symptoms,
of,
PD,
patients,
",",
5,
mg,
/,
kg,
AMN082,
reverses,
the,
increased,
reaction,
time,
to,
respond,
to,
a,
cue,
of,
bilateral,
6,
-,
OHDA,
-,
lesioned,
rats,
.,
In,O
addition,O
",",O
AMN082,B
reduces,O
the,O
duration,O
of,O
haloperidol,B
-,I
induced,I
catalepsy,I
in,O
a,O
mGlu7,B
receptor,I
-,I
dependent,I
manner,I
in,O
wild,O
-,O
type,O
but,O
not,O
mGlu7,B
receptor,I
knockout,I
mice,I
.,O
Higher,O
doses,O
of,O
AMN082,B
(,O
10,O
and,O
20,O
mg,O
/,O
kg,O
p,O
.,O
o,O
.,O
),O
have,O
no,O
effect,O
on,O
the,O
same,O
models,O
of,O
PD,O
.,O
Overall,O
these,O
findings,O
suggest,O
that,O
mGlu7,B
receptor,I
activation,I
can,O
reverse,O
motor,O
dysfunction,O
associated,O
with,O
reduced,O
dopamine,O
activity,O
.,O
Selective,O
ligands,O
of,O
mGlu7,B
receptor,O
subtypes,O
may,O
thus,O
be,O
considered,O
as,O
promising,O
compounds,O
for,O
the,O
Two,O
weeks,O
before,O
his,O
admission,O
",",O
sorafenib,B
had,O
been,O
started,O
.,O
He,O
was,O
diagnosed,O
with,O
non,B
-,I
ST,I
-,I
elevation,I
myocardial,I
infarction,I
by,O
laboratory,O
data,O
and,O
electrocardiogram,O
.,O
Enhanced,O
heart,O
magnetic,O
resonance,O
imaging,O
also,O
showed,O
subendocardial,O
infarction,O
.,O
However,O
",",O
there,O
was,O
no,O
stenosis,O
in,O
coronary,O
arteries,O
on,O
angiography,O
.,O
Coronary,B
artery,I
spasm,I
was,O
induced,O
by,O
a,O
provocative,O
test,O
.,O
Cessation,O
of,O
sorafenib,B
and,O
administration,O
o...nt,O
of,O
oral,O
nicorandil,B
reduced,O
his,O
symptoms,O
and,O
maintained,O
stable,O
angina,O
status,O
.,O
We,O
report,O
the,O
first,O
case,O
of,O
sorafenib,B-Chemical
-,I-Chemical
induced,I-Chemical
coronary,O
artery,O
spasm,O
.,O
Sorafenib,B-Chemical
is,O
a,O
multikinase,O
inhibitor,O
that,O
targets,O
signaling,O
pathways,O
necessary,O
for,O
cellular,O
proliferation,O
and,O
survival,O
.,O
On,O
the,O
other,O
hand,O
",",O
the,O
Rho,O
/,O
ROCK,O
pathway,O
has,O
an,O
important,O
role,O
in,O
the,O
pathogenesis,O
of,O
coronary,O
artery,O
spasm,O
.,O
Our,
report,
may,
show,
an,
adverse,
effect,
on,
the,
Rho,
/,
ROCK,
pathway,
by,
sorafenib,
use,
.,
A,
novel,
animal,
model,
to,
evaluate,
the,
ability,
of,
a,
drug,
delivery,
system,
to,
promote,
the,
passage,
through,
the,
BBB,
.,
The,
purpose,
of,
this,
investigation,
was,
to,
explore,
the,
potentiality,
of,
a,
novel,
animal,
model,
to,
be,
used,
for,
the,
in,
vivo,
evaluation,
of,
the,
ability,
of,
a,
drug,
delivery,
system,
to,
promote,
the,
passage,
through,
the,
blood,
-,
brain,
barrier,
(,
BBB,
),
and,
/,
or,
to,
improve,
the,
brain,
localization,
of,
a,
bioactive,
compound,
.,
A,O
Tween,B
80,I
-,I
coated,I
poly,I
-,I
L,I
-,I
lactid,I
acid,I
nanoparticles,I
was,O
used,O
as,O
a,O
model,O
of,O
colloidal,O
drug,O
delivery,O
system,O
",",O
able,O
to,O
trespass,O
the,O
BBB,O
.,O
Tacrine,B
",",O
administered,O
in,O
LiCl,O
pre,O
-,O
treated,O
rats,O
",",O
induces,O
electrocorticographic,O
seizures,O
and,O
delayed,O
hippocampal,O
damage,O
.,O
The,O
toxic,O
effects,O
of,O
tacrine,O
-,O
loaded,O
poly,O
-,O
L,O
-,O
lactid,O
acid,O
nanoparticles,O
(,O
5mg,O
/,O
kg,O
),O
",",O
a,O
saline,O
solution,O
of,O
tacrine,O
(,O
5mg,O
/,O
kg,O
),O
and,O
an,O
empty,O
colloidal,O
nanoparticle,O
suspension,O
were,O
compared,O
following,O
i,O
.,O
p,O
.,O
administration,O
in,O
LiCl,B
-,I
pre,O
-,O
treated,O
Wistar,O
rats,O
.,O
All,O
the,O
animals,O
treated,O
with,Ellipsis
tacrine,B
only,O
in,O
60,O
%,O
of,O
animals,O
.,O
Empty,O
nanoparticles,O
provided,O
similar,O
results,O
to,O
control,O
(,O
saline,B
-,I
treated,I
),O
group,O
of,O
animals,O
.,O
In,O
conclusion,O
",",O
the,O
evaluation,O
of,O
time,O
-,O
to,O
-,O
onset,O
of,O
symptoms,O
and,O
the,O
severity,O
of,O
neurodegenerative,O
processes,O
induced,O
by,O
the,O
tacrine,B
-,I
lithium,I
model,O
of,O
epilepsy,O
in,O
the,O
rat,O
",",O
could,O
be,O
used,O
to,O
evaluate,O
preliminarily,O
the,O
capability,O
of,O
a,O
drug,O
delivery,O
system,O
to,O
trespass,O
(,O
or,O
not,O
),O
the,O
BBB,B
in,O
vivo,O
.,O
High,O
-,O
dose,O
tranexamic,B
Acid,I
is,O
associated,O
with,O
nonischemic,O
clinical,O
seizures,O
in,O
cardiac,O
surgical,O
patients,O
.,O
BACKGROUND,O
:,O
In,O
2,O
separate,O
centers,O
",",O
we,O
observed,O
a,O
notable,O
increase,O
in,O
the,O
incidence,O
of,O
postoperative,O
convulsive,O
seizures,O
from,O
1,O
.,O
3,O
%,O
to,O
3,O
.,O
8,O
%,O
in,O
patients,O
having,O
undergone,O
major,O
cardiac,O
surgical,O
procedures,O
.,O
These,O
events,O
were,O
temporally,O
coincident,O
with,O
the,O
initial,O
use,O
of,O
high,O
-,O
dose,O
tranexamic,B
acid,I
(,I
TXA,I
),I
therapy,O
after,O
withdrawal,O
of,O
aprotinin,O
from,O
general,O
clinical,O
usage,O
.,O
The,O
purpose,O
of,O
this,O
review,O
was,O
to,O
perform,O
a,O
retrospective,O
analysis,O
to,O
examine,O
whether,O
there,O
was,O
a,O
relation,O
between,O
TXA,B
usage,O
and,O
seizures,O
after,O
cardiac,O
surgery,O
.,O
METHODS,O
:,O
An,O
in,O
-,O
depth,O
chart,O
review,O
was,O
undertaken,O
in,O
all,O
24,O
patients,O
who,O
developed,O
perioperative,O
seizures,O
.,O
Electroencephalographic,O
activity,O
was,O
recorded,O
in,O
11,O
of,O
these,O
patients,O
",",O
and,O
all,O
patients,O
had,O
a,O
formal,O
neurological,O
evaluation,O
and,O
brain,O
imaging,O
studies,O
.,O
RESULTS,O
:,O
Twenty,O
-,O
one,O
of,O
the,O
24,O
patients,O
did,O
not,O
have,O
evidence,O
of,O
new,O
cerebral,B
ischemic,I
injury,I
",",O
but,O
seizures,O
were,O
likely,O
due,O
to,O
ischemic,B
brain,I
injury,I
in,O
3,O
patients,O
.,O
All,O
patients,O
with,O
seizures,O
did,O
not,O
have,O
permanent,O
neurological,O
abnormalities,O
.,O
All,O
24,O
patients,O
with,O
seizures,O
received,O
high,O
doses,O
of,O
TXA,B
intraoperatively,O
ranging,O
from,O
61,O
to,O
259,O
mg,O
/,O
kg,O
",",O
had,O
a,O
mean,O
age,O
of,O
69,O
.,O
9,O
years,O
",",O
and,O
21,O
of,O
24,O
had,O
undergone,O
open,O
chamber,O
rather,O
than,O
coronary,O
bypass,O
procedures,O
.,O
All,O
but,O
one,O
patient,O
were,O
managed,O
using,O
cardiopulmonary,O
bypass,O
.,O
No,O
evidence,O
of,O
brain,O
ischemic,B
",",O
metabolic,B
",",O
or,O
hyperthermia,O
-,O
induced,O
causes,O
for,O
their,O
seizures,O
was,O
apparent,O
.,O
CONCLUSION,O
:,O
Our,O
results,O
suggest,O
that,O
use,O
of,O
high,O
-,O
dose,O
TXA,B
in,O
older,O
patients,O
in,O
conjunction,O
with,O
cardiopulmonary,O
bypass,O
and,O
open,O
-,O
chamber,O
cardiac,O
surgery,O
is,O
associated,O
with,O
clinical,O
seizures,O
in,O
susceptible,O
patients,O
.,O
Electrocardiographic,O
changes,O
and,O
cardiac,O
arrhythmias,O
in,O
patients,O
receiving,O
psychotropic,O
drugs,O
.,O
Eight,O
patients,O
had,O
c...cellaril,B
(,O
thioridazine,I
),O
appeared,O
to,O
be,O
responsible,O
for,O
five,O
cases,O
of,O
ventricular,O
tachycardia,O
",",O
one,O
Supraventricular,O
tachycardia,O
developed,O
in,O
one,O
patient,O
receiving,O
Thorazine,B
(,O
chlorpromazine,I
),O
.,O
Aventyl,B
(,O
nortriptyline,I
),O
and,O
Elavil,B
(,O
amitriptyline,I
),O
each,O
produced,O
left,O
bundle,O
branch,O
block,O
in,O
a,O
73,O
year,O
old,O
woman,O
.,O
Electrocardiographic,O
T,O
and,O
U,O
wave,O
abnormalities,O
were,O
present,O
in,O
most,O
patients,O
.,O
The,O
ventricular,O
arrhythmias,O
responded,O
to,O
intravenous,O
administration,O
of,O
lidocaine,B
and,O
to,O
direct,O
current,O
electric,O
shock,O
;,O
ventricular,O
pacing,O
was,O
required,O
in,O
some,O
instances,O
and,O
intravenous,O
administration,O
of,O
propranolol,B
combined,O
with,O
ventricular,O
pacing,O
in,O
one,O
.,O
The,O
tachyarrhythmias,B
generally,O
subsided,O
within,O
48,O
hours,O
after,O
administration,O
of,O
the,O
drugs,B
was,O
stopped,O
.,O
Five,O
of,O
the,O
eight,O
patients,O
were,O
50,O
years,O
of,O
age,O
or,O
younger,O
;,O
only,O
one,O
clearly,O
had,O
antecedent,O
heart,O
disease,O
.,O
Major,O
cardiac,O
arrhythmias,O
are,O
a,B
potential,O
hazard,O
in,O
patients,O
without,O
heart,O
disease,O
who,O
are,O
receiving,O
customary,O
therapeutic,O
doses,O
of,O
psychotropic,B
drugs,I
.,O
A,O
prospective,O
clinical,O
trial,O
is,O
suggested,O
to,O
quantify,O
the,O
risk,O
of,O
cardiac,O
complications,O
to,O
patients,O
We,O
have,O
used,O
a,O
murine,O
model,O
of,O
AIDS,O
",",O
infection,O
of,O
female,O
C57BL,O
/,O
6,O
mice,O
with,O
0,O
and,O
2,O
.,O
5,O
mg,O
/,O
ml,O
.,O
AZT,B
produced,O
anaemia,O
in,O
both,O
groups,O
",",O
in,O
a,O
dose,O
-,O
dependent,O
fashion,O
.,O
Despite,O
the,O
anaemia,O
",",O
the,O
number,O
of,O
splenic,O
and,O
bone,O
marrow,O
BFU,B
-,I
e,I
in,O
AZT,B
treated,O
mice,O
increased,O
up,O
to,O
five,O
-,O
fold,O
over,O
levels,O
observed,O
in,O
infected,O
untreated,O
animals,O
after,O
15,O
d,O
of,O
treatment,O
.,O
Colony,O
formation,O
by,O
splenic,O
and,O
bone,O
marrow,O
BFUe,B
was,O
stimulated,O
at,O
lower,O
concentrations,O
of,O
EPO,O
in,O
mice,O
receiving,O
AZT,B
for,O
15,O
d,O
than,O
for,O
infected,O
",",O
untreated,O
mice,O
.,O
By,O
day,O
30,O
",",O
sensitivity,O
of,O
both,O
splenic,B
and,O
bone,B
marrow,I
BFU,I
-,I
e,I
of,I
treated,I
animals,I
returned,O
to,O
that,O
observed,O
from,O
cells,O
of,O
infected,O
untreated,O
animals,O
.,O
The,O
mean,O
plasma,O
levels,O
of,O
EPO,B
observed,O
in,O
AZT,B
treated,I
mice,I
were,O
appropriate,O
for,O
the,O
degree,O
of,O
anaemia,O
observed,O
when,O
compared,O
with,O
phenylhydrazine,B
(,I
PHZ,I
),I
treated,I
mice,I
.,O
The,
numbers,
of,
BFU,
-,
e,
and,
the,
percentage,
of,
bone,
marrow,
erythroblasts,
observed,
were,
comparable,
in,
AZT,
and,
PHZ,
treated,
mice,
with,
similar,
degrees,
of,
anaemia,
.,
However,
",",
reticulocytosis,
was,
inappropriate,
for,
the,
degree,
of,
anaemia,
observed,
in,
AZT,
treated,
infected,
mice,
.,
AZT,
-,
induced,
peripheral,
anaemia,
in,
the,
face,
of,
increased,
numbers,
of,
BFU,
-,
e,
and,
increased,
levels,
of,
plasma,
EPO,
suggest,
a,
lesion,
in,
terminal,
differentiation,
.,
Sedation,O
depth,O
during,O
spinal,O
anesthesia,O
and,O
the,O
development,O
of,O
postoperative,O
delirium,O
in,O
elderly,O
patients,O
under...ective,O
:,O
To,O
determine,O
whether,O
limiting,O
intraoperative,O
sedation,O
depth,O
during,O
spinal,O
anesthesia,O
for,O
hip,O
fracture,O
repair,O
in,O
elderly,O
patients,O
can,O
decrease,O
the,O
prevalence,O
of,O
postoperative,O
delirium,O
.,O
PATIENTS,O
AND,O
METHODS,O
:,O
We,O
performed,O
a,O
double,O
-,O
blind,O
",",O
randomized,O
controlled,O
trial,O
at,O
an,O
aca...t,B
fracture,I
repair,I
under,O
spinal,B
anesthesia,I
with,O
propofol,B
sedation,I
.,O
Sedation,O
depth,O
was,O
titrated,O
using,O
Postoperative,O
delirium,O
was,O
assessed,O
as,O
defined,O
by,O
Diagnostic,B
and,I
Statistical,B
Manual,I
of,I
Mental,I
Disorders,I
(,O
Third,B
Edition,I
Revised,I
),O
criteria,O
using,O
the,O
Confusion,B
Assessment,I
Method,I
beginning,O
at,O
any,O
time,O
from,O
the,O
second,O
day,O
after,O
surgery,O
.,O
RESULTS,O
:,O
From,O
April,O
2,O
",",O
2005,O
",",O
through,O
October,O
30,O
",",O
2008,O
",",O
a,O
total,O
of,O
114,O
patients,O
were,O
randomized,O
.,O
The,O
prevalence,O
of,O
postoperative,O
delirium,O
was,O
significantly,O
lower,O
in,O
the,O
light,O
sedation,O
group,O
(,O
11,O
/,O
57,O
[,O
19,O
%,O
],O
vs,O
23,O
/,O
57,O
[,O
40,O
%,O
],O
in,O
the,O
deep,O
sedation,O
group,O
;,O
P,O
=,O
.,O
02,O
),O
",",O
indicating,O
that,O
1,O
incident,O
of,O
delirium,O
will,O
be,O
prevented,O
for,O
every,O
4,O
.,O
7,O
patients,O
treated,O
with,O
light,O
sedation,O
.,O
The,O
mean,O
+,O
/,O
-,O
SD,O
number,O
of,O
days,O
of,O
delirium,O
during,O
hospitalization,O
was,O
lower,O
in,O
the,O
light,O
sedation,O
group,O
than,O
in,O
the,O
deep,O
sedation,O
group,O
(,O
0,O
.,O
5,
+,
/,
-,
1,
.,
5,
days,
vs,
1,
.,
4,
+,
/,
-,
4,
.,
0,
days,
;,
P,
=,
.,
01,
),
.,
CONCLUSION,
:,
The,
use,
of,
light,
propofol,
sedation,
decreased,
the,
prevalence,
of,
postoperative,
delirium,
by,
50,
%,
compared,
with,
deep,
sedation,
.,
Limiting,
depth,
of,
sedation,
during,
spinal,
anesthesia,
is,
a,
simple,
",",
safe,
",",
and,
cost,
-,
effective,
intervention,
for,
preventing,
postoperative,
delirium,
in,
elderly,
patients,
that,
could,
be,
widely,
and,
readily,
adopted,
.,
The,O
protective,O
role,O
of,O
Nrf2,B
in,O
streptozotocin,B
-,I
induced,I
diabetic,I
nephropathy,I
.,O
OBJECTIVE,O
:,O
Diabetic,O
nep...by,O
the,O
production,O
of,O
reactive,O
oxygen,O
species,O
(,O
ROS,B
),O
.,O
Nrf2,B
is,O
the,O
primary,O
transcription,O
Here,
",",
we,
report,
our,
findings,
demonstrating,
a,
protective,
role,
of,
Nrf2,
against,
diabetic,
nephropathy,
.,
RESEARCH,
DESIGN,
AND,
METHODS,
:,
We,
explore,
the,
protective,
role,
of,
Nrf2,
against,
diabetic,
nephropathy,
using,
human,
kidney,
biopsy,
tissues,
from,
diabetic,
nephropathy,
patients,
",",
a,
streptozotocin,
-,
induced,
diabetic,
nephropathy,
model,
in,
Nrf2,
(,
-,
/,
-,
),
mice,
",",
and,
cultured,
human,
mesangial,
cells,
.,
RESULTS,
:,
The,
glomeruli,
of,
human,
diabetic,
nephropathy,
patients,
were,
under,
oxidative,
stress,
and,
had,
elevated,
Nrf2,
levels,
.,
In,
the,
animal,
study,
",",
Nrf2,
was,
demonstrated,
to,
be,
crucial,
in,
ameliorating,
streptozotocin,
-,
induced,
renal,
damage,
.,
This,
is,
evident,
by,
Nrf2,
(,
-,
/,
-,
),
mice,
having,
higher,
ROS,
production,
and,
suffering,
from,
greater,
oxidative,
DNA,
damage,
and,
renal,
injury,
compared,
with,
Nrf2,
(,
+,
/,
+,
),
mice,
.,
Mechanistic,O
studies,O
in,O
both,O
in,O
vivo,O
and,O
in,O
vitro,O
systems,O
showed,O
that,O
the,O
Nrf2,B
-,I
mediated,I
Furthermore,O
",",O
activation,O
or,O
overexpression,O
of,O
Nrf2,B
inhibited,O
the,O
promoter,O
activity,O
of,O
TGF,B
-,I
beta1,I
in,O
a,O
dose,O
-,O
dependent,O
manner,O
",",O
whereas,O
knockdown,O
of,O
Nrf2,B
by,O
siRNA,O
enhanced,O
TGF,B
-,I
beta1,I
transcription,O
and,O
fibronectin,O
production,O
.,O
CONCLUSIONS,O
:,O
This,O
work,O
clearly,O
indicates,O
a,O
protective,O
role,O
of,O
Nrf2,B
in,O
diabetic,O
nephropathy,O
",",O
suggesting,O
that,O
dietary,O
or,O
therapeutic,O
activation,O
of,O
Nrf2,B
could,O
be,O
used,O
as,O
a,O
strategy,O
to,O
prevent,O
or,O
slow,O
down,O
the,O
progression,O
of,O
diabetic,O
nephropathy,O
.,O
Metformin,
prevents,
experimental,
gentamicin,
-,
induced,
nephropathy,
by,
a,
mitochondria,
-,
dependent,
pathway,
.,
The,
antidiabetic,
drug,
metformin,
can,
diminish,
apoptosis,
induced,
by,
oxidative,
stress,
in,
endothelial,
cells,
and,
prevent,
vascular,
dysfunction,
even,
in,
nondiabetic,
patients,
.,
Here,
we,
tested,
whether,
it,
has,
a,
beneficial,
effect,
in,
a,
rat,
model,
of,
gentamicin,
toxicity,
.,
Mitochondrial,B
analysis,I
",",O
respiration,B
intensity,I
",",O
levels,B
of,I
reactive,I
oxygen,I
species,I
",",O
permeability,B
transition,I
Metformin,
also,
protected,
the,
kidney,
from,
histological,
damage,
6,
days,
after,
gentamicin,
administration,
.,
These,
in,
vivo,
markers,
of,
kidney,
dysfunction,
and,
their,
correction,
by,
metformin,
were,
complemented,
by,
in,
vitro,
studies,
of,
mitochondrial,
function,
.,
We,
found,
that,
gentamicin,
treatment,
depleted,
respiratory,
components,
(,
cytochrome,
c,
",",
NADH,
),
",",
probably,
due,
to,
the,
opening,
of,
mitochondrial,
transition,
pores,
.,
These,O
injuries,O
",",O
partly,O
mediated,O
by,O
a,O
rise,O
in,O
reactive,B
oxygen,I
species,I
from,O
the,O
electron,O
transfer,O
chain,O
",",O
were,O
significantly,O
decreased,O
by,O
metformin,B
.,O
Thus,O
",",O
our,O
study,O
suggests,O
that,O
pleiotropic,O
effects,O
of,O
metformin,O
can,O
lessen,O
gentamicin,O
nephrotoxicity,O
and,O
improve,O
mitochondrial,O
homeostasis,O
.,O
Risk,O
of,O
nephropathy,O
after,O
consumption,O
of,O
nonionic,O
contrast,O
media,O
by,O
children,O
undergoing,O
cardiac,O
angiography,O
:,O
a,O
prospective,O
study,O
.,O
Despite,O
increasing,O
reports,O
on,O
nonionic,B
contrast,I
media,I
-,I
induced,I
nephropathy,I
(,O
CIN,B
),O
in,O
hospitalized,O
adult,O
patients,O
during,O
cardiac,O
procedures,O
",",O
the,O
studies,O
in,O
pediatrics,O
are,O
limited,O
",",O
with,O
even,O
less,O
focus,O
on,O
possible,O
predisposing,O
factors,O
and,O
preventive,O
measures,O
for,O
patients,O
undergoing,O
cardiac,O
angiography,O
.,O
This,
prospective,
study,
determined,
the,
incidence,
of,
CIN,
for,
two,
nonionic,
contrast,
media,
(,
CM,
),
",",
iopromide,
and,
iohexol,
",",
among,
80,
patients,
younger,
than,
18,
years,
and,
compared,
the,
rates,
for,
this,
complication,
in,
relation,
to,
the,
type,
and,
dosage,
of,
CM,
and,
the,
presence,
of,
cyanosis,
.,
The,
80,
patients,
in,
the,
study,
consecutively,
received,
either,
iopromide,
(,
group,
A,
",",
n,
=,
40,
),
or,
iohexol,
(,
group,
B,
",",
n,
=,
40,
),
.,
Serum,
sodium,
(,
Na,
),
",",
potassium,
(,
K,
),
",",
and,
creatinine,
(,
Cr,
),
were,
measured,
24,
h,
before,
angiography,
as,
baseline,
values,
",",
then,
measured,
again,
at,
12,
-,
",",
24,
-,
",",
and,
48,
-,
h,
intervals,
after,
CM,
use,
.,
Urine,
samples,
for,
Na,
and,
Cr,
also,
were,
checked,
at,
the,
same,
intervals,
.,
Risk,
of,
renal,
failure,
",",
Injury,
to,
the,
kidney,
",",
Failure,
of,
kidney,
function,
",",
Loss,
of,
kidney,
function,
",",
and,
End,
-,
stage,
renal,
damage,
(,
RIFLE,
criteria,
),
were,
used,
to,
define,
CIN,
and,
its,
incidence,
in,
the,
study,
population,
.,
Accordingly,O
",",O
among,O
the,O
15,O
CIN,B
patients,O
(,O
18,O
.,O
75,O
%,O
),O
",",O
7,O
.,O
5,O
%,O
of,O
the,O
patients,O
in,O
group,O
A,O
had,O
increased,O
risk,O
and,O
3,O
.,O
75,O
%,O
had,O
renal,B
injury,O
",",O
whereas,O
5,O
%,O
of,O
group,O
B,O
had,O
increased,O
risk,O
and,O
2,O
.,O
5,O
%,O
had,O
renal,B
injury,O
.,O
Whereas,O
33,O
.,O
3,O
%,O
of,O
the,O
patients,O
with,O
CIN,B
were,O
among,O
those,O
who,O
received,O
the,O
proper,O
dosage,O
of,O
CM,B
",",O
the,O
percentage,O
increased,O
to,O
66,O
.,O
6,
%,
among,
those,
who,
received,
larger,
doses,
",",
with,
a,
significant,
difference,
in,
the,
incidence,
of,
CIN,
related,
to,
the,
different,
dosages,
of,
CM,
(,
p,
=,
0,
.,
014,
),
.,
Among,
the,
15,
patients,
with,
CIN,
",",
6,
had,
cyanotic,
congenital,
heart,
diseases,
",",
but,
the,
incidence,
did,
not,
differ,
significantly,
from,
that,
for,
the,
noncyanotic,
patients,
(,
p,
=,
0,
.,
243,B
),I
.,O
Although,O
clinically,O
silent,O
",",O
CIN,B
is,O
not,O
rare,O
in,O
pediatrics,O
.,O
The,O
incidence,O
depends... isoflurane,O
-,O
induced,O
hypotension,O
in,O
humans,O
.,O
The,O
effect,O
of,O
isoflurane,B
-,I
induced,O
hypotension,O
on,O
glomerular,O
function,O
and,O
renal,O
blood,O
flow,O
was,O
investigated,O
in,O
20,O
human,O
subjects,O
.,O
Glomerular,O
filtration,O
rate,O
(,O
GFR,B
),O
and,O
effective,O
renal,O
plasma,O
flow,O
(,O
ERPF,B
),O
were,O
measured,O
by,O
inulin,B
and,O
para,B
-,I
aminohippurate,I
(,I
PAH,I
),I
clearance,I
",",O
respectively,O
.,O
Anesthesia,O
was,O
maintained,O
with,O
fentanyl,B
",",O
nitrous,O
oxide,O
",",O
oxygen,O
",",O
and,O
isoflurane,B
.,O
Hypotension,O
was,O
induced,O
for,O
236,O
.,O
9,O
+,O
/,O
-,O
15,O
.,O
1,O
min,O
by,O
increasing,O
the,O
Renal,B
vascular,I
resistance,I
increased,O
during,O
anesthesia,O
but,O
decreased,O
when,O
hypotension,O
was,O
induced,O
",",O
allowing,O
the,O
maintenance,O
of,O
renal,O
blood,O
flow,O
.,O
We,O
conclude,O
that,O
renal,O
compensatory,O
mechanisms,O
are,O
preserved,O
during,O
isoflurane,B
-,I
induced,I
hypotension,I
and,O
that,O
renal,O
function,O
and,O
hemodynamics,O
quickly,O
return,O
to,O
normal,O
when,O
normotension,O
is,O
resumed,O
.,O
Brainstem,B
dysgenesis,I
in,O
an,O
infant,O
prenatally,O
exposed,O
to,O
cocaine,B
.,O
Many,O
authors,O
described,O
the,O
effects,O
on,O
the,O
fetus,O
of,O
maternal,O
cocaine,B
abuse,O
during,O
pregnancy,O
.,O
Vasoconstriction,O
appears,O
to,O
be,O
the,O
common,O
mechanism,O
of,O
action,O
leading,O
to,O
a,O
wide,O
range,O
of,O
fetal,O
anomalies,O
.,O
We,O
report,O
on,O
an,O
infant,O
with,O
multiple,O
cranial,O
-,O
nerve,O
involvement,O
attributable,O
to,O
brainstem,B
dysgenesis,I
",",O
born,O
to,O
a,O
cocaine,B
-,O
addicted,O
mother,O
.,O
A,O
cross,O
-,O
sectional,O
evaluation,O
of,O
the,O
effect,O
of,O
risperidone,B
and,O
selective,O
serotonin,O
reuptake,O
inhibitors,O
on,O
bone,O
mineral,O
density,O
in,O
boys,O
.,O
OBJECTIVE,O
:,O
The,O
aim,O
of,O
the,O
present,O
study,O
was,O
to,O
investigate,O
the,O
effect,O
of,O
risperidone,B
-,O
induced,O
hyperprolactinemia,O
on,O
trabecular,O
bone,O
mineral,O
density,O
(,O
BMD,O
),O
in,O
children,O
and,O
adolescents,O
.,O
METHOD,O
:,O
Medically,O
healthy,O
7,O
-,O
to,O
17,O
-,O
year,O
-,O
old,O
males,O
chronically,O
treated,O
",",O
in,O
a,O
naturalistic,O
setting,O
",",O
with,O
risperidone,B
were,O
recruited,O
for,O
this,O
cross,O
-,O
sectional,O
study,O
through,O
child,O
psychiatry,O
outpatient,O
clinics,O
between,O
November,O
2005,O
and,O
June,O
2007,O
.,O
Anthropometric,O
measurements,O
and,O
laboratory,O
testing,O
were,O
conducted,O
.,O
The,O
clinical,O
diagnoses,O
were,O
based,O
on,O
chart,O
review,O
",",O
and,O
developmental,O
and,O
treatment,O
history,O
was,O
obtained,O
from,O
the,O
medical,O
record,O
.,O
Volumetric,B
BMD,I
of,O
the,O
ultradistal,B
radius,I
was,O
measured,O
using,O
peripheral,O
quantitative,O
computed,O
tomography,O
",",O
and,O
areal,O
BMD,B
of,O
the,O
lumbar,B
spine,I
was,O
estimated,O
using,O
dual,O
-,O
energy,O
x,O
-,O
ray,O
absorptiometry,O
.,O
RESULTS,O
:,O
Hyperprolactinemia,B
was,O
present,O
in,O
49,O
%,O
of,O
83,O
boys,O
(,O
n,O
=,O
41,O
),O
treated,O
with,O
risperidone,O
for,O
a,O
mean,O
of,O
2,O
.,O
9,O
years,O
.,O
Serum,O
testosterone,O
concentration,O
increased,O
with,O
pubertal,O
status,O
but,O
was,O
not,O
affected,O
by,O
hyperprolactinemia,O
.,O
As,O
expected,O
",",O
bone,O
mineral,O
content,O
and,O
BMD,O
increased,O
with,O
sexual,O
maturity,O
.,O
After,O
adjusting,O
for,O
the,O
stage,O
of,O
sexual,O
development,O
and,O
height,O
and,O
BMI,O
z,O
scores,O
",",O
serum,O
prolactin,B
was,O
negatively,O
associated,O
with,O
trabecular,O
volumetric,O
BMD,O
at,O
the,O
ultradistal,O
radius,O
(,O
P,O
<,O
.,O
03,O
),O
.,O
Controlling,O
for,O
relevant,O
covariates,O
",",O
we,O
also,O
found,O
treatment,O
with,O
selective,O
serotonin,B
reuptake,I
inhibitors,I
(,O
SSRIs,O
),O
to,O
be,O
associated,O
with,O
lower,O
trabecular,O
BMD,O
at,O
the,O
radius,O
(,O
P,O
=,O
.,O
03,O
),O
and,O
BMD,B
z,I
score,I
at,O
the,O
lumbar,B
spine,I
(,O
P,B
<,B
.,O
05,O
),O
.,O
These,O
findings,O
became,O
more,O
marked,O
when,O
the,O
analysis,O
was,O
restricted,O
to,O
non,O
-,O
Hispanic,O
white,O
patients,O
.,O
Of,O
13,O
documented,O
fractures,O
",",O
3,O
occurred,O
after,O
risperidone,O
and,O
SSRIs,O
were,O
started,O
",",O
and,O
none,O
occurred,O
in,O
patients,O
with,O
hyperprolactinemia,O
.,O
CONCLUSIONS,O
:,O
This,O
is,O
the,O
first,O
study,O
to,O
link,O
risperidone,O
-,O
induced,O
hyperprolactinemia,O
and,O
SSRI,O
treatment,O
to,O
lower,O
BMD,B
in,O
children,O
and,O
adolescents,O
.,O
Future,
research,
should,
evaluate,
the,
longitudinal,
course,
of,
this,
adverse,
event,
to,
determine,
its,
temporal,
stability,
and,
whether,
a,
higher,
fracture,
rate,
ensues,
.,
Fear,
-,
potentiated,
startle,
",",
but,
not,
light,
-,
enhanced,
startle,
",",
is,
enhanced,
by,
anxiogenic,
drugs,
.,
RATIONALE,
AND,
OBJECTIVES,
:,
The,
light,
-,
enhanced,
startle,
paradigm,
(,
LES,
),
is,
suggested,
to,
model,
anxiety,
",",
because,
of,
the,
non,
-,
specific,
cue,
and,
the,
long,
-,
term,
effect,
.,
In,O
contrast,O
",",O
the,O
fear,B
-,I
potentiated,I
startle,I
(,O
FPS,O
),O
is,O
suggested,O
to,O
model,O
conditioned,O
fe...iatric,O
structures,O
in,O
the,O
presence,O
of,O
the,O
anxiogenic,O
action,O
of,O
the,O
same,O
drug,O
in,O
rats,O
.,O
"
",O
METHODS,O
:,O
Male,O
Wistar,O
rats,O
received,O
each,O
dose,O
of,O
the,O
alpha,B
(,I
2,I
),I
-,I
adrenoceptor,I
antagonist,I
yohimbine,I
(,I
0,I
.,I
25,I
-,I
1,I
.,I
0mg,I
/,I
kg,I
),I
",",O
the,O
5,B
-,I
HT,I
(,I
2C,I
),I
receptor,I
agonist,I
m,I
-,I
chlorophenylpiperazine,I
(,I
mCPP,I
",",I
0,I
.,I
5,I
-,I
2,I
.,I
0mg,I
/,I
kg,I
),I
or,O
the,O
GABA,B
(,I
A,I
),I
inverse,I
receptor,I
agonist,I
pentylenetetrazole,I
(,I
PTZ,I
",",I
3,I
-,I
30mg,I
/,I
kg,I
),I
and,O
were,O
subsequently,O
tested,O
in,O
either,O
LES,O
or,O
FPS,O
.,O
RESULTS,O
:,O
None,O
of,O
the,O
drugs,O
enhanced,O
LES,B
",",O
whereas,O
mCPP,B
increased,O
percentage,O
FPS,B
and,O
yohimbine,B
increased,O
absolute,O
FPS,B
values,O
.,O
Furthermore,O
",",O
yohimbine,B
increased,O
baseline,O
startle,O
amplitude,O
in,O
the,O
LES,B
",",O
while,O
mCPP,B
suppressed,O
baseline,O
startle,O
in,O
both,O
the,O
LES,B
and,O
FPS,B
and,O
PTZ,B
suppressed,O
baseline,O
startle,O
in,O
the,O
FPS,B
.,O
CONCLUSIONS,O
:,O
In,O
contrast,O
to,O
findings,O
in,O
the,O
FPS,B
paradigm,O
",",O
none,O
of,O
the,O
drugs,O
were,O
able,O
to,O
exacerbate,O
the,O
LES,B
response,O
.,O
Thus,O
",",O
a,O
clear,O
pharmacological,O
differentiation,O
was,O
found,O
between,O
LES,B
and,O
FPS,B
.,O
Rosaceiform,B
dermatitis,O
associated,O
with,O
topical,O
tacrolimus,B
treatment,O
.,O
We,O
describe,O
herein,O
3,O
patients,O
who,O
developed,O
rosacea,O
-,O
like,O
dermatitis,O
eruptions,O
while,O
using,O
0,O
.,O
03,
%,
or,
0,
.,
1,
%,
tacrolimus,
ointment,
for,
facial,
dermatitis,
.,
Skin,
biopsy,
specimens,
showed,
telangiectasia,
and,
noncaseating,
epithelioid,
granulomatous,
tissue,
formation,
in,
the,
papillary,
to,
mid,
dermis,
.,
Continuous,
topical,
use,
of,
immunomodulators,
such,
as,
tacrolimus,
or,
pimecrolimus,
should,
be,
regarded,
as,
a,
potential,
cause,
of,
rosaceiform,
dermatitis,
",",
although,
many,
cases,
have,
not,
been,
reported,
.,
Coenzyme,B
Q10,I
treatment,O
ameliorates,O
acute,O
cisplatin,B
nephrotoxicity,O
in,O
mice,O
.,O
The,O
nephroprotective,O
effect,O
of,O
co....,O
Coenzyme,B
Q10,I
treatment,O
(,O
10,O
mg,O
/,O
kg,O
/,O
day,O
",",O
i,O
.,O
p,O
.,O
),O
was,O
applied,O
for,O
6,O
consecutive,O
days,O
",",O
starting,O
1,O
day,O
before,O
cisplatin,O
administration,O
.,O
Coenzyme,O
Q10,O
significantly,O
reduced,O
blood,O
urea,B
nitrogen,I
and,O
serum,O
creatinine,B
levels,I
which,O
were,O
increased,O
Also,O
",",O
histopathological,O
renal,B
tissue,I
damage,O
mediated,O
by,O
cisplatin,B
was,O
ameliorated,O
by,O
coenzyme,B
Q10,I
treatment,O
.,O
Immunohistochemical,O
analysis,O
revealed,O
that,O
coenzyme,B
Q10,I
significantly,O
decreased,O
the,O
cisplatin,B
-,I
induced,B
overexpression,O
of,O
inducible,B
nitric,I
oxide,I
synthase,I
",",O
nuclear,B
factor,I
-,I
kappaB,I
",",O
caspase,B
-,I
3,I
and,O
p53,B
in,O
renal,B
tissue,I
.,O
It,O
was,O
concluded,O
that,O
coenzyme,B
Q10,I
represents,O
a,O
potential,O
therapeutic,O
option,O
to,O
protect,O
against,O
acute,O
Liver,O
biopsy,O
showed,O
cholestasis,B
with,O
both,O
cytological,O
and,O
architectural,O
alterations,O
of,O
interlobular,O
bile,O
ducts,O
.,O
Azathioprine,B
withdrawal,O
resulted,O
after,O
7,O
weeks,O
in,O
the,O
resolution,O
of,O
clinical,O
and,O
biochemical,O
abnormalities,O
.,O
It,O
is,O
believed,O
that,O
this,O
is,O
the,O
first,O
reported,O
case,O
of,O
reversible,O
azathioprine,O
-,O
induced,O
cholestasis,O
associated,O
with,O
histological,O
evidence,O
of,O
bile,O
duct,O
injury,O
.,O
Dopamine,B
is,O
not,O
essential,O
for,O
the,O
development,O
of,O
methamphetamine,B
-,I
induced,O
neurotoxicity,O
.,O
It,O
is,O
widely,O
believed,O
that,O
dopamine,B
(,O
DA,O
),O
mediates,O
methamphetamine,B
(,O
METH,O
),O
-,I
induced,O
toxicity,O
to,O
brain,O
dopaminergic,O
neurons,O
",",O
because,O
drugs,O
that,O
interfere,O
with,O
DA,O
neurotransmission,O
decrease,O
toxicity,O
",",O
whereas,O
drugs,O
that,O
increase,O
DA,O
neurotransmission,O
enhance,O
toxicity,O
.,O
However,O
",",O
temperature,O
effects,O
of,O
drugs,O
that,O
have,O
been,O
used,O
to,O
manipulate,O
brain,O
DA,B
neurotransmission,O
confound,O
interpretation,O
of,O
the,O
data,O
.,O
Here,O
we,O
show,O
that,O
the,O
recently,O
reported,O
ability,O
of,O
L,B
-,I
dihydroxyphenylalanine,I
to,O
reverse,O
the,O
protective,O
effect,O
of,O
alpha,O
-,O
methyl,O
-,O
para,O
-,O
tyrosine,O
on,O
METH,B
-,I
induced,O
DA,B
neurotoxicity,O
is,O
also,O
confounded,O
by,O
drug,O
effects,O
on,O
body,O
temperature,O
.,O
Further,O
",",O
we,O
show,O
that,O
mice,O
genetically,O
engineered,O
to,O
be,O
deficient,O
in,O
brain,B
DA,I
develop,O
METH,B
Taken,O
together,O
",",O
these,O
findings,O
demonstrate,O
that,O
DA,B
is,O
not,O
essential,O
for,O
the,O
development,O
of,O
METH,B
-,I
induced,I
dopaminergic,O
neurotoxicity,O
and,O
suggest,O
that,O
mechanisms,O
independent,O
of,O
DA,B
warrant,O
more,O
intense,O
investigation,O
.,O
Swallowing,O
-,O
induced,O
atrial,O
tachyarrhythmia,O
triggered,O
by,O
salbutamol,B
:,O
case,O
report,O
and,O
review,O
of,O
the,O
literature,O
.,O
CASE,O
:,O
A,O
49,O
-,O
year,O
-,O
old,O
patient,O
experienced,O
chest,O
discomfort,O
while,O
swallowing,O
.,O
On,O
The,O
patient,O
noticed,O
that,O
before,O
these,O
episodes,O
he,O
had,O
been,O
using,O
an,O
inhalator,O
of,O
salbutamol,B
.,O
After,O
stopping,O
the,O
beta,O
-,O
agonist,O
",",O
and,O
after,O
a,O
week,O
with,O
the,O
atenolol,O
",",O
the,O
arrhythmia,O
disappeared,O
.,O
DISCUSSION,O
:,O
Swallowing,O
-,O
induced,O
atrial,O
tachyarrhythmia,O
(,O
SIAT,B
),O
is,O
a,O
rare,O
phenomenon,O
.,O
Fewer,O
than,O
50,O
cases,O
of,O
SIAT,O
have,O
been,O
described,O
in,O
the,O
literature,O
.,O
This,O
article,O
summarizes,O
all,O
the,O
cases,O
published,O
",",O
creating,O
a,O
comprehensive,O
review,O
of,O
the,O
current,O
knowledge,O
and,O
approach,O
to,O
SIAT,B
.,O
It,O
discusses,O
demographics,O
",",O
clinical,O
characteristics,O
and,O
types,O
of,O
arrhythmia,O
",",O
postulated,O
mechanisms,O
of,O
SIAT,B
",",O
and,O
different,O
treatment,O
possibilities,O
such,O
as,O
medications,O
",",O
surgery,O
",",O
and,O
radiofrequency,B
catheter,O
ablation,O
(,O
RFCA,B
),O
.,O
CONCLUSION,O
:,O
Salbutamol,B
is,O
presented,O
here,O
as,O
a,O
possible,O
trigger,O
for,O
SIAT,O
.,O
Although,O
it,O
is,O
The,O
ability,O
of,O
insulin,B
treatment,O
to,O
reverse,O
or,O
prevent,O
the,O
changes,O
in,O
urinary,B
bladder,I
function,I
caus...treatment,O
.,O
2,O
.,O
Diabetes,O
of,O
2,O
months,O
duration,O
resulted,O
in,O
decreases,O
in,O
body,O
weight,O
and,O
3,
.,
Insulin,
treatment,
also,
prevented,
the,
increases,
in,
contractile,
responses,
of,
bladder,
body,
strips,
from,
diabetic,
rats,
to,
nerve,
stimulation,
",",
ATP,
",",
and,
bethanechol,
.,
4,
.,
Diabetes,
of,
4,
months,
duration,
also,
resulted,
in,
decreases,
in,
body,
weight,
",",
and,
increases,
in,
fluid,
consumption,
",",
urine,
volume,
",",
frequency,
of,
micturition,
",",
and,
average,
volume,
per,
micturition,
",",
effects,
which,
were,
reversed,
by,
insulin,
treatment,
for,
the,
final,
2,
months,
of,
the,
study,
.,
5,O
.,O
Insulin,B
treatment,O
reversed,O
the,O
increases,O
in,O
contractile,O
responses,O
of,O
bladder,O
body,O
strips,O
from,O
diabetic,O
rats,O
to,O
nerve,O
stimulation,O
",",O
ATP,B
",",O
and,O
bethanechol,B
.,O
6,O
.,O
The,O
data,O
indicate,O
that,O
the,O
effects,O
of,O
streptozotocin,O
-,O
induced,O
diabetes,O
on,O
urinary,O
bladder,O
function,O
are,O
both,O
prevented,O
and,O
reversed,O
by,O
insulin,O
treatment,O
.,O
Glutamatergic,O
neurotransmission,O
mediated,O
by,O
NMDA,B
receptors,O
in,O
the,O
inferior,O
colliculus,O
can,O
modulate,O
haloperidol,O
-,O
induced,O
catalepsy,O
.,O
The,O
inferior,O
colliculus,O
(,O
IC,B
),O
is,O
primarily,O
involved,O
in,O
the,O
processing,O
of,O
auditory,O
information,O
",",O
but,O
it,O
is,O
distinguished,O
from,O
other,O
auditory,O
nuclei,O
in,O
the,O
brainstem,O
by,O
its,O
connections,O
with,O
structures,O
of,O
the,O
motor,O
system,O
.,O
